U.S. patent application number 15/376073 was filed with the patent office on 2017-03-30 for antibacterial agents.
The applicant listed for this patent is Achaogen, Inc.. Invention is credited to Stephen W. KALDOR, Ramesh Annasaheb KASAR, Qing LU, Heinz Ernst MOSER, Phillip A. PATTEN, Brian D. PATTERSON, Dan WANG.
Application Number | 20170088549 15/376073 |
Document ID | / |
Family ID | 39816683 |
Filed Date | 2017-03-30 |
United States Patent
Application |
20170088549 |
Kind Code |
A1 |
MOSER; Heinz Ernst ; et
al. |
March 30, 2017 |
ANTIBACTERIAL AGENTS
Abstract
Antibacterial compounds of formula (I) are provided:
##STR00001## as well as stereoisomers, pharmaceutically acceptable
salts, esters, and prodrugs thereof; pharmaceutical compositions
comprising such compounds; methods of treating bacterial infections
by the administration of such compounds; and processes for the
preparation of such compounds.
Inventors: |
MOSER; Heinz Ernst; (San
Mateo, CA) ; LU; Qing; (Foster City, CA) ;
PATTEN; Phillip A.; (Portola Valley, CA) ; WANG;
Dan; (Fremont, CA) ; KASAR; Ramesh Annasaheb;
(Bellevue, WA) ; KALDOR; Stephen W.; (San Diego,
CA) ; PATTERSON; Brian D.; (San Francisco,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Achaogen, Inc. |
South San Francisco |
CA |
US |
|
|
Family ID: |
39816683 |
Appl. No.: |
15/376073 |
Filed: |
December 12, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14223971 |
Mar 24, 2014 |
|
|
|
15376073 |
|
|
|
|
12635551 |
Dec 10, 2009 |
|
|
|
14223971 |
|
|
|
|
PCT/US2008/066766 |
Jun 12, 2008 |
|
|
|
12635551 |
|
|
|
|
60943494 |
Jun 12, 2007 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 211/08 20130101;
C07D 211/56 20130101; C07D 211/94 20130101; C07D 213/56 20130101;
C07C 259/06 20130101; C07D 217/22 20130101; C07C 2601/08 20170501;
C07D 233/64 20130101; C07D 239/90 20130101; C07D 271/107 20130101;
C07D 295/155 20130101; C07D 333/36 20130101; C07D 207/08 20130101;
C07D 211/26 20130101; C07D 207/32 20130101; C07D 277/46 20130101;
C07D 207/09 20130101; C07D 231/14 20130101; C07D 211/46 20130101;
C07D 233/36 20130101; C07D 241/52 20130101; C07D 249/08 20130101;
C07D 263/58 20130101; C07D 309/04 20130101; C07D 207/10 20130101;
C07D 295/096 20130101; C07D 207/06 20130101; C07D 209/46 20130101;
C07D 239/26 20130101; C07D 295/135 20130101; C07D 239/70 20130101;
C07D 263/32 20130101; C07D 277/82 20130101; C07D 295/092 20130101;
C07D 295/26 20130101; C07D 335/02 20130101; C07D 207/34 20130101;
C07D 211/34 20130101; C07D 277/40 20130101; C07D 241/12 20130101;
C07D 263/34 20130101; C07D 207/12 20130101; C07C 2601/14 20170501;
C07C 2601/02 20170501; A61P 43/00 20180101; C07D 267/10 20130101;
C07D 333/34 20130101; C07D 211/38 20130101; A61P 31/04 20180101;
C07D 231/56 20130101; C07D 239/42 20130101; C07D 239/88 20130101;
C07D 277/30 20130101; C07D 309/12 20130101; C07C 2601/04 20170501;
C07D 285/12 20130101; C07D 213/61 20130101; C07D 307/14 20130101;
C07D 241/08 20130101; C07D 333/06 20130101; C07D 207/337 20130101;
C07D 275/02 20130101; C07D 207/48 20130101; C07D 217/24 20130101;
C07D 261/08 20130101; C07D 471/04 20130101; C07C 311/08 20130101;
C07D 207/16 20130101; C07D 213/36 20130101; C07D 261/20 20130101;
C07D 213/38 20130101; C07D 213/74 20130101; C07D 207/46 20130101;
C07D 233/26 20130101; C07D 295/15 20130101; C07D 309/08 20130101;
C07D 333/24 20130101; C07D 231/12 20130101; C07D 205/04 20130101;
C07D 413/04 20130101 |
International
Class: |
C07D 471/04 20060101
C07D471/04; C07D 207/06 20060101 C07D207/06; C07D 295/15 20060101
C07D295/15; C07D 295/155 20060101 C07D295/155; C07D 239/26 20060101
C07D239/26; C07D 241/12 20060101 C07D241/12; C07D 271/107 20060101
C07D271/107; C07D 285/12 20060101 C07D285/12; C07D 205/04 20060101
C07D205/04; C07D 333/24 20060101 C07D333/24; C07D 211/34 20060101
C07D211/34; C07D 211/26 20060101 C07D211/26; C07D 207/34 20060101
C07D207/34; C07D 263/32 20060101 C07D263/32; C07D 217/24 20060101
C07D217/24; C07D 209/46 20060101 C07D209/46; C07D 239/88 20060101
C07D239/88; C07D 217/22 20060101 C07D217/22; C07D 263/58 20060101
C07D263/58; C07D 277/82 20060101 C07D277/82; C07D 261/20 20060101
C07D261/20; C07D 231/56 20060101 C07D231/56; C07D 207/12 20060101
C07D207/12; C07D 207/09 20060101 C07D207/09; C07D 309/08 20060101
C07D309/08; C07D 335/02 20060101 C07D335/02; C07D 211/56 20060101
C07D211/56; C07D 241/08 20060101 C07D241/08; C07D 207/46 20060101
C07D207/46; C07D 233/64 20060101 C07D233/64; C07D 213/56 20060101
C07D213/56; C07D 275/02 20060101 C07D275/02; C07D 261/08 20060101
C07D261/08; C07D 231/12 20060101 C07D231/12; C07C 311/08 20060101
C07C311/08; C07D 413/04 20060101 C07D413/04; C07C 259/06 20060101
C07C259/06 |
Goverment Interests
STATEMENT OF GOVERNMENT INTEREST
[0002] This invention was made with government support under
Contract No. HDTRA1-07-C-0079 awarded by the United States
Department of Defense. The government has certain rights in this
invention.
Claims
1. A compound having the following formula (I): ##STR00559## or a
stereoisomer, pharmaceutically acceptable salt, ester, or prodrug
thereof, wherein: E is selected from the group consisting of: (1)
H, (2) substituted or unsubstituted C.sub.1-C.sub.6-alkyl, (3)
substituted or unsubstituted C.sub.2-C.sub.6-alkenyl, (4)
substituted or unsubstituted C.sub.2-C.sub.6-alkynyl, (5)
substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl, (6)
substituted or unsubstituted aryl, (7) substituted or unsubstituted
heterocyclyl, and (8) substituted or unsubstituted heteroaryl; L is
absent or selected from the group consisting of: (1) substituted or
unsubstituted C.sub.1-C.sub.6-alkyl, (2)
--(NR.sup.3L).sub.0-1--(CH.sub.2).sub.0-4--NR.sup.3L--(CH.sub.2).sub.-
0-4--, (3)
--(NR.sup.3L).sub.0-1--C(R.sup.1L,R.sup.2L)--NR.sup.3L--C(R.sup-
.1L,R.sup.2L)--, (4)
--C(R.sup.1L,R.sup.2L)--O--C(R.sup.1L,R.sup.2L)--, (5)
--(CH.sub.2).sub.0-4--NR.sup.3L--C(R.sup.1L,R.sup.2L)--CONH--(CH.sub.-
2).sub.0-4--, (6) --CO--C(R.sup.1L,R.sup.2L)--NHCO--, (7)
--CONR.sup.3L--, (8) --NR.sup.3LCO--, (9) --NR.sup.3L--, (10)
--SO.sub.2NR.sup.3L--, (11) --NR.sup.3L--C(.dbd.O)--NR.sup.3L--,
(12) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl, (13)
substituted or unsubstituted aryl, (14) substituted or
unsubstituted heterocyclyl, and (15) substituted or unsubstituted
heteroaryl, wherein: each R.sup.1L, R.sup.2L, and R.sup.3L is
independently selected from the group consisting of: (a) H, (b)
substituted or unsubstituted C.sub.1-C.sub.6-alkyl, (c)
C.sub.1-C.sub.6-alkyl substituted with aryl, (d)
C.sub.1-C.sub.6-alkyl substituted with heterocyclyl, and (e)
C.sub.1-C.sub.6-alkyl substituted with heteroaryl, or R.sup.1L and
R.sup.3L, together with the atoms to which they are attached can
form a substituted or unsubstituted heterocyclic ring, having from
3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring
are selected from N, O and S; D is absent or selected from the
group consisting of: (1) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, (2) substituted or unsubstituted aryl,
(3) substituted or unsubstituted heterocyclyl, and (4) substituted
or unsubstituted heteroaryl; G is selected from the group
consisting of: (1) --NR.sup.1GC(.dbd.O)--, (2)
--C(.dbd.O)NR.sup.1G--, (3)
--(CH.sub.2).sub.0-4NHCH.sub.2C(.dbd.O)NR.sup.1G--, (4)
--CR.sup.2G.dbd.CR.sup.2G--, (5) --S(.dbd.O)--, (6) --SO.sub.2--,
(7) --C(R.sup.3G).sub.2--S(.dbd.O)--, (8)
--S(.dbd.O)--C(R.sup.3G).sub.2--, (9)
--C(R.sup.3G).sub.2--SO.sub.2--, (10)
--SO.sub.2--C(R.sup.3G).sub.2--, (11)
--CR.sup.3G.dbd.CR.sup.3G--CR.sup.3G.dbd.CR.sup.3G--, (12)
--C(R.sup.3G).sub.2--, (13) --CR.sup.3G.dbd.CR.sup.3G--C.ident.C--,
(14) --C.ident.C--CR.sup.3G.dbd.CR.sup.3G--, (15)
--C(.dbd.O)--C.ident.C--, (16) --C.ident.C--C(.dbd.O)--, (17)
substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl, (18)
substituted or unsubstituted aryl, (19) substituted or
unsubstituted heterocyclyl, and (20) substituted or unsubstituted
heteroaryl, wherein: R.sup.1G is substituted or unsubstituted
C.sub.1-C.sub.6-alkyl; each R.sup.2G is independently selected from
the group consisting of H, a halogen atom, and substituted or
unsubstituted C.sub.1-C.sub.6-alkyl, and at least one R.sup.2G is
not H; and R.sup.3G is selected from the group consisting of H, a
halogen atom, and substituted or unsubstituted
C.sub.1-C.sub.6-alkyl; Y is absent or selected from the group
consisting of: (1) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, (2) substituted or unsubstituted aryl,
(3) substituted or unsubstituted heterocyclyl, and (4) substituted
or unsubstituted heteroaryl; X is selected from the group
consisting of: (1) --(C.dbd.O)NR.sub.4--, (2)
--C.sub.1-C.sub.6-alkyl-(C.dbd.O)NR.sub.4--, (3)
--C.sub.2-C.sub.6-alkenyl-(C.dbd.O)NR.sub.4--, (4)
--C.sub.2-C.sub.6-alkynyl-(C.dbd.O)NR.sub.4--, (5)
--CH.sub.2NR.sub.4--, (6) --SO.sub.2NR.sub.4--, (7)
--S(.dbd.O)NR.sub.4--, (8) --NR.sub.4C(.dbd.O)--, and (9)
--NR.sub.4--, or X and A, together with the atoms to which they are
attached can form a heterocyclic ring, having from 5 to 8 ring
atoms, wherein 1-2 ring atoms of the heterocyclic ring are selected
from N, O and S, or when Y is a bicyclic substituted or
unsubstituted heterocyclyl or heteroaryl, then X is absent; R.sub.3
is H or substituted or unsubstituted C.sub.1-C.sub.6-alkyl, or
R.sub.3 and A, together with the atom to which they are attached
can form a substituted or unsubstituted 3-10 membered cycloalkyl or
a heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4
ring atoms of the heterocyclic ring are selected from N, O and S;
R.sub.4 is (1) H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or (2) R.sub.4 and A, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S, or (3) R.sub.4 and Y, together with the atoms to which
they are attached, form a bicyclic substituted or unsubstituted
heterocyclyl or heteroaryl; n is an integer from 0-6; A is selected
from the group consisting of: (1) H, (2)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)(CH.sub.2).sub.0-4OR.sup.3-
a, (3)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a), (4)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)N(R.sup.4a)COR.sup.3a, (5)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)NHCON(R.sup.4a,R.sup.5a),
(6)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)NHC(.dbd.NH)N(R.sup.4a,R.sup.5a),
(7) --CH(R.sup.1a,R.sup.2a), (8) --C.ident.CH, (9)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)CN, (10)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)CO.sub.2R.sup.3a, (11)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)CON(R.sup.4a,R.sup.5a),
(12) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl, (13)
substituted or unsubstituted aryl, (14) substituted or
unsubstituted heterocyclyl, and (15) substituted or unsubstituted
heteroaryl, wherein: each R.sup.1a, R.sup.2a, R.sup.3a, R.sup.4a,
and R.sup.5a is independently selected from the group consisting
of: (a) H, (b) a halogen atom, (c) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, (d) substituted or unsubstituted aryl, (e)
substituted or unsubstituted heterocyclyl, and (f) substituted or
unsubstituted heteroaryl, or R.sup.4a and R.sup.5a together with
the N atom to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 5 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S; Q is absent or selected from the group consisting of:
(1) --C(.dbd.O)N(R.sub.1,R.sub.2), (2)
--NHC(.dbd.O)N(R.sub.1,R.sub.2), (3)
--N(OH)C(.dbd.O)N(R.sub.1,R.sub.2), (4)
--CH(OH)C(.dbd.O)N(R.sub.1,R.sub.2), (5) --CH[N(R.sup.2q,
R.sup.3q)]C(.dbd.O)N(R.sub.1,R.sub.2), (6)
--CHR.sup.1qC(.dbd.O)N(R.sub.1, R.sub.2), (7) --CO.sub.2H, (8)
--C(.dbd.O)NHSO.sub.2R.sup.4q, (9) --SO.sub.2NH.sub.2, (10)
--N(OH)C(.dbd.O)R.sup.1q, (11) --N(OH)SO.sub.2R.sup.4q, (12)
--NHSO.sub.2R.sup.4q, (13) --SH, (14)
--CH(SH)(CH.sub.2).sub.0-1C(.dbd.O)N(R.sub.1,R.sub.2), (15)
--CH(SH)(CH.sub.2).sub.0-1CO.sub.2H, (16)
--CH(OH)(CH.sub.2).sub.0-1CO.sub.2H, (17)
--CH(SH)CH.sub.2CO.sub.2R.sup.1q, (18)
--CH(OH)(CH.sub.2)SO.sub.2NH.sub.2, (19)
--CH(CH.sub.2SH)NHCOR.sup.1q, (20)
--CH(CH.sub.2SH)NHSO.sub.2R.sup.4q, (21)
--CH(CH.sub.2SR.sup.5q)CO.sub.2H, (22)
--CH(CH.sub.2SH)NHSO.sub.2NH.sub.2, (23) --CH(CH.sub.2OH)CO.sub.2H,
(24) --CH(CH.sub.2OH)NHSO.sub.2NH.sub.2, (25)
--C(.dbd.O)CH.sub.2CO.sub.2H, (26)
--C(.dbd.O)(CH.sub.2).sub.0-1CONH.sub.2, (27)
--OSO.sub.2NHR.sup.5q, (28) --SO.sub.2NHNH.sub.2, (29)
--P(.dbd.O)(.dbd.O).sub.2, ##STR00560## and (33)
--N(OH)C(.dbd.O)CR.sub.1R.sub.2, wherein: R.sub.1 is selected from
the group consisting of: (1) --H, (2) --OH, (3)
--OC.sub.1-C.sub.6-alkyl, (4) --N(R.sup.2q, R.sup.3q), and (5)
substituted or unsubstituted C.sub.1-C.sub.6-alkyl; R.sub.2 is
selected from the group consisting of: (1) H, (2) substituted or
unsubstituted C.sub.1-C.sub.6-alkyl, (3) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, (4) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, (5) substituted or
unsubstituted aryl, (6) substituted or unsubstituted heterocyclyl,
and (7) substituted or unsubstituted heteroaryl, or R.sub.1 and
R.sub.2, together with the N atom to which they are attached can
form a substituted or unsubstituted heterocyclic ring, having from
3 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring
are selected from N, O and S; and each R.sup.1q, R.sup.2q,
R.sup.3q, R.sup.4q, and R.sup.5q is independently selected from the
group consisting of H and C.sub.1-C.sub.6 alkyl.
2. A compound of claim 1 wherein G is selected from the group
consisting of: (1) --C.ident.C--, (2) --C.ident.C--C.ident.C--, (3)
--CR.sup.3G.dbd.CR.sup.3G--C.ident.C--, and (4)
--C.ident.C--CR.sup.3G.dbd.CR.sup.3G--.
3. A compound of claim 2 wherein G is selected from the group
consisting of: (1) --C.ident.C--, (2) --C.ident.C--C.ident.C--, (3)
--CH.dbd.CH--C.ident.C--, and (4) --C.ident.C--CH.dbd.CH--.
4. A compound of claim 3 wherein G is --C.ident.C--.
5. A compound of claim 3 wherein G is --C.ident.C--C.ident.C--.
6. A compound of claim 3 wherein G is --CH.dbd.CH--C.ident.C--.
7. A compound of claim 6 wherein G has the following structure:
##STR00561##
8. A compound of claim 3 wherein G is --C.ident.C--CH.dbd.CH--.
9. A compound of claim 8 wherein G has the following structure:
##STR00562##
10. A compound of any one of claims 1-9 wherein X is
--(C.dbd.O)NR.sub.4--.
11. A compound of claim 10 wherein X is --(C.dbd.O)NH--.
12. A compound of any one of claims 1-11 wherein Q is
--(C.dbd.O)N(R.sub.1,R.sub.2).
13. A compound of claim 12 wherein Q is --(C.dbd.O)NHOH.
14. A compound of any one of claims 1-13 wherein n is 0.
15. A compound of any one of claims 1-14 wherein R.sub.3 is H.
16. A compound of any one of claims 1-15 wherein Y is substituted
or unsubstituted aryl.
17. A compound of claim 16 wherein Y is substituted or
unsubstituted phenyl.
18. A compound of claim 17 wherein Y is unsubstituted phenyl.
19. A compound of any one of claims 1-18 wherein A is selected from
the group consisting of: (1)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)(CH.sub.2).sub.0-4OR.sup.3a,
(2) --(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a),
and (3) --CH(R.sup.1a,R.sup.2a).
20. A compound of claim 19 wherein A is selected from the group
consisting of --CH(CH.sub.3).sub.2, --CH.sub.2OH,
--CH.sub.2NH.sub.2, --CHCH.sub.3OH, --CHCH.sub.3NH.sub.2 and
--C(CH.sub.3).sub.2OH.
21. A compound of claim 19 wherein A is
--C(CH.sub.3).sub.2NH.sub.2.
22. A compound of any one of claims 1-18 wherein A is selected from
the group consisting of: (1) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, (2) substituted or unsubstituted aryl,
(3) substituted or unsubstituted heterocyclyl, and (4) substituted
or unsubstituted heteroaryl.
23. A compound of claim 22 wherein A is selected from the group
consisting of ##STR00563##
24. A compound of any one of claims 1-23 wherein R.sub.3 is H and
##STR00564## has the following structure: ##STR00565##
25. A compound of claim 24 wherein A is --CHCH.sub.3OH or
--CHCH.sub.3NH.sub.2 ##STR00566## and has one of the following
structures: ##STR00567##
26. A compound of any one of claims 1-25 wherein D is present.
27. A compound of claim 26 wherein D is substituted or
unsubstituted heteroaryl.
28. A compound of claim 27 wherein heteroaryl is selected from the
group consisting of: ##STR00568##
29. A compound of claim 26 wherein D is substituted or
unsubstituted aryl.
30. A compound of claim 29 wherein D is substituted or
unsubstituted phenyl.
31. A compound of claim 30 wherein D is unsubstituted phenyl.
32. A compound of any one of claims 1-25 wherein D is absent.
33. A compound of any one of claims 1-32 wherein L is present.
34. A compound of claim 33 wherein L is substituted or
unsubstituted alkyl
35. A compound of claim 34 wherein wherein L is --CH.sub.3--.
36. A compound of claim 33 wherein L is --CH.sub.2--NH--.
37. A compound of any one of claims 1-32 wherein L is absent.
38. A compound having the following formula (I): ##STR00569## or a
stereoisomer, pharmaceutically acceptable salt, ester, or prodrug
thereof, wherein: E is selected from the group consisting of: (1)
H, (2) substituted or unsubstituted C.sub.1-C.sub.6-alkyl, (3)
substituted or unsubstituted C.sub.2-C.sub.6-alkenyl, (4)
substituted or unsubstituted C.sub.2-C.sub.6-alkynyl, (5)
substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl, (6)
substituted or unsubstituted aryl, (7) substituted or unsubstituted
heterocyclyl, and (8) substituted or unsubstituted heteroaryl; L is
absent or selected from the group consisting of: (1) substituted or
unsubstituted C.sub.1-C.sub.6-alkyl, (2)
--(NR.sup.3L).sub.0-1--(CH.sub.2).sub.0-4--NR.sup.3L--(CH.sub.2).sub.-
0-4--, (3)
--(NR.sup.3L).sub.0-1--C(R.sup.1L,R.sup.2L)--NR.sup.3LC(R.sup.1-
L,R.sup.2L)--, (4)
--C(R.sup.1L,R.sup.2L)--O--C(R.sup.1L,R.sup.2L)--, (5)
--(CH.sub.2).sub.0-4--NR.sup.3L--C(R.sup.1L,
R.sup.2L)--CONH--(CH.sub.2).sub.0-4--, (6)
--CO--C(R.sup.1L,R.sup.2L)--NHCO--, (7) --CONR.sup.3L--, (8)
--NR.sup.3LCO--, (9) --NR.sup.3L--, (10) --SO.sub.2NR.sup.3L--,
(11) --NR.sup.3L--C(.dbd.O)--NR.sup.3L--, (12) substituted or
unsubstituted C.sub.3-C.sub.10-cycloalkyl, (13) substituted or
unsubstituted aryl, (14) substituted or unsubstituted heterocyclyl,
and (15) substituted or unsubstituted heteroaryl, wherein: each
R.sup.1L, R.sup.2L, and R.sup.3L is independently selected from the
group consisting of: (a) H, (b) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, (c) C.sub.1-C.sub.6-alkyl substituted with
aryl, (d) C.sub.1-C.sub.6-alkyl substituted with heterocyclyl, and
(e) C.sub.1-C.sub.6-alkyl substituted with heteroaryl, or R.sup.1L
and R.sup.3L, together with the atoms to which they are attached
can form a substituted or unsubstituted heterocyclic ring, having
from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic
ring are selected from N, O and S; D is absent or selected from the
group consisting of: (1) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, (2) substituted or unsubstituted aryl,
(3) substituted or unsubstituted heterocyclyl, and (4) substituted
or unsubstituted heteroaryl; G is selected from the group
consisting of: (1) --(CH.sub.2).sub.0-4--O--(CH.sub.2).sub.0-4--,
(2) --(CH.sub.2).sub.0-4--S--(CH.sub.2).sub.0-4--, (3)
--(CH.sub.2).sub.0-4--NR.sup.1G--(CH.sub.2).sub.0-4--, (4)
--C(.dbd.O)--, (5) --NR.sup.1GC(.dbd.O)--, (6)
--C(.dbd.O)NR.sup.1G--, (7)
--(CH.sub.2).sub.0-4NHCH.sub.2C(.dbd.O)NR.sup.1G--, (8)
--C.ident.C--, (9) --C.ident.C--C.ident.C--, (10)
--CR.sup.2G.dbd.CR.sup.2G--, (11) --S(.dbd.O)--, (12) --SO.sub.2--,
(13) --C(R.sup.3G).sub.2--S(.dbd.O)--, (14)
--S(.dbd.O)--C(R.sup.3G).sub.2--, (15)
--C(R.sup.3G).sub.2--SO.sub.2--, (16)
--SO.sub.2--C(R.sup.3G).sub.2--, (17)
--CR.sup.3G.dbd.CR.sup.3G--CR.sup.3G.dbd.CR.sup.3G--, (18)
--C(R.sup.3G).sub.2--, (19) --CR.sup.3G.dbd.CR.sup.3G--C.ident.C--,
(20) --C.ident.C--CR.sup.3G.dbd.CR.sup.3G--, (21)
--C(.dbd.O)--C.ident.C--, (22) --C.ident.C--C(.dbd.O)--, (23)
substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl, (24)
substituted or unsubstituted aryl, (25) substituted or
unsubstituted heterocyclyl, and (26) substituted or unsubstituted
heteroaryl, wherein: R.sup.1G is substituted or unsubstituted
C.sub.1-C.sub.6-alkyl; each R.sup.2G and R.sup.3G is independently
selected from the group consisting of H, a halogen atom, and
substituted or unsubstituted C.sub.1-C.sub.6-alkyl; Y is absent or
selected from the group consisting of: (1) substituted or
unsubstituted C.sub.3-C.sub.10-cycloalkyl, (2) substituted or
unsubstituted aryl, (3) substituted or unsubstituted heterocyclyl,
and (4) substituted or unsubstituted heteroaryl; X is selected from
the group consisting of: (1) --(C.dbd.O)NR.sub.4--, (2)
--C.sub.1-C.sub.6-alkyl-(C.dbd.O)NR.sub.4--, (3)
--C.sub.2-C.sub.6-alkenyl-(C.dbd.O)NR.sub.4--, (4)
--C.sub.2-C.sub.6-alkynyl-(C.dbd.O)NR.sub.4--, (5)
--CH.sub.2NR.sub.4--, (6) --SO.sub.2NR.sub.4--, (7)
--S(.dbd.O)NR.sub.4--, (8) --NR.sub.4C(.dbd.O)--, and (9)
--NR.sub.4--, or X and A, together with the atoms to which they are
attached can form a heterocyclic ring, having from 5 to 8 ring
atoms, wherein 1-2 ring atoms of the heterocyclic ring are selected
from N, O and S, or when Y is a bicyclic substituted or
unsubstituted heterocyclyl or heteroaryl, then X is absent; R.sub.3
is H or substituted or unsubstituted C.sub.1-C.sub.6-alkyl, or
R.sub.3 and A, together with the atom to which they are attached
can form a substituted or unsubstituted 3-10 membered cycloalkyl or
a heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4
ring atoms of the heterocyclic ring are selected from N, O and S;
R.sub.4 is (1) H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or (2) R.sub.4 and A, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S, or (3) R.sub.4 and Y, together with the atoms to which
they are attached, form a bicyclic substituted or unsubstituted
heterocyclyl or heteroaryl; n is an integer from 0-6; A is selected
from the group consisting of: (1) --C(R.sup.1a,R.sup.2a)OR.sup.3a,
(2) --C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a), (3) substituted or
unsubstituted C.sub.3-C.sub.10-cycloalkyl, (4) substituted or
unsubstituted aryl, (5) substituted or unsubstituted heterocyclyl,
and (6) substituted or unsubstituted heteroaryl, wherein: each
R.sup.1a and R.sup.2a is independently selected from the group
consisting of substituted or unsubstituted C.sub.1-C.sub.6-alkyl;
each R.sup.1a, R.sup.4a, and R.sup.5a is independently selected
from the group consisting of: (a) H, (b) a halogen atom, (c)
substituted or unsubstituted C.sub.1-C.sub.6-alkyl, (d) substituted
or unsubstituted aryl, (e) substituted or unsubstituted
heterocyclyl, and (f) substituted or unsubstituted heteroaryl, or
R.sup.4a and R.sup.5a together with the N atom to which they are
attached can form a substituted or unsubstituted heterocyclic ring,
having from 5 to 8 ring atoms, wherein 1-2 ring atoms of the
heterocyclic ring are selected from N, O and S; and when A is
--C(R.sup.1a,R.sup.2a)OR.sup.3a, the compound is not
2-{[(4'-ethyl-1,1'-biphenyl-4-yl)carbonyl]amino}-3-hydroxy-3-methy-
lbutanoic acid, 4'-ethyl-N-{2-hydroxy-1-[(hydroxyamino)
carbonyl]-2-methylpropyl}-1,1'-biphenyl-4-carboxamide or
N-{2-hydroxy-1-[(hydroxyamino)carbonyl]-2-methylpropyl}-4-(phenylethynyl)-
benzamide; Q is absent or selected from the group consisting of:
(1) --C(.dbd.O)N(R.sub.1,R.sub.2), (2)
--NHC(.dbd.O)N(R.sub.1,R.sub.2), (3)
--N(OH)C(.dbd.O)N(R.sub.1,R.sub.2), (4)
--CH(OH)C(.dbd.O)N(R.sub.1,R.sub.2), (5) --CH[N(R.sup.2q,
R.sup.3q)]C(.dbd.O)N(R.sub.1,R.sub.2), (6)
--CHR.sup.1qC(.dbd.O)N(R.sub.1, R.sub.2), (7) --CO.sub.2H, (8)
--C(.dbd.O)NHSO.sub.2R.sup.4q, (9) --SO.sub.2NH.sub.2, (10)
--N(OH)C(.dbd.O)R.sup.1g, (11) --N(OH)SO.sub.2R.sup.4q, (12)
--NHSO.sub.2R.sup.4q, (13) --SH, (14)
--CH(SH)(CH.sub.2).sub.0-4C(.dbd.O)N(R.sub.1,R.sub.2), (15)
--CH(SH)(CH.sub.2).sub.0-1CO.sub.2H, (16)
--CH(OH)(CH.sub.2).sub.0-1CO.sub.2H, (17)
--CH(SH)CH.sub.2CO.sub.2R.sup.1q, (18)
--CH(OH)(CH.sub.2)SO.sub.2NH.sub.2, (19)
--CH(CH.sub.2SH)NHCOR.sup.1q, (20)
--CH(CH.sub.2SH)NHSO.sub.2R.sup.4q, (21)
--CH(CH.sub.2SR.sup.5q)CO.sub.2H, (22)
--CH(CH.sub.2SH)NHSO.sub.2NH.sub.2, (23) --CH(CH.sub.2OH)CO.sub.2H,
(24) --CH(CH.sub.2OH)NHSO.sub.2NH.sub.2, (25)
--C(.dbd.O)CH.sub.2CO.sub.2H, (26)
--C(.dbd.O)(CH.sub.2).sub.0-1CONH.sub.2, (27)
--OSO.sub.2NHR.sup.5q, (28) --SO.sub.2NHNH.sub.2, (29)
--P(.dbd.O)(OH).sub.2, ##STR00570## and (33)
--N(OH)C(.dbd.O)CR.sub.1R.sub.2, wherein: R.sub.1 is selected from
the group consisting of: (1) --H, (2) --OH, (3)
--OC.sub.1-C.sub.6-alkyl, (4) --N(R.sup.2q, R.sup.3q), and (5)
substituted or unsubstituted C.sub.1-C.sub.6-alkyl; R.sub.2 is
selected from the group consisting of: (1) H, (2) substituted or
unsubstituted C.sub.1-C.sub.6-alkyl, (3) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, (4) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, (5) substituted or
unsubstituted aryl, (6) substituted or unsubstituted heterocyclyl,
and (7) substituted or unsubstituted heteroaryl, or R.sub.1 and
R.sub.2, together with the N atom to which they are attached can
form a substituted or unsubstituted heterocyclic ring, having from
3 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring
are selected from N, O and S; and each R.sup.1q, R.sup.2q,
R.sup.3q, R.sup.4q, and R.sup.5q is independently selected from the
group consisting of H and C.sub.1-C.sub.6 alkyl.
39. A compound of claim 38 wherein A is
--C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a).
40. A compound of claim 39 wherein A is
--C(CH.sub.3).sub.2NH.sub.2.
41. A compound of claim 38 wherein A is
--C(R.sup.1a,R.sup.2a)OR.sup.3a.
42. A compound of claim 38 wherein A is selected from the group
consisting of: (1) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, (2) substituted or unsubstituted aryl,
(3) substituted or unsubstituted heterocyclyl, and (4) substituted
or unsubstituted heteroaryl.
43. A compound of claim 42 wherein A is selected from the group
consisting of ##STR00571##
44. A compound of any one of claims 38-43 wherein R.sub.3 is H and
##STR00572## has the following structure: ##STR00573##
45. A compound of any one of claims 38-44 wherein G is selected
from the group consisting of: (1) --C.ident.C--, (2)
--C.ident.C--C.ident.C--, (3)
--CR.sup.3G.dbd.CR.sup.3G--C.ident.C--, and (4)
--C.ident.C--CR.sup.3G.dbd.CR.sup.3G--.
46. A compound of claim 45 wherein G is selected from the group
consisting of: (1) --C.ident.C--, (2) --C.ident.C--C.ident.C--, (3)
--CH.dbd.CH--C.ident.C--, and (4) --C.ident.C--CH.dbd.CH--.
47. A compound of claim 46 wherein G is --C.ident.C--.
48. A compound of claim 46 wherein G is
--C.ident.C--C.ident.C--C.ident.C--.
49. A compound of claim 46 wherein G is
--CH.dbd.CH--C.ident.C--.
50. A compound of claim 49 wherein G has the following structure:
##STR00574##
51. A compound of claim 46 wherein G is
--C.ident.C--CH.dbd.CH--.
52. A compound of claim 51 wherein G has the following structure:
##STR00575##
53. A compound of any one of claims 38-52 wherein X is
--(C.dbd.O)NR.sub.4--.
54. A compound of claim 53 wherein X is --(C.dbd.O)NH--.
55. A compound of any one of claims 38-54 wherein Q is
--(C.dbd.O)N(R.sub.1,R.sub.2).
56. A compound of claim 55 wherein Q is --(C.dbd.O)NHOH.
57. A compound of any one of claims 38-56 wherein n is 0.
58. A compound of any one of claims 38-57 wherein R.sub.3 is H.
59. A compound of any one of claims 38-58 wherein Y is substituted
or unsubstituted aryl.
60. A compound of claim 59 wherein Y is substituted or
unsubstituted phenyl.
61. A compound of claim 60 wherein Y is unsubstituted phenyl.
62. A compound of any one of claims 38-61 wherein D is present.
63. A compound of claim 62 wherein D is substituted or
unsubstituted heteroaryl.
64. A compound of claim 63 wherein heteroaryl is selected from the
group consisting of: ##STR00576##
65. A compound of claim 62 wherein D is substituted or
unsubstituted aryl.
66. A compound of claim 65 wherein D is substituted or
unsubstituted phenyl.
67. A compound of claim 66 wherein D is unsubstituted phenyl.
68. A compound of any one of claims 38-61 wherein D is absent.
69. A compound of any one of claims 38-68 wherein L is present.
70. A compound of claim 69 wherein L is substituted or
unsubstituted alkyl
71. A compound of claim 70 wherein wherein L is --CH.sub.3--.
72. A compound of claim 69 wherein L is --CH.sub.2--NH--.
73. A compound of any one of claims 38-68 wherein L is absent.
74. A pharmaceutical composition comprising a compound of any one
of claims 1-73 and a pharmaceutically acceptable carrier or
diluent.
75. A method for treating a subject with a gram-negative bacterial
infection comprising administering to the subject in need thereof
an antibacterially effective amount of a compound of any one of
claims 1-73 or a pharmaceutical composition of claim 74.
76. A method for treating a subject with a gram-negative bacterial
infection comprising co-administering to the subject in need
thereof an antibacterially effective amount of a compound of any
one of claims 1-73 or a pharmaceutical composition of claim 74 and
a second antibacterial agent.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 14/223,971, filed Mar. 24, 2014 (allowed),
which is a continuation of U.S. patent application Ser. No.
12/635,551, filed Dec. 10, 2009 (now abandoned), which is a
continuation of International PCT Application No.
PCT/US2008/066766, filed Jun. 12, 2008, which claims the benefit
under 35 U.S.C. .sctn.119(e) of U.S. Provisional Patent Application
No. 60/943,494, filed Jun. 12, 2007. The foregoing applications are
incorporated herein by reference in their entireties.
BACKGROUND OF THE INVENTION
[0003] Field of the Invention
[0004] This invention pertains generally to treating infections
cause by gram-negative bacteria. More specifically, the invention
described herein pertains to treating gram-negative infections by
inhibiting activity of
UDP-3-O--(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase
(LpxC). The present invention provides small molecule inhibitors of
LpxC, pharmaceutical formulations containing such inhibitors,
methods of treating patients with such pharmaceutical formulations,
and methods of preparing such pharmaceutical formulations and
inhibitors. The inhibitors can be used to treat gram-negative
infections of patients alone and in combination with other
antibacterials.
[0005] Description of the Related Art
[0006] Over the past several decades, the frequency of
antimicrobial resistance and its association with serious
infectious diseases have increased at alarming rates. The
increasing prevalence of resistance among nosocomial pathogens is
particularly disconcerting. Of the over 2 million nosocomial
infections occurring each year in the United States, 50 to 60% are
caused by antimicrobial-resistant strains of bacteria. This high
rate of resistance increases the morbidity, mortality, and costs
associated with nosocomial infections. In the United States,
nosocomial infections are thought to contribute to or cause more
than 77,000 deaths per year and cost approximately $5 to $10
billion annually. Among gram-positive organisms, the most important
resistant pathogens are methicillin-(oxacillin-)resistant
Staphylococcus aureus, .beta.-lactam-resistant and
multidrug-resistant pneumococci, and vancomycin-resistant
enterococci. Important causes of gram-negative resistance include
extended-spectrum .beta.-lactamases (ESBLs) in Klebsiella
pneumoniae, Escherichia coli, and Proteus mirabilis, high-level
third-generation cephalosporin (Amp C) .beta.-lactamase resistance
among Enterobacter species and Citrobacter freundii, and
multidrug-resistance genes observed in Pseudomonas aeruginosa,
Acinetobacter, and Stenotrophomonas maltophilia (see Jones, R. N.,
"Resistance patterns among nosocomial pathogens: Trends over the
past few years" Chest., 2001, 119 (Supp 2), 397S-404S).
[0007] The problem of antibacterial resistance is compounded by the
existence of bacterial strains resistant to multiple
antibacterials. For example, Pseudomonas aeruginosa isolates
resistant to fluoroquinolones are virtually all resistant to
additional antibacterials (see Sahm, D. F. et al., "Evaluation of
current activities of fluoroquinolones against gram-negative
bacilli using centralized in vitro testing and electronic
surveillance" Antimicrobial Agents and Chemotherapy, 2001, 45,
267-274).
[0008] Thus there is a need for new antibacterials, particularly
antibacterials with novel mechanisms of action. Most of the
antibacterial discovery effort in the pharmaceutical industry is
aimed at development of drugs effective against gram-positive
bacteria. However, there is also a need for new gram-negative
antibacterials. Gram-negative bacteria are in general more
resistant to a large number of antibacterials and chemotherapeutic
agents than are gram-positive bacteria. A survey of recently
reported antibacterials of natural origin showed that over 90%
lacked activity against Escherichia coli, although they were active
against gram-positive bacteria. The outer membrane of gram-negative
bacteria contributes to this intrinsic resistance by acting as an
efficient permeability barrier, because the narrow porin channels
limit the penetration of hydrophilic solutes and the low fluidity
of the lipopolysaccharide leaflet slows down the inward diffusion
of lipophilic solutes. A second mechanism also contributes to the
intrinsic resistance of gram-negative bacteria. Recent studies
showed that multiple drug efflux pumps, sometimes with unusually
broad specificity, act as this second factor to create the general
intrinsic resistance of gram-negative bacteria. When their
expression levels are elevated as a consequence of physiological
regulation or genetic alteration, they can frequently produce
impressive levels of resistance to a wide variety of antimicrobial
agents (see Nikaido H., "Antibacterial resistance caused by
gram-negative multidrug efflux pumps" Clinical Infectious Diseases,
1998, 27 (Supp 1), S32-41).
[0009] Historically, most development of antimicrobial agents has
been relatively empirical. Active compounds have generally been
found via screening soil, sewage, water, and other natural
substances to detect antimicrobial-producing organisms, or by
screening various chemical compounds. Once a leading candidate has
been found and its chemical structure determined, a series of
analogs is made to identify an optimal compound for further
clinical development. A more rational approach involves the
defining of new targets, such as genes or enzymatic functions,
responsible for a crucial cellular essential activity. Once this
has been done, inhibitors or blockers of the function or gene
product can be developed.
[0010] In order to identify potential targets for novel
gram-negative antibacterial agents, studies aimed at identifying
all essential and important genes in Pseudomonas aeruginosa have
been performed. Among the essential genes identified was LpxC, that
encodes the enzyme
uridyldiphospho-3-O--(R-hydroxydecanoyl)-N-acetylglucosamine
deacetylase (LpxC). This enzyme is the first committed step in the
synthesis of lipid A, the lipid moiety of lipopolysaccharide, that
is an essential component of all gram-negative bacteria. It
therefore is an attractive target for novel antibacterials. In
order to be useful as antibacterial agents, LpxC inhibitors would
not only have to inhibit the enzymatic activity of LpxC from a
variety of bacteria, but would have to defeat the intrinsic
resistance mechanisms of gram-negative bacteria, as described above
(i.e., they would have to penetrate the outer membrane and be
relatively unsusceptible to multidrug efflux pumps).
[0011] To date, researchers have identified a few compounds with
antibacterial activity that target lipid A biosynthesis. For
example, International PCT Publication No. WO 97/42179 to Patchett
et al. discloses compounds of the formula:
##STR00002##
The compounds possess activity against certain gram-negative
organisms, for example Escherichia coli, but are not active against
other medically important gram-negative bacteria, for example
Pseudomonas aeruginosa. Subsequent studies have found that the
primary reason for their inactivity against particular, medically
important gram-negative bacteria is their poor ability to inhibit
P. aeruginosa LpxC; efflux by the major multidrug efflux pump or
inability to penetrate the outer membrane were not the critical
factors.
[0012] Jackman et al. (J. Biol. Chem., 2000, 275(15), 11002-11009)
discuss the mechanism of lipid A biosynthesis in the context of
gram-negative bacteria and disclose a new class of
hydroxamate-containing inhibitors of LpxC. Wyckoff et al. (Trends
in Microbiology, 1998, 6(4), 154-159) discuss the role of LpxC in
lipid A biosynthesis and its role in regulation and disclose a few
oxazoline hydroxamic acids that inhibit bacterial growth. However,
Wyckoff et al. also discuss the shortcomings of the available
deacetylase inhibitors as bactericidal agents against Pseudomonas
and note that more work is needed to be done in the area.
[0013] U.S. Patent Application Publication No. 2001/0053555
(published Dec. 20, 2001, corresponding to International PCT
Publication No. WO 98/18754 published May 7, 1998) discloses a
combinatorial library of hydroxylamine, hydroxamic acid,
hydroxyurea and hydroxylsulfonamide compounds purported to be
potentially useful as inhibitors of metalloproteases, and U.S. Pat.
No. 6,281,245 claims a method of inhibiting a deformylase enzyme by
administering one of the hydroxylamine compounds from the
combinatorial library disclosed in U.S. Patent Application
Publication No. 2001/0053555. Related to the foregoing patent
publications is International PCT Publication No. WO 99/57097
(published Nov. 11, 1999) that discloses a method of solid phase
synthesis of the hydroxylamine library of compounds.
[0014] International PCT Publication No. WO 00/61134 to British
Biotech Pharmaceuticals Limited (published Oct. 19, 2000) discloses
compounds of the formula:
##STR00003##
The compounds are useful as antimicrobial agents and are believed
to have bactericidal activity due, at least in part, to
intracellular inhibition of bacterial polypeptide deformylase.
[0015] In earlier International PCT Publication No. WO 99/39704 to
British Biotech Pharmaceuticals Limited (published Aug. 12, 1999),
compounds of the following formula were disclosed:
##STR00004##
The compounds are useful as antimicrobial agents useful against
gram-negative and gram positive bacteria.
[0016] De Novo Pharmaceuticals LTD disclosed in International PCT
Publication No. WO 02/50081 (published Jun. 27, 2002), certain
antibacterial and antiprotozoal agents having the formulae shown
below:
##STR00005##
The patent publication discusses that the antibacterial activity is
due, at least in part, to intracellular inhibition of bacterial
polypeptide deformylase.
[0017] More recently, certain compounds having activity against
gram-negative bacterial infections were disclosed in U.S. Patent
Application Publication No. 2004/0229955 (published Nov. 18,
2004).
[0018] Although there have been advances in the field, there
remains a need for LpxC inhibitors that have activity as
bactericidal agents against gram-negative bacteria. It is,
accordingly, an object of this invention to provide compounds and
combinations of such compounds for use in the preparation of
antibacterials and other pharmaceuticals capable of inhibiting
gram-negative bacterial infections.
BRIEF SUMMARY OF THE INVENTION
[0019] The present invention provides novel compounds,
pharmaceutical formulations including the compounds, methods of
inhibiting UDP-3-O--(R-3-hydroxydecanoyl)-N-acetylglucosamine
deacetylase (LpxC), and methods of treating gram-negative bacterial
infections.
[0020] In one aspect, the present invention provides compounds
having the following formula (I):
##STR00006##
including stereoisomers, pharmaceutically acceptable salts, esters,
and prodrugs thereof.
[0021] In a first embodiment, the present invention provides
compounds of formula (I) wherein:
[0022] E is selected from the group consisting of: [0023] (1) H,
[0024] (2) substituted or unsubstituted C.sub.1-C.sub.6-alkyl,
[0025] (3) substituted or unsubstituted C.sub.2-C.sub.6-alkenyl,
[0026] (4) substituted or unsubstituted C.sub.2-C.sub.6-alkynyl,
[0027] (5) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0028] (6) substituted or
unsubstituted aryl, [0029] (7) substituted or unsubstituted
heterocyclyl, and [0030] (8) substituted or unsubstituted
heteroaryl;
[0031] L is absent or selected from the group consisting of: [0032]
(1) substituted or unsubstituted C.sub.1-C.sub.6-alkyl, [0033] (2)
--(NR.sup.3L).sub.0-1--(CH.sub.2).sub.0-4--NR.sup.3L--(CH.sub.2).sub.0-4--
-, [0034] (3)
--(NR.sup.3L).sub.0-1--C(R.sup.1L,R.sup.2L)--NR.sup.3L,
--C(R.sup.1L,R.sup.2L)--, [0035] (4)
--C(R.sup.1L,R.sup.2L)--O--C(R.sup.1L,R.sup.2L)--, [0036] (5)
--(CH.sub.2).sub.0-4--NR.sup.3L--C(R.sup.1L,R.sup.2L)--CONH--(CH.sub.2).s-
ub.0-4--, [0037] (6) --CO--C(R.sup.1L,R.sup.2L)--NHCO--, [0038] (7)
--CONR.sup.3L--, [0039] (8) --NR.sup.3LCO--, [0040] (9)
--NR.sup.3L--, [0041] (10) --SO.sub.2NR.sup.3L--, [0042] (11)
--NR.sup.3L--C(.dbd.O)--NR.sup.3L--, [0043] (12) substituted or
unsubstituted C.sub.3-C.sub.10-cycloalkyl, [0044] (13) substituted
or unsubstituted aryl, [0045] (14) substituted or unsubstituted
heterocyclyl, and [0046] (15) substituted or unsubstituted
heteroaryl, [0047] wherein: [0048] each R.sup.1L, R.sup.2L, and
R.sup.3L is independently selected from the group consisting of:
[0049] (a) H, [0050] (b) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, [0051] (c) C.sub.1-C.sub.6-alkyl substituted
with aryl, [0052] (d) C.sub.1-C.sub.6-alkyl substituted with
heterocyclyl, and [0053] (e) C.sub.1-C.sub.6-alkyl substituted with
heteroaryl, [0054] or R.sup.1L and R.sup.3L, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S;
[0055] D is absent or selected from the group consisting of: [0056]
(1) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl,
[0057] (2) substituted or unsubstituted aryl, [0058] (3)
substituted or unsubstituted heterocyclyl, and [0059] (4)
substituted or unsubstituted heteroaryl;
[0060] G is selected from the group consisting of: [0061] (1)
--NR.sup.1GC(.dbd.O)--, [0062] (2) --C(.dbd.O)NR.sup.1G--, [0063]
(3) --(CH.sub.2).sub.0-4NHCH.sub.2C(.dbd.O)NR.sup.1G--, [0064] (4)
--CR.sup.2G.dbd.CR.sup.2G--, [0065] (5) --S(.dbd.O)--, [0066] (6)
--SO.sub.2--, [0067] (7) --C(R.sup.3G).sub.2--S(.dbd.O)--, [0068]
(8) --S(.dbd.O)--C(R.sup.3G).sub.2--, [0069] (9)
--C(R.sup.3G).sub.2--SO.sub.2--, [0070] (10)
--SO.sub.2--C(R.sup.3G).sub.2--, [0071] (11)
--CR.sup.3G.dbd.CR.sup.3G--CR.sup.3G.dbd.CR.sup.3G--, [0072] (12)
--C(R.sup.3G).sub.2--, [0073] (13)
--CR.sup.3G.dbd.CR.sup.3G--C.ident.C--, [0074] (14)
--C.ident.C--CR.sup.3G.dbd.CR.sup.3G--, [0075] (15)
--C(.dbd.O)--C.ident.C--, [0076] (16) --C.ident.C--C(.dbd.O)--,
[0077] (17) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0078] (18) substituted or
unsubstituted aryl, [0079] (19) substituted or unsubstituted
heterocyclyl, and [0080] (20) substituted or unsubstituted
heteroaryl, [0081] wherein: [0082] R.sup.1G is substituted or
unsubstituted C.sub.1-C.sub.6-alkyl; [0083] each R.sup.2G is
independently selected from the group consisting of H, a halogen
atom, and substituted or unsubstituted C.sub.1-C.sub.6-alkyl, and
at least one R.sup.2G is not H; and [0084] R.sup.3G is selected
from the group consisting of H, a halogen atom, and substituted or
unsubstituted C.sub.1-C.sub.6-alkyl;
[0085] Y is absent or selected from the group consisting of: [0086]
(1) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl,
[0087] (2) substituted or unsubstituted aryl, [0088] (3)
substituted or unsubstituted heterocyclyl, and [0089] (4)
substituted or unsubstituted heteroaryl;
[0090] X is selected from the group consisting of: [0091] (1)
--(C.dbd.O)NR.sub.4--, [0092] (2)
--C.sub.1-C.sub.6-alkyl-(C.dbd.O)NR.sub.4--, [0093] (3)
--C.sub.2-C.sub.6-alkenyl-(C.dbd.O)NR.sub.4--, [0094] (4)
--C.sub.2-C.sub.6-alkynyl-(C.dbd.O)NR.sub.4--, [0095] (5)
--CH.sub.2NR.sub.4--, [0096] (6) --SO.sub.2NR.sub.4--, [0097] (7)
--S(.dbd.O)NR.sub.4--, [0098] (8) --NR.sub.4C(.dbd.O)--, and [0099]
(9) --NR.sub.4--, [0100] or X and A, together with the atoms to
which they are attached can form a heterocyclic ring, having from 5
to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring
are selected from N, O and S, [0101] or when Y is a bicyclic
substituted or unsubstituted heterocyclyl or heteroaryl, then X is
absent;
[0102] R.sub.3 is H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or R.sub.3 and A, together with the atom to
which they are attached can form a substituted or unsubstituted
3-10 membered cycloalkyl or a heterocyclic ring, having from 3 to
10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring are
selected from N, O and S;
[0103] R.sub.4 is (1) H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or (2) R.sub.4 and A, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S, or (3) R.sub.4 and Y, together with the atoms to which
they are attached, form a bicyclic substituted or unsubstituted
heterocyclyl or heteroaryl;
[0104] n is an integer from 0-6;
[0105] A is selected from the group consisting of: [0106] (1) H,
[0107] (2)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)(CH.sub.2).sub.0-4OR.sup.3a,
[0108] (3)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a),
[0109] (4)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)N(R.sup.4a)COR.sup.3a,
[0110] (5)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)NHCON(R.sup.4a,R.sup.5a),
[0111] (6)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)NHC(NH)N(R.sup.4a,R.sup.5a),
[0112] (7) --CH(R.sup.1a,R.sup.2a), [0113] (8) --C.ident.CH, [0114]
(9) --(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)CN, [0115] (10)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)CO.sub.2R.sup.3a, [0116]
(11)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)CON(R.sup.4a,R.sup.5a),
[0117] (12) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0118] (13) substituted or
unsubstituted aryl, [0119] (14) substituted or unsubstituted
heterocyclyl, and [0120] (15) substituted or unsubstituted
heteroaryl, [0121] wherein: [0122] each R.sup.1a, R.sup.2a,
R.sup.3a, R.sup.4a, and R.sup.5a is independently selected from the
group consisting of: [0123] (a) H, [0124] (b) a halogen atom,
[0125] (c) substituted or unsubstituted C.sub.1-C.sub.6-alkyl,
[0126] (d) substituted or unsubstituted aryl, [0127] (e)
substituted or unsubstituted heterocyclyl, and [0128] (f)
substituted or unsubstituted heteroaryl, [0129] or R.sup.4a and
R.sup.5a together with the N atom to which they are attached can
form a substituted or unsubstituted heterocyclic ring, having from
5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring
are selected from N, O and S;
[0130] Q is absent or selected from the group consisting of: [0131]
(1) --C(.dbd.O)N(R.sub.1,R.sub.2), [0132] (2)
--NHC(.dbd.O)N(R.sub.1,R.sub.2), [0133] (3)
--N(OH)C(.dbd.O)N(R.sub.1,R.sub.2), [0134] (4)
--CH(OH)C(.dbd.O)N(R.sub.1,R.sub.2), [0135] (5) --CH[N(R.sup.2q,
R.sup.3q)]C(.dbd.O)N(R.sub.1,R.sub.2), [0136] (6)
--CHR.sup.1qC(.dbd.O)N(R.sub.1, R.sub.2), [0137] (7) --CO.sub.2H,
[0138] (8) --C(.dbd.O)NHSO.sub.2R.sup.4q, [0139] (9)
--SO.sub.2NH.sub.2, [0140] (10) --N(OH)C(.dbd.O)R.sup.1q, [0141]
(11) --N(OH)SO.sub.2R.sup.4q, [0142] (12) --NHSO.sub.2R.sup.4q,
[0143] (13) --SH, [0144] (14)
--CH(SH)(CH.sub.2).sub.0-1C(.dbd.O)N(R.sub.1,R.sub.2), [0145] (15)
--CH(SH)(CH.sub.2).sub.0-1CO.sub.2H, [0146] (16)
--CH(OH)(CH.sub.2).sub.0-1CO.sub.2H, [0147] (17)
--CH(SH)CH.sub.2CO.sub.2R.sup.1q, [0148] (18)
--CH(OH)(CH.sub.2)SO.sub.2NH.sub.2, [0149] (19)
--CH(CH.sub.2SH)NHCOR.sup.1q, [0150] (20)
--CH(CH.sub.2SH)NHSO.sub.2R.sup.4q, [0151] (21)
--CH(CH.sub.2SR.sup.5q)CO.sub.2H, [0152] (22)
--CH(CH.sub.2SH)NHSO.sub.2NH.sub.2, [0153] (23)
--CH(CH.sub.2OH)CO.sub.2H, [0154] (24)
--CH(CH.sub.2OH)NHSO.sub.2NH.sub.2, [0155] (25)
--C(.dbd.O)CH.sub.2CO.sub.2H, [0156] (26)
--C(.dbd.O)(CH.sub.2).sub.0-1CONH.sub.2, [0157] (27)
--OSO.sub.2NHR.sup.5q, [0158] (28) --SO.sub.2NHNH.sub.2, [0159]
(29) --P(.dbd.O)(OH).sub.2,
[0159] ##STR00007## [0160] and [0161] (33)
--N(OH)C(.dbd.O)CR.sub.1R.sub.2, [0162] wherein: [0163] R.sub.1 is
selected from the group consisting of: [0164] (1) --H, [0165] (2)
--OH, [0166] (3) --OC.sub.1-C.sub.6-alkyl, [0167] (4) --N(R.sup.2q,
R.sup.3q), and [0168] (5) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl; [0169] R.sub.2 is selected from the group
consisting of: [0170] (1) H, [0171] (2) substituted or
unsubstituted C.sub.1-C.sub.6-alkyl; [0172] (3) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, [0173] (4) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, [0174] (5) substituted or
unsubstituted aryl, [0175] (6) substituted or unsubstituted
heterocyclyl, and [0176] (7) substituted or unsubstituted
heteroaryl, [0177] or R.sub.1 and R.sub.2, together with the N atom
to which they are attached can form a substituted or unsubstituted
heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring
atoms of the heterocyclic ring are selected from N, O and S; and
[0178] each R.sup.1q, R.sup.2q, R.sup.3q, R.sup.4q, and R.sup.5q is
independently selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl.
[0179] In a second embodiment, the present invention provides
compounds of formula (I) wherein:
[0180] E is selected from the group consisting of: [0181] (1) H,
[0182] (2) substituted or unsubstituted C.sub.1-C.sub.6-alkyl,
[0183] (3) substituted or unsubstituted C.sub.2-C.sub.6-alkenyl,
[0184] (4) substituted or unsubstituted C.sub.2-C.sub.6-alkynyl,
[0185] (5) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0186] (6) substituted or
unsubstituted aryl, [0187] (7) substituted or unsubstituted
heterocyclyl, and [0188] (8) substituted or unsubstituted
heteroaryl;
[0189] L is absent or selected from the group consisting of: [0190]
(1) substituted or unsubstituted C.sub.1-C.sub.6-alkyl, [0191] (2)
--(NR.sup.3L).sub.0-1--(CH.sub.2).sub.0-4--NR.sup.3L--(CH.sub.2).sub.0-4--
-, [0192] (3)
--(NR.sup.3L).sub.0-1--C(R.sup.1L,R.sup.2L)--NR.sup.3L--C(R.sup.1L,R.sup.-
2L)--, [0193] (4)
--C(R.sup.1L,R.sup.2L)--O--C(R.sup.1L,R.sup.2L)--, [0194] (5)
--(CH.sub.2).sub.0-4--NR.sup.3L--C(R.sup.1L,R.sup.2L)--CONH--(CH.sub.2).s-
ub.0-4--, [0195] (6) --CO--C(R.sup.1L,R.sup.2L)--NHCO--, [0196] (7)
--CONR.sup.3L--, [0197] (8) --NR.sup.3LCO--, [0198] (9)
--NR.sup.3L--, [0199] (10) --SO.sub.2NR.sup.3L--, [0200] (11)
--NR.sup.3L--C(.dbd.O)--NR.sup.3L--, [0201] (12) substituted or
unsubstituted C.sub.3-C.sub.10-cycloalkyl, [0202] (13) substituted
or unsubstituted aryl, [0203] (14) substituted or unsubstituted
heterocyclyl, and [0204] (15) substituted or unsubstituted
heteroaryl, [0205] wherein: [0206] each R.sup.1L, R.sup.2L, and
R.sup.3L is independently selected from the group consisting of:
[0207] (a) H, [0208] (b) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, [0209] (c) C.sub.1-C.sub.6-alkyl substituted
with aryl, [0210] (d) C.sub.1-C.sub.6-alkyl substituted with
heterocyclyl, and [0211] (e) C.sub.1-C.sub.6-alkyl substituted with
heteroaryl, [0212] or R.sup.1L and R.sup.3L, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S;
[0213] D is absent or selected from the group consisting of: [0214]
(1) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl,
[0215] (2) substituted or unsubstituted aryl, [0216] (3)
substituted or unsubstituted heterocyclyl, and [0217] (4)
substituted or unsubstituted heteroaryl;
[0218] G is selected from the group consisting of: [0219] (1)
--(CH.sub.2).sub.0-4--O--(CH.sub.2).sub.0-4--, [0220] (2)
--(CH.sub.2).sub.0-4--S--(CH.sub.2).sub.0-4--, [0221] (3)
--(CH.sub.2).sub.0-4--NR.sup.1G--(CH.sub.2).sub.0-4--, [0222] (4)
--C(.dbd.O)--, [0223] (5) --NR.sup.1GC(.dbd.O)--, [0224] (6)
--C(.dbd.O)NR.sup.1G--, [0225] (7)
--(CH.sub.2).sub.0-4NHCH.sub.2C(.dbd.O)NR.sup.1G--, [0226] (8)
--C.ident.C--, [0227] (9) --C.ident.C--C.ident.C--, [0228] (10)
--CR.sup.2G.dbd.CR.sup.2G--, [0229] (11) --S(.dbd.O)--, [0230] (12)
--SO.sub.2--, [0231] (13) --C(R.sup.3G).sub.2--S(.dbd.O)--, [0232]
(14) --S(.dbd.O)--C(R.sup.3G).sub.2--, [0233] (15)
--C(R.sup.3G).sub.2--SO.sub.2--, [0234] (16)
--SO.sub.2--C(R.sup.3G).sub.2--, [0235] (17)
--CR.sup.3G.dbd.CR.sup.3G--CR.sup.3G.dbd.CR.sup.3G--, [0236] (18)
--C(R.sup.3G).sub.2--, [0237] (19)
--CR.sup.3G.dbd.CR.sup.3G--C.ident.C--, [0238] (20)
--C.ident.C--CR.sup.3G.dbd.CR.sup.3G--, [0239] (21)
--C(.dbd.O)--C.ident.C--, [0240] (22) --C.ident.C--C(.dbd.O)--,
[0241] (23) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0242] (24) substituted or
unsubstituted aryl, [0243] (25) substituted or unsubstituted
heterocyclyl, and [0244] (26) substituted or unsubstituted
heteroaryl, [0245] wherein: [0246] R.sup.1G is substituted or
unsubstituted C.sub.1-C.sub.6-alkyl; [0247] each R.sup.2G and
R.sup.3G is independently selected from the group consisting of H,
a halogen atom, and substituted or unsubstituted
C.sub.1-C.sub.6-alkyl;
[0248] Y is absent or selected from the group consisting of: [0249]
(1) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl,
[0250] (2) substituted or unsubstituted aryl, [0251] (3)
substituted or unsubstituted heterocyclyl, and [0252] (4)
substituted or unsubstituted heteroaryl;
[0253] X is selected from the group consisting of: [0254] (1)
--(C.dbd.O)NR.sub.4--, [0255] (2)
--C.sub.1-C.sub.6-alkyl-(C.dbd.O)NR.sub.4--, [0256] (3)
--C.sub.2-C.sub.6-alkenyl-(C.dbd.O)NR.sub.4--, [0257] (4)
--C.sub.2-C.sub.6-alkynyl-(C.dbd.O)NR.sub.4--, [0258] (5)
--CH.sub.2NR.sub.4--, [0259] (6) --SO.sub.2NR.sub.4--, [0260] (7)
--S(.dbd.O)NR.sub.4--, [0261] (8) --NR.sub.4C(.dbd.O)--, and [0262]
(9) --NR.sub.4--, [0263] or X and A, together with the atoms to
which they are attached can form a heterocyclic ring, having from 5
to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring
are selected from N, O and S, [0264] or when Y is a bicyclic
substituted or unsubstituted heterocyclyl or heteroaryl, then X is
absent;
[0265] R.sub.3 is H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or R.sub.3 and A, together with the atom to
which they are attached can form a substituted or unsubstituted
3-10 membered cycloalkyl or a heterocyclic ring, having from 3 to
10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring are
selected from N, O and S;
[0266] R.sub.4 is (1) H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or (2) R.sub.4 and A, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S, or (3) R.sub.4 and Y, together with the atoms to which
they are attached, form a bicyclic substituted or unsubstituted
heterocyclyl or heteroaryl;
[0267] n is an integer from 0-6;
[0268] A is selected from the group consisting of: [0269] (1)
--C(R.sup.1a,R.sup.2a)OR.sup.3a, [0270] (2)
--C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a), [0271] (3) substituted
or unsubstituted C.sub.3-C.sub.10-cycloalkyl, [0272] (4)
substituted or unsubstituted aryl, [0273] (5) substituted or
unsubstituted heterocyclyl, and [0274] (6) substituted or
unsubstituted heteroaryl, [0275] wherein: [0276] each R.sup.1a and
R.sup.2a is independently selected from the group consisting of
substituted or unsubstituted C.sub.1-C.sub.6-alkyl; [0277] each
R.sup.1a, R.sup.4a, and R.sup.5a is independently selected from the
group consisting of: [0278] (a) H, [0279] (b) a halogen atom,
[0280] (c) substituted or unsubstituted C.sub.1-C.sub.6-alkyl,
[0281] (d) substituted or unsubstituted aryl, [0282] (e)
substituted or unsubstituted heterocyclyl, and [0283] (f)
substituted or unsubstituted heteroaryl, [0284] or R.sup.4a and
R.sup.Sa together with the N atom to which they are attached can
form a substituted or unsubstituted heterocyclic ring, having from
5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring
are selected from N, O and S; and [0285] when A is
--C(R.sup.1a,R.sup.2a)OR.sup.3a, the compound is not
2-{[(4'-ethyl-1,1'-biphenyl-4-yl)carbonyl]amino}-3-hydroxy-3-methylbutano-
ic acid, 4'-ethyl-N-{2-hydroxy-1-[(hydroxyamino)
carbonyl]-2-methylpropyl}-1,1'-biphenyl-4-carboxamide or
N-{2-hydroxy-1-[(hydroxyamino)carbonyl]-2-methylpropyl}-4-(phenylethynyl)-
benzamide;
[0286] Q is absent or selected from the group consisting of: [0287]
(1) --C(.dbd.O)N(R.sub.1,R.sub.2), [0288] (2)
--NHC(.dbd.O)N(R.sub.1,R.sub.2), [0289] (3)
--N(OH)C(.dbd.O)N(R.sub.1,R.sub.2), [0290] (4)
--CH(OH)C(.dbd.O)N(R.sub.1,R.sub.2), [0291] (5) --CH[N(R.sup.2q,
R.sup.3q)]C(.dbd.O)N(R.sub.1,R.sub.2), [0292] (6)
--CHR.sup.1qC(.dbd.O)N(R.sub.1, R.sub.2), [0293] (7) --CO.sub.2H,
[0294] (8) --C(.dbd.O)NHSO.sub.2R.sup.4q, [0295] (9)
--SO.sub.2NH.sub.2, [0296] (10) --N(OH)C(.dbd.O)R.sup.1q, [0297]
(11) --N(OH)SO.sub.2R.sup.4q, [0298] (12) --NHSO.sub.2R.sup.4q,
[0299] (13) --SH, [0300] (14)
--CH(SH)(CH.sub.2).sub.0-1C(.dbd.O)N(R.sub.1,R.sub.2), [0301] (15)
--CH(SH)(CH.sub.2).sub.0-1CO.sub.2H, [0302] (16)
--CH(OH)(CH.sub.2).sub.0-1CO.sub.2H, [0303] (17)
--CH(SH)CH.sub.2CO.sub.2R.sup.1q, [0304] (18)
--CH(OH)(CH.sub.2)SO.sub.2NH.sub.2, [0305] (19)
--CH(CH.sub.2SH)NHCOR.sup.1q, [0306] (20)
--CH(CH.sub.2SH)NHSO.sub.2R.sup.4q, [0307] (21)
--CH(CH.sub.2SR.sup.5q)CO.sub.2H, [0308] (22)
--CH(CH.sub.2SH)NHSO.sub.2NH.sub.2, [0309] (23)
--CH(CH.sub.2OH)CO.sub.2H, [0310] (24)
--CH(CH.sub.2OH)NHSO.sub.2NH.sub.2, [0311] (25)
--C(.dbd.O)CH.sub.2CO.sub.2H, [0312] (26)
--C(.dbd.O)(CH.sub.2).sub.0-1CONH.sub.2, [0313] (27)
--OSO.sub.2NHR.sup.5q, [0314] (28) --SO.sub.2NHNH.sub.2, [0315]
(29) --P(.dbd.O)(OH).sub.2,
[0315] ##STR00008## [0316] and [0317] (33)
--N(OH)C(.dbd.O)CR.sub.1R.sub.2, [0318] wherein: [0319] R.sub.1 is
selected from the group consisting of: [0320] (1) --H, [0321] (2)
--OH, [0322] (3) --OC.sub.1-C.sub.6-alkyl, [0323] (4) --N(R.sup.2q,
R.sup.3q), and [0324] (5) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl; [0325] R.sub.2 is selected from the group
consisting of: [0326] (1) H, [0327] (2) substituted or
unsubstituted C.sub.1-C.sub.6-alkyl, [0328] (3) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, [0329] (4) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, [0330] (5) substituted or
unsubstituted aryl, [0331] (6) substituted or unsubstituted
heterocyclyl, and [0332] (7) substituted or unsubstituted
heteroaryl, [0333] or R.sub.1 and R.sub.2, together with the N atom
to which they are attached can form a substituted or unsubstituted
heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring
atoms of the heterocyclic ring are selected from N, O and S; and
[0334] each R.sup.1q, R.sup.2q, R.sup.3q, R.sup.4q, and R.sup.5q is
independently selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl.
[0335] In another aspect, the present invention provides a
pharmaceutical composition comprising a compound of formula (I) and
a pharmaceutically acceptable carrier or diluent.
[0336] In another aspect, the present invention provides a
pharmaceutical composition or formulation comprising an effective
amount of a compound of formula (I) and a pharmaceutically
acceptable carrier or diluent.
[0337] In another aspect, the present invention provides a method
of inhibiting a deacetylase enzyme in gram-negative bacteria,
thereby affecting bacterial growth, comprising administering to a
patient in need of such inhibition a compound of formula (I).
[0338] In another aspect, the present invention provides a method
of inhibiting LpxC, thereby modulating the virulence of a bacterial
infection, comprising administering to a patient in need of such
inhibition a compound of formula (I).
[0339] In another aspect, the present invention provides a method
for treating a subject with a gram-negative bacterial infection
comprising administering to the subject in need thereof an
antibacterially effective amount of a compound of formula (I) with
a pharmaceutically acceptable carrier. In a more specific
embodiment of the method of treatment, the subject is a mammal and
in certain embodiments, a human.
[0340] In another aspect, the present invention provides a method
of administering an inhibitory amount of a compound of formula (I)
to a subject infected with a fermentative or non-fermentative
gram-negative bacteria. In a more specific embodiment of the method
of administering an inhibitory amount of a compound of formula (I)
to a subject infected with a fermentative or non-fermentative
gram-negative bacteria, the gram-negative bacteria are selected
from the group consisting of Pseudomonas aeruginosa,
Stenotrophomonas maltophila, Burkholderia cepacia, Alcaligenes
xylosoxidans, Acinetobacter, Enterobacteriaceae, Haemophilus,
Franciscellaceae (Franciscella tularensis) and Neisseria
species.
[0341] In another aspect, the present invention provides a method
of administering an inhibitory amount of a compound of formula (I)
to a subject infected with gram-negative bacteria, such as a member
of the Enterobacteriaceae which is selected from the group
consisting of organisms such as Serratia, Proteus, Klebsiella,
Enterobacter, Citrobacter, Salmonella, Providencia, Yersinia
(Yersinia pestis), Morganella, Cedecea, and Edwardsiella species
and Escherichia coli.
[0342] In another aspect, the present invention provides a method
of co-administering a compound of formula (I) with other
therapeutic agents that are selected for their particular
usefulness against the condition that is being treated. For
example, a compound of formula (I) is useful in combination with
other anti-bacterial agents. The compound of formula (I) augments
the sensitivity of gram-negative bacteria to existing classes of
antibacterials. Combinations of the presently disclosed compounds
with other anti-bacterial agents are within the scope of the
invention. Such anti-bacterial agents include, but are not limited
to, erythromycin, rifampicin, Nalidixic acid, carbenicillin,
bacitracin, cycloserine, fosfomycin, and vancomycin.
[0343] These and other aspects of the invention will be evident
upon reference to the following detailed description.
DETAILED DESCRIPTION OF THE INVENTION
[0344] Unless the context requires otherwise, throughout the
specification and claims which follow, the word "comprise" and
variations thereof, such as, "comprises" and "comprising" are to be
construed in an open, inclusive sense, that is as "including, but
not limited to".
[0345] Reference throughout this specification to "one embodiment"
or "an embodiment" means that a particular feature, structure or
characteristic described in connection with the embodiment is
included in at least one embodiment of the present invention. Thus,
the appearances of the phrases "in one embodiment" or "in an
embodiment" in various places throughout this specification are not
necessarily all referring to the same embodiment. Furthermore, the
particular features, structures, or characteristics may be combined
in any suitable manner in one or more embodiments.
[0346] The present invention provides novel compounds, methods for
inhibiting LpxC in gram-negative bacteria, and novel methods for
treating bacterial infections. The compounds provided herein can be
formulated into pharmaceutical formulations and medicaments that
are useful in the methods of the invention. The invention also
provides for the use of the compounds in preparing medicaments and
pharmaceutical formulations, for use of the compounds in inhibiting
LpxC, and for use of the compounds in treating bacterial infections
in a subject.
[0347] The following abbreviations and definitions are used
throughout this application:
[0348] "LpxC" is an abbreviation that stands for
UDP-3-O--(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase.
[0349] Generally, reference to a certain element such as hydrogen
or H is meant to include all isotopes of that element. For example,
if a substituent group is defined to include hydrogen or H, it also
includes deuterium and tritium.
[0350] "Alkyl" refers to a straight or branched, saturated
hydrocarbon chain radical consisting solely of carbon and hydrogen
atoms, and having from one to twelve carbon atoms, preferably one
to eight carbon atoms (C.sub.1-C.sub.8-alkyl) or one to six carbon
atoms (C.sub.1-C.sub.6-alkyl). Thus the phrase includes straight
chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl,
hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like.
The phrase also includes branched chain isomers of straight chain
alkyl groups, including but not limited to, the following, that are
provided by way of example: --CH(CH.sub.3).sub.2,
--CH(CH.sub.3)(CH.sub.2CH.sub.3), --CH(CH.sub.2CH.sub.3).sub.2,
--C(CH.sub.3).sub.3, --C(CH.sub.2CH.sub.3).sub.3,
--CH.sub.2CH(CH.sub.3).sub.2,
--CH.sub.2CH(CH.sub.3)(CH.sub.2CH.sub.3),
--CH.sub.2CH(CH.sub.2CH.sub.3).sub.2, --CH.sub.2C(CH.sub.3).sub.3,
--CH.sub.2C(CH.sub.2CH.sub.3).sub.3,
--CH(CH.sub.3)CH(CH.sub.3)(CH.sub.2CH.sub.3),
--CH.sub.2CH.sub.2CH(CH.sub.3).sub.2,
--CH.sub.2CH.sub.2CH(CH.sub.3)(CH.sub.2CH.sub.3),
--CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3).sub.2,
--CH.sub.2CH.sub.2C(CH.sub.3).sub.3,
--CH.sub.2CH.sub.2C(CH.sub.2CH.sub.3).sub.3,
--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2,
--CH(CH.sub.3)CH(CH.sub.3)CH(CH.sub.3).sub.2,
--CH(CH.sub.2CH.sub.3)CH(CH.sub.3)CH(CH.sub.3)(CH.sub.2CH.sub.3)
and the like.
[0351] "Alkenyl" refers to a straight or branched, unsaturated
hydrocarbon chain radical containing at least one double bond,
consisting solely of carbon and hydrogen atoms and having from two
to twelve carbon atoms, preferably two to eight carbon atoms
(C.sub.2-C.sub.8-alkenyl) or two to six carbon atoms
(C.sub.2-C.sub.6-alkenyl). Representative alkenyl radicals include,
but are not limited to, vinyl, --CH.dbd.CH(CH.sub.3),
--CH.dbd.C(CH.sub.3).sub.2, --C(CH.sub.3).dbd.CH.sub.2,
--C(CH.sub.3).dbd.CH(CH.sub.3), --C(CH.sub.2CH.sub.3).dbd.CH.sub.2,
cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl,
pentadienyl, hexadienyl and the like.
[0352] "Alkynyl" refers to a straight or branched, unsaturated
hydrocarbon chain radical containing at least one triple bond, and,
optionally, at least one double bond, consisting solely of carbon
and hydrogen atoms and having from two to twelve carbon atoms,
preferably two to eight carbon atoms (C.sub.2-C.sub.8-alkynyl) or
two to six carbon atoms (C.sub.2-C.sub.6-alkynyl). Representative
alkynyl radicals include, but are not limited to --C.ident.CH,
--C.ident.C(CH.sub.3), --C.ident.C(CH.sub.2CH.sub.3),
--CH.sub.2C.ident.CH, --CH.sub.2C.ident.C(CH.sub.3),
--CH.sub.2C.ident.C(CH.sub.2CH.sub.3) and the like.
[0353] "Alkoxy" refers to a radical of the formula --OR.sub.a where
R.sub.a is an alkyl, alkenyl or alkynyl radical as defined above
containing one to twelve carbon atoms. Unless stated otherwise
specifically in the specification, an alkoxy group may be
optionally substituted.
[0354] "Alkylamino" refers to a radical of the formula --NHR.sub.a
or --NR.sub.aR.sub.a where each R.sub.a is, independently, an
alkyl, alkenyl or alkynyl radical as defined above containing one
to twelve carbon atoms. Unless stated otherwise specifically in the
specification, an alkylamino group may be optionally
substituted.
[0355] "Thioalkyl" refers to a radical of the formula --SR.sub.a
where R.sub.a is an alkyl, alkenyl or alkynyl radical as defined
above containing one to twelve carbon atoms. Unless stated
otherwise specifically in the specification, a thioalkyl group may
be optionally substituted.
[0356] "Aryl" refers to aromatic monocyclic or multicyclic
hydrocarbon ring systems consisting only of hydrogen and carbon
atoms and containing from 6 to 19 carbon atoms, where the ring
system may be partially or fully saturated, e.g., phenyl, biphenyl,
anthracenyl, naphthyl, and the like.
[0357] "Cycloalkyl" refers to a non-aromatic monocyclic or
polycyclic hydrocarbon radical consisting solely of carbon and
hydrogen atoms, which may include fused or bridged ring systems,
having from three to fifteen carbon atoms, preferably having from
three to ten carbon atoms (C.sub.3-C.sub.10-cycloalkyl), and which
is saturated or unsaturated. Monocyclic radicals include, for
example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptly, cyclooctyl, and the like. Polycyclic radicals include,
for example, adamantine, norbornane, decalinyl,
7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
[0358] "Heteroaryl" or "heteroaryl ring" refers to a 5- to
18-membered aromatic ring radical which consists of three to
seventeen carbon atoms and from one to ten heteroatoms selected
from the group consisting of nitrogen, oxygen and sulfur. For
purposes of this invention, the heteroaryl radical may be a
monocyclic, bicyclic or polycyclic ring system, which may include
fused or bridged ring systems; the nitrogen, carbon or sulfur atoms
in the heteroaryl radical may be optionally oxidized; and the
nitrogen atom may be optionally quaternized. Heteroaryl radicals
include, for example, azepinyl, acridinyl, benzimidazolyl,
benzthiazolyl, be nzindolyl, benzodioxolyl, benzofuranyl,
benzooxazolyl, benzothiazolyl, benzothiadiazolyl,
benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl,
benzoxazolyl, benzo-1,3-dioxolyl, benzodioxinyl, benzopyranyl,
benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl
(benzothiophenyl), benzotriazolyl,
benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl,
dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl,
isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl,
isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl,
isoxazolyl, naphthyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl,
oxazolyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl,
phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl,
pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl,
pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl,
tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl,
tetrazolyl, triazinyl, thiophenyl (i.e., thienyl), and the
like.
[0359] "Heterocyclic ring" includes both "heterocyclyl" and
"heteroaryl" groups.
[0360] "Heterocyclyl" refers to a 3- to 18-membered non-aromatic
ring radical which consists of two to seventeen carbon atoms and
from one to ten heteroatoms selected from the group consisting of
nitrogen, oxygen and sulfur. Unless stated otherwise specifically
in the specification, the heterocyclyl radical may be a monocyclic,
bicyclic or polycyclic ring system, which may include fused or
bridged ring systems; and the nitrogen, carbon or sulfur atoms in
the heterocyclyl radical may be optionally oxidized; the nitrogen
atom may be optionally quaternized; and the heterocyclyl radical
may be partially or fully saturated. Heterocyclyl radicals include,
for example, dioxolanyl, thienyl[1,3]dithianyl,
decahydroisoquinolyl, imidazolinyl, imidazolidinyl,
isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl,
octahydroisoindolyl, oxiranyl, 2-oxopiperazinyl, 2-oxopiperidinyl,
2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl,
4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl,
thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl,
thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl,
1,1-dioxo-thiomorpholinyl, and the like.
[0361] Representative heteroaryl and heterocyclyl radicals include,
but are not limited to: unsaturated 3 to 8 membered rings
containing 1 to 4 nitrogen atoms such as, but not limited to
pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl,
dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g.
4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl etc.),
tetrazolyl, (e.g. 1H-tetrazolyl, 2H tetrazolyl, etc.); saturated 3
to 8 membered rings containing 1 to 4 nitrogen atoms such as, but
not limited to, pyrrolidinyl, imidazolidinyl, piperidinyl,
piperazinyl; condensed unsaturated heterocyclic groups containing 1
to 4 nitrogen atoms such as, but not limited to, indolyl,
isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl,
isoquinolyl, indazolyl, benzotriazolyl; unsaturated 3 to 8 membered
rings containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms such
as, but not limited to, oxazolyl, isoxazolyl, oxadiazolyl (e.g.
1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.);
saturated 3 to 8 membered rings containing 1 to 2 oxygen atoms and
1 to 3 nitrogen atoms such as, but not limited to, morpholinyl;
unsaturated condensed heterocyclic groups containing 1 to 2 oxygen
atoms and 1 to 3 nitrogen atoms, for example, benzoxazolyl,
benzoxadiazolyl, benzoxazinyl (e.g. 2H-1,4-benzoxazinyl etc.);
unsaturated 3 to 8 membered rings containing 1 to 3 sulfur atoms
and 1 to 3 nitrogen atoms such as, but not limited to, thiazolyl,
isothiazolyl, thiadiazolyl (e.g. 1,2,3-thiadiazolyl,
1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.);
saturated 3 to 8 membered rings containing 1 to 2 sulfur atoms and
1 to 3 nitrogen atoms such as, but not limited to, thiazolodinyl;
saturated and unsaturated 3 to 8 membered rings containing 1 to 2
sulfur atoms such as, but not limited to, thienyl,
dihydrodithiinyl, dihydrodithionyl, tetrahydrothiophene,
tetrahydrothiopyran; unsaturated condensed heterocyclic rings
containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms such as,
but not limited to, benzothiazolyl, benzothiadiazolyl,
benzothiazinyl (e.g. 2H-1,4-benzothiazinyl, etc.),
dihydrobenzothiazinyl (e.g. 2H-3,4-dihydrobenzothiazinyl, etc.),
unsaturated 3 to 8 membered rings containing oxygen atoms such as,
but not limited to furyl; unsaturated condensed heterocyclic rings
containing 1 to 2 oxygen atoms such as benzodioxolyl (e.g.
1,3-benzodioxoyl, etc.); unsaturated 3 to 8 membered rings
containing an oxygen atom and 1 to 2 sulfur atoms such as, but not
limited to, dihydrooxathiinyl; saturated 3 to 8 membered rings
containing 1 to 2 oxygen atoms and 1 to 2 sulfur atoms such as
1,4-oxathiane; unsaturated condensed rings containing 1 to 2 sulfur
atoms such as benzothienyl, benzodithiinyl; and unsaturated
condensed heterocyclic rings containing an oxygen atom and 1 to 2
oxygen atoms such as benzoxathiinyl. Heterocyclyl group also
include those described above in which one or more S atoms in the
ring is double-bonded to one or two oxygen atoms (sulfoxides and
sulfones). For example, heterocyclyl groups include
tetrahydrothiophene, tetrahydrothiophene oxide, and
tetrahydrothiophene 1,1-dioxide. Preferred heterocyclyl groups
contain 5 or 6 ring members. More preferred heterocyclyl groups
include morpholine, piperazine, piperidine, pyrrolidine, imidazole,
pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole,
thiomorpholine, thiomorpholine in which the S atom of the
thiomorpholine is bonded to one or more 0 atoms, pyrrole,
homopiperazine, oxazolidin-2-one, pyrrolidin-2-one, oxazole,
quinuclidine, thiazole, isoxazole, furan, and tetrahydrofuran.
[0362] The term "substituted" used herein means any of the above
groups (i.e., alkyl, alkenyl, alkynyl, alkylamino, alkoxy,
alkylthio, aryl, cycloalkyl, heteroaryl and/or heterocyclyl)
wherein at least one hydrogen atom is replaced by a bond to a
non-hydrogen atoms such as, but not limited to: a halogen atom such
as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl
groups, alkoxy groups, and ester groups; a sulfur atom in groups
such as thiol groups, alkyl and aryl sulfide groups, sulfone
groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in
groups such as amines, amides, alkylamines, dialkylamines,
arylamines, alkylarylamines, diarylamines, N-oxides, imides, and
enamines; a silicon atom in groups such as trialkylsilyl groups,
dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl
groups; and other heteroatoms in various other groups.
"Substituted" also means any of the above groups in which one or
more bonds are replaced by a higher-order bond (e.g., a double- or
triple-bond) to a heteroatom such as oxygen in oxo, carbonyl,
carboxyl, and ester groups; and nitrogen in groups such as imines,
oximes, hydrazones, and nitriles. "Substituted" further means any
of the above groups in which one or more bonds are replaced by a
bond to an alkyl, alkenyl, alkynyl, amino, aryl, cyano, cycloalkyl,
halogen, heteroaryl, heterocyclyl, hydroxyl, imino, nitro, oxo or
thioxo group. For example, "substituted" includes any of the above
groups in which one or more hydrogen atoms are replaced with
--NR.sub.gR.sub.h, --NR.sub.gC(.dbd.O)R.sub.h,
--NR.sub.gC(.dbd.O)NR.sub.gR.sub.h, --NR.sub.gC(.dbd.O)OR.sub.h,
--NR.sub.gSO.sub.2R.sub.h, --OC(.dbd.O)NR.sub.gR.sub.h, --OR.sub.g,
--SR.sub.g, --SOR.sub.g, --SO.sub.2R.sub.g, --OSO.sub.2R.sub.g,
--SO.sub.2OR.sub.g, .dbd.NSO.sub.2R.sub.g, and
--SO.sub.2NR.sub.gR.sub.h. "Substituted" also means any of the
above groups in which one or more hydrogen atoms are replaced with
--C(.dbd.O)R.sub.g, --C(.dbd.O)OR.sub.g,
--C(.dbd.O)NR.sub.gR.sub.h, --CH.sub.2SO.sub.2R.sub.g,
--CH.sub.2SO.sub.2NR.sub.gR.sub.h. In the foregoing, R.sub.g and
R.sub.h are the same or different and independently hydrogen,
alkyl, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, aryl,
cycloalkyl, heterocyclyl and/or heteroaryl. In addition, the
foregoing substituents may also be optionally substituted with one
or more of the above substituents.
[0363] For example, representative substituted alkyl groups include
trifluoromethyl. Representative heteroaryl and heterocyclyl groups
include 2-methylbenzimidazolyl, 5-methylbenzimidazolyl,
5-chlorobenzthiazolyl, 1-methylpiperazinyl, and 2-chloropyridyl.
Representative substituted aryl groups include tolyl and
hydroxyphenyl. Other representative substitutents include straight
and branched chain alkyl groups, --CH.sub.3, --C.sub.2H.sub.5,
--CH.sub.2OH, --OH, --OCH.sub.3, --OC.sub.2H.sub.5, --OCF.sub.3,
--CN, --NO.sub.2, --CO.sub.2H, --CO.sub.2CH.sub.3, --CONH.sub.2,
--NH.sub.2, --F, --Cl, --Br, --CF.sub.3, --N(CH.sub.3).sub.2,
--NHSO.sub.2CH.sub.3, and --NHCOCH.sub.3.
[0364] "Amino" refers to the --NH.sub.2 radical.
[0365] "Cyano" refers to the --CN radical.
[0366] "Halogen" refers to bromo, chloro, fluoro or iodo.
[0367] "Hydroxyl" refers to the --OH radical.
[0368] "Imino" refers to the .dbd.NH substituent.
[0369] "Nitro" refers to the --NO.sub.2 radical.
[0370] "Oxo" refers to the .dbd.O substituent.
[0371] "Thioxo" refers to the .dbd.S substituent.
[0372] "Fused" refers to any ring structure described herein which
is fused to an existing ring structure in the compounds of the
present invention. When the fused ring is a heterocyclyl ring or a
heteroaryl ring, any carbon atom on the existing ring structure
which becomes part of the fused heterocyclyl ring or the fused
heteroaryl ring may be replaced with a nitrogen atom.
[0373] The term "protected" with respect to hydroxyl groups, amine
groups, and sulfhydryl groups refers to forms of these
functionalities that are protected from undesirable reaction with a
protecting group known to those skilled in the art such as those
set forth in Protective Groups in Organic Synthesis, Greene, T. W.;
Wuts, P. G. M., John Wiley & Sons, New York, N.Y., (3rd
Edition, 1999) that can be added or removed using the procedures
set forth therein. Examples of protected hydroxyl groups include,
but are not limited to, silyl ethers such as those obtained by
reaction of a hydroxyl group with a reagent such as, but not
limited to, t-butyldimethyl-chlorosilane, trimethylchlorosilane,
triisopropylchlorosilane, triethylchlorosilane; substituted methyl
and ethyl ethers such as, but not limited to methoxymethyl ether,
methythiomethyl ether, benzyloxymethyl ether, t-butoxymethyl ether,
2-methoxyethoxymethyl ether, tetrahydropyranyl ethers,
1-ethoxyethyl ether, allyl ether, benzyl ether; esters such as, but
not limited to, benzoylformate, formate, acetate, trichloroacetate,
and trifluoracetate. Examples of protected amine groups include,
but are not limited to, amides such as, formamide, acetamide,
trifluoroacetamide, and benzamide; imides, such as phthalimide, and
dithiosuccinimide; and others. Examples of protected sulfhydryl
groups include, but are not limited to, thioethers such as S-benzyl
thioether, and S-4-picolyl thioether; substituted S-methyl
derivatives such as hemithio, dithio and aminothio acetals; and
others.
[0374] The term "pharmaceutically acceptable salt" includes a salt
with an inorganic base, organic base, inorganic acid, organic acid,
or basic or acidic amino acid. As salts of inorganic bases, the
invention includes, for example, alkali metals such as sodium or
potassium; alkaline earth metals such as calcium and magnesium or
aluminum; and ammonia. As salts of organic bases, the invention
includes, for example, trimethylamine, triethylamine, pyridine,
picoline, ethanolamine, diethanolamine, and triethanolamine. As
salts of inorganic acids, the instant invention includes, for
example, hydrochloric acid, hydroboric acid, nitric acid, sulfuric
acid, and phosphoric acid. As salts of organic acids, the instant
invention includes, for example, formic acid, acetic acid,
trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid,
maleic acid, citric acid, succinic acid, malic acid,
methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic
acid. As salts of basic amino acids, the instant invention
includes, for example, arginine, lysine and ornithine. Acidic amino
acids include, for example, aspartic acid and glutamic acid.
[0375] The term "pharmaceutically acceptable ester" refers to
esters that hydrolyze in vivo and include those that break down
readily in the human body to leave the parent compound or a salt
thereof. Suitable ester groups include, for example, those derived
from pharmaceutically acceptable aliphatic carboxylic acids,
particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic
acids, in which each alkyl or alkenyl moiety advantageously has not
more than 6 carbon atoms. Representative examples of particular
esters include, but are not limited to, formates, acetates,
propionates, butyrates, acrylates and ethylsuccinates.
[0376] The term "pharmaceutically acceptable prodrug" as used
herein refers to those prodrugs of the compounds of the present
invention that are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of humans and lower
animals without undue toxicity, irritation, allergic response, and
the like, commensurate with a reasonable benefit/risk ratio, and
effective for their intended use, as well as the zwitterionic
forms, where possible, of the compounds of the invention. The term
"prodrug" refers to compounds that are rapidly transformed in vivo
to yield the parent compound of the above formula, for example by
hydrolysis in blood. A thorough discussion is provided in T.
Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14
of the A.C.S. Symposium Series, and in Edward B. Roche, ed.,
Bioreversible Carriers in Drug Design, American Pharmaceutical
Association and Pergamon Press, 1987, both of which are
incorporated herein by reference.
[0377] The term "antibacterial agent" refers to agents synthesized
or modified in the laboratory that have either bactericidal or
bacteriostatic activity. An "active" agent in this context will
inhibit the growth of P. aeruginosa and other gram-negative
bacteria. The term "inhibiting the growth" indicates that the rate
of increase in the numbers of a population of a particular
bacterium is reduced. Thus, the term includes situations in which
the bacterial population increases but at a reduced rate, as well
as situations where the growth of the population is stopped, as
well as situations where the numbers of the bacteria in the
population are reduced or the population even eliminated. If an
enzyme activity assay is used to screen for inhibitors, one can
make modifications in uptake/efflux, solubility, half-life, etc. to
compounds in order to correlate enzyme inhibition with growth
inhibition. The activity of antibacterial agents is not necessarily
limited to bacteria but may also encompass activity against
parasites, virus, and fungi.
[0378] The subject invention also includes isotopically-labeled
LpxC inhibitors, that are structurally identical to those disclosed
herein, but for the fact that one or more atoms are replaced by an
atom having an atomic mass or mass number different from the atomic
mass or mass number usually found in nature. Examples of isotopes
that can be incorporated into compounds of the invention include
isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous,
sulfur, fluorine and chlorine, such as .sup.2H, .sup.3H, .sup.13C,
.sup.14C, .sup.15N, .sup.18O, .sup.17O, .sup.31P, .sup.32P,
.sup.35S, .sup.18F and .sup.36Cl, respectively. Compounds of the
present invention, prodrugs thereof, and pharmaceutically
acceptable salts of said compounds and of said prodrugs that
contain the aforementioned isotopes and/or other isotopes of other
atoms are within the scope of this invention. Certain isotopically
labeled compounds of the present invention, for example those into
which radioactive isotopes such as .sup.3H and .sup.14C are
incorporated, are useful in drug and/or substrate tissue
distribution assays. Tritiated, i.e., .sup.3H, and carbon-14, i.e.,
.sup.14C, isotopes are particularly preferred for their ease of
preparation and detectability. Further, substitution with heavier
isotopes such as deuterium, i.e., .sup.2H, may afford certain
therapeutic advantages resulting from greater metabolic stability,
for example increased in vivo half-life or reduced dosage
requirements and, hence, may be preferred in some circumstances.
Isotopically labeled compounds of this invention and prodrugs
thereof can generally be prepared by carrying out known or
referenced procedures and by substituting a readily available
isotopically labeled reagent for a non-isotopically labeled
reagent.
[0379] As noted above, in one aspect, the present invention
provides compounds having the following formula (I):
##STR00009##
including stereoisomers, pharmaceutically acceptable salts, esters,
and prodrugs thereof.
[0380] In a first embodiment, the present invention provides
compounds of formula (I) wherein:
[0381] E is selected from the group consisting of: [0382] (1) H,
[0383] (2) substituted or unsubstituted C.sub.1-C.sub.6-alkyl,
[0384] (3) substituted or unsubstituted C.sub.2-C.sub.6-alkenyl,
[0385] (4) substituted or unsubstituted C.sub.2-C.sub.6-alkynyl,
[0386] (5) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0387] (6) substituted or
unsubstituted aryl, [0388] (7) substituted or unsubstituted
heterocyclyl, and [0389] (8) substituted or unsubstituted
heteroaryl;
[0390] L is absent or selected from the group consisting of: [0391]
(1) substituted or unsubstituted C.sub.1-C.sub.6-alkyl, [0392] (2)
--(NR.sup.3L).sub.0-1--(CH.sub.2).sub.0-4--NR.sup.3L--(CH.sub.2).sub.0-4--
-, [0393] (3)
--(NR.sup.3L).sub.0-1--C(R.sup.1L,R.sup.2L)--NR.sup.3L
C(R.sup.1L,R.sup.2L)--, [0394] (4)
--C(R.sup.1L,R.sup.2L)--O--C(R.sup.1L,R.sup.2L)--, [0395] (5)
--(CH.sub.2).sub.0-4--NR.sup.3L--C(R.sup.1L,R.sup.2L)--CONH--(CH.sub.2).s-
ub.0-4--, [0396] (6) --CO--C(R.sup.1L,R.sup.2L)--NHCO--, [0397] (7)
--CONR.sup.3L--, [0398] (8) --NR.sup.3LCO--, [0399] (9)
--NR.sup.3L--, [0400] (10) --SO.sub.2NR.sup.3L--, [0401] (11)
--NR.sup.3L--C(.dbd.O)--NR.sup.3L--, [0402] (12) substituted or
unsubstituted C.sub.3-C.sub.10-cycloalkyl, [0403] (13) substituted
or unsubstituted aryl, [0404] (14) substituted or unsubstituted
heterocyclyl, and [0405] (15) substituted or unsubstituted
heteroaryl, [0406] wherein: [0407] each R.sup.1L, R.sup.2L, and
R.sup.3L is independently selected from the group consisting of:
[0408] (a) H, [0409] (b) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, [0410] (c) C.sub.1-C.sub.6-alkyl substituted
with aryl, [0411] (d) C.sub.1-C.sub.6-alkyl substituted with
heterocyclyl, and [0412] (e) C.sub.1-C.sub.6-alkyl substituted with
heteroaryl, [0413] or R.sup.1L and R.sup.3L, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S;
[0414] D is absent or selected from the group consisting of: [0415]
(1) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl,
[0416] (2) substituted or unsubstituted aryl, [0417] (3)
substituted or unsubstituted heterocyclyl, and [0418] (4)
substituted or unsubstituted heteroaryl;
[0419] G is selected from the group consisting of: [0420] (1)
--NR.sup.1GC(.dbd.O)--, [0421] (2) --C(.dbd.O)NR.sup.1G--, [0422]
(3) --(CH.sub.2).sub.0-4NHCH.sub.2C(.dbd.O)NR.sup.1G--, [0423] (4)
--CR.sup.2G.dbd.CR.sup.2G--, [0424] (5) --S(.dbd.O)--, [0425] (6)
--SO.sub.2--, [0426] (7) --C(R.sup.3G).sub.2--S(.dbd.O)--, [0427]
(8) --S(.dbd.O)--C(R.sup.3G).sub.2--, [0428] (9)
--C(R.sup.3G).sub.2--SO.sub.2--, [0429] (10)
--SO.sub.2--C(R.sup.3G).sub.2--, [0430] (11)
--CR.sup.3G.dbd.CR.sup.3G--CR.sup.3G.dbd.CR.sup.3G--, [0431] (12)
--C(R.sup.3G).sub.2--, [0432] (13)
--CR.sup.3G.dbd.CR.sup.3G--C.ident.C--, [0433] (14)
--C.ident.C--CR.sup.3G.dbd.CR.sup.3G--, [0434] (15)
--C(.dbd.O)--C.ident.C--, [0435] (16) --C.ident.C--C(.dbd.O)--,
[0436] (17) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0437] (18) substituted or
unsubstituted aryl, [0438] (19) substituted or unsubstituted
heterocyclyl, and [0439] (20) substituted or unsubstituted
heteroaryl, [0440] wherein: [0441] R.sup.1G is substituted or
unsubstituted C.sub.1-C.sub.6-alkyl; [0442] each R.sup.2G is
independently selected from the group consisting of H, a halogen
atom, and substituted or unsubstituted C.sub.1-C.sub.6-alkyl, and
at least one R.sup.2G is not H; and [0443] R.sup.3G is selected
from the group consisting of H, a halogen atom, and substituted or
unsubstituted C.sub.1-C.sub.6-alkyl;
[0444] Y is absent or selected from the group consisting of: [0445]
(1) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl,
[0446] (2) substituted or unsubstituted aryl, [0447] (3)
substituted or unsubstituted heterocyclyl, and [0448] (4)
substituted or unsubstituted heteroaryl;
[0449] X is selected from the group consisting of: [0450] (1)
--(C.dbd.O)NR.sub.4--, [0451] (2)
--C.sub.1-C.sub.6-alkyl-(C.dbd.O)NR.sub.4--, [0452] (3)
--C.sub.2-C.sub.6-alkenyl-(C.dbd.O)NR.sub.4--, [0453] (4)
--C.sub.2-C.sub.6-alkynyl-(C.dbd.O)NR.sub.4--, [0454] (5)
--CH.sub.2NR.sub.4--, [0455] (6) --SO.sub.2NR.sub.4--, [0456] (7)
--S(.dbd.O)NR.sub.4--, [0457] (8) --NR.sub.4C(.dbd.O)--, and [0458]
(9) --NR.sub.4--, [0459] or X and A, together with the atoms to
which they are attached can form a heterocyclic ring, having from 5
to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring
are selected from N, O and S, [0460] or when Y is a bicyclic
substituted or unsubstituted heterocyclyl or heteroaryl, then X is
absent;
[0461] R.sub.3 is H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or R.sub.3 and A, together with the atom to
which they are attached can form a substituted or unsubstituted
3-10 membered cycloalkyl or a heterocyclic ring, having from 3 to
10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring are
selected from N, O and S;
[0462] R.sub.4 is (1) H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or (2) R.sub.4 and A, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S, or (3) R.sub.4 and Y, together with the atoms to which
they are attached, form a bicyclic substituted or unsubstituted
heterocyclyl or heteroaryl;
[0463] n is an integer from 0-6;
[0464] A is selected from the group consisting of: [0465] (1) H,
[0466] (2)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)(CH.sub.2).sub.0-4OR.sup.3a,
[0467] (3)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a),
[0468] (4)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)N(R.sup.4a)COR.sup.3a,
[0469] (5)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)NHCON(R.sup.4a,R.sup.5a),
[0470] (6)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)NHC(.dbd.NH)N(R.sup.4a,R.sup.-
5a), [0471] (7) --CH(R.sup.1a,R.sup.2a), [0472] (8) --C.ident.CH,
[0473] (9) --(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)CN, [0474] (10)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)CO.sub.2R.sup.3a, [0475]
(11)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)CON(R.sup.4a,R.sup.5a),
[0476] (12) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0477] (13) substituted or
unsubstituted aryl, [0478] (14) substituted or unsubstituted
heterocyclyl, and [0479] (15) substituted or unsubstituted
heteroaryl, [0480] wherein: [0481] each R.sup.1a, R.sup.2a,
R.sup.3a, R.sup.4a, and R.sup.5a is independently selected from the
group consisting of: [0482] (a) H, [0483] (b) a halogen atom,
[0484] (c) substituted or unsubstituted C.sub.1-C.sub.6-alkyl,
[0485] (d) substituted or unsubstituted aryl, [0486] (e)
substituted or unsubstituted heterocyclyl, and [0487] (f)
substituted or unsubstituted heteroaryl, [0488] or R.sup.4a and
R.sup.5a together with the N atom to which they are attached can
form a substituted or unsubstituted heterocyclic ring, having from
5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring
are selected from N, O and S;
[0489] Q is absent or selected from the group consisting of: [0490]
(1) --C(.dbd.O)N(R.sub.1,R.sub.2), [0491] (2)
--NHC(.dbd.O)N(R.sub.1,R.sub.2), [0492] (3)
--N(OH)C(.dbd.O)N(R.sub.1,R.sub.2), [0493] (4)
--CH(OH)C(.dbd.O)N(R.sub.1,R.sub.2), [0494] (5) --CH[N(R.sup.2q,
R.sup.3q)]C(.dbd.O)N(R.sub.1,R.sub.2), [0495] (6)
--CHR.sup.19C(.dbd.O)N(R.sub.1, R.sub.2), [0496] (7) --CO.sub.2H,
[0497] (8) --C(.dbd.O)NHSO.sub.2R.sup.4q, [0498] (9)
--SO.sub.2NH.sub.2, [0499] (10) --N(OH)C(.dbd.O)R.sup.1q, [0500]
(11) --N(OH)SO.sub.2R.sup.4q, [0501] (12) --NHSO.sub.2R.sup.4q,
[0502] (13) --SH, [0503] (14)
--CH(SH)(CH.sub.2).sub.0-1C(.dbd.O)N(R.sub.1,R.sub.2), [0504] (15)
--CH(SH)(CH.sub.2).sub.0-1CO.sub.2H, [0505] (16)
--CH(OH)(CH.sub.2).sub.0-1 CO.sub.2H, [0506] (17)
--CH(SH)CH.sub.2CO.sub.2R.sup.1q, [0507] (18)
--CH(OH)(CH.sub.2)SO.sub.2NH.sub.2, [0508] (19)
--CH(CH.sub.2SH)NHCOR.sup.1q, [0509] (20)
--CH(CH.sub.2SH)NHSO.sub.2R.sup.4q, [0510] (21)
--CH(CH.sub.2SR.sup.5q)CO.sub.2H, [0511] (22)
--CH(CH.sub.2SH)NHSO.sub.2NH.sub.2, [0512] (23)
--CH(CH.sub.2OH)CO.sub.2H, [0513] (24)
--CH(CH.sub.2OH)NHSO.sub.2NH.sub.2, [0514] (25)
--C(.dbd.O)CH.sub.2CO.sub.2H, [0515] (26)
--C(.dbd.O)(CH.sub.2).sub.0-1CONH.sub.2, [0516] (27)
--OSO.sub.2NHR.sup.5q, [0517] (28) --SO.sub.2NHNH.sub.2, [0518]
(29) --P(.dbd.O)(OH).sub.2,
[0518] ##STR00010## [0519] and [0520] (33)
--N(OH)C(.dbd.O)CR.sub.1R.sub.2, [0521] wherein: [0522] R.sub.1 is
selected from the group consisting of: [0523] (1) --H, [0524] (2)
--OH, [0525] (3) --OC.sub.1-C.sub.6-alkyl, [0526] (4) --N(R.sup.2q,
R.sup.3q), and [0527] (5) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl; R.sub.2 is selected from the group
consisting of: [0528] (1) H, [0529] (2) substituted or
unsubstituted C.sub.1-C.sub.6-alkyl, [0530] (3) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, [0531] (4) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, [0532] (5) substituted or
unsubstituted aryl, [0533] (6) substituted or unsubstituted
heterocyclyl, and [0534] (7) substituted or unsubstituted
heteroaryl, [0535] or R.sub.1 and R.sub.2, together with the N atom
to which they are attached can form a substituted or unsubstituted
heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring
atoms of the heterocyclic ring are selected from N, O and S; and
[0536] each R.sup.1q, R.sup.2q, R.sup.3q, R.sup.4q, and R.sup.5q is
independently selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl.
[0537] In certain embodiments of the above embodiment, G is
selected from the group consisting of: [0538] (1) --C.ident.C--,
[0539] (2) --C.ident.C--C.ident.C--, [0540] (3)
--CR.sup.3G.dbd.CR.sup.3G--C.ident.C--, and [0541] (4)
--C.ident.C--CR.sup.3G.dbd.CR.sup.3G--. For example, G may be
--C.ident.C--, --C.ident.C--C.ident.C--, --CH.dbd.CH--C.ident.C--
or --C.ident.C--CH.dbd.CH--. In embodiments wherein G is
--CH.dbd.CH--C.ident.C--, G may have one of the following
structures:
##STR00011##
[0541] and in embodiments wherein G is --C.ident.C--CH.dbd.CH--, G
may have one of the following structures:
##STR00012##
[0542] In certain embodiments of the above embodiments, X is
--(C.dbd.O)NR.sub.4--. For example, X may be --(C.dbd.O)NH--.
[0543] In certain embodiments of the above embodiments, Q is
--(C.dbd.O)N(R.sub.1,R.sub.2). For example, Q may be
--(C.dbd.O)NHOH.
[0544] In certain embodiments of the above embodiments, n is 0.
[0545] In certain embodiments of the above embodiments, R.sub.3 is
H.
[0546] In certain embodiments of the above embodiments, Y is
substituted or unsubstituted aryl. For example, Y may be
substituted or unsubstituted phenyl.
[0547] In certain embodiments of the above embodiments, A is
selected from the group consisting of: [0548] (1)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)(CH.sub.2).sub.0-4OR.sup.3a,
[0549] (2)
--(CH.sub.2).sub.0-4C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a), and
[0550] (3) --CH(R.sup.1a,R.sup.2a). For example, A may be
--CH(CH.sub.3).sub.2, --CH.sub.2OH, --CH.sub.2NH.sub.2,
--CHCH.sub.3OH, --CHCH.sub.3NH.sub.2 or --C(CH.sub.3).sub.2OH, or A
may be --C(CH.sub.3).sub.2NH.sub.2.
[0551] In other certain embodiments of the above embodiments, A is
selected from the group consisting of: [0552] (1) substituted or
unsubstituted C.sub.3-C.sub.10-cycloalkyl, [0553] (2) substituted
or unsubstituted aryl, [0554] (3) substituted or unsubstituted
heterocyclyl, and [0555] (4) substituted or unsubstituted
heteroaryl. For example, A may be:
##STR00013##
[0556] In certain embodiments of the above embodiments, R.sub.3 is
H and
##STR00014##
has the following structure:
##STR00015##
For example, when A is --CHCH.sub.3OH or --CHCH.sub.3NH.sub.2,
##STR00016##
has one of the following structures:
##STR00017##
[0557] In certain embodiments of the above embodiments, D is
present. For example, D may be substituted or unsubstituted
heteroaryl (such as, for example, a heteroaryl is selected from the
group consisting of:
##STR00018##
[0558] Alternatively, D may be substituted or unsubstituted aryl
(such as, for example, substituted or unsubstituted phenyl),
[0559] In other certain embodiments of the above embodiments, D is
absent.
[0560] In certain embodiments of the above embodiments, L is
present. For example, L may be substituted or unsubstituted alkyl
(such as --CH.sub.3--) or L may be --CH.sub.2--NH--.
[0561] In other certain embodiments of the above embodiments, L is
absent.
[0562] In a second embodiment, the present invention provides
compounds of formula (I) wherein:
[0563] E is selected from the group consisting of: [0564] (1) H,
[0565] (2) substituted or unsubstituted C.sub.1-C.sub.6-alkyl,
[0566] (3) substituted or unsubstituted C.sub.2-C.sub.6-alkenyl,
[0567] (4) substituted or unsubstituted C.sub.2-C.sub.6-alkynyl,
[0568] (5) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0569] (6) substituted or
unsubstituted aryl, [0570] (7) substituted or unsubstituted
heterocyclyl, and [0571] (8) substituted or unsubstituted
heteroaryl;
[0572] L is absent or selected from the group consisting of: [0573]
(1) substituted or unsubstituted C.sub.1-C.sub.6-alkyl, [0574] (2)
--(NR.sup.3L).sub.0-1--(CH.sub.2).sub.0-4--NR.sup.3L--(CH.sub.2).sub.0-4--
-, [0575] (3)
--(NR.sup.3L).sub.0-1--C(R.sup.1L,R.sup.2L)--NR.sup.3L
C(R.sup.1L,R.sup.2L)--, [0576] (4)
--C(R.sup.1L,R.sup.2L)--O--C(R.sup.1L,R.sup.2L)--, [0577] (5)
--(CH.sub.2).sub.0-4--NR.sup.3L--C(R.sup.1L,R.sup.2L)--CONH--(CH.sub.2).s-
ub.0-4--, [0578] (6) --CO--C(R.sup.1L,R.sup.2L)--NHCO--, [0579] (7)
--CONR.sup.3L--, [0580] (8) --NR.sup.3LCO--, [0581] (9)
--NR.sup.3L--, [0582] (10) --SO.sub.2NR.sup.3L--, [0583] (11)
--NR.sup.3L--C(.dbd.O)--NR.sup.3L--, [0584] (12) substituted or
unsubstituted C.sub.3-C.sub.10-cycloalkyl, [0585] (13) substituted
or unsubstituted aryl, [0586] (14) substituted or unsubstituted
heterocyclyl, and [0587] (15) substituted or unsubstituted
heteroaryl, [0588] wherein: [0589] each R.sup.1L, R.sup.2L, and
R.sup.3L is independently selected from the group consisting of:
[0590] (a) H, [0591] (b) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, [0592] (c) C.sub.1-C.sub.6-alkyl substituted
with aryl, [0593] (d) C.sub.1-C.sub.6-alkyl substituted with
heterocyclyl, and [0594] (e) C.sub.1-C.sub.6-alkyl substituted with
heteroaryl, [0595] or R.sup.1L and R.sup.3L, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S;
[0596] D is absent or selected from the group consisting of: [0597]
(1) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl,
[0598] (2) substituted or unsubstituted aryl, [0599] (3)
substituted or unsubstituted heterocyclyl, and [0600] (4)
substituted or unsubstituted heteroaryl;
[0601] G is selected from the group consisting of: [0602] (1)
--(CH.sub.2).sub.0-4--O--(CH.sub.2).sub.0-4--, [0603] (2)
--(CH.sub.2).sub.0-4--S--(CH.sub.2).sub.0-4--, [0604] (3)
--(CH.sub.2).sub.0-4--NR.sup.1G--(CH.sub.2).sub.0-4--, [0605] (4)
--C(.dbd.O)--, [0606] (5) --NR.sup.1GC(.dbd.O)--, [0607] (6)
--C(.dbd.O)NR.sup.1G--, [0608] (7)
--(CH.sub.2).sub.0-4NHCH.sub.2C(.dbd.O)NR.sup.1G--, [0609] (8)
--C.ident.C--, [0610] (9) --C.ident.C--C.ident.C--, [0611] (10)
--CR.sup.2G.dbd.CR.sup.2G--, [0612] (11) --S(.dbd.O)--, [0613] (12)
--SO.sub.2--, [0614] (13) --C(R.sup.3G).sub.2--S(.dbd.O)--, [0615]
(14) --S(.dbd.O)--C(R.sup.3G).sub.2--, [0616] (15)
--C(R.sup.3G).sub.2--SO.sub.2--, [0617] (16)
--SO.sub.2--C(R.sup.3G).sub.2--, [0618] (17)
--CR.sup.3G.dbd.CR.sup.3G--CR.sup.3G.dbd.CR.sup.3G--, [0619] (18)
--C(R.sup.3G).sub.2--, [0620] (19)
--CR.sup.3G.dbd.CR.sup.3G--C.ident.C--, [0621] (20)
--C.ident.C--CR.sup.3G.dbd.CR.sup.3G--, [0622] (21)
--C(.dbd.O)--C.ident.C--, [0623] (22) --C.ident.C--C(.dbd.O)--,
[0624] (23) substituted or unsubstituted
C.sub.3-C.sub.10-cycloalkyl, [0625] (24) substituted or
unsubstituted aryl, [0626] (25) substituted or unsubstituted
heterocyclyl, and [0627] (26) substituted or unsubstituted
heteroaryl, [0628] wherein: [0629] R.sup.1G is substituted or
unsubstituted C.sub.1-C.sub.6-alkyl; [0630] each R.sup.2G and
R.sup.3G is independently selected from the group consisting of H,
a halogen atom, and substituted or unsubstituted
C.sub.1-C.sub.6-alkyl;
[0631] Y is absent or selected from the group consisting of: [0632]
(1) substituted or unsubstituted C.sub.3-C.sub.10-cycloalkyl,
[0633] (2) substituted or unsubstituted aryl, [0634] (3)
substituted or unsubstituted heterocyclyl, and [0635] (4)
substituted or unsubstituted heteroaryl;
[0636] X is selected from the group consisting of: [0637] (1)
--(C.dbd.O)NR.sub.4--, [0638] (2)
--C.sub.1-C.sub.6-alkyl-(C.dbd.O)NR.sub.4--, [0639] (3)
--C.sub.2-C.sub.6-alkenyl-(C.dbd.O)NR.sub.4--, [0640] (4)
--C.sub.2-C.sub.6-alkynyl-(C.dbd.O)NR.sub.4--, [0641] (5)
--CH.sub.2NR.sub.4--, [0642] (6) --SO.sub.2NR.sub.4--, [0643] (7)
--S(.dbd.O)NR.sub.4--, [0644] (8) --NR.sub.4C(.dbd.O)--, and [0645]
(9) --NR.sub.4--, [0646] or X and A, together with the atoms to
which they are attached can form a heterocyclic ring, having from 5
to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring
are selected from N, O and S, [0647] or when Y is a bicyclic
substituted or unsubstituted heterocyclyl or heteroaryl, then X is
absent;
[0648] R.sub.3 is H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or R.sub.3 and A, together with the atom to
which they are attached can form a substituted or unsubstituted
3-10 membered cycloalkyl or a heterocyclic ring, having from 3 to
10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring are
selected from N, O and S;
[0649] R.sub.4 is (1) H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl, or (2) R.sub.4 and A, together with the
atoms to which they are attached can form a substituted or
unsubstituted heterocyclic ring, having from 3 to 8 ring atoms,
wherein 1-2 ring atoms of the heterocyclic ring are selected from
N, O and S, or (3) R.sub.4 and Y, together with the atoms to which
they are attached, form a bicyclic substituted or unsubstituted
heterocyclyl or heteroaryl;
[0650] n is an integer from 0-6;
[0651] A is selected from the group consisting of: [0652] (1)
--C(R.sup.1a,R.sup.2a)OR.sup.3a, [0653] (2)
--C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a), [0654] (3) substituted
or unsubstituted C.sub.3-C.sub.10-cycloalkyl, [0655] (4)
substituted or unsubstituted aryl, [0656] (5) substituted or
unsubstituted heterocyclyl, and [0657] (6) substituted or
unsubstituted heteroaryl, [0658] wherein: [0659] each R.sup.1a and
R.sup.2a is independently selected from the group consisting of
substituted or unsubstituted C.sub.1-C.sub.6-alkyl; [0660] each
R.sup.3a, R.sup.4a, and R.sup.5a is independently selected from the
group consisting of: [0661] (a) H, [0662] (b) a halogen atom,
[0663] (c) substituted or unsubstituted C.sub.1-C.sub.6-alkyl,
[0664] (d) substituted or unsubstituted aryl, [0665] (e)
substituted or unsubstituted heterocyclyl, and [0666] (f)
substituted or unsubstituted heteroaryl, [0667] or R.sup.4a and
R.sup.5a together with the N atom to which they are attached can
form a substituted or unsubstituted heterocyclic ring, having from
5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring
are selected from N, O and S; and [0668] when A is
--C(R.sup.1a,R.sup.2a)OR.sup.3a, the compound is not
2-{[(4'-ethyl-1,1'-biphenyl-4-yl)carbonyl]amino}-3-hydroxy-3-methylbutano-
ic acid, 4'-ethyl-N-{2-hydroxy-1-[(hydroxyamino)
carbonyl]-2-methylpropyl}-1,1'-biphenyl-4-carboxamide or
N-{2-hydroxy-1-[(hydroxyamino)carbonyl]-2-methylpropyl}-4-(phenylethynyl)-
benzamide;
[0669] Q is absent or selected from the group consisting of: [0670]
(1) --C(.dbd.O)N(R.sub.1,R.sub.2), [0671] (2)
--NHC(.dbd.O)N(R.sub.1,R.sub.2), [0672] (3)
--N(OH)C(.dbd.O)N(R.sub.1,R.sub.2), [0673] (4)
--CH(OH)C(.dbd.O)N(R.sub.1,R.sub.2), [0674] (5) --CH[N(R.sup.2q,
R.sup.3q)]C(.dbd.O)N(R.sub.1,R.sub.2), [0675] (6)
--CHR.sup.1qC(.dbd.O)N(R.sub.1, R.sub.2), [0676] (7) --CO.sub.2H,
[0677] (8) --C(.dbd.O)NHSO.sub.2R.sup.4q, [0678] (9)
--SO.sub.2NH.sub.2, [0679] (10) --N(OH)C(.dbd.O)R.sup.1q, [0680]
(11) --N(OH)SO.sub.2R.sup.4q, [0681] (12) --NHSO.sub.2R.sup.4q,
[0682] (13) --SH, [0683] (14)
--CH(SH)(CH.sub.2).sub.0-1C(.dbd.O)N(R.sub.1,R.sub.2), [0684] (15)
--CH(SH)(CH.sub.2).sub.0-1CO.sub.2H, [0685] (16)
--CH(OH)(CH.sub.2).sub.0-1CO.sub.2H, [0686] (17)
--CH(SH)CH.sub.2CO.sub.2R.sup.1q, [0687] (18)
--CH(OH)(CH.sub.2)SO.sub.2NH.sub.2, [0688] (19)
--CH(CH.sub.2SH)NHCOR.sup.1q, [0689] (20)
--CH(CH.sub.2SH)NHSO.sub.2R.sup.4q, [0690] (21)
--CH(CH.sub.2SR.sup.5q)CO.sub.2H, [0691] (22)
--CH(CH.sub.2SH)NHSO.sub.2NH.sub.2, [0692] (23)
--CH(CH.sub.2OH)CO.sub.2H, [0693] (24)
--CH(CH.sub.2OH)NHSO.sub.2NH.sub.2, [0694] (25)
--C(.dbd.O)CH.sub.2CO.sub.2H, [0695] (26)
--C(.dbd.O)(CH.sub.2).sub.0-1CONH.sub.2, [0696] (27)
--OSO.sub.2NHR.sup.5q, [0697] (28) --SO.sub.2NHNH.sub.2, [0698]
(29) --P(.dbd.O)(OH).sub.2,
[0698] ##STR00019## [0699] and [0700] (33)
--N(OH)C(.dbd.O)CR.sub.1R.sub.2, [0701] wherein: [0702] R.sub.1 is
selected from the group consisting of: [0703] (1) --H, [0704] (2)
--OH, [0705] (3) --OC.sub.1-C.sub.6-alkyl, [0706] (4) --N(R.sup.2q,
R.sup.3q), and [0707] (5) substituted or unsubstituted
C.sub.1-C.sub.6-alkyl; [0708] R.sub.2 is selected from the group
consisting of: [0709] (1) H, [0710] (2) substituted or
unsubstituted C.sub.1-C.sub.6-alkyl, [0711] (3) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, [0712] (4) substituted or
unsubstituted C.sub.2-C.sub.6-alkenyl, [0713] (5) substituted or
unsubstituted aryl, [0714] (6) substituted or unsubstituted
heterocyclyl, and [0715] (7) substituted or unsubstituted
heteroaryl, [0716] or R.sub.1 and R.sub.2, together with the N atom
to which they are attached can form a substituted or unsubstituted
heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring
atoms of the heterocyclic ring are selected from N, O and S; and
[0717] each R.sup.1q, R.sup.2q, R.sup.3q, R.sup.4q, and R.sup.5q is
independently selected from the group consisting of H and
C.sub.1-C.sub.6 alkyl.
[0718] In certain embodiments of the above embodiment, A is
--C(R.sup.1a,R.sup.2a)N(R.sup.4a,R.sup.5a). For example, A may be
--C(CH.sub.3).sub.2NH.sub.2.
[0719] In other certain embodiments of the above embodiment, A is
--C(R.sup.1a,R.sup.2a)OR.sup.3a.
[0720] In other certain embodiments of the above embodiments, A is
selected from the group consisting of: [0721] (1) substituted or
unsubstituted C.sub.3-C.sub.10-cycloalkyl, [0722] (2) substituted
or unsubstituted aryl, [0723] (3) substituted or unsubstituted
heterocyclyl, and [0724] (4) substituted or unsubstituted
heteroaryl. For example, A may be:
##STR00020##
[0725] In certain embodiments of the above embodiments, R.sub.3 is
H and
##STR00021##
has the following structure:
##STR00022##
[0726] In certain embodiments of the above embodiments, G is
selected from the group consisting of: [0727] (1) --C.ident.C--,
[0728] (2) --C.ident.C--C.ident.C--, [0729] (3)
--CR.sup.3G.dbd.CR.sup.3G--C.ident.C--, and [0730] (4)
--C.ident.C--CR.sup.3G.dbd.CR.sup.3G--. For example, G may be
--C.ident.C--, --C.ident.C--C.ident.C--, --CH.dbd.CH--C.ident.C--,
or --C.ident.C--CH.dbd.CH--. In embodiments wherein G is
--CH.dbd.CH--C.ident.C--, G may have one of the following
structures:
##STR00023##
[0730] and in embodiments wherein G is --C.ident.C--CH.dbd.CH--, G
may have one of the following structures:
##STR00024##
[0731] In certain embodiments of the above embodiments, X is
--(C.dbd.O)NR.sub.4--. For example, X may be --(C.dbd.O)NH--.
[0732] In certain embodiments of the above embodiments, Q is
--(C.dbd.O)N(R.sub.1,R.sub.2). For example, Q may be
--(C.dbd.O)NHOH.
[0733] In certain embodiments of the above embodiments, n is 0.
[0734] In certain embodiments of the above embodiments, R.sub.3 is
H.
[0735] In certain embodiments of the above embodiments, Y is
substituted or unsubstituted aryl. For example, Y may be
substituted or unsubstituted phenyl.
[0736] In certain embodiments of the above embodiments, D is
present. For example, D may be substituted or unsubstituted
heteroaryl (such as, for example, a heteroaryl is selected from the
group consisting of:
##STR00025## ##STR00026##
Alternatively, D may be substituted or unsubstituted aryl (such as,
for example, substituted or unsubstituted phenyl),
[0737] In other certain embodiments of the above embodiments, D is
absent.
[0738] In certain embodiments of the above embodiments, L is
present. For example, L may be substituted or unsubstituted alkyl
(such as --CH.sub.3--) or L may be --CH.sub.2--NH--.
[0739] In other certain embodiments of the above embodiments, L is
absent.
[0740] In various other embodiments of all of the foregoing
embodiments, E-L-D-G-Y taken together, may be selected from the
group consisting of:
##STR00027## ##STR00028## ##STR00029## ##STR00030## ##STR00031##
##STR00032##
wherein R is selected from the group consisting of --CH.sub.3,
--C.sub.2H.sub.5, --CH.sub.2OH, --OH, --OCH.sub.3,
--OC.sub.2H.sub.5, --OCF.sub.3, --CN, --NO.sub.2, --CO.sub.2,
--CO.sub.2CH.sub.3, --CONH.sub.2, --NH.sub.2, --F, --Cl, --Br,
--CF.sub.3, --N(CH.sub.3).sub.2, --NHSO.sub.2CH.sub.3, and
--NHCOCH.sub.3.
[0741] In various other embodiments of all of the foregoing
embodiments, G may be selected from the group consisting of:
##STR00033##
[0742] In various other embodiments of all of the foregoing
embodiments, A may be:
##STR00034##
[0743] In various other embodiments of all of the foregoing
embodiments, the compound may have the structure:
##STR00035##
[0744] In various other embodiments of all of the foregoing
embodiments, X is --(C.dbd.O)NR.sub.4--, and R.sub.4 and A,
together with the atoms to which they are attached, form a
substituted heterocyclic ring, and the compounds have the following
structure:
##STR00036##
[0745] In various other embodiments of all of the foregoing
embodiments, X is --(C.dbd.O)NR.sub.4--, and the compounds have the
following structure:
##STR00037##
[0746] In various other embodiments of all of the foregoing
embodiments, X and A, together with the atoms to which they are
attached form a heterocyclic ring, and the compounds have the
following structure:
##STR00038##
[0747] In various other embodiments of all of the foregoing
embodiments, Q is --N(OH)C(.dbd.O)CR.sub.1R.sub.2 and at least one
of R.sub.1 and R.sub.2 is not H or C.sub.1-C.sub.6-alkyl.
[0748] In various other embodiments of all of the foregoing
embodiments, X is selected from the group consisting of: [0749] (1)
--SO.sub.2NR.sub.4--, [0750] (2) --S(.dbd.O)NR.sub.4--, [0751] (3)
--NR.sub.4C(.dbd.O)--, and [0752] (4) --NR.sub.4--, wherein R.sub.4
is H or substituted or unsubstituted C.sub.1-C.sub.6-alkyl, or
R.sub.4 and A, together with the atoms to which they are attached
can form a substituted or unsubstituted heterocyclic ring, having
from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic
ring are selected from N, O and S,
[0753] or X is selected from the group consisting of: [0754] (1)
--(C.dbd.O)NR.sub.4--, [0755] (2)
--C.sub.1-C.sub.6-alkyl-(C.dbd.O)NR.sub.4--, [0756] (3)
--C.sub.2-C.sub.6-alkenyl-(C.dbd.O)NR.sub.4--, [0757] (4)
--C.sub.2-C.sub.6-alkynyl-(C.dbd.O)NR.sub.4--, [0758] (5)
--CH.sub.2NR.sub.4--, [0759] (6) --SO.sub.2NR.sub.4--, [0760] (7)
--S(.dbd.O)NR.sub.4--, [0761] (8) --NR.sub.4C(.dbd.O)--, and [0762]
(9) --NR.sub.4--, wherein R.sub.4 and Y, together with the atoms to
which they are attached, form a bicyclic substituted or
unsubstituted heterocyclyl or heteroaryl,
[0763] or when Y is a bicyclic substituted or unsubstituted
heterocyclyl or heteroaryl, then X is absent.
[0764] For example, in more specific embodiments, X may be --NH--
and Y may be a bicyclic substituted or unsubstituted heterocyclyl
or heteroaryl. In such embodiments, Y may be selected from the
group consisting of:
##STR00039##
wherein: R.sup.y1 is S, O, NH or N(C.sub.1-C.sub.6-alkyl); R.sup.y2
is N, CH, or C(C.sub.1-C.sub.6-alkyl); and R.sup.y3 is S or 0.
[0765] In other more specific embodiments, X may be
--(C.dbd.O)NR.sub.4-- and R.sub.4 and Y, together with the atoms to
which they are attached, may form a bicyclic substituted or
unsubstituted heterocyclyl or heteroaryl. In such embodiments,
R.sub.4 and Y may form:
##STR00040##
[0766] In other more specific embodiments, Y may be a bicyclic
substituted or unsubstituted heterocyclyl or heteroaryl and X may
be absent. In such embodiments, Y may be:
##STR00041##
[0767] In various other embodiments of all of the foregoing
embodiments, --X--C(AR.sub.3)--(CH.sub.2).sub.n-Q is
--X.sub.1-Q.sub.1 wherein:
[0768] X.sub.1 is absent or selected from the group consisting of:
[0769] (1) --(C.dbd.O)--, [0770] (2) --CR.sup.x--, [0771] (3)
--(C.dbd.O)NR.sup.x--, and [0772] (4) --NR.sup.x(C.dbd.O)--, [0773]
wherein R.sup.x is H or substituted or unsubstituted
C.sub.1-C.sub.6-alkyl;
[0774] Q.sub.1 is selected from the group consisting of:
##STR00042## [0775] wherein: [0776] R.sup.1Q is a carbon or a
nitrogen ring atom, [0777] each R.sup.2Q is absent or is a carbon
ring atom, [0778] R.sup.1Q and an adjacent R.sup.2Q optionally form
a double bond, and [0779] each carbon ring atom is optionally
substituted with a substituted or unsubstituted C.sub.1-C.sub.6
alkyl, or an oxo substituent.
[0780] For example, --X.sub.1-Q.sub.1 may be:
##STR00043##
wherein R.sup.3Q is H or substituted or unsubstituted
C.sub.1-C.sub.6 alkyl.
[0781] In various other embodiments or all of the foregoing
embodiments, A contains at least one halogen atom.
[0782] In another aspect, the invention provides a method of
inhibiting a deacetylase enzyme in a gram-negative bacteria,
thereby affecting bacterial growth, comprising administering to a
patient in need of such inhibition a compound of formula (I).
[0783] In another aspect, the invention provides a method of
inhibiting LpxC, thereby modulating the virulence of a bacterial
infection, comprising administering to a patient in need of such
inhibition a compound of formula (I). In certain embodiments of the
method of inhibiting LpxC using a compound of formula (I), the
IC.sub.50 value of the compound is less than or equal to 10 .mu.M
with respect to LpxC. In other embodiments, the IC.sub.50 value is
less than or equal to 1 .mu.M, is less than or equal to 0.1 .mu.M,
is less than or equal to 0.050 .mu.M, is less than or equal to
0.030 .mu.M, is less than or equal to 0.025 .mu.M, or is less than
or equal to 0.010 .mu.M.
[0784] In another aspect, the invention provides a method for
treating a subject with a gram-negative bacterial infection
comprising administering to the subject in need thereof an
antibacterially effective amount of a compound of formula (I) with
a pharmaceutically acceptable carrier. In certain embodiments, the
subject may be a mammal, and in some embodiments, a human.
[0785] In another aspect, the invention provides a method of
administering an inhibitory amount of a compound of formula (I) to
fermentative or non-fermentative gram-negative bacteria. In a more
specific embodiment of the method of administering an inhibitory
amount of a compound of formula (I) to fermentative or
non-fermentative gram-negative bacteria, the gram-negative bacteria
are selected from the group consisting of Pseudomonas aeruginosa,
Stenotrophomonas maltophila, Burkholderia cepacia, Alcaligenes
xylosoxidans, Acinetobacter, Enterobacteriaceae, Haemophilus,
Franciscellaceae (Franciscella tularensis) and Neisseria
species.
[0786] In another aspect, the invention provides a method of
administering an inhibitory amount of a compound of formula (I) to
gram-negative bacteria, such as Enterobacteriaceae which is
selected from the group consisting of organisms such as Serratia,
Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella,
Providencia, Yersinia (Yersinia pestis), Morganella, Cedecea, and
Edwardsiella species and Escherichia coli.
[0787] In another aspect, the invention provides a pharmaceutical
composition or formulation comprising an effective amount of a
compound of formula (I) with a pharmaceutically acceptable carrier
thereof.
[0788] In another aspect, the invention provides a method of
co-administering a compound of formula (I) with other therapeutic
agents that are selected for their particular usefulness against
the condition that is being treated. For example, a compound of
formula (I) is useful in combination with other anti-bacterial
agents. The compound of formula (I) augments the sensitivity of
gram-negative bacteria to existing classes of antibacterials.
Combinations of the presently disclosed compounds with other
anti-bacterial agents are within the scope of the invention. Such
anti-bacterial agents include, but are not limited to,
erythromycin, rifampicin, Nalidixic acid, carbenicillin,
bacitracin, cycloserine, fosfomycin, and vancomycin.
[0789] A further aspect of the invention is the use of LpxC
inhibitors for the treatment of an infection, particularly a
bacterial infection. A bacterial infection treated with the
compounds of the invention can be a primary infection or a
co-infection caused by a species of bacteria and one or more
additional infectious agents selected from the group consisting of
bacteria, virus, parasite and fungus.
[0790] The term "treating", as used herein, refers to reversing,
alleviating, inhibiting the progress of, or preventing the disorder
or condition to which such term applies, or one or more symptoms of
such disorder or condition. The term "treatment", as used herein,
refers to the act of treating, as "treating" is defined immediately
above.
[0791] The compounds of the invention can be used for treating
conditions caused by the bacterial production of endotoxin and, in
particular, by gram-negative bacteria and bacteria that use LpxC in
the biosynthesis of lipopolysaccharide (LPS) or endotoxin.
[0792] The compounds of the invention also are useful in the
conditions that are caused or exacerbated by the bacterial
production of lipid A and LPS or endotoxin, such as sepsis, septic
shock, systemic inflammation, localized inflammation, chronic
obstructive pulmonary disease (COPD) and acute exacerbations of
chronic bronchitis (AECB). For these conditions, treatment includes
the administration of a compound of the invention, or a combination
of compounds of the invention, optionally with a second agent
wherein the second agent is a second antibacterial agent or a
second non-antibacterial agent.
[0793] For sepsis, septic shock, systemic inflammation, localized
inflammation, chronic obstructive pulmonary disease (COPD) and
acute exacerbations of chronic bronchitis (AECB), preferred second
non-antibacterial agents include antiendotoxins including endotoxin
receptor-binding antibodies, endotoxin-binding antibodies,
anti-CD14-binding protein antibodies,
antilipopolysaccharide-binding protein antibodies and tyrosine
kinase inhibitors.
[0794] In treatment of serious or chronic respiratory tract
infections, the compounds of the present invention may also be used
with second non-antibacterial agents administered via inhalation.
Representative non-antibacterial agents used in this treatment
include anti-inflammatory steroids, non-steroidal anti-inflammatory
agents, bronchiodilators, mucolytics, anti-asthma therapeutics and
lung fluid surfactants. In particular, the non-antibacterial agent
may be selected from a group consisting of albuterol, salbuterol,
budesonide, beclomethasone, dexamethasone, nedocromil,
beclomethasone, fluticasone, flunisolide, triamcinolone, ibuprofin,
rofecoxib, naproxen, celecoxib, nedocromil, ipratropium,
metaproterenol, pirbuterol, salmeterol, formoterol, indacaterol,
bronchiodilators, mucolytics, calfactant, beractant, poractant
alfa, surfaxin and pulmozyme (also called domase alfa).
[0795] The compounds of the invention can be used, alone or in
combination with a second antibacterial agent for the treatment of
a serious or chronic respiratory tract infection including serious
lung and nosocomial infections such as those caused by Enterobacter
aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella
pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Serratia
marcescens, Stenotrophomonas maltophilia, Pseudomonas aeruginosa,
Burkholderia cepacia, Acinetobacter calcoaceticus, Alcaligenes
xylosoxidans, Flavobacterium meningosepticum, Providencia stuartii
and Citrobacter freundi, community lung infections such as those
caused by Haemophilus Influenzae, Legionella species, Moraxella
catarrhalis, Branhamella catarrhalis, Enterobacter species,
Acinetobacter species, Klebsiella species, and Proteus species, and
infections caused by other bacterial species such as Neisseria
species, Shigella species, Salmonella species, Helicobacter pylori,
Vibrionaceae and Bordetella species as well as the infections is
caused by a Brucella species, Francisella tularensis and/or
Yersinia Pestis.
[0796] When used for treating subjects infected with gram-negative
bacterial infections, the compounds of the present invention can be
used to sensitize gram-negative bacteria to the effects of a second
agent.
[0797] When the compounds of the present invention are used in
combination with a second antibacterial agent, non-limiting
examples of antibacterial agents may be selected from the following
groups:
[0798] (1) Macrolides or ketolides such as erythromycin,
azithromycin, clarithromycin and telithromycin;
[0799] (2) Beta-lactams such as penicillin G, penicillin V,
methicillin, oxacillin, cloxacillin, dicloxacillin, nafcillin,
ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin,
piperacillin, azlocillin, temocillin, cepalothin, cephapirin,
cephradine, cephaloridine, cefazolin, cefamandole, cefuroxime,
cephalexin, cefprozil, cefaclor, loracarbef, cefoxitin,
cefinetazole, cefotaxime, ceftizoxime, ceftriaxone, cefoperazone,
ceftazidime, cefixime, cefpodoxime, ceftibuten, cefdinir,
cefpirome, cefepime, aztreonam, imipenem, meropenem, ertapenem,
doripenem, ceftobiprole, and ceftaroline;
[0800] (3) Quinolones such as nalidixic acid, oxolinic acid,
norfloxacin, pefloxacin, enoxacin, ofloxacin, levofloxacin,
ciprofloxacin, temafloxacin, lomefloxacin, fleroxacin,
grepafloxacin, sparfloxacin, trovafloxacin, clinafloxacin,
gatifloxacin, moxifloxacin, sitafloxacin, garenoxacin, gemifloxacin
and pazufloxacin;
[0801] (4) Antibacterial sulfonanmides and antibacterial
sulphanilamides, including para-aminobenzoic acid, sulfadiazine,
sulfisoxazole, sulfamethoxazole and sulfathalidine;
[0802] (5) Aminoglycosides such as streptomycin, neomycin,
kanamycin, paromycin, gentamicin, tobramycin, amikacin, netilmicin,
spectinomycin, sisomicin, dibekacin and isepamicin;
[0803] (6) Tetracyclines such as tetracycline, chlortetracycline,
demeclocycline, minocycline, oxytetracycline, methacycline,
tigecycline, doxycycline;
[0804] (7) Rifamycins such as rifampicin (also called rifampin),
rifapentine, rifabutin, bezoxazinorifamycin and rifaximin;
[0805] (8) Lincosamides such as lincomycin and clindamycin;
[0806] (9) Glycopeptides such as telavancin, vancomycin and
teicoplanin or lipopeptides such as daptomycin;
[0807] (10) Streptogramins such as quinupristin and
daflopristin;
[0808] (11) Oxazolidinones such as linezolid;
[0809] (12) Polymyxin, colistin and colymycin; and
[0810] (13) Trimethoprim and bacitracin.
[0811] The second antibacterial agent may be administered in
combination with the compounds of the present inventions, wherein
the second antibacterial agent is administered prior to,
simultaneously, or after the compound or compounds of the present
invention. When simultaneous administration of a compound of the
invention with a second agent is desired and the route of
administration is the same, then a compound of the invention may be
formulated with a second agent into the same dosage form. An
example of a dosage form containing a compound of the invention and
a second agent is a tablet or a capsule.
[0812] When used for treating a serious or chronic respiratory
tract infections, the compounds of the invention may be used alone
or in combination with a second antibacterial agent administered
via inhalation. In the case of inhalation, a preferred second
antibacterial agent is selected from a group consisting of
tobramycin, gentamicin, aztreonam, ciprofloxacin, polymyxin,
colistin, colymycin, azithromycin and clarithromycin.
[0813] Pharmaceutical Compositions
[0814] Pharmaceutical compositions of the present invention
comprise a therapeutically effective amount of a compound of the
present invention formulated together with one or more
pharmaceutically acceptable carriers. As used herein, the term
"pharmaceutically acceptable carrier" means a non-toxic, inert
solid, semi-solid or liquid filler, diluent, encapsulating material
or formulation auxiliary of any type. Some examples of materials
that can serve as pharmaceutically acceptable carriers are sugars
such as lactose, glucose and sucrose; starches such as corn starch
and potato starch; cellulose and its derivatives such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; excipients such as cocoa
butter and suppository waxes; oils such as peanut oil, cottonseed
oil; safflower oil; sesame oil; olive oil; corn oil and soybean
oil; glycols; such a propylene glycol; esters such as ethyl oleate
and ethyl laurate; agar; buffering agents such as magnesium
hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water;
isotonic saline; Ringer's solution; ethyl alcohol, and phosphate
buffer solutions, as well as other non-toxic compatible lubricants
such as sodium lauryl sulfate and magnesium stearate, as well as
coloring agents, releasing agents, coating agents, sweetening,
flavoring and perfuming agents, preservatives and antioxidants can
also be present in the composition, according to the judgment of
the formulator. The pharmaceutical compositions of this invention
can be administered to humans and other animals orally, rectally,
parenterally, intracisternally, intravaginally, intraperitoneally,
topically (as by powders, ointments, or drops), bucally, or as an
oral or nasal spray, or a liquid aerosol or dry powder formulation
for inhalation.
[0815] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, microemulsions, solutions,
suspensions, syrups and elixirs. In addition to the active
compounds, the liquid dosage forms may contain inert diluents
commonly used in the art such as, for example, water or other
solvents, solubilizing agents and emulsifiers such as ethyl
alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl
alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,
dimethylformamide, oils (in particular, cottonseed, groundnut,
corn, germ, olive, castor, and sesame oils), glycerol,
tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid
esters of sorbitan, and mixtures thereof. Besides inert diluents,
the oral compositions can also include adjuvants such as wetting
agents, emulsifying and suspending agents, sweetening, flavoring,
and perfuming agents.
[0816] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions may be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0817] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions that can be dissolved or dispersed in sterile water or
other sterile injectable medium prior to use.
[0818] In order to prolong the effect of a drug, it is often
desirable to slow the absorption of the drug from subcutaneous or
intramuscular injection. This may be accomplished by the use of a
liquid suspension of crystalline or amorphous material with poor
water solubility. The rate of absorption of the drug then depends
upon its rate of dissolution that, in turn, may depend upon crystal
size and crystalline form. Alternatively, delayed absorption of a
parenterally administered drug form may be accomplished by
dissolving or suspending the drug in an oil vehicle. Injectable
depot forms are made by forming microencapsule matrices of the drug
in biodegradable polymers such as polylactide-polyglycolide.
Depending upon the ratio of drug to polymer and the nature of the
particular polymer employed, the rate of drug release can be
controlled. Examples of other biodegradable polymers include
poly(orthoesters) and poly(anhydrides). Depot injectable
formulations may also be prepared by entrapping the drug in
liposomes or microemulsions that are compatible with body
tissues.
[0819] Compositions for rectal or vaginal administration are
preferably suppositories that can be prepared by mixing the
compounds of this invention with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound.
[0820] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, acetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
[0821] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like.
[0822] The solid dosage forms of tablets, dragees, capsules, pills,
and granules can be prepared with coatings and shells such as
enteric coatings and other coatings well known in the
pharmaceutical formulating art. They may optionally contain
opacifying agents and can also be of a composition that they
release the active ingredient(s) only, or preferentially, in a
certain part of the intestinal tract, optionally, in a delayed
manner. Examples of embedding compositions that can be used include
polymeric substances and waxes.
[0823] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like.
[0824] The active compounds can also be in micro-encapsulated form
with one or more excipients as noted above. The solid dosage forms
of tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active compound may be admixed with at least one inert diluent such
as sucrose, lactose or starch. Such dosage forms may also comprise,
as is normal practice, additional substances other than inert
diluents, e.g., tableting lubricants and other tableting aids such
a magnesium stearate and microcrystalline cellulose. In the case of
capsules, tablets and pills, the dosage forms may also comprise
buffering agents. They may optionally contain opacifying agents and
can also be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
substances and waxes.
[0825] Dosage forms for topical or transdermal administration of a
compound of this invention include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or
buffers as may be required. Ophthalmic formulations, ear drops, and
the like are also contemplated as being within the scope of this
invention.
[0826] The ointments, pastes, creams and gels may contain, in
addition to an active compound of this invention, excipients such
as animal and vegetable fats, oils, waxes, paraffins, starch,
tragacanth, cellulose derivatives, polyethylene glycols, silicones,
bentonites, silicic acid, talc and zinc oxide, or mixtures
thereof.
[0827] Compositions of the invention may also be formulated for
delivery as a liquid aerosol or inhalable dry powder. Liquid
aerosol formulations may be nebulized predominantly into particle
sizes that can be delivered to the terminal and respiratory
bronchioles where bacteria reside in patients with bronchial
infections, such as chronic bronchitis and pneumonia. Pathogenic
bacteria are commonly present throughout airways down to bronchi,
bronchioli and lung parenchema, particularly in terminal and
respiratory bronchioles. During exacerbation of infection, bacteria
can also be present in alveoli. Liquid aerosol and inhalable dry
powder formulations are preferably delivered throughout the
endobronchial tree to the terminal bronchioles and eventually to
the parenchymal tissue.
[0828] Aerosolized formulations of the invention may be delivered
using an aerosol forming device, such as a jet, vibrating porous
plate or ultrasonic nebulizer, preferably selected to allow the
formation of a aerosol particles having with a mass medium average
diameter predominantly between 1 to 5 .mu.m. Further, the
formulation preferably has balanced osmolarity ionic strength and
chloride concentration, and the smallest aerosolizable volume able
to deliver effective dose of the compounds of the invention to the
site of the infection. Additionally, the aerosolized formulation
preferably does not impair negatively the functionality of the
airways and does not cause undesirable side effects.
[0829] Aerosolization devices suitable for administration of
aerosol formulations of the invention include, for example, jet,
vibrating porous plate, ultrasonic nebulizers and energized dry
powder inhalers, that are able to nebulize the formulation of the
invention into aerosol particle size predominantly in the size
range from 1-5 pm. Predominantly in this application means that at
least 70% but preferably more than 90% of all generated aerosol
particles are 1 to 5 .mu.m range. A jet nebulizer works by air
pressure to break a liquid solution into aerosol droplets.
Vibrating porous plate nebulizers work by using a sonic vacuum
produced by a rapidly vibrating porous plate to extrude a solvent
droplet through a porous plate. An ultrasonic nebulizer works by a
piezoelectric crystal that shears a liquid into small aerosol
droplets. A variety of suitable devices are available, including,
for example, AeroNeb and AeroDose vibrating porous plate nebulizers
(AeroGen, Inc., Sunnyvale, Calif.), Sidestream7 nebulizers
(Medic-Aid Ltd., West Sussex, England), Pari LC7 and Pari LC Star7
jet nebulizers (Pari Respiratory Equipment, Inc., Richmond, Va.),
and Aerosonic (DeVilbiss Medizinische Produkte (Deutschland) GmbH,
Heiden, Germany) and UltraAire7 (Omron Healthcare, Inc., Vernon
Hills, Ill.) ultrasonic nebulizers.
[0830] Compounds of the invention may also be formulated for use as
topical powders and sprays that can contain, in addition to the
compounds of this invention, excipients such as lactose, talc,
silicic acid, aluminum hydroxide, calcium silicates and polyamide
powder, or mixtures of these substances. Sprays can additionally
contain customary propellants such as chlorofluorohydrocarbons.
[0831] Transdermal patches have the added advantage of providing
controlled delivery of a compound to the body. Such dosage forms
can be made by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux
of the compound across the skin. The rate can be controlled by
either providing a rate controlling membrane or by dispersing the
compound in a polymer matrix or gel.
[0832] According to the methods of treatment of the present
invention, bacterial infections are treated or prevented in a
patient such as a human or lower mammal by administering to the
patient a therapeutically effective amount of a compound of the
invention, in such amounts and for such time as is necessary to
achieve the desired result. By a "therapeutically effective amount"
of a compound of the invention is meant a sufficient amount of the
compound to treat bacterial infections, at a reasonable
benefit/risk ratio applicable to any medical treatment. It will be
understood, however, that the total daily usage of the compounds
and compositions of the present invention will be decided by the
attending physician within the scope of sound medical judgment. The
specific therapeutically effective dose level for any particular
patient will depend upon a variety of factors including the
disorder being treated and the severity of the disorder; the
activity of the specific compound employed; the specific
composition employed; the age, body weight, general health, sex and
diet of the patient; the time of administration, route of
administration, and rate of excretion of the specific compound
employed; the duration of the treatment; drugs used in combination
or coincidental with the specific compound employed; and like
factors well known in the medical arts.
[0833] The total daily dose of the compounds of this invention
administered to a human or other mammal in single or in divided
doses can be in amounts, for example, from 0.01 to 50 mg/kg body
weight or more usually from 0.1 to 25 mg/kg body weight. Single
dose compositions may contain such amounts or submultiples thereof
to make up the daily dose. In general, treatment regimens according
to the present invention comprise administration to a patient in
need of such treatment from about 10 mg to about 2000 mg of the
compound(s) of this invention per day in single or multiple
doses.
[0834] Methods of formulation are well known in the art and are
disclosed, for example, in Remington: The Science and Practice of
Pharmacy, Mack Publishing Company, Easton, Pa., 19th Edition
(1995). Pharmaceutical compositions for use in the present
invention can be in the form of sterile, non-pyrogenic liquid
solutions or suspensions, coated capsules, suppositories,
lyophilized powders, transdermal patches or other forms known in
the art.
[0835] A "kit" as used in the instant application includes a
container for containing the pharmaceutical compositions and may
also include divided containers such as a divided bottle or a
divided foil packet. The container can be in any conventional shape
or form as known in the art that is made of a pharmaceutically
acceptable material, for example a paper or cardboard box, a glass
or plastic bottle or jar, a resealable bag (for example, to hold a
"refill" of tablets for placement into a different container), or a
blister pack with individual doses for pressing out of the pack
according to a therapeutic schedule. The container employed can
depend on the exact dosage form involved, for example a
conventional cardboard box would not generally be used to hold a
liquid suspension. It is feasible that more than one container can
be used together in a single package to market a single dosage
form. For example, tablets may be contained in a bottle that is in
turn contained within a box.
[0836] An example of such a kit is a so-called blister pack.
Blister packs are well known in the packaging industry and are
being widely used for the packaging of pharmaceutical unit dosage
forms (tablets, capsules, and the like). Blister packs generally
consist of a sheet of relatively stiff material covered with a foil
of a preferably transparent plastic material. During the packaging
process, recesses are formed in the plastic foil. The recesses have
the size and shape of individual tablets or capsules to be packed
or may have the size and shape to accommodate multiple tablets
and/or capsules to be packed. Next, the tablets or capsules are
placed in the recesses accordingly and the sheet of relatively
stiff material is sealed against the plastic foil at the face of
the foil that is opposite from the direction in which the recesses
were formed. As a result, the tablets or capsules are individually
sealed or collectively sealed, as desired, in the recesses between
the plastic foil and the sheet. Preferably the strength of the
sheet is such that the tablets or capsules can be removed from the
blister pack by manually applying pressure on the recesses whereby
an opening is formed in the sheet at the place of the recess. The
tablet or capsule can then be removed via said opening.
[0837] It maybe desirable to provide a written memory aid, where
the written memory aid is of the type containing information and/or
instructions for the physician, pharmacist or other health care
provider, or subject, e.g., in the form of numbers next to the
tablets or capsules whereby the numbers correspond with the days of
the regimen that the tablets or capsules so specified should be
ingested or a card that contains the same type of information.
Another example of such a memory aid is a calendar printed on the
card e.g., as follows "First Week, Monday, Tuesday," . . . etc. . .
. "Second Week, Monday, Tuesday, . . . " etc. Other variations of
memory aids will be readily apparent. A "daily dose" can be a
single tablet or capsule or several tablets or capsules to be taken
on a given day. When the kit contains separate compositions, a
daily dose of one or more compositions of the kit can consist of
one tablet or capsule while a daily dose of another one or more
compositions of the kit can consist of several tablets or
capsules.
[0838] Another specific embodiment of a kit is a dispenser designed
to dispense the daily doses one at a time in the order of their
intended use. Preferably, the dispenser is equipped with a
memory-aid, so as to further facilitate compliance with the
regimen. An example of such a memory-aid is a mechanical counter,
that indicates the number of daily doses that has been dispensed.
Another example of such a memory-aid is a battery-powered
micro-chip memory coupled with a liquid crystal readout, or audible
reminder signal that, for example, reads out the date that the last
daily dose has been taken and/or reminds one when the next dose is
to be taken.
[0839] The kits of the present invention may also include, in
addition to LpxC inhibitors, one or more additional
pharmaceutically active compounds. Preferably, the additional
compound is another LpxC inhibitor or another compound useful to
bacterial infections. The additional compounds may be administered
in the same dosage form as the LpxC inhibitor or in different
dosage forms. Likewise, the additional compounds can be
administered at the same time as the LpxC inhibitor or at different
times.
[0840] Compositions of the present compounds may also be used in
combination with other known antibacterial agents of similar
spectrum to (1) synergistically enhance treatment of severe
Gram-negative infections covered by the spectrum of this compound
or (2) add coverage in severe infections in which multiple
organisms are suspected in which another agent of a different
spectrum may be required in addition to this compound. Potential
agents include members of the aminoglycosides, penicillins,
cephalosporins, fluoroquinolones, macrolides, glycopeptides,
lipopeptides and oxazolidinones. The treatment can involve
administering a composition having both active agents or
administration of the inventive compounds followed by or preceded
by administration of an additional active antibacterial agent.
[0841] Characterization and Purification Methods
[0842] Referring to the examples that follow, compounds of the
present invention were characterized by high performance liquid
chromatography (HPLC) using a Waters Millenium chromatography
system with a 2690 Separation Module (Milford, Mass.). The
analytical columns were Alltima C-18 reversed phase, 4.6.times.250
mm from Alltech (Deerfield, Ill.). A gradient elution was used,
typically starting with 5% acetonitrile/95% water and progressing
to 100% acetonitrile over a period of 40 minutes. All solvents
contained 0.1% trifluoroacetic acid (TFA). Compounds were detected
by ultraviolet light (UV) absorption at either 220 or 254 nm. HPLC
solvents were from Burdick and Jackson (Muskegan, Mich.), or Fisher
Scientific (Pittsburgh, Pa.). In some instances, purity was
assessed by thin layer chromatography (TLC) using glass or plastic
backed silica gel plates, such as, for example, Baker-Flex Silica
Gel 1 B2-F flexible sheets. TLC results were readily detected
visually under ultraviolet light, or by employing well known iodine
vapor and other various staining techniques.
[0843] Mass spectrometric analysis was performed on one of two LCMS
instruments: a Waters System. (Alliance HT HPLC and a Micromass ZQ
mass spectrometer; Column: Eclipse XDB-C-18, 2.1.times.50 mm;
solvent system: 5-95% (or 35-95%, or 65-95% or 95-95%) acetonitrile
in water with 0.05% TFA; flow rate 0.8 mL/min; molecular weight
range 500-1500; cone Voltage 20 V; column temperature 40.degree.
C.) or a Hewlett Packard System (Series 1100 HPLC; Column: Eclipse
XDB-C18, 2.1.times.50 mm; solvent system: 1-95% acetonitrile in
water with 0.05% TFA; flow rate 0.4 mL/min; molecular weight range
150-850; cone Voltage 50 V; column temperature 30.degree. C.). All
masses are reported as those of the protonated parent ions.
[0844] GCMS analysis was performed on a Hewlet Packard instrument
(HP6890 Series gas chromatograph with a Mass Selective Detector
5973; injector volume: 1 .mu.L; initial column temperature:
50.degree. C.; final column temperature: 250 C; ramp time: 20
minutes; gas flow rate: 1 mL/min; column: 5% phenyl methyl
siloxane, Model #HP 190915-443, dimensions: 30.0 m.times.25
m.times.0.25 m).
[0845] Nuclear magnetic resonance (NMR) analysis was performed with
a Varian 300 Mhz NMR (Palo Alto, Calif.). The spectral reference
was either TMS or the known chemical shift of the solvent. Some
compound samples were run at elevated temperatures (e.g. 75.degree.
C.) to promote increased sample solubility.
[0846] The purity of some of the invention compounds was assessed
by elemental analysis (Desert Analytics, Tucson, Ariz.)
[0847] Melting points were determined on a Laboratory Devices
Mel-Temp apparatus (Holliston, Mass.).
[0848] Preparative separations were carried out using a Flash 40
chromatography system and KP-Sil, 60A (Biotage, Charlottesville,
Va.), or by flash column chromatography using silica gel (230-400
mesh) packing material, or by HPLC using a C-18 reversed phase
column. Typical solvents employed for the Flash 40 Biotage system
and flash column chromatography were dichloromethane, methanol,
ethyl acetate, hexane, acetone, aqueous hydroxyamine and triethyl
amine. Typical solvents employed for the reverse phase HPLC were
varying concentrations of acetonitrile and water with 0.1%
trifluoroacetic acid.
[0849] Compounds of the present invention can be readily
synthesized using the methods described herein, or other methods,
that are well known in the art. For example, the synthesis of
hxdroxamic acids or similar scaffolds having a wide variety of
substituents are comprehensively reviewed in Kline, T., et al.,
"Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa
deacetylase LpxC" J. Med Chem. 2002, 45(14), 3112-29; U.S. Pat. No.
5,925,659; Pirrung, M. C., et al., "A Convenient Procedure for the
Preparation of Amino Acid Hydrokamates from Esters" J. Org. Chem.
1995, 60, 8084-8085; Nhu, K., et al., "A New and Efficient Solid
Phase Synthesis of Hydroxamic Acids" J. Org. Chem. 1997, 62,
7088-7089; Internationa PCT Publication No. WO98/18754; Mellor, S.
L., et al., "N-Fmoc-aminoxy-2-chlortrityl Polystyrene Resin: A
Facile Solid-phase Methodology for the Synthesis of Hydroxamic
Acids" Tetrahedron Lett. 1997, 38, 3311-3314; Khan, S. I., et al.,
"A Facile and Convenient Solid-phase Procedure for Synthesizing
Nucleoside Hydroxamic Acids" Terahedron. Lett. 1998, 39, 8031-8034;
Zhang, Y., et al., "Design, Combinatorial Chemical Synthesis, and
in vitro Characterization of Novel Urea Based Gelatinase
Inhibitors" Bioorg. Med. Chem. Lett. 1999, 9, 2823-2826; Ito, Y.,
et al., "Synthetic Reactions by Complex Catalysts. XXXI, A Novel
and Versatile Method of Heterocycle Synthesis" J. Am Chem. Soc.
1973, 95, 4447-4448; Ito, Y., et al., "Synthetic Reactions by
Complex Catalysts XXXV" Syn. Commun. 1974, 4, 97-103; Witte, H., et
al., "Cyclische Imidsaurester aus Nitrilen and Aminoalkoholen"
Liebigs Ann. Chem. 1974, 996-1009; Pattenden, G., et al.,
"Naturally Occurring Linear Fused Thiazoline-Thiazole Containing
Metabolites: Total Synthesis of (-) Didehydromirabazole A, a
Cytotoxic Alkaloid from Blue-Green Algae" J. Chem. Soc. Perkin
Trans 1993, 1, 1629-1636; Boyce, R. J., et al., "Total Synthesis of
Thiangazole, A Novel Naturally Occurring HIV-1 Inhibitor from
Polyangium sp." Tetrahedron 1995, 51, 7321-7330; Galeotti, N., et
al., "Synthesis of Peptidyl Aldehydes from Thiazolines"
Tetrahedron. Lett. 1997, 38, 2459-2462; Charette, A. B., et al.,
"Mild Method for the Synthesis of Thiazolines from Secondary and
Tertiary Amides" J. Org. Chem. 1998, 63, 908-909; Bergeron, R. J.,
et al., "Effects of C-4 Stereochemistry and C-4' Hydroxylation on
the Iron Clearing Efficiency and Toxicity of Desferrithiocin
Analogues" J. Med. Chem. 1999, 42, 2432-2440; Raman, P., et al.,
"Titanium (IV)-mediated Tandem Deprotection-cyclodehydration of
Protected Cysteine N-Amides: Biomimetic Synthesis of Thiazoline-
and Thiazole-containing Heterocycles" Org. Lett. 2000, 2,
3289-3292; Fernandez, X., et al., "Novel Synthesis of
2-Thioazolines" Tetrahedron Lett. 2000, 41, 3381-3384; and Wipf,
P., et al., "C. Thiolysis of Oxazolinenes: A New, Selective Method
for the Direct Conversion of Peptide Oxazolines into Thiazolines"
Tetrahedron Lett. 1995, 36, 6395-6398, which are incorporated
herein by reference.
[0850] The synthesis of other non-hydroxamates compounds or more
generally zinc binding groups are reviewed in Pirrung, M. C., et
al., "Inhibition of the Antibacterial Target
UDP-(3-O-acyl)-N-acetylglucosamine Deacetylase (LpxC): Isoxazoline
Zinc Amidase Inhibitors Bearing Diverse Metal Binding Groups" J.
Med. Chem. 2002, 45(19), 4359-4370; Jackman, J. E., et al.,
"Antibacterial agents that target lipid A biosynthesis in
gram-negative bacteria: inhibition of diverse
UDP-3-O--(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylases by
substrate analogs containing zinc binding motifs" J. Bio. Chem.
2000, 275(15), 11002-11009; Brooks, C. D. W., et al, "Modulators of
Leukotriene Biosynthesis and Receptor Activation" J. Med. Chem.
1996, 39(14), 2629-2654; Jeng, A. Y., et al., "Endothelin
converting enzyme inhibitors" Current Pharmaceutical Design 1997,
3(6), 597-614; Zask, A., et al., "Inhibition of matrix
metalloproteinases: structure based design" Current Pharmaceutical
Design 1996, 2(6), 624-661; Skotnicki, J. S., et al., Current
Opinion in Drug Discovery & Development 2003, 6(5),
742-759.
[0851] The foregoing may be better understood by reference to the
following examples, that are presented for illustration and not to
limit the scope of the inventive concepts.
EXAMPLES
[0852] The following are abbreviations used in the examples: [0853]
AcOH: Acetic acid [0854] aq: Aqueous [0855] ATP: Adenosine
triphosphate [0856] Boc: tert-butoxycarbonyl [0857] Boc-Thr(OBn)-OH
3-(R)-Benzyloxy-2-(S)-tert-butoxycarbonylaminobutyric acid [0858]
DAP or Dap: Diaminopropionate [0859] DCM:
4-(Dicyanomethylene)-2-methyl-6-(4-dimethylaminostyryl)-4H-pyran
[0860] DEAD: Diethyl azodicarboxylate [0861] DIEA:
Diisopropylethylamine [0862] DME: 1,2-dimethoxyethane [0863] DMF:
N,N-Dimethylformamide [0864] DMSO: Dimethyl sulfoxide [0865] DPPA:
Diphenyl phosphoryl azide [0866] Et.sub.3N: Triethylamine [0867]
EDC: N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide [0868] EDCI:
1-(3-dimethylaminopropyl)3-ethylcarbodiimide [0869] EtOAc: Ethyl
acetate [0870] EtOH: Ethanol [0871] Fmoc:
9-fluorenylmethoxycarbonyl [0872] Gly-OH: glycine [0873] HATU:
O-(7-azabenzotriaazol-1-yl)-N,N,N'N'=tetramethyluronium
hexafluorophophate [0874] HBTU:
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate [0875] Hex: hexane [0876] HOBt: butyl alcohol
[0877] HOBT: 1-Hydroxybenzotriazole [0878] HPLC: High Pressure
Liquid Chromatography [0879] IC.sub.50 value: The concentration of
an inhibitor that causes a 50% reduction in a measured activity.
[0880] iPrOH: Isopropanol [0881] LC/MS: Liquid Chromatography/Mass
Spectrometry [0882] LRMS: Low Resolution Mass Spectrometry [0883]
MeOH: Methanol [0884] NaOMe: sodium methoxide [0885] nm: Nanometer
[0886] NMP: N-Methylpyrrolidone [0887] PPh.sub.3: triphenyl
phosphine [0888] RP-HPLC: Reversed-phase high-pressure liquid
chromatography [0889] RT: Room temperature [0890] sat: Saturated
[0891] TEA: Triethylamine [0892] TFA: Trifluoroacetic acid [0893]
THF: Tetrahydrofuran [0894] Thr: Threonine [0895] TLC: Thin Layer
Chromatography [0896] Trt-Br: Tert-butyl bromide
[0897] Nomenclature for the Example compounds was provided using
ACD Name version 5.07 software (Nov. 14, 2001) available from
Advanced Chemistry Development, Inc. In addition, some of the
compounds were named using ChemDraw Ultra 9.0 and ChemDraw Ultra
11.0 software available from CambridgeSoft Corporation. Some of the
compounds and starting materials were named using standard IUPAC
nomenclature.
Synthesis of N-Aryl Threonine Analogues and Formation of
Hydroxamate
Example 1
Synthesis of
3-bromo-4-fluoro-N-{(1S,2R)-2-hydroxy-1-[(hydroxyamino)carbonyl]propyl}be-
nzamide (3)
Preparation of
(2S,3R)-2-(3-bromo-4-fluoro-benzoylamino)-3-hydroxy-butyric acid
methyl ester (2)
[0898] Diisopropylethylamine (6.8 mL, 39.0 mmol) was added to a
stirred solution of 3-bromo-4-fluorobenzoic acid (1) (2.152 g, 9.83
mmol), L-threonine methyl ester hydrochloride (1.968 g, 11.6 mmol),
EDCI (2.218 g, 11.6 mmol) and HOBt (1.410 g, 10.4 mmol) in
anhydrous DMF (60 mL) at 0.degree. C. under N.sub.2. The solution
was stirred at 0.degree. C. for 1 h and at room temperature for 20
h. The solution was diluted with EtOAc (300 mL) and washed with 1.0
M HCl (2.times.80 mL), saturated NaHCO.sub.3 (2.times.80 mL),
H.sub.2O (4.times.80 mL), dried over MgSO.sub.4, filtered and
concentrated in vacuo to give a colorless syrup which solidified on
standing to afford 3.280 g (100%) of (2) as a white solid, mp
73-74.degree. C. MS (ES+) m/z 333.9 (C.sub.12H.sub.13BrFNO.sub.4+H
requires 334.00).
Preparation of
3-bromo-4-fluoro-N-{(1S,2R)-2-hydroxy-1-[(hydroxyamino)carbonyl]propyl}be-
nzamide (3)
[0899] To a solution of hydroxylamine hydrochloride (66 mg, 0.95
mmol) in anhydrous MeOH (2.0 mL) at 0.degree. C. under N.sub.2
atmosphere was added sodium methoxide (25 wt % in MeOH, 360 mg,
1.67 mmol). A precipitate formed immediately and the cloudy white
solution was stirred for 10 minutes at 0.degree. C. A solution of
(2) (284 mg, 0.850 mmol) in MeOH (2.0 mL) was added and the
reaction stirred 2 h at 0.degree. C. and then warmed gradually to
room temperature overnight (17 h total). Aqueous 1.0 M HCl (10 mL)
was added and the solution extracted with 4:1 chloroform/isopropyl
alcohol (4.times.20 mL). The organic layers were combined, dried
over Na.sub.2SO.sub.4 and concentrated to give a pink foam. The
crude solid was triturated with diethyl ether (2.times.8 mL) and
dried in vacuo to give (3) as a white foam: mp 152-153.degree. C.
Rf (10:1 CH.sub.2Cl.sub.2/MeOH on silica gel)=0.53.
Preparation of Hydroxamates
Example 2
Synthesis of
4-benzoyl-N-{(1S,2R)-2-hydroxy-1-[(hydroxyamino)carbonyl]propyl}benzamide
(2)
[0900] To a solution of hydroxylamine hydrochloride (121 mg, 1.74
mmol) in anhydrous MeOH (2.0 mL) at 0.degree. C. under N.sub.2
atmosphere was added sodium methoxide (25 wt % in MeOH, 680 mg,
3.14 mmol). A precipitate was immediately observed and the cloudy
white solution was stirred for 10 minutes at 0.degree. C. A
solution of methyl
(2S,3R)-3-hydroxy-2-{[4-(phenylcarbonyl)phenyl]carbonylamino}butanoate
(1) (534 mg, 1.56 mmol) in MeOH (3.0 nL) was added and the reaction
stirred 3 h at 0.degree. C., then warmed gradually to ambient
temperature overnight (18 h total). Aqueous 0.5 M HCl (20 mL) was
added and the solution extracted with 5:1 chloroform/isopropyl
alcohol (4.times.40 mL). The organic layers were combined, dried
over Na.sub.2SO.sub.4 and concentrated to give an orange foam.
Purification by silica gel chromatography (increasing eluant
polarity from 30:1 CH.sub.2Cl.sub.2/MeOH to 15:1
CH.sub.2Cl.sub.2/MeOH) afforded 228 mg (43%) of (2).
Example 3
Synthesis of
(2R,3R)-3-hydroxy-1-{[4-(trifluoromethoxy)phenyl]carbonyl}pyrrolidine-2-c-
arbohydroxamic acid (3)
Preparation of
((2R,3R)-3-hydroxy-1-{[4-(trifluoromethoxy)phenyl]carbonyl)}
pyrrolidin-2-yl)-N-(phenylmethoxy)carboxamide (2)
[0901] To a solution of
(2R,3R)-3-hydroxy-1-{[4-(trifluoromethoxy)phenyl]
carbonyl}pyrrolidine-2-carboxylic acid (1) (405 mg, 1.27 mmol),
benzylhydroxylamine hydrochloride (243 mg, 1.52 mmol), HATU (556
mg, 1.46 mmol), and HOBt (178 mg, 1.32 mmol) in DMF (10 mL) at
0.degree. C. was added diisopropylethylamine (710 .mu.L, 4.07 mmol)
with stirring. The cooling bath was removed after one hour and the
reaction mixture stirred at ambient temperature for 18 h and then
diluted with EtOAc (200 mL). The organic layer was washed with 1.0
M HCl (2.times.60 mL), sat. NaHCO.sub.3 (2.times.60 mL) and
H.sub.2O (5.times.60 mL), dried over MgSO.sub.4 and concentrated to
give 493 mg (92%) of (2), a colorless oil that slowly crystallized
upon standing. Rf (25:1 CH.sub.2Cl.sub.2/MeOH)=0.35.
Preparation of
(2R,3R)-3-hydroxy-1-{[4-(trifluoromethoxy)phenyl]carbonyl}pyrrolidine-2-c-
arbohydroxamic acid (3)
[0902] To a solution of (2) (143 mg, 0.337 mmol) in EtOH (10 mL)
was added 20% Pd(OH).sub.2/C (50 mg). The solution was purged with
hydrogen gas (approx. 0.5 L from a 1 L balloon) and then stirred
under an atmosphere of H.sub.2 (balloon pressure). TLC analysis
showed no starting material after one hour. The solution was
diluted with EtOAc (10 mL) and filtered through celite, washing
with 20:1 EtOAc/EtOH (50 mL) The solution was concentrated and
dried in vacuo to afford 90 mg (80%) of (3) as a sticky white foam:
mp 64-65.degree. C. Rf (10:1 CH.sub.2Cl.sub.2/MeOH)=0.29.
Synthesis of N-Benzyl Threonine Analogues by Reductive
Amination
Example 4
Synthesis of
(2S,3R-3-hydroxy-2-{[(4-phenylphenyl)methyl]amino}butanehydroxamic
acid (3)
[0903] Triethyl amine (1.70 mL, 12.1 mmol) was added to a stirred
suspension of L-threonine methyl ester hydrochloride (1.030 g, 6.07
mmol) and 4-biphenylcarboxaldehyde (1) (1.104 g, 6.06 mmol) in THF
(25 mL). After 20 min, NaBH(OAc).sub.3 (1.800 g, 8.49 mmol) was
added and the suspension stirred for 20 h. The reaction was
monitored by TLC (50:1 DCM/MeOH, R.sub.f=0.4). The reaction mixture
was quenched with saturated NaHCO.sub.3 (50 mL), extracted with
EtOAc (2.times.120 mL), dried over MgSO.sub.4, filtered and
concentrated to give a yellow oil. Purification by silica gel
chromatography (150:1 DCM/MeOH) afforded 1.220 g (67% yield, 98%
pure) of (2) as a pale yellow oil. HPLC (260 nm, 34 min run) 14.2
min; LRMS (ES+) m/z 299.9 (C.sub.18H.sub.21NO.sub.3+H requires
300.10).
[0904] Compound (3) was then formed by the addition of NH.sub.2OH
in MeOH/NaOMe at 0.degree. C., warming to ambient temperature of
the period of several hours. LCMS MH+301.15.
General Methods for Making Phenyl-Benzoic Acids and Phenyl-Benzoate
Esters (See Example 5 Below)
##STR00044##
[0905] Suzuki Procedures Using Pd(Dppf)Cl.sub.2-DCM Catalyst and a
THF/H.sub.2O Mixture
##STR00045##
TABLE-US-00001 Reagent MW Eq. g/ml mmol BromoArene #1 ~300 1 100 mg
~0.33 Boronic Acid #2 -- 1.2 -- ~0.40 Na.sub.2CO.sub.3 105.99 3 104
m ~0.99 Pd(dppf)Cl.sub.2 816.63 0.1-0.2 27-54 mg ~0.033-0.066 THF
(3) (sparged with 0.75 ml argon for 5 min.) water (1) (sparged with
0.25 ml argon for 5 min.)
[0906] 1 eq aryl halide (1) was added to 1.2 eq. (2) and
Pd(dppf)Cl.sub.2 in THF, followed by addition of water and stirred
8 hours at RT. Upon completion (usually over night), the reactions
are diluted with ethyl acetate (5-10 ml) and water (1 ml). The
organic layer is separated and washed with NaHCO.sub.3 (2.times.3
ml), water (1.times.3 ml), brine (1.times.3 ml), dried with
Na.sub.2SO.sub.4, filtered and concentrated in an 8 ml glass vial.
The residue is dissolved in DMSO and injected on a preparatory HPLC
reverse phase column to afford >80% yield.
Suzuki Procedures Using Pd(Dppf)Cl.sub.2-DCM Catalyst and DMF
Solvent
##STR00046##
TABLE-US-00002 [0907] Reagent MW Eq. g/ml mmol BromoArene #1 ~500 1
20 mg ~0.04 Boronic Acid #2 ~200 2 ~14 mg ~0.08 Pd(dppf)Cl.sub.2
816.63 0.25 10 mg ~0.01-0.02 TEA 101.19 5 28 .mu.L ~0.2 DMF (dry
& sparged with 0.5 ml argon for 5 min.)
[0908] The haloarene (1) and boronic acid (2) were weighed out and
placed in the reaction flask. The DMF was sparged with argon for
5-10 minutes, followed by TEA addition, and the reaction was
lightly bubbled with argon. The solid Pd(dppf)Cl.sub.2 catalyst was
added in one portion. The vial was flushed with argon, capped tight
and stirred or shaken at .about.80.degree. C. Upon reaching
completion (over night), the reaction was filtered and injected on
a preparatory HPLC reverse phase column (80% yield).
Synthesis of Methyl DAP Analogues
Example 5
3-(R)-Amino-2-(S)-[(4'-ethyl-biphenyl-4-carbonyl)-amino]-butyl-hydroxamic
acid (8)
Preparation of N-triphenylmethyl allo-threonine Methyl Ester
(2)
[0909] *For similar-procedures see: Righi, P., et al., B. Organic
Letters 2002, 4(4), 497-500.
[0910] A solution of trityl bromide (3.2 g, 10.0 mmol) in
CHCl.sub.3 (40 ml) was added dropwise to a stirred solution of
allo-threonine methyl ester HCl salt (1) (2.0 g, 12.0 mmol) and
DIEA (5.2 ml, 30.0 mmol) in CHCl.sub.3 (60 ml) at rt under N.sub.2.
The reaction could be followed by TLC eluting with EtOAc/Hex
(40:60) (Rf=0.3). After stirring 12 h, the reaction was
concentrated to a brown oil. The crude product was diluted with
EtOAc (170 ml) and washed with 0.2 N citric acid (2.times.50 ml),
water (2.times.50 ml), brine (50 ml), dried (Na.sub.2SO.sub.4),
filtered and concentrated under reduced pressure to yield 3.73 g
(85% yield, 95% pure) of (2) as a yellow solid. HPLC (220 nm, 41
min. run) 30.90 min.; HPLC (220 nm, 17 min. run) 14.86 min.;
LCMS:LC (214 nm) 3.06 min., MS (ES+) m/z 376.2
(C.sub.24H.sub.25NO.sub.3+H requires 376.18).
Preparation of 3-(R)-Azido-2-(S)-(trityl-amino)-butyric Acid Methyl
Ester (3)
[0911] *For similar procedures see: Matsuda, A., et al., J. Med.
Chem. 1991, 34, 999-1002.
[0912] A solution of pure DEAD (2.9 ml, 17.8 mmol) in THF (5 ml)
was added slowly dropwise to a stirred solution of
trt-allo-threonine methyl ester (2) (4.1 g, 10.9 mmol) and
PPh.sub.3 (2.9 g, 10.9 mmol) in THF (40 ml) at 0.degree. C. under
N.sub.2. After 3 min., a solution of DPPA (6.4 ml, 29.7 mmol) in
THF (5 ml) was added to the orange-yellow reaction solution at
0.degree. C. After 1 h, the reaction was allowed to warm to rt.
After 40 h, the reaction had reached completion by TLC
(Hexane/DCM/EtOAc (64:20:16) (Rf=0.6)) and LCMS. The yellow
solution was concentrated to give 18 g of crude material that was
purified by column chromatography eluting with Hexane/EtOAc (88:12)
giving 3.5 g of 70% pure product after evaporation. The product was
purified again (to remove trityl alcohol and a crotyl side-product
formed during the reaction by elimination) by column chromatography
eluting with Hexane/DCM/EtOAc (76:20:4) giving 1.65 g (38% yield)
of (3) as a pale yellow oil after concentration and drying in
vacuo. Note that the trityl protecting group would hydrolyze when
exposed to TFA while running the sample on HPLC.
[0913] Alternately, the reaction could be carried out in dry DCM. A
reaction using 5.44 g (14.5 mmol) of trt-allo-threonine methyl
ester (2) in DCM (100 ml) with PPh.sub.3 (3.8 g, 14.5 mmol), pure
DEAD (3.4 ml, 21.8 mmol) in DCM (5 ml) and DPPA (6.3 ml, 24.0 mmol)
in DCM (10 ml) were combined following the procedure above. After 3
days, the reaction did not progress further by TLC and LCMS. After
the same work up, 2.97 g of the product was obtained in 51%
yield.
[0914] HPLC (220 nm, 41 min. run) 40.5 min.; HPLC (220 nm, 17 min.
run) 16.32 min.; LCMS: LC (214 nm) 3.7 min., MS (ES+) m/z 401.2
(C.sub.24H.sub.25N.sub.3O.sub.2+H requires 401.15).
Preparation of 2-(S)-Amino-3-(R)-azido-butyric acid methyl ester
HCl salt (4)
[0915] A solution of Trt-Azido-Thr-OMe (3) (4.8 g, 12.0 mmol) was
dissolved in a 95% TFA/DCM solution (60 ml) at rt with stirring.
After 2.5 h, the reaction was complete by LCMS. The bright yellow
solution was diluted with 0.5 N aq. HCl (300 ml). The aqueous layer
was extracted with DCM (2.times.30 ml) and then lyophilized to
dryness. The white solid was dissolved in AcCN/water (50:50) (100
ml) and again lyophilized to dryness to produce a consistent powder
and remove as much of the TFA as possible. The azido-Thr product
(4), 2.26 g (97% yield, 95% pure) of a white solid, was obtained as
the HCl salt. HPLC (220 nm, 41 min. run) 7.91 min.; HPLC (220 nm,
17 min. run) 3.36 min; LCMS: LC (214 nm) 0.48 min., MS (ES+) m/z
159.3 (C.sub.5H.sub.10N.sub.4O.sub.2+H requires 159.08).
Preparation of
3-(R)-Azido-2-(S-[(4'-ethyl-biphenyl-4-carbonyl)-amino]-butyric
acid methyl ester (6)
[0916] An EDC.HCl (249 mg, 1.3 mmol) was added to a stirred
colorless solution of azido-Thr-OMe.HCl (4) (195 mg, 1.0 mmol),
HOBT (158 mg, 1.0 mmol), 4'-Ethyl-biphenyl-4-carboxylic acid (5)
(226 mg, 1.0 mmol) and DIEA (0.44 ml, 2.5 mmol) in DCM (10 ml) at
rt under N.sub.2. After 24 h, the reaction had reached completion
by TLC (Hexane/EtOAc (60:40) (Rf=0.3)) and LCMS. The reaction was
evaporated under reduced pressure to a brown tar. The crude product
was dissolved in EtOAc (100 ml) and washed with 0.2N aq. HCl
(2.times.50 ml), aq. sat. NaHCO.sub.3 (50 ml), brine (50 ml), dried
(Na.sub.2SO.sub.4), filtered and concentrated under reduced
pressure to yield a crude brown solid. The crude material was
further purified by column chromatography eluting with Hexane/EtOAc
(70:30) giving 245 mg (67% yield) of pure product (6) after
evaporation and drying in vacuo. HPLC (220 nn, 41 min. run) 33.87
min.; HPLC (220 nm, 17 min. run) 15.61 min; LCMS: LC (214 nm) 3.25
min., MS (ES+) m/z 367.2 (C.sub.20H.sub.22N.sub.4O.sub.3+H requires
367.17).
Preparation of
3-(R)-Amino-2-(S)-[(4'-ethyl-biphenyl-4-carbonyl)-amino]-butyric
acid methyl ester (7)
[0917] A solution of biphenyl azido-Thr methyl ester (6) (244 mg,
0.67 mmol) in MeOH (10 ml) was made by sonicating until the milky
precipitate cleared. After bubbling nitrogen through the reaction
solution for 30 sec., 10% Pd/C was added in one portion. The
reaction was stirred under nitrogen at RT. The reaction was exposed
to aspirator vacuum to remove the nitrogen and then opened to the
hydrogen gas at balloon pressure (.about.1 atm). The reaction
stirred for 3 h at which time the hydrogen was exchanged for
nitrogen. The reaction was filtered through a pad of celite to
remove the palladium. The celite pad was washed with MeOH (30 ml).
The combined fractions of MeOH were evaporated under reduced
pressure and dried in vacuo to give 225 mg (99% yield) of pure
product (7) as a white solid. HPLC (220 nm, 17 min. run) 10.79
min.; LCMS: LC (214 nm) 2.21 min., MS (ES+) m/z 341.2
(C.sub.20H.sub.24N.sub.2O.sub.2+H requires 341.18).
Preparation of
3-(R)-Amino-2-(S)-[(4'-ethyl-biphenyl-4-carbonyl)-amino]-butyl-hydroxamic
acid (8)
[0918] To a stirred suspension of biphenyl-amino-Thr methyl ester
(7) (225 mg, 0.6 mmol) and hydroxylamine HCl salt (460 mg, 6.6
mmol) in MeOH (7 ml) and DCM (5 ml) was added fresh solid NaOMe
powder (430 mg, 7.92 mmol) in one portion. After stirring for 2
min. at rt under nitrogen, the pH of the reaction on wet pH paper
was approximately 7-8. The suspension had change from larger
particles of white solid to a finely-divided milky consistency. The
pH of the reaction was checked after adding small portions of NaOMe
(50-100 mg) and allowing 2 min. for the reaction to equilibrate.
The pH of the reaction reached a stable 11-12 after the final
portion of NaOMe was added (250 mg total). The reaction was
initiated at pH 11 and proceeded quickly. After 30 min., the
reaction reached 85% completion as determined by LCMS, and the
reaction was placed in a -10.degree. C. bath. The cold mixture
filtered over fine filter paper on a Buchner funnel. The white
residue was washed with MeOH (15 ml). The organic fractions were
collected and concentrated under reduced pressure to give crude
product (750 mg). The crude product (only one 150 mg portion) was
dissolved in DMSO (1 ml), AcCN (1000 and water (100 .mu.l), passed
through a Teflon syringe filter, and the clear filtrate was
injected on a preparative HPLC. The purification used a 20.times.50
mm Ultro 120 C18 column running a 22 ml/min 2% gradient
(AcCN/water, 0.1% TFA) for 16 min. The purified fractions were
lyophilized to dryness. The product as the TFA salt was dissolved
in AcCN/water (50:50) (5 ml), 1N aq. HCl (1 equivalent) and
lyophilized again to give 11.5 mg of (8) as a white powder as an
HCl salt (23% yield). HPLC (220 nm, 41 min. run) 19.31 min.; HPLC
(220 nm, 17 min. run) 9.39 min; LCMS: LC (214 nm) 1.98 min., MS
(ES+) m/z 342.2 (C.sub.19H.sub.23N.sub.3O.sub.3+H requires
342.17).
Synthesis of 4'-Benzamide Biphenyl Threonine Hydroxamic Acid
Example 6
Biphenyl-4,4'-dicarboxylic acid 4'-[(3-Boc-amino-propyl)-amide]
4-[((2R)-hydroxy-(1S)-hydroxycarbamoyl-propyl)-amide] (6)
and
Example 7
Biphenyl-4,4'-dicarboxylic acid 4'-[(3-amino-propyl)-amide]
4-[((2R)-hydroxy-(1S)-hydroxycarbamoyl-propyl)-amide] (7)
Synthesis of
(2S,3R)-2-amino-3-(phenylmethoxys)-N-(phenylmethoxy)butanamide
(1)
[0919] To a suspension of benzylhydroxylamine hydrochloride (8.310
g, 52.06 mmol), Boc-Thr(OBn)-OH (14.01 g, 45.28 mmol), EDCI (10.01
g, 52.21 mmol), and HOBt (6.90 g, 51.06 mmol) in CH.sub.2Cl.sub.2
(300 mL) at 0.degree. C. was added diisopropylethylamine (28.3 mL,
162 mmol) with stirring. The cooling bath was removed after one
hour and the reaction mixture stirred at ambient temperature for 20
h and was then diluted with CH.sub.2Cl.sub.2 (300 mL). The organic
layer was washed with 1.0 M HCl (2.times.200 mL), sat. NaHCO.sub.3
(2.times.200 mL) and brine (200 mL), dried over MgSO.sub.4 and
concentrated to give 14.5 g of a white solid. The crude solid was
treated with a solution of trifluoroacetic acid (90 mL) in
CH.sub.2Cl.sub.2 (90 mL) and stirred for 2.5 h. The reaction
mixture was concentrated by rotary evaporation and then diluted
with CH.sub.2Cl.sub.2 (600 mL). The organic layer was washed with
sat. NaHCO.sub.3 (2.times.200 mL), dried over MgSO.sub.4 and
concentrated to give a dark orange oil. Purification by silica gel
chromatography (50:1 CH.sub.2Cl.sub.2/MeOH) afforded (1) (8.9 g) as
a pale yellow oil. Rf (50:1 CH.sub.2Cl.sub.2/MeOH on silica
gel)=0.2.
Preparation of
(1S,2R)-4'-(2-benzyloxy-1-benzyloxycarbamoyl-propylcarbamoyl)-biphenyl-4--
carboxylic acid (3)
[0920] To a suspension of 4,4'-biphenyldicarboxylic acid (2) (1.360
g, 5.61 mmol) in DMF (180 mL) was added BOP (2.007 g, 4.54 mmol)
and DIEA (1.7 mL, 9.8 mmol). A solution of (1) (944 mg, 3.00 mmol)
in DMF (20 mL) was added and the reaction stirred for 18 h. The
solution was diluted with EtOAc (250 mL) and washed with 1.0 M HCl
(500 mL). The aqueous layer was extracted with EtOAc (250 mL) and
the organic layers combined. The organic layer was washed with 1.0
M HCl (250 mL), dried over MgSO.sub.4, and concentrated to give a
crude yellow solid. Purification by silica gel chromatography (60:1
CH.sub.2Cl.sub.2/MeOH) gave 210 mg (3) (13% yield) as a yellow
solid. R.sub.f=0.80 (10:1 CH.sub.2Cl.sub.2/MeOH); LRMS (ES+) m/z
539.1 (C.sub.32H.sub.30N.sub.2O.sub.6+H requires 539.22).
Preparation of biphenyl-4,4'-dicarboxylic acid
4'-[(3-(Boc)-amino-propyl)-amide]4-[(2R)-benzyloxy-(1S)-benzyloxycarbamoy-
l-propyl)-amide] (5)
[0921] To a solution of (3) (200 mg, 0.371 mmol), EDCI (78 mg,
0.407 mmol), and HOBt (52 mg, 0.385 mmol) in DMF (2 mL) was added
t-Butyl N-(3-aminopropyl)carbamate (4) (71 mg, 0.407 mmol) and DIEA
(180 .mu.L, 1.0 mmol). The reaction mixture was stirred 24 h,
diluted with EtOAc (150 mL), washed with 1.0 M HCl (2.times.60 mL),
saturated NaHCO.sub.3 (2.times.60 mL), H.sub.2O (3.times.60 mL),
dried over MgSO.sub.4 and concentrated to give a crude white solid.
Purification by silica gel chromatography (25:1
CH.sub.2Cl.sub.2/MeOH) afforded 194 mg (75% yield) of (5) as a
white solid. R.sub.f=0.15 (50:1 CH.sub.2Cl.sub.2/MeOH); LRMS (ES+)
m/z 695.2 (C.sub.40H.sub.46N.sub.4O.sub.7+H requires 695.35).
Preparation of Biphenyl-4,4'-dicarboxylic acid
4'-[(3-Boc-amino-propyl)-amide]4-[((2R)-hydroxy-(1S)-hydroxycarbamoyl-pro-
pyl)-amide] (6)
[0922] A solution of (5) (190 mg, 0.273 mmol) in THF (5 mL) and
MeOH (3 mL) was charged with Pd(OH).sub.2 (20%/C, 20 mg, 0.04 mmol)
and stirred under a hydrogen atmosphere (balloon pressure) for 16
h. The crude mixture was filtered through a plug of celite eluting
with 2:1 MeOH/THF (15 mL) and concentrated to give an orange syrup.
Purification by silica gel chromatography (5:1:1
THF/MeOH/CH.sub.2Cl.sub.2) afforded 110 mg (78% yield) of (6) as a
white foam, mp 75-77.degree. C. R.sub.f=0.20 (10:1
CH.sub.2Cl.sub.2/MeOH); LRMS (ES+) m/z 515.4
(C.sub.26H.sub.34N.sub.4O.sub.7+H requires 515.26).
Preparation of Biphenyl-4,4'-dicarboxylic acid
4'-[(3-amino-propyl)-amide]4-[((2R)-hydroxy-(1S)-hydroxycarbamoyl-propyl)-
-amide] (7)
[0923] A flask containing (6) (80 mg, 0.155 mmol) was treated with
50% TFA/CH.sub.2Cl.sub.2 (6.0 mL) and stirred for 2.5 h. The
reaction mixture was concentrated by rotary evaporation to give a
brown syrup. Purification by RP-HPLC (C.sub.18 column, CH.sub.3CN
gradient 5-70%, 0.1% TFA, UV analysis 300 nm, 36 min) and
lyophilization of the collected fractions afforded 14 mg (21%
yield) of (7) as a white solid. LRMS (ES+) m/z 415.3
(C.sub.21H.sub.26N.sub.4O.sub.5+H requires 415.20); RP-HPLC (300
nm, 36 min run) 18.2 min.
Example 8
Synthesis of
N-(2-(N-hydroxycarbamoyl)(2S)-2-{[4-(4-ethylphenyl)phenyl]carbonylamino}e-
thyl)acetamide (4)
Preparation of
3-Acetylamino-2-(9H-fluoren-9-ylmethoxycarbonylamino)-propionic
acid (2)
[0924] Acetic anhydride (425 uL) in THF (5 ml) was added to a
cloudy mixture of Fmoc-DAP-H (1) (980 mg, 3.0 mmol) and pyridine
(483 uL, 6.0 mmol) in THF (15 ml) with stirring at rt. After 4
hours, the clear pale yellow solution had reacted completely by
LCMS. The reaction was evaporated under reduced pressure. The
residue was dissolved in EtOAc (150 ml) and washed with 0.1M
NaHSO.sub.4 (50 ml), water (50 ml), sat. brine (50 ml), dried with
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give 1.1 g of crude product as a white solid. The crude product
was purified by prep. HPLC to give 0.99 g (90% yield) of (2).
Preparation of (2-Acetylamino-1-hydroxycarbamoyl-ethyl)-carbamic
acid 9H-fluoren-9-ylmethyl ester trityl resin (3)
[0925] A solution of (2) (980 mg, 0.56 mmol), HATU (0.146 g, 0.56
mmol) in NMP (1.7 ml) was made. After 2 min. of shaking, the
activated acid was added to the deprotected H.sub.2N--O-Trt Resin
(120 mg, 0.113 mmol) at rt with shaking. Deprotection of the Fmoc
group from the resin was accomplished using 20% piperizine in DMF
(4 ml) for 2 hours twice. The resin was drained and washed with DMF
(2.times.5 ml) and DCM (2.times.5 ml).] After shaking for 20 hours,
the reaction was drained and washed with DMF (2.times.5 ml) and DCM
(2.times.5 ml). The resin (3) was dried and used as is in the next
reaction.
Preparation of
N-(2-(N-hydroxycarbamoyl)(2S)-2-{[4-(4-ethylphenyl)phenyl]
carbonylamino}ethyl)acetamide (4)
[0926] Resin (3) was treated with 20% piperizine in DMF (4 ml) for
2 hours twice. The resin was drained and washed with DMF (2.times.5
ml) and DCM (2.times.5 ml). The resin was dried in vacuo. A
solution of 4'-Ethyl-biphenyl-4-carboxylic acid (91 mg, 0.4 mmol),
HATU (152 g, 0.4 mmol) in NMP (1.0 ml) was made. After 2 min. of
shaking, the activated acid was added to the deprotected
H-DAP(Ac)-Trt resin (120 mg, 0.113 mmol) at rt with shaking. After
shaking for 18 hours, the reaction was drained and washed with DMF
(2.times.5 ml) and DCM (2.times.5 ml). The resin was dried in
vacuo. The product was cleaved from the resin through treatment
with a solution of TFA (500 uL), DCM (500 uL) and water (50 uL) for
25 min. The resin was filtered and washed with fresh DCM (2 ml).
The combined TFA and DCM fractions are evaporated under reduced
pressure. The residue was diluted with CH.sub.3CN/water (1:1) (10
ml) and lyophilized. The crude product was purified by prep. HPLC.
The crude product was dissolved in DMSO (1 ml), passed through a
Teflon syringe filter, and the clear filtrate was injected on a
preparative HPLC. The purification used a 20.times.50 mm Ultro 120
C18 column running a 22 ml/min 2% gradient (AcCN/water, 0.1% TFA)
for 16 min. The purified fractions were lyophilized to dryness. The
solid residue was lyophilized again from CH.sub.3CN/water (1:1) (5
ml) give 8.6 mg of pure product (4) (.about.21% yield).
Example 9
Synthesis of 4'-Ethyl-biphenyl-4-carboxylic acid
(1-hydroxycarbamoyl-2-methanesulfonylamino-ethyl)-amide (3)
Preparation of 4'-Ethyl-biphenyl-4-carboxylic acid
(2-amino-1-hydroxycarbamoyl-ethyl)-amide trityl resin (2)
[0927] Pd(PPh.sub.3).sub.4 (438 mg, 0.35 mmol) was added to a vial
containing biphenyl-DAP(Alloc)-Trt Resin (1) (500 mg, 0.35 mmol),
dimethyl barbituric acid (600 mg, 3.5 mmol) and PPh.sub.3 (438 mg,
0.35 mmol) in DCM (11 ml) at rt under argon. The mixture was
sparged with argon and shaken for 16 hours. The bright yellow
mixture was drained and washed with DMF (8.times.10 ml) and DCM
(8.times.10). The resin was dried in vacuo to give the deprotected
DAP resin (2).
Preparation of 4'-Ethyl-biphenyl-4-carboxylic acid
(1-hydroxycarbamoyl-2-methane sulfonylamino-ethyl)-amide (3)
[0928] Methanesulfonyl chloride (85 uL, 1.1 mmol) was added to a
mixture of deprotected DAP resin (2) (160 mg, 0.11 mmol) and
lutidine (190 uL, 1.6 mmol) in DCM (1.5 ml). After shaking for 16
hours, the mixture was drained and washed with DMF 10.times.2 ml)
and DCM (5.times.2 ml). The product was cleaved from the resin
through treatment with TFA/water (4:1) (1.5 ml). After shaking for
45 min., the TFA solution was collected from the resin by
filtration, and the resin was washed with TFA (1 ml) and TFA/water
(1:1) (10 ml). The combined TFA fractions were concentrated under
reduced pressure to a reddish-brown solid. The product, identified
by LCMS, was purified by prep. HPLC using a 20.times.50 mm Ultro
120 C18 column running a 22 ml/min 4% gradient (AcCN/water, 0.1%
TFA) for 16 min. The purified fractions were lyophilized to
dryness. The solid residue was lyophilized again from
CH.sub.3CN/water (1:1) (5 ml) give 4 mg of pure product as a white
solid (3) (.about.9% yield).
Example 10
Synthesis of 4'-Ethyl-biphenyl-4-carboxylic acid
[2-(3,3-dimethyl-ureido)-1-hydroxycarbamoyl-ethyl]-amide (3)
(Continued from (2) of Example 9 above)
[0929] Dimethylcarbamyl chloride (103 mg, 0.96 mmol) was added to a
mixture of deprotected DAP resin (2) (125 mg, 0.096 mmol) and
lutidine (225 uL, 1.92 mmol) in DCM (1.5 ml). After shaking at rt
for 5 hours, the mixture was drained and washed with DCM (5.times.2
ml), DMF (5.times.2 ml) and DCM (5.times.2 ml). The product was
cleaved from the resin through treatment with TFA/water (4:1) (1.5
ml). After shaking for 45 min., the TFA solution was collected from
the resin by filtration, and the resin was washed with TFA/water
(1:1) (2 ml). The combined TFA fractions were concentrated under
reduced pressure to a reddish-brown solid. The product, identified
by LCMS, was purified by prep. HPLC using a 20.times.50 mm Ultro
120 C18 column running a 22 mvmin 4% gradient (AcCN/water, 0.1%
TFA) for 16 min. The purified fractions were lyophilized to
dryness. The solid residue was lyophilized again from
CH.sub.3CN/water (1:1) (5 ml) give 5 mg of pure product as a white
solid (3) (.about.13% yield).
Example 11
Synthesis of 4'-Ethyl-biphenyl-4-carboxylic acid
[2-(2-amino-ethylamino)-1-hydroxycarbamoyl-ethyl]-amide (2)
[0930] NaBH.sub.3CN (3.1 mg, 0.05 mmol) followed by acetic acid (6
uL, 1.0 mmol) were sequentially added to a stirred suspension of
biphenyl-DAP-hydroxamate (1) (20 mg, 0.096 mmol) and
Boc-amino-acetaldehyde (6.4 mg, 0.4 mmol) in MeOH (1.5 ml) in a 4
ml vial. The reaction was followed by LCMS. After stirring 12
hours, the cloudy reaction was only 50% complete. The reaction was
concentrated under reduced pressure to a thick slurry that was
dissolved in DMSO. The product was purified by prep. HPLC using a
20.times.50 mm Ultro 120 C18 column running a 22 ml/min 3% gradient
(AcCN/water, 0.1% TFA) for 16 min. The purified fractions were
lyophilized to dryness. The dried powder was dissolved in
CH.sub.3CN/water (1:1) (1 ml) and 1M HCl (700 uL). After heating at
50.degree. C. for 75 min., the reaction mixture was again
lyophilized to dryness to produce 7.1 mg of (2) as a 2.times.HCl
salt white powder (.about.17% yield).
Example 12
Synthesis of
N-(1-(N-hydroxycarbamoyl)1S,2R)-2-hydroxypropyl)[4-(2-phenylethynyl)pheny-
l]carboxamide
Preparation of 4-Phenylethynyl-benzoic acid (3)
[0931] 4-iodo-benzoic acid methyl ester (1) (20.0 g, 76.34 mmol),
ethynyl-benzene (2) (8.56 g, 83.96 mmol),
PdCl.sub.2(PPh.sub.3).sub.2 (0.65 g, 0.92 mmol), and CuI (0.35 g,
1.83 mmol) were mixed with THF (110 ml) in a round bottom under
argon. The dry THF was sparged with dry, oxygen-free argon for at
least 5 min. immediately before use. The reaction was cooled to
10.degree. C. and TEA (16 ml) was added. The cooling bath was
removed and the reaction was stirred at RT under argon. After 2.5
h, the reaction was diluted with EtOAc (400 ml) and the solids were
filtered off through a pad of celite. The organic filtrate was
washed with 1M HCl (60 ml), sat. aq. NaHCO.sub.3 (60 ml), water (60
ml), brine (60 ml), dried with Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The crude solid methyl ester
was dissolved in MeOH (400 ml), 6M NaOH (30 ml) and water (50 ml).
The reaction was stirred at 70.degree. C. until a clear solution
was formed (about 1 h). The reaction could be followed by LCMS. The
reaction was cooled and diluted with water (500 ml) and hexane (100
ml). The pH was adjusted to pH 6-7. The white solid that formed was
collected and washed with water (3.times.60 ml) and hexane
(3.times.60 ml). The solid (3) was dried in vacuo yielding 17.3 g
(approximately quantitative yield in 99% purity).
Preparation of 3-hydroxy-2-(4-phenylethynyl-benzoylamino)-butyric
acid methyl ester (4)
[0932] A solution of threonine methyl ester (1.66 g, 9.8 mmol) and
DIEA (1.53 ml, 8.8 mmol) in DMF (10 ml) was added to a stirred
solution of (3) (1.55 g, 7.0 mmol) and DIEA (1.53 ml, 8.8 mmol) in
DMF (11 ml) at rt. After 12 h, the reaction was diluted with EtOAc
(300 ml) and washed with 0.5M HCl (2.times.60 ml), sat. aq.
NaHCO.sub.3 (60 ml), 50% diluted brine (60 ml), sat. brine (60 ml),
dried with Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. Upon drying in vacuo, 2.34 g of white solid (4)
was obtained (approximately quantitative yield in 99% purity).
Preparation of
N-(2-Hydroxy-1hydroxycarbamoyl-propyl)-4-phenylethynyl-benzamide
(5)
[0933] A solution of (4) (2.34 g, 7.0 mmol) in MeOH (20 ml) and DCM
(30 ml) was added to a cooled (-10.degree. C. bath) suspension of
hydroxylamine HCl salt (4.81 g, 70.0 mmol) and NaOMe (4.16 g, 77.0
mmol) in MeOH (30 ml). Follow reaction by LCMS. After stirring for
2 hours, the reaction seems to stall at 50% completion. Add an
additional 1 equivalent of NaOMe (0.416 g). After 3 hours, the
reaction was 75% complete. Add an additional 0.5 equivalent of
NaOMe (0.21 g). After 4 hours, the reaction was 90% complete. Add
an additional 0.15 equivalent of NaOMe (0.064 g) for a total of
12.65 equivalents of NaOMe. The pH of the reaction was between
11-12 and had reacted about 95% completion. The reaction was
diluted with EtOAc (500 ml) and washed with sat. aq. NaHCO.sub.3
(2.times.60 ml), 50% diluted brine (60 ml), sat. brine (60 ml),
dried with Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. The residue was dissolved in minimal DMA. The
product was purified by prep. HPLC using a reverse phase Ultro 120
C18 column running a 2% gradient (AcCN/water, 0.1% TFA). The
purified fractions were lyophilized to dryness. The product as the
TFA salt dissolved in AcCN/water (50:50) (80 ml), 1N aq. HCl (13
equivalent) and lyophilized again to give 1.3 g of white powder (5)
in 55% yield and >97% purity.
Example 13
Synthesis of
3-(R)-Amino-2-(S)-(3-phenylethynyl-benzoylamino)-butyl-hydroxamic
acid (10)
Preparation of
3-(R)-Azido-2-(S)-(3-phenylethynyl-benzoylamino)-butyric acid
methyl ester (9)
[0934] Compound (9) was made by the same procedures as for compound
(6) in Example 5 above using compound (3) from Example 12 above.
The product (9) was obtained in 92% yield (952 mg). HPLC (220 nm,
41 min. run) 32.64 min.; HPLC (220 nm, 17 min. run) 15.08 min LCMS:
LC (214 nm) 3.16 min., MS (ES+) m/z 363.1
(C.sub.20H.sub.18N.sub.4O.sub.3+H requires 363.14).
Preparation of
3-(R)-Amino-2-(S)-(3-phenylethynyl-benzoylamino)-butyl-hydroxamic
acid (10)
[0935] Triphenylphosphine (526 mg, 2.0 mmol) was added to a stirred
solution of (9) (726 mg, 2.0 mmol) at rt. After 3 days the reaction
reached completion as judged by TLC (EtOAc/Hex (2:1)) and LCMS. The
reaction was concentrated under reduced pressure to give an ivory
colored solid. The crude amino-phosphine was dissolved in MeOH (20
ml) to give a pale yellow solution. To the solution of
amino-phosphine was added sequentially hydroxylamine HCl salt (1.4
g, 20.0 mmol) followed by fresh solid NaOMe powder (1.3 g, 24.0
mmol) to make a milky pH 10 suspension. After 36 h, the reaction
was complete by LCMS. The reaction was evaporated under reduced
pressure to give a yellow solid that was dried in vacuo. The crude
product (2.75 g) was triturated with ether (3.times.50 ml) to
remove impurities (P(O)Ph.sub.3) and then was dissolved in abs.
EtOH (120 ml) with sonication for 15 min. A fine white powder was
suction filtered off, and the clear yellow ethanolic portion was
concentrated to a small volume. The crude product was dissolved in
DMSO (8 ml) and purified by preparative HPLC (Ultro 120 C18
75.times.300 mm column) running a gradient (AcCN/water, 0.1% TFA)
from 5 to 70% for 55 min. The purified fractions were pooled
together and lyophilized to dryness. The product as the TFA salt
was dissolved in AcCN/water (50:50) (100 ml), IN aq. HCl (1
equivalent) and lyophilized again to give 325 mg of (10) as a light
yellow powder as the HCl salt (43% yield). HPLC (220 nm, 41 min.
run) 18.31 min.; HPLC (220 nm, 17 min. run) 9.11 min; LCMS: LC (214
nm) 1.91 min., MS (ES+) m/z 338.1 (C.sub.19H.sub.19N.sub.3O.sub.3+H
requires 338.14).
Synthesis of 4'-(N-Acylamnino)-Tolan Dap Analogs
Example 14
Synthesis of
4-({4-[(aminoacetyl)amino]phenyl}ethynyl)-N-[(1S)-1-(aminomethyl)-2-(hydr-
oxyamino)-2-oxoethyl]benzamide
Preparation of 2-N-Boc-amino-N-(4-iodo-phenyl)-acetamide (2)
[0936] A solution of Boc-Gly-OH (1.752 g, 10.0 mmol) in DCM (18 mL)
and DMF (1 mL) was treated with EDCI (1.994 g, 10.4 mmol) and HOBt
(1.351 g, 10.0 mmol). After stirring 15 min, 4-iodoaniline (1)
(2.290 g, 10.4 mmol) was added and the reaction monitored by TLC
(25:1 DCM/MeOH (R.sub.f=0.6)). After 24 h the solution was diluted
with EtOAc (250 mL), washed with 1.0 M HCl (3.times.100 mL), sat.
NaHCO.sub.3 (3.times.100 mL), brine (3.times.100 mL), dried over
MgSO.sub.4, filtered and concentrated in vacuo to afford 2.900 g
(77% yield) of (2) as a white solid.
Preparation of
(2S)-3-N-Boc-amino-(4-ethynyl-benzoylamino)-propionic acid methyl
ester (4)
[0937] Diethylamine (3.5 mL, 20.0 mmol) was added to a stirred
solution of 4-ethynylbenzoic acid (3) (910 mg, 6.22 mmol),
H-Dap(Boc)-OMe hydrochloride (1.903 g, 7.47 mmol), EDCI (1.432 g,
7.47 mmol), and HOBt (910 mg, 6.73 mmol) in DMF (50.0 mL). After
stirring 20 h, the reaction mixture was diluted with EtOAc (400
mL), washed with 1.0 M HCl (2.times.100 mL), saturated NaHCO.sub.3
(2.times.100 mL), H.sub.2O (4.times.100 mL), dried over MgSO.sub.4,
filtered and concentrated in vacuo to give 2.140 g (99% yield) of
(4) as a tan solid, mp=110-111.degree. C. LRMS (ES+) m/z 346.9
(C.sub.18H.sub.22N.sub.2O.sub.5+H requires 347.10).
Preparation of Methyl (2
S)-3-[(tert-butoxy)carbonylamino]-2-({4-[2-(4-{2-[(tert-butoxy)carbonyl
amino]acetylamino}phenyl)ethynyl]phenyl}carbonylamino) propanoate
(5)
[0938] To a suspension of methyl
(2S)-3-[(tert-butoxy)carbonylamino]-2-[(4-ethynylphenyl)carbonylamino]pro-
panoate (4) (200 mg, 0.577 mmol) and
2-[(tert-butoxy)carbonylamino]-N-(4-iodophenyl)acetamide (2) (476
mg, 1.26 mmol) was added Et.sub.3N (350 .mu.L, 2.5 mmol). The
solution was purged with a stream of N.sub.2 for several minutes
and PdCl.sub.2(PPh.sub.3)2 (20 mg, 0.028 mmol) and CuI (10.6 mg,
0.055 mmol) were added. The reaction mixture was stirred at ambient
temperature for 22 h and then concentrated by rotary evaporation.
The crude black residue was chromatographed twice by silica gel
chromatography (30:1 CH.sub.2Cl.sub.2/MeOH) to give 285 mg (83%) of
(5) as a yellow foam.
Preparation of
N-(4-{2-[4-(N-{1-(N-hydroxycarbamoyl)(1S)-2-[(tert-butoxy)carbonyl
amino]ethyl}carbamoyl)phenyl]ethynyl}phenyl)-2-[(tert-butoxy)carbonylamin-
o]acetamide (6)
[0939] To a solution of hydroxylamine hydrochloride (98 mg, 1.41
mmol) in MeOH (1.3 mL) at 0.degree. C. was added 25 wt % NaOMe (460
mg, 2.13 mmol). The solution was stirred at 0.degree. C. for 15 min
and then charged with a solution of (5) (279 mg, 0.469 mmol) in THF
(1.5 mL) and MeOH (0.6 mL). The reaction was stirred at 0.degree.
C. for 30 min and at room temperature for 2.5 h. The reaction
mixture was diluted with 4:1 CHCl.sub.3/iPrOH (50 ml) and washed
with 0.1 M HCl (30 mL). The layers were separated and the aqueous
layer extracted once more with 4:1 CHCl.sub.3/iPrOH (30 ml). The
organic layers were combined, dried over Na.sub.2SO.sub.4, filtered
and concentrated. The crude residue was suspended in 10:1
CH.sub.2Cl.sub.2/MeOH (4 mL), filtered, and washed with 50:1
CH.sub.2Cl.sub.2/MeOH (2 mL) and Et.sub.2O (10 mL) to afford 180 mg
(64%) of (6) as a white powder.
Preparation of
4-({4-[(aminoacetyl)amino]phenyl}ethynyl)-N-[(1S)-1-(aminomethyl)-2-(hydr-
oxyamino)-2-oxoethyl]benzamide (7)
[0940] To an oven-dried flask containing (6) (130 mg, 0.218 mmol)
was added 1:1 TFA/CH.sub.2Cl.sub.2 (2.5 mL). The resulting pink
solution was stirred for 2 h and concentrated to give a pink gum.
The crude residue was rinsed with CH.sub.2Cl.sub.2 (4 mL),
concentrated by rotary evaporation and dissolved in THF (2 mL) and
MeOH (0.4 mL). A solution of 4 M HCl in dioxane (200 .mu.L) was
added and the resulting precipitate filtered and washed with
Et.sub.2O (10 mL) to afford 90 mg of (7) as a pale tan powder.
Reaction of Iodoaniline with Bromoacetyl Bromide
##STR00047##
[0941] Bromoacetyl bromide (175 .mu.L, 2.00 mmol) was added
dropwise over 5 minutes to a solution of 4-iodoaniline (438 mg,
2.00 mmol) and Et.sub.3N (280 .mu.L, 2.00 mmol) in benzene (5 mL).
The reaction was stirred 1 hour, treated with morpholine (1.0 mL,
11.5 mmol) and stirred overnight. The reaction mixture was diluted
with EtOAc (200 mL), washed with aqueous 0.1 M KOH (50 nmL),
H.sub.2O (50 mL), dried over MgSO.sub.4 and concentrated to give a
yellow oil. Purification by silica gel chromatography (100:1
CH.sub.2Cl.sub.2/MeOH) afforded 630 mg (91%) of
N-(4-iodophenyl)-2-morpholin4-ylacetamide as a waxy tan solid. This
product was converted to analogues in a similar manner as Example
14.
Example A
Preparation of
4-[4-(6-Chloro-pyridin-3-yl)-buta-1,3-diynyl]-benzoic acid methyl
ester
[0942] DIEA (9.7 ml, 55.1 mmol) was added to a stirred solution of
4-iodo-benzoic acid (5.49 g, 22.2 mmol), HOAT (3.08 g, 22.6 mmol),
EDC (4.33 g, 22.6 mmol) in DMF (85 ml). After 2 min.,
H-DAP(Boc)-OMe (1) was added in one portion. After 12 hours, the
reaction was found complete by LCMS. The reaction was diluted with
EtOAc/hexane (1:1) (500 ml). The organic phase-was washed with 1N
HCl (2.times.80 ml), IN NaOH (2.times.80 ml), water (2.times.80
ml), sat. brine (80 ml), dried with Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give crude product. The
residue was filtered through a filter plug of silica eluting with
EtOAc/hexane (1:1). The fractions with product were evaporated to
give 9.3 g of product
(3-tert-Butoxycarbonylamino-2-(4-iodo-benzoylamino)-propionic acid
methyl ester) in 93% yield. This product was converted to analogues
in a similar manner as the aforementioned Examples.
Example 15
N-(1-(N-hydroxycarbamoyl)(1S,2R)-2-hydroxypropyl)(4-{2-[4-(morpholin4-ylme-
thyl)phenyl]ethynyl}phenyl)carboxamide (5)
Preparation of (2S,
3R)-2-[4-(4-formyl-phenylethynyl)-benzoylaminol-3-hydroxy-butyric
acid methyl ester (3)
[0943] A solution of
(2S,3R)-methyl-2-(4-ethynylbenzamido)-3-hydroxybutanoate (1) (745
mg, 2.85 mmol), 4-iodobenzaldehyde (2) (902 mg, 3.89 mmol), and
Et.sub.3N (900 .mu.L, 6.5 mmol) in THF (50 mL) was purged with a
stream of N.sub.2 for two minutes and then treated with
PdCl.sub.2(PPh.sub.3).sub.2 (70 mg, 0.10 mmol) and CuI (34 mg, 0.18
mmol). The reaction mixture was stirred 40 h, concentrated by
rotary evaporation and purified by silica gel chromatography (40:1
DCM/MeOH) to give 0.833 g (80% yield) of (3) as a pale yellow
powder, mp=143-144.degree. C. R.sub.f=0.3 (25:1 DCM/MeOH); LRMS
(ES+) m/z 366.1 (C.sub.21H.sub.19NO.sub.5+H requires 366.13); HPLC
(300 nm, 47 min) 15.3 min.
Preparation of (2S,
3R)-3-Hydroxy-2-[4-(4-morpholin4-ylmethyl-phenylethynyl)-benzoylamino]-bu-
tyric acid methyl ester (4)
[0944] Sodium triacetoxyborohydride (0.670 g, 3.16 mmol) was added
to a solution of benzaldehyde (3) (0.822 g, 2.25 mmol) and
morpholine (260 .mu.L, 2.97 mmol) in THF (15 mL) under N.sub.2
atmosphere and the reaction monitored by TLC (25:1 DCM/MeOH,
R.sub.f=0.2). After stirring 4 h, the reaction mixture was quenched
with saturated NaHCO.sub.3 (150 mL), extracted with EtOAc
(3.times.100 mL), dried over MgSO.sub.4, filtered and concentrated
to give a yellow syrup. Purification by silica gel chromatography
(35:1 DCM/MeOH) afforded 0.844 g (86% yield) of (4) as a sticky
white foam.
Preparation of (2S,
3R)--N-(2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-(4-morpholin-4-ylmethyl-ph-
enylethynyl)-benzamide (5)
[0945] Sodium methoxide (25 wt % in MeOH, 1.860 g, 8.60 mmol) was
added to a stirred solution of hydroxylamine hydrochloride (400 mg,
5.76 mmol) in anhydrous MeOH (5 mL) at 0.degree. C. under N.sub.2
atmosphere. After stirring 20 min, a solution of methyl ester (4)
(829 mg, 1.90 mmol) in 1:1 MeOH/THF (6 mL) was added and the
reaction mixture stirred at 0.degree. C. for 1 h and at room
temperature for 4 h. The reaction was quenched with 1.0 M HCl (6
mL), concentrated by rotary evaporation to remove organic solvents,
and diluted with DMSO (4 mL). Analytical RP-HPLC (C.sub.18 column,
CH.sub.3CN gradient 5-35%, 0.1% TFA, UV analysis 300 nm, 16 min)
indicated a purity of 85% for the crude product mixture.
Purification by preparative RP-HPLC and lyophilization of the
collected fractions gave 701 mg (81%) of (5) as a fluffy white
solid. LRMS (ES+) m/z 438.1 (C.sub.24H.sub.27N.sub.3O.sub.5+H
requires 438.20); RP-HPLC (300 nm, 16 min run) 8.7 min.
Resin Procedures for Synthesizing Tolanyl Hydroxamates
Example 16
Synthesis of
4-[(4-{[(benzylamino)acetyl]amino}phenyl)ethynyl]-N-{(1S,2R)-2-hydroxy-1--
[(hydroxyamino)carbonylipropyl}benzamide
##STR00048##
[0946] 1. Coupling to Fmoc Hydroxylamine Resin
[0947] The resin was pre-swelled by adding DCM and shaking for 30
min. The resin was drained, 20% piperdine was added in DMF, the
resin was shaken 1.25 hours, and finally drained and washed in
2.times.DMF and 2.times.DCM. After draining completely, 20%
piperdine in DMF was added to attain cleavage in 1.25 hours. The
resin was washed 4.times.DMF, 4.times.DCM and drained completely.
In a separate flask, the amino acid (Fmoc-Thr tBu-OH, or Fmoc-DAP
Boc-OH, 4 eq) was mixed, HATU (4 eq), DMF (60 ml) and Hunig's (8
eq) base were added and stirred for 2-3 min. The mixture was added
to the resin and shaken 20-24 hours. Subsequently, the resin was
drained and run with a standard wash (1.times.DCM, 4.times.DMF and
4.times.DCM). The Fmoc was removed from the amino acid by adding
20% piperdine in DMF and shaken 1.25 hours, drained, and given the
standard wash (1.times.DCM, 4.times.DMF and 4.times.DCM).
2. Coupling of 4-Iodobenzoic Acid to Amino Acid Resin
[0948] A mixture of 4-iodobenzoic acid (4 eq), HBTU (4 eq), DMF (60
ml) was shaken for several minutes. Hunig's base (8 eq) was
subsequently added and the mixture was shaken further for 2-3 min.
The pre-activated mixture was then added to the prepared Thr or DAP
resin (Fmoc removed, 7.5 g, 5.775 mmol). The reaction is shaken
12-16 hours followed by the standard wash (1.times.DCM, 4.times.DMF
and 4.times.DCM).
3. Alkyne Coupling on Resin
[0949] To the 4-iodobenzoic resin (4 g, 3.08 mmol) was added
4-aminophenylacetylene (3 eq), Pd(PPh.sub.3).sub.2Cl.sub.2 (0.04
eq), CuI (0.08 eq) and THF (purged with Argon). After mixing for 1
min., TEA (4.5 eq) was added and the reaction was shaken 12 hours
at RT under argon.
4. Aniline Coupling with Bromoacetyl Chloride on Resin
[0950] To aniline resin (4 g, 3.08 mmol) was added DCM (30 ml)
lutidine (10 eq) and shaken for 1 min. Bromoacetyl chloride (8 eq)
in DCM (5 ml) was added slowly. After the addition, the slurry was
shaken for 1.5 to 1.75 hours. Subsequent draining and a wash with
2.times.DCM, 4.times.DMF and 4.times.DCM was then performed.
5. Displacement with Amines on Resin
[0951] To the bromoacetyl resin (125 mg), was added NMP (1.5 ml)
followed by amine (0.2 g or ml, ie excess) and the slurry was
shaken for 12-16 hours at RT. To neutralize the salt, TEA was
added. The imidazole was heated at 38.degree. C. for 24 h (in the
case of anilines, they were heated at 38.degree. C. for 48 h). The
reaction mixture was drained and washed 4.times.DMF and
4.times.DCM.
6. Cleavage from Resin and Deprotection of Thr tBu and DAP Boc
[0952] The resin (125 mg) was soaked in TFA/water (80:20 v/v) (1.5
ml) at RT for 45 min. Upon cleavage the solution was collected and
the resin was washed with more TFA/water mixture (0.75 ml). To the
TFA/product solution was added acetonitrile/water solution (1:1
v/v, 10 ml) and pure water (2.5 ml). The mixture was frozen in
liquid nitrogen for 15 min and lyophilized. The dry residue was
dissolved in the acetonitrile/water solution (1:1 v/v, 10 ml) again
followed by addition of 1M aq. HCl (1.2 eq per basic nitrogen),
frozen, and lyophilized to a powder.
Synthesis of 3'-Nitro-Tolan Threonine Hydroxamic Acid
Example 17
(1S,2R)--N-(2-hydroxy-1-hydroxycarbamoyl-propyl)-4-(3-nitro-phenylethynyl)-
-benzamide
Preparation of
(1S,2R)--N-(2-tert-butoxy-1-hydroxycarbamoyl-propyl)-4-ethynyl-benzamide
on Hydroxylamine 2-chlorotrityl Resin (3)
[0953] Fmoc-threonine resin (1) (0.522 g, 0.365 mmol, 0.70 mmol)
was swelled in DCM (5 mL) for 2 h and drained. The resin was
treated with 20% piperidine in DMF (6 mL) for 1 hour, washed with
DMF (4.times.6 mL) and DCM (4.times.6 mL) and drained completely.
In a separate flask, 4-ethynylbenzoic acid (2) (0.160 g, 1.10
mmol), DIC (0.280 mL, 1.79 mmol), HOBt (0.148 g, 1.10 mmol) and
DIEA (0.4 mL, 2.30 mmol) were dissolved in DCM (1 mL) and DMF (4
mL), stirred 15 min and added to the resin. After shaking for 36 h,
the mixture was drained, washed with DMF (4.times.6 mL) and DCM
(4.times.6 mL) and dried in vacuo to give 0.495 g of (3) as a
yellow resin.
Preparation of
(1S,2R)--N-(2-hydroxy-1-hydroxycarbamoyl-propyl)-4-(3-nitro-phenylethynyl-
)-benzamide (5)
[0954] Resin (3) (100 mg, 0.070 mmol) was swelled in DCM (2 mL) for
1 h and drained. A solution of 1-iodo-3-nitrobenzene (4) (87.1 mg,
0.350 mmol) and Et.sub.3N (150 .mu.L, 1.10 mmol) in DMF (1.5 mL)
was purged with a stream of N.sub.2 bubbles for two minutes and
added to the resin. After mixing for 5 min,
PdCl.sub.2(PPh.sub.3).sub.2 (10.0 mg, 0.014 mmol) and CuI (7.0 mg,
0.036 mmol) were added and the mixture shaken for 26 h. The resin
was drained, washed with DMF (3.times.2 mL), DCM (3.times.2 mL) and
cleaved with 10% TFA/DCM (1.5 mL) for 20 min. The solution was
collected and the resin was rinsed with additional 10% TFA/DCM (1.0
mL). The cleavage fractions were combined, treated with neat TFA
(2.0 mL), stirred for 1 h at rt and concentrated by rotary
evaporation to give a crude brown residue. Purification by RP-HPLC
(C.sub.18 column, CH.sub.3CN gradient 5-65%, 0.1% TFA, UV analysis
300 nm, 28 min) and lyophilization of the collected fractions
afforded 6.0 mg (22% yield) of (5) as a white foam. LRMS (ES+) m/z
384.2 (C.sub.19H.sub.17N.sub.3O.sub.6+H requires 384.15); RP-HPLC
(300 nm, 28 min run) 15.2 min.
Synthesis of 4'-Trifluoromethoxy-Tolan Dap Hydroxamic Acid
Example 18
(1S)--N-(2-amino-1-hydroxycarbamoyl-ethyl)-4-(4-trifluoromethoxy-phenyleth-
ynyl)-benzamide (5)
Preparation of
(1S)--N-(2-(Boc)-amino-1-hydroxycarbamoyl-ethyl)-4-ethynyl-benz-amide
on Hydroxylamine 2-chlorotrityl Resin (3)
[0955] Fmoc-Dap resin (1) (1.330 g, 0.931 mmol, 0.70 mmol/g) was
swelled in DCM (15 mL) for 2 h and drained. The resin was treated
with 20% piperidine in DMF (20 mL) for 1 hour, washed with DMF
(3.times.15 mL) and DCM (3.times.15 mL) and drained completely. In
a separate flask, 4-ethynylbenzoic acid (2) (0.408 g, 2.793 mmol),
DIC (0.70 mL, 4.470 mmol), HOBt (0.377 g, 2.793 mmol) and DIEA (1.0
mL, 5.7 mmol) were dissolved in DCM (10 mL) and DMF (2 mL), stirred
15 min and added to the resin. After shaking for 36 h, the mixture
was drained, washed with DMF (3.times.15 mL) and DCM (3.times.15
mL) and dried in vacuo to give 1.290 g of (3) as a yellow
resin.
Preparation of
(1S)--N-(2-amino-1-hydroxycarbamoyl-ethyl)-4-(4-trifluoromethoxy-phenylet-
hynyl)-benzamide (5)
[0956] Resin (3) (120 mg, 0.084 mmol) was swelled in DCM (2 mL) for
1 h and drained. A solution of 4-(trifluoromethoxy)iodobenzene (4)
(96.8 mg, 0.336 mmol) and Et.sub.3N (150 .mu.L, 1.10 mmol) in DMF
(2.0 mL) was purged with a stream of N.sub.2 bubbles for two
minutes and added to the resin. After mixing for 5 min,
PdCl.sub.2(PPh.sub.3).sub.2 (18.0 mg, 0.025 mmol) and CuI (8.0 mg,
0.042 mmol) were added and the mixture shaken for 24 h. The resin
was drained, washed with DMF (3.times.2 mL), DCM (3.times.2 mL) and
cleaved with 10% TFA/DCM (2.0 mL) for 20 min. The solution was
collected and the resin was rinsed with additional 10% TFA/DCM (1.0
mL). The cleavage fractions were combined, treated with neat TFA
(3.0 mL), stirred for 1 h at rt and concentrated by rotary
evaporation to give a crude brown residue. Purification by RP-HPLC
(C.sub.18 column, CH.sub.3CN gradient 5-55%, 0.1% TFA, UV analysis
300 nm, 28 min) and lyophilization of the collected fractions
afforded 9.0 mg (25% yield) of (5) as a white solid. LRMS (ES+) m/z
408.0 (C.sub.19H.sub.16F.sub.3N.sub.3O.sub.4+H requires 408.11);
RP-HPLC (300 nm, 28 min run) 18.0 min.
Example 19
Synthesis of
N-(1-(N-hydroxycarbamoyl)(1S,2R)-2-hydroxypropyl)[4-(4-phenylbuta-1,3-diy-
nyl)phenyl]carboxamide
[0957] 4-(2,2-Dibromo-vinyl)-benzoic acid methyl ester (2) was made
by the method of Wang, S., et al., J. Org. Chem. 1999, 64,
8873-8879.
[0958] A solution of (2) (5.76 g, 18.0 mmol), ethynyl-benzene (3)
(2.57 g, 25.2 mmol), Pd.sub.2dba.sub.3 (164 mg, 0.18 mmol),
tris(4-methoxyphenyl) phosphine (TMPP) (253 mg, 0.72 mmol) were
dissolved in argon sparged (5 min.) DMF (60 ml). The reaction was
sparged with argon for 1 min. TEA (7.5 ml, 54.0 mmol) was added to
the stirred reaction mixture that was then heated under argon at
85.degree. C. for 3.5 hours. The reaction was found complete by
LCMS. The reaction was cooled to rt and diluted with EtOAc/hexane
(1:1) (300 ml). The organic phase was washed with 1M HCl
(2.times.50 ml), 1M NaOH (3.times.50 ml), water (2.times.50 ml),
sat. brine (50 ml), dried with Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to obtain 5.25 g of crude
product as an oil. The oil was treated with approximately 20 ml of
a solution of 20% EtOAc/hexane that was heated to dissolve the
residue. The walls of the flask were washed with the 20%
EtOAc/hexane solution (5 ml) that upon cooling gave 1.45 g of pure
product (31% yield) as a white solid. The balance of the crude
reaction product was purified by flash chromatography using EtOAc
(8%)/hexane as eluant. The pure fractions were evaporated and dried
in vacuo to give addition product typically 25-30% addition
yield.
[0959] 4-(4-Phenyl-buta-1,3-diynyl)-benzoic acid methyl ester (4)
was made according to the method of Wang, S., et al., Org. Lett.
2000, 2(18), 2857-2860.
Preparation of 4-(4-Phenyl-buta-1,3-diynyl)-benzoic acid (5)
[0960] A 3M aq. solution of NaOH (20 ml) was added to a stirred
solution of methyl ester (4) (1.45 g, 5.6 mmol) in MeOH (100 ml) at
rt. The reaction solution was heated to reflux for 45 min. until
the reaction turned clear. All of the starting material was gone by
TLC and HPLC. The reaction was cooled to rt and some MeOH
(.about.50 ml) was removed by evaporation under reduced pressure.
Water (100 ml) was added to the mixture. Conc. HCl was added
dropwise to the stirred solution until acidic by pH paper (pH2).
The white precipitate that formed was collected by suction
filtration. The solid was washed with water (3.times.20 ml) and
hexane (2.times.20 ml) to give after drying 1.35 g of (5) in 99%
yield.
[0961] Subsequent conversion of compound (5) to
N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(penta-1,3-diyny-
l)benzamide (7) was performed according to the method described in
Example 12 for the synthesis of
N-(2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-phenylethynyl-benzamide
(compound 5). LCMS MH+363.13.
Example B
Synthesis of
N-[(1S)-1-(aminomethyl)-2-(hydroxyamino)-2-oxoethyl]-4-[4-(4-aminophenyl)-
buta-1,3-diynyl]benzamide
Preparation of
2-{4-[4-(4-Amino-phenyl)-buta-1,3-diynyl]-benzoylamino}-3-tert-butoxycarb-
onyl amino-propionic acid methyl ester (2)
[0962] DIEA (10.5 ml, 60.3 mmol) was added to a stirred solution of
4-[4-(4-Amino-phenyl)-buta-1,3-diynyl]-benzoic acid (1) (5.0 g,
19.1 mmol), HOBT (2.72 g, 20.1 mmol), EDC (3.85 g, 20.1 mmol) in
DMF (80 ml). After 2 min., H-DAP(Boc)-OMe (5.12 g, 2.1 mmol) was
added in one portion. After 12 hours at rt, the reaction was found
complete by LCMS. The reaction was diluted with EtOAc/hexane (4:1)
(500 ml). The organic phase was washed with 1N NaOH (2.times.80
ml), water (2.times.80 ml), sat. brine (80 ml), dried with
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give crude product. The residue was filtered through a filter
plug of silica eluting with EtOAc/hexane (4:1). The fractions with
product were evaporated to give 8.02 g of (2) in 91% yield.
Subsequent conversion of (2) to the final hydroxamic acid was
performed according to the method described in Example 12 for the
synthesis of
N-(2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-phenylethynyl-benzamide
(compound 5).
Synthesis of 4-(Buta-1,3-diynyl)-benzoic Acid (4) for making
1,3-diynyl analogues (such as Example 20 below)
Preparation of 4-(4-trimethylsilanyl-buta-1,3-diynyl)-benzoic acid
methyl ester (3)
[0963] A solution of methyl 4-iodobenzoate (2) (4.510 g, 17.2
mmol), PdCl.sub.2(PPh.sub.3).sub.2 (483 mg, 0.690 mmol), and CuI
(262 mg, 1.37 mmol) in CH.sub.3CN (50 mL) was cooled to 0.degree.
C. under N.sub.2 atmosphere in the absence of light. Triethylamine
(7.2 mL, 52.0 mmol) was added, followed by
trimethylsilyl-1,3-butadiyne (1) (5.240 g, 42.8 mmol) and the
reaction stirred 3 h at 0.degree. C. and 30 h at ambient
temperature. Removal of solvent by rotary evaporation afforded a
crude black residue that was purified by silica gel chromatography
(95:5 hexanes/EtOAc) to give 3.450 g (79% yield) of (3) as a brown
solid, mp=67-68.degree. C.
Preparation of 4-(buta-1,3-diynyl)-benzoic acid (4)
[0964] Potassium hydroxide (3.700 g, 65.9 mmol) was dissolved in
H.sub.2O (10 mL) and added to a solution of (3) (3.420 g, 13.5
mmol) in THF (26 mL) in the absence of light. After stirring 16 h,
the reaction was quenched with 1.0 M HCl (120 mL) and the resulting
precipitate was filtered, washed with 1:1 hexanes/benzene (150 mL)
and dried in vacuo to afford 2.100 g (91% yield, 98% pure) of (4)
as a brown solid, mp>230.degree. C. Although diyne (4) was found
to be unstable at room temperature it could be stored for several
weeks at 0.degree. C. with only small amounts of decomposition
observed by TLC. R.sub.f=0.2 (4:1 Hexanes/EtOAc); HPLC (300 nm, 28
min run) 16.0 min; LRMS (ES+) m/z 171.0 (C.sub.11H.sub.6O.sub.2+H
requires 171.04).
Synthesis of a 3'-Nitrophenyl-Diacetylenic-Dap Hydroxamic Acid
Example 20
N-(1-(N-hydroxycarbamoyl)(1S)-2-aminoethyl){4-[4-(3-nitrophenyl)buta-1,3-d-
iynyl]phenyl}carboxamide (6)
Preparation of Fmoc-Dap(Boc)-NHOH on hydroxylamine 2-chlorotrityl
resin (2)
[0965] A suspension of N-Fmoc-hydroxylamine 2-chlorotrityl resin
(1) (3.288 g, 2.53 mmol, 0.77 mmol/g, Novabiochem) in DCM (40 mL)
was shaken for 2 h and drained. The resin was treated with 20%
piperidine in DMF (40 mL) for 1 hour, washed with DMF (2.times.40
mL), treated a second time with 20% piperidine in DMF (40 mL),
washed with DMF (3.times.40 mL) and DCM (3.times.40 mL) and drained
completely. In a separate flask, Fmoc-Dap(Boc)-OH (3.175 g, 7.44
mmol), HATU (2.829 g, 7.44 mmol) and DIEA (4.3 mL, 24.7 mmol) were
dissolved in DMF (35 mL), stirred three minutes and added to the
resin. After shaking for 48 h, the mixture was drained, washed with
DMF (4.times.40 mL) and DCM (4.times.40 mL) and dried in vacuo to
give 3.530 g of (2) as a yellow resin.
Preparation of
(S)--N-(2-N-Fmoc-amino-1-hydroxycarbamoyl-ethyl)-4-buta-1,3-diynyl-benzam-
ide on hydroxylamine 2-chlorotrityl resin (4)
[0966] Resin (2) (3.530 g, 2.53 mmol, 0.71 mmol/g) was swelled in
DCM (40 mL) for 2 h and drained. The resin was treated with 20%
piperidine in DMF (40 mL) for 1 hour, washed with DMF (4.times.40
mL) and DCM (4.times.40 mL) and drained completely. In a separate
flask, 4-buta-1,3-diynyl-benzoic acid (3) (1.076 g, 6.32 mmol),
EDCI (1.457 g, 7.60 mmol), HOBt (1.048 g, 7.75 mmol) and DIEA (2.2
mL, 12.6 mmol) were dissolved in DCM (25 mL) and DMF (5 mL),
stirred 45 min and added to the resin. After shaking for 48 h, the
mixture was drained, washed with DMF (4.times.40 mL) and DCM
(4.times.40 mL) and dried in vacuo to give 3.35 g of (4) as a pale
brown resin.
Preparation of
(S)--N-(2-amino-1-hydroxycarbamoyl-ethyl)-4-[4-(3-nitro-phenyl)-buta-1,3--
diynyl]-benzamide (6)
[0967] Resin (4) (176 mg, 0.135 mmol) was swelled in DCM (3 mL) for
1 h and drained. A solution of 1-iodo-3-nitrobenzene (5) (118 mg,
0.474 mmol) and Et.sub.3N (200 .mu.L, 1.43 mmol) in DMF (3.0 mL)
was purged with a stream of N.sub.2 bubbles for two minutes and
added to the resin. After mixing for 5 min,
PdCl.sub.2(PPh.sub.3).sub.2 (6.0 mg, 0.009 mmol) and CuI (10.0 mg,
0.052 mmol) were added and the mixture shaken for 36 h. The resin
was drained, washed with DMF (4.times.3 mL), DCM (4.times.3 mL) and
cleaved with 10% TFA/DCM (2 mL) for 20 min. The solution was
collected and the resin was rinsed with additional 10% TFA/DCM (2
mL). The cleavage fractions were combined, treated with neat TFA
(4.0 mL), stirred for 1 h at rt and concentrated by rotary
evaporation to give a crude brown residue. Purification by RP-HPLC
(C.sub.18 column, CH.sub.3CN gradient 5-65%, 0.1% TFA, UV analysis
300 nm, 30 min) and lyophilization of the collected fractions
afforded 12.0 mg (22%) of 470 as a white solid. LRMS (ES+) m/z
392.9 (C.sub.20H.sub.16N.sub.4O.sub.5+H requires 393.11); RP-HPLC
(300 nm, 30 min run) 14.9 min.
Synthesis of 4'-Benzamide Diacetylene Dap Hydroxamic Acid
Example 21
N-((2S)-amino-1-hydroxycarbamoyl- ethyl)-4-{4-[4-(2-amino-
ethylcarbamoyl)-phenyl]-buta-1,3-diynyl}-benzamide (3)
[0968]
(1S)--N-(2-(Boc)-amino-1-hydroxycarbamoyl-ethyl)-4-ethynyl-benz-ami-
de on hydroxylamine-2-chloro resin (1) (145 mg, 0.111 mmol) was
swelled in DCM (2 mL) for 1 h and drained. A solution of
4-ethynylbenzamide (2) (124 mg, 0.288 mmol) and Et.sub.3N (100
.mu.L, 0.72 mmol) in DMF (2.0 mL) was added and the resin agitated
for 5 min. A mixture of PdCl.sub.2(PPh.sub.3).sub.2 (21 mg, 0.030
mmol) and CuI (22 mg, 0.110 mmol) was added and the resin was
agitated for 60 h. The resin was drained, washed with DMF
(3.times.2 mL), DCM (3.times.2 mL) and cleaved with 10% TFA/DCM
(1.5 mL) for 20 min. The solution was collected and the resin was
rinsed with additional 10% TFA/DCM (1.0 mL). The cleavage fractions
were combined, treated with neat TFA (2.0 mL), stirred for 1 h at
rt and concentrated by rotary evaporation to give a crude brown
residue. Purification by RP-HPLC (C.sub.18 column, CH.sub.3CN
gradient 5-55%, 0.1% TFA, UV analysis 300 nm, 26 min) and
lyophilization of the collected fractions afforded 2.6 mg (5%
yield) of (3). LRMS (ES+) m/z 434.0
(C.sub.23H.sub.23N.sub.5O.sub.4+H requires 434.19); RP-HPLC (300
nm, 26 min run) 15.3 min.
Synthesis of N-[4-Butadiynyl-benzoyl]-Thr(tBu) on Resin (Continued
to make Examples 22 and 23)
Preparation of (2S,
3R)-2-N-Fmoc-amino-3-tert-butoxy-N-hydroxy-butyramide on
hydroxylamine 2-chlorotrityl resin (2)
[0969] A suspension of N-Fmoc-hydroxylamine 2-chlorotrityl resin
(1) (3.188 g, 2.45 mmol, 0.77 mmol/g, Novabiochem) in DCM (40 mL)
was shaken for 2 h and drained. The resin was treated with 20%
piperidine in DMF (40 mL) for 1 hour, washed with DMF (2.times.40
mL), treated a second time with 20% piperidine in DMF (40 mL),
washed with DMF (3.times.40 mL) and DCM (3.times.40 mL) and drained
completely. In a separate flask, Fmoc-Thr(tBu)-OH (2.927 g, 7.36
mmol), HATU (2.798 g, 7.36 mmol) and DIEA (4.3 mL, 24.6 mmol) were
dissolved in DMF (40 mL), stirred three minutes and added to the
resin. After shaking for 24 h, the mixture was drained, washed with
DMF (4.times.40 mL) and DCM (4.times.40 mL) and dried in vacuo to
give 3.500 g of (2) as a yellow resin.
Preparation of
4-buta-1,3-diynyl-N-(2-tert-butoxy-1-hydroxycarbamoyl-propyl)-benzamide
on hydroxylamine 2-chlorotrityl Resin (4)
[0970] Resin (2) (2.030 g, 1.56 mmol, 0.77 mmol/g) was swelled in
DCM (20 mL) for 2 h and drained. The resin was treated with 20%
piperidine in DMF (20 mL) for 1 hour, washed with DMF (4.times.20
mL) and DCM (4.times.20 mL) and drained completely. In a separate
flask, 4-buta-1,3-diynyl-benzoic acid (3) (0.617 g, 3.63 mmol),
EDCI (0.834 g, 4.35 mmol), HOBt (0.588 g, 4.35 mmol) and DIEA (1.0
mL, 5.7 mmol) were dissolved in DCM (15 mL) and DMF (4 mL), stirred
45 min and added to the resin. After shaking for 36 h, the mixture
was drained, washed with DMF (4.times.20 mL) and DCM (4.times.20
mL) and dried in vacuo to give 1.900 g of (4) as a pale brown
resin.
Synthesis of Diacetylenic Threonine Hydroxamic Acids
Example 22
(2S,3R)-4-[4-(3-aminomethyl-phenyl)-buta-1,3-diynyl]-N-(2-hydroxy-1-hydrox-
ycarbamoyl-propyl)-benzamide (3)
[0971] Resin (1) (resin (4) obtained from previous synthesis) (100
mg, 0.077 mmol) was swelled in DCM (2 mL) for 1 h and drained. A
solution of 3-iodobenzylamine hydrochloride (2) (83.0 mg, 0.308
mmol) and Et.sub.3N (250 .mu.L, 1.80 mmol) in DMF (1.5 mL) was
purged with a stream of N.sub.2 bubbles for two minutes and added
to the resin. After mixing for 5 min, PdCl.sub.2(PPh.sub.3).sub.2
(11.0 mg, 0.016 mmol) and CuI (7.0 mg 0.037 mmol) were added and
the mixture shaken for 36 h. The resin was drained, washed with DMF
(4.times.2 mL), DCM (4.times.2 mL) and cleaved with 10% TFA/DCM
(1.5 mL) for 20 min. The solution was collected and the resin was
rinsed with additional 10% TFA/DCM (1.5 mL). The cleavage fractions
were combined, treated with neat TFA (3.0 mL), stirred for 1 h at
rt and concentrated by rotary evaporation to give a crude brown
residue. Purification by RP-HPLC (C.sub.18 column, CH.sub.3CN
gradient 5-65%, 0.1% TFA, UV analysis 300 nm, 28 min) and
lyophilization of the collected fractions afforded 4.3 mg (14%) of
(3) as a white solid. LRMS (ES+) m/z 392.0
(C.sub.22H.sub.21N.sub.3O.sub.4+H requires 392.15); RP-HPLC (300
nm, 28 min run) 10.0 min.
Synthesis of Diacetylenic Benzylamine Analogues
Example 23
[0972] (1S,
2R)--N-2-bydroxy-1-hydroxycarbamoyl-propyl)-4-[4-(4-meorphoin-4-ylmethyl--
phenyl)-buta-1,3-diynyl]-benzamide (4)
Preparation of Threonine Diacetylenic Benzaldehyde on Resin (3)
[0973] Resin (1) (resin (4) obtained from prior synthesis)) (1.00
g, 0.77 mmol) was pre-swelled in DCM (25 mL) for 14 h and drained.
A solution of 4-iodobenzaldehyde (2) (715 mg, 3.08 mmol) and
Et.sub.3N (1.00 mL, 7.17 mmol) in DMF (20 mL) was purged with
N.sub.2 for two minutes and added to the resin. After mixing for 5
min, PdCl.sub.2(PPh.sub.3).sub.2 (40.0 mg, 0.057 mmol) and CuI
(19.0 mg, 0.100 mmol) were added and the reaction shaken for 48 h.
The resin was drained, washed with DMF (4.times.20 mL), DCM
(4.times.20 mL) and dried in vacuo to give 1.100 g of (3) as a dark
yellow resin.
Preparation of (1 S.
2R)--N-2-hydroxy-1-hydroxycarbamoyl-propyl)-4-[4-(4-morpholin-4-ylmethyl--
phenyl)-buta-1,3-diynyl]-benzamide (4)
[0974] A solution of morpholine (75 .mu.L, 0.860 mmol) and
trimethyl orthoformate (100 .mu.L, 0.914 mmol) in THF (3.0 mL) was
added to a Teflon-lined screw-capped vial containing the
resin-bound diacetylenic benzaldehyde (3). The resin was agitated
for 10 min, treated successively with acetic acid (100 .mu.L, 1.75
mmol) and a solution of NaCNBH.sub.3 (40.0 mg, 0.637 nmmol) in MeOH
(1.0 mL) and shaken for 44 h. The resin was filtered, washed with
DMF (3.times.3 mL) and DCM (3.times.3 mL) and drained. Cleavage
from the resin was achieved by treatment with 10% TFA/DCM (2.0 mL)
and shaking 20 min. The solution was collected and the resin was
rinsed with additional 10% TFA/DCM (2.0 mL). The cleavage fractions
were combined, treated with neat TFA (3.0 mL), stirred for 1 h at
rt and concentrated by rotary evaporation to give a crude yellow
residue. Purification by RP-HPLC (C.sub.18 column, CH.sub.3CN
gradient 5-35%, 0.1% TFA, UV analysis 300 nm, 18 min) and
lyophilization of the collected fractions afforded 19.0 mg (29%) of
(4) as a fluffy yellow solid. LRMS (ES+) m/z 462.0
(C.sub.26H.sub.27N.sub.3O.sub.5+H requires 462.10); HPLC (300 nm,
18 min run) 10.3 min.
Synthesis of 4'-Benzamide Diacetylene Threonine Hydroxamic Acid
Example 24
(1S,2R)--N-(2-hydroxy-1-hydroxycarbamoyl-propyl)-4-{4-[4-(2-amino-ethylcar-
bamoyl)-phenyl]-buta-1,3-diynyl}-benzamide (5)
Preparation of N-(2-trityl-amino-ethyl)-4-ethynyl-benzamide (3)
[0975] To a solution of 4-ethynylbenzoic acid (1) (292 mg, 2.00
mmol), EDCI (382 mg, 2.00 mmol), and HOBt (270 mg, 2.00 mmol) in
DMF (10 mL) was added N-trityl ethylenediamine (2) (810 mg, 2.67
mmol) and DIEA (1.4 mL, 8.0 mmol). The reaction mixture was stirred
24 h, diluted with EtOAc (200 mL), washed with 0.5 M HCl (60 mL),
saturated NaHCO.sub.3 (2.times.60 mL), H.sub.2O (4.times.60 mL),
dried over MgSO.sub.4 and concentrated to give 836 mg (97% yield)
of (3) as a white solid, mp 50-51.degree. C. R.sub.f=0.40 (1:1
Hexanes/EtOAc).
Preparation of
(1S,2R)--N-(2-hydroxy-1-hydroxycarbamoyl-propyl)-4-{4-[4-(2-amino-ethylca-
rbamoyl-phenyl]-buta-1,3-diynyl}-benzamide (5)
[0976] Resin (4) (resin (1) from above syntheses) (150 mg, 0.116
mmol) was swelled in DCM (2 mL) for 1 h and drained. A solution of
4-ethynylbenzamide (3) (151 mg, 0.350 mmol) and Et.sub.3N (150
.mu.L, 1.10 mmol) in DMF (2.0 mL) was added and the resin agitated
for 5 min. A mixture of PdCl.sub.2(PPh.sub.3).sub.2 (21 mg, 0.030
mmol) and CuI (28 mg, 0.147 mmol) was added and the resin was
agitated for 60 h. The resin was drained, washed with DMF
(3.times.2 mL), DCM (3.times.2 mIL) and cleaved with 10% TFA/DCM
(1.5 mL) for 20 min. The solution was collected and the resin was
rinsed with additional 10% TFA/DCM (1.0 mL). The cleavage fractions
were combined, treated with neat TFA (2.0 mL), stirred for 1 h at
rt and concentrated by rotary evaporation to give a crude brown
residue. Purification by RP-HPLC (C.sub.18 column, CH.sub.3CN
gradient 5-65%, 0.1% TFA, UV analysis 300 nm, 26 min) and
lyophilization of the collected fractions afforded 2.0 mg (4%
yield) of (5). LRMS (ES+) m/z 449.1
(C.sub.24H.sub.24N.sub.4O.sub.5+H requires 449.18); RP-HPLC (300
nmn, 26 min run) 17.0 min.
Synthesis of 3'-Pyridine Diacetylene Threonine Hydroxamic Acid
Example 25
N-((2R)-hydroxy-(1S)-hydroxycarbamoyl-propyl)-4-(4-pyridin-3-yl-buta-1,3-d-
iynyl)-benzamide (3)
[0977]
(1S,2R)--N-(2-tert-butoxy-1-hydroxycarbamoyl-propyl)-4-ethynyl-benz-
amide on hydroxylamine 2-chlorotrityl resin (1) (142 mg, 0.109
mmol) was swelled in DCM (2 mL) for 1 h and drained. A solution of
3-ethynylpyridine (2) (38 mg, 0.368 mmol) and Et.sub.3N (200 .mu.L,
1.4 mmol) in DMF (2 mL) was added and the resin agitated for 5 min.
A mixture of PdCl.sub.2(PPh.sub.3).sub.2 (22 mg, 0.031 mmol) and
CuI (25 mg, 0.131 mmol) was added and the resin was agitated for 72
h. The resin was drained, washed with DMF (3.times.2 mL), DCM
(3.times.2 mL) and cleaved with 10% TFA/DCM (1.5 mL) for 20 min.
The solution was collected and the resin was rinsed with additional
10% TFA/DCM (1.0 mL). The cleavage fractions were combined, treated
with neat TFA (2.0 mL), stirred for 1 h at rt and concentrated by
rotary evaporation to give a crude brown residue. Purification by
RP-HPLC (C.sub.18 column, CH.sub.3CN gradient 5-65%, 0.1% TFA, UV
analysis 300 nm, 24 min) and lyophilization of the collected
fractions afforded 4.4 mg (11% yield) of (3). LRMS (ES+) m/z 364.0
(C.sub.20H.sub.17N.sub.3O.sub.4+H requires 364.13); RP-HPLC (300
nm, 24 min run) 11.2 min.
Example 26
Synthesis of N-(1-(N-hydroxycarbamoyl)(1S,2R)-2-hydroxy propyl)
{4-[4-(6-morpholin4-yl(3-pyridyl))buta-1,3-diynyl]phenyl}carboxamide
(5)
Preparation of
4-[4-(6-Chloro-pyridin-3-yl)-buta-1,3-diynyl]-benzoic acid methyl
ester
[0978] 4-[4-(6-Chloro-pyridin-3-yl)-buta-1,3-diynyl]-benzoic acid
was made according to the method of Wang Shen and Sheela A. Thomas
in Org. Lett. 2000, 2(18), 2857-2860.
[0979] A solution of 4-(2,2-dibromo-vinyl)-benzoic acid methyl
ester (1) (9.6 g, 30.0 mmol), 2-chloro-5-ethynyl-pyridine (2) (5.43
g, 39.0 mmol), Pd.sub.2dba.sub.3 (274 mg, 0.3 mmol),
tris(4-methoxyphenyl) phosphine (TMPP) (422 mg, 1.2 mmol) were
dissolved in argon sparged (5 min.) DMF (60 ml). The reaction was
sparged with argon for 1 min. TEA (12.5 ml, 90.0 mmol) was added to
the stirred reaction mixture that was then heated under argon at
85.degree. C. for 3 hours. The reaction was found complete by LCMS.
The reaction was cooled to rt and diluted with EtOAc/hexane (1:1)
(500 ml). The organic phase was washed with 1 M NaOH (2.times.80
ml), water (2.times.80 ml), sat. brine (80 ml), dried with
Na.sub.2SO.sub.4, filtered concentrated under reduced pressure to
give crude product. The residue was filtered through a filter plug
of silica eluting with EtOAc/hexane (1:1). The fractions with
product were evaporated to give 9.06 g of product in good purity
(.about.96% pure). The material was taken on without further
purification.
Preparation of
4-[4-(6-Chloro-pyridin-3-yl)-buta-1,3-diynyl]-benzoic Acid (3)
[0980] A 6M aq. solution of NaOH (15 ml) was added to a stirred
solution of 4-[4-(6-Chloro-pyridin-3-yl)-buta-1,3-diynyl]-benzoic
acid methyl ester (9.06 g, 30 mmol) in MeOH (350 ml) at rt. The
reaction solution was heated to reflux for 3 hours. The reaction
stayed a mixture and did not turn clear. HPLC and LCMS indicated
that the reaction was forming side products. The reaction was
cooled to rt and some MeOH (.about.200 ml) was removed by
evaporation under reduced pressure. Water (400 ml) was added to the
mixture. Conc. HCl was added dropwise to the stirred solution until
acidic by pH paper (pH2). The yellow precipitate that formed was
collected by suction filtration. The solid was washed with water
(3.times.20 ml) and hexane (2.times.20 ml) to give the crude
product. HPLC indicated that there was approximately 40% product in
the mixture. The crude reaction product was purified by flash
chromatography using EtOAc (8-10%)/hexane as eluant. The pure
fractions were evaporated and dried in vacuo to give 4.2 g of
product (3) in 50% yield.
Preparation of
[4-[4-(6-chloro-pyridin-3-yl)-buta-1,3-diynyl]-benzoyl]-HN-Thr(OtBu)-hydr-
oxamic acid trityl resin (4)
[0981] (3) was coupled to a tert-butyl protected threonine
pre-loaded on hydroxylamine 2-chlorotrityl resin following the same
procedure as used for Example 26. The coupling employed DIC and
HOBT. [N-Fmoc-hydroxylamine 2-chlorotrityl resin was purchased from
Novabiochem cat. #01-64-0165.]
Preparation of
N-(2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-[4-(6-morpholin-4-yl-pyridin-3--
yl)-buta-1,3-diynyl]-benzamide (5)
[0982] A solution of morpholine (300 uL) in NMP (1 ml) was added to
a vial containing (4) (150 mg, 0.12 mmol). The reaction mixture was
purged with argon and heated to 85-90.degree. C. for 24 hours. The
resin was drained and washed with DMF and DCM alternately several
times. The product was cleaved from the resin through treatment
with a TFA/water solution (80:20) (1.5 ml) for 45 min. The resin
was filtered and washed with fresh TFA/water solution (80:20) (0.5
ml). The combined TFA and organic fractions were diluted with
CH.sub.3CN/water (1:1) (10 ml), water (2 ml) and lyophilized. The
crude product was purified by prep. HPLC. The crude product was
dissolved in DMSO (1 ml), passed through a Teflon syringe filter,
and the clear filtrate was injected on a preparative HPLC. The
purification used a 20.times.50 mm Ultro 120 C18 column running a
22 ml/min 2% gradient (AcCN/water, 0.1% TFA) for 16 min. The
purified fractions were lyophilized to dryness to give 2.2 mg of
pure product (5) as the TFA salt (.about.32% yield).
Example 27
Synthesis of
4-[4-(4-Amino-phenyl)-buta-1,3-diynyl]-N-(2-hydroxy-1-hydroxycarbamoyl-pr-
opyl)-benzamide (4)
Preparation of 2
{4-[4-(4-Amino-phenyl)-buta-1,3-diynyl]-benzoylamino}-3-tert-butoxycarbon-
yl oxy-butyric hydroxamic acid trityl resin (3)
[0983] DIEA (2.7 ml, 15.6 mmol) was added to a stirred solution of
4-[4-(4-Amino-phenyl)-buta-1,3-diynyl]-benzoic acid (2) (1.64 g,
6.3 mmol), HOBT (0.85 g, 6.3 mmol), DIC (0.98 ml, 6.3 mmol) in DMF
(50 ml). After 2 min., H-Thr(Boc)-NHO-Trt resin (1) (5.8 g, 4.5
mmol) was added in one portion. [N-Fmoc-hydroxylamine
2-chiorotrityl resin was purchased from Novabiochem cat.
#01-64-0165.] After 12 hours at rt, the reaction was found complete
by LCMS. The resin was drained and washed with DMF and DCM
alternately 3 times each. The product (3) was used as is in
subsequent reactions without further treatment.
Preparation of
4-]4-(4-Ainino-phenyl)-buta-1,3-diynyl]-N-(2-hydroxy-1-hydroxy
carbamoyl-propyl)-benzamide (4)
[0984] The product (4) (120 mg, 0.09 mmol) was cleaved from resin
(3) through treatment with a TFA/water solution (80:20) (1.5 ml)
for 45 min. The resin was filtered and washed with fresh TFA/water
solution (80:20) (0.5 ml). The combined TFA and organic fractions
were diluted with CH.sub.3CN/water (1:1) (10 ml), water (2 ml) and
lyophilized. The crude product was purified by prep. HPLC. The
crude product was dissolved in DMSO (1 ml), passed through a Teflon
syringe filter, and the clear filtrate was injected on a
preparative HPLC. The purification used a 20.times.50 mm Ultro 120
C18 column running a 22 ml/min 2% gradient (AcCN/water, 0.1% TFA)
for 16 min. The purified fractions were lyophilized to dryness to
give 2.2 mg of pure product as the TFA salt. The product was
lyophilized again from CH.sub.3CN/water with 10 equivalents of HCl
to remove most of the TFA to yield 2 mg of (4) as the HCl salt
(.about.53% yield).
Example 28
Synthesis of
4-{4-[4-(2-Dimethylamino-acetylamino)-phenyl]-buta-1,3-diynyl}-N-(2-hydro-
xy-1-hydroxycarbamoyl-propyl)-benzamide (6) (Continued from
Compound (3) of Example 27 Above)
Preparation of
2-{4-(4-[4-(2-Bromo-acetylamino)-phenyl]-buta-1,3-diynyl}-benzoylamino)-3-
-tert-butoxycarbonyloxy-butyric acid hydroxamate trityl resin
(5)
[0985] A solution of bromo-acetyl chloride (0.75 g, 0.58 mmol) in
DCM (2 ml) was added to a mixture of (3) (0.75 g, 0.58 mmol),
lutidine (1.1 ml, 9.2 mmol) and DCM (4 ml) at rt with shaking.
After shaking for 1.5 hours, the reaction was found complete by
LCMS. The resin was drained and washed with DCM (2.times.10 ml),
DMF (3.times.10 ml) and DCM (3.times.10 ml) again. The resin was
drained and dried in vacuo. The product resin (5) was used as is in
subsequent reactions without further treatment.
Preparation of
4-{4-[4-(2-Dimethylamino-acetylamino)-phenyl]-buta-1,3-diynyl}-N-(2-hydro-
xy-1-hydroxycarbamoyl-propyl)-benzamide (6)
[0986] A solution of dimethyl amine (0.2 ml) in NMP (1.2 ml) was
added to (5) (125 mg, 0.09 mmol) at rt with shaking. After shaking
for 12 hours, the reaction was found complete by LCMS. The resin
was drained and washed with DCM (2.times.10), DMF (3.times.10) and
DCM (3.times.10) again. The product (6 ml) was cleaved from the
resin through treatment with a TFA/water solution (80:20) (1.5 ml)
for 45 min. The resin was filtered and washed with fresh TFA/water
solution (80:20) (0.5 ml). The combined TFA and organic fractions
were diluted with CH.sub.3CN/water (1:1) (10 ml), water (2 ml) and
lyophilized. The crude product was purified by prep. HPLC. The
crude product was dissolved in DMSO (1 ml), passed through a Teflon
syringe filter, and the clear filtrate was injected on a
preparative HPLC. The purification used a 20.times.50 mm Ultro 120
C18 column running a 22 ml/min 2% gradient (AcCN/water, 0.1% TFA)
for 16 min. The purified fractions were lyophilized to dryness to
give 2 mg of pure product (6) as the TFA salt (.about.37%
yield).
Example 29
Synthesis of
4-{4-[4-(2-Amino-4-methyl-pentanoylamino)-phenyl]-buta-1,3-diynyl}-N-(2-h-
ydroxy-1-hydroxycarbamoyl-propyl)-benzamide (7) (Continued from
compound (3) of Example 27 Above)
[0987] A solution of Fmoc-L-leucine (0.135 g, 0.38 mmol), HATU
(0.146 g, 0.38 mmol) in DMF (1.5 ml) was made. After 2 min. of
shaking, the activated acid was added to (3) (125 mg, 0.09 mmol) at
rt with shaking. After shaking for 36 hours, the reaction was
drained and washed with DCM (2.times.4 ml), DMF (3.times.4 ml) and
DCM (3.times.4 ml) again. The resin was treated with 20% piperizine
in DMF (4 ml) for 2 hours twice. The resin was drained and washed
with DMF and DCM alternately several times. The product was cleaved
from the resin through treatment with a TFA/water solution (80:20)
(1.5 ml) for 45 min. The resin was filtered and washed with fresh
TFA/water solution (80:20) (0.5 ml). The combined TFA and organic
fractions were diluted with CH3CN/water (1:1) (10 ml), water (2 ml)
and lyophilized. The crude product was purified by prep. HPLC. The
crude product was dissolved in DMSO (1 ml), passed through a Teflon
syringe filter, and the clear filtrate was injected on a
preparative HPLC. The purification used a 20.times.50 mm Ultro 120
C18 column running a 22 ml/min 2% gradient (AcCN/water, 0.1% TFA)
for 16 min. The purified fractions were lyophilized to dryness to
give 1.7 mg of pure product (7) as the TFA salt (.about.30%
yield).
Example 30
Step 1
##STR00049##
[0989] NaBH(OAc).sub.3 (1.38 g, 6.03 mmol) was added at 0.degree.
C. to a solution of 4-iodobenzylaldehyde (1.0 g, 4.31 mmol) and
morpholine (462 mg, 5.37 mmol) in THF (30 mL). The reaction mixture
was then warmed to rt and stirred overnight. The solvent was
removed (RV) and the residue was extracted with EtOAc (2.times.)
from aqueous NaHCO.sub.3 (pH=8.about.9). The combined organic
extracts were dried (NaSO.sub.4) and concentrated to dryness (RV).
Column chromatography (silica gel, EtOAc/DCM 0-100%) yielded
compound (1) (980 mg, 74.8% yield, M+=304.0).
Step 2
##STR00050##
[0991] A solution of compound (1) (2.0 g, 6.6 mmol) and propargyl
alcohol (407 mg, 7.26 mmol) in THF (20 mL) was purged by nitrogen
for 30 min, followed by addition of PdCl.sub.2(PPh.sub.3).sub.2
(55.6 mg, 0.079 mmol) and CuI (30 mg, 0.158 mmol). The reaction
mixture was cooled to 0.degree. C. and triethyl amine (1.0 g, 9.9
mmol) was added. The reaction mixture was warmed to rt and stirred
overnight under N.sub.2. The reaction mixture was filtered through
a plug of celit and the filtrate was concentrated. The residue was
treated with water (200 mL) and extracted with EtOAc (200
mL.times.2). The combined organic layers were washed with water
(200 mL.times.2), brine (200 mL) and dried (NaSO.sub.4). The crude
product was purified by chromatography on silica gel eluting with
EtOAc/Hexane (0-50%) to give 1.5 g of the product (2) (98.7% yield,
M+H.sup.+=232.0).
Step 3
##STR00051##
[0993] Dess-Martin reagent (1.37 g, 3.25 mmol) was added to a
solution of compound (2) (500 mg, 2.1 mmol) in CH.sub.2Cl.sub.2 (5
mL) at 0.degree. C. The reaction mixture was warmed to rt and
stirred overnight. The reaction mixture was diluted with
CH.sub.2Cl.sub.2 (200 mL), basified with NaHCO.sub.3 (saturated) to
pH=8-9 and then washed with water (200 mL) and brine (200 mL),
dried (NaSO.sub.4) and concentrated under reduced pressure. The
crude product (3) (900 mg, MS+H.sup.+=230.0) was not very stable
and used directly in the next reaction without further
purification.
Step 4
##STR00052##
[0995] A mixture of 4-bromomethyl-benzoylic methyl ester (1.0 g,
4.37 mmol) and P(OEt).sub.3 (3 mL) in a sealed tube was heated at
150.degree. C. overnight. Cooled to rt, the reaction mixture was
diluted with EtOAc (200 mL), washed with water (100 mL.times.2) and
brine (100 mL), dried (NaSO.sub.4) and concentrated under reduced
pressure. The crude product was purified by chromatography on
silica gel eluting with EtOAc/Hexane (0-100%) to give compound (4)
(800 mg, 64.0% yield, M+H.sup.+=286.9).
Step 5
##STR00053##
[0997] To a solution of compound (4) (741 mg, 2.59 mmol) in THF (5
mL) was added NaH (114 mg, 2.85 mmol). Stirred at rt for one hour,
followed by addition of compound (3) (900 mg) in THF solution (5
mL), the resulting mixture was stirred at rt overnight and
concentrated under reduced pressure. The residue was treated with
EtOAc (300 mL), washed with water (200 ml.times.2) and brine (200
ml), dried (NaSO.sub.4) and concentrated under reduced pressure.
The crude product was purified by chromatography on silica gel
eluting with EtOAc/Hexane (0-60%) to give compound (5) (188 mg,
20.0% yield, M+H.sup.+=362.0).
Step 6
##STR00054##
[0999] To a solution of compound (5) (188 mg, 0.521 mmol) in MeOH
(5 mL) was added NaOH (84 mg, 1.08 mmol). The reaction mixture was
heated at reflux for 4 hrs and cooled to rt, the reaction mixture
was neutralized to pH=7 with HCl solution (4 N in dioxane). Removal
of solvent under reduced pressure, the solid residue was washed
with CH.sub.2Cl.sub.2. The combined CH.sub.2Cl.sub.2 was evaporated
to give crude compound (6) (259 mg, 70% purity, 100% yield,
MS.sup.+=348.0).
Step 7
##STR00055##
[1001] To a solution of compound (5) (320 mg, 0.886 mmol) in MeOH
(5 mL) was added NaOH (142 mg, 3.54 mmol). The reaction mixture was
heated at reflux for 4 hrs and cooled to rt. The reaction mixture
was concentrated under reduced pressure. The crude product was
purified by prep. HPLC to give compound (6a) (105.5 mg, 25.8%
yield, MS.sup.+=348.0) and (6b) (30.9 mg, 7.4%, MS.sup.+=348.0) as
TFA salt.
Step 8
##STR00056##
[1003] To a solution of compound (6) (44 mg, 0.126 mmol) and methyl
3-Boc-2, 3-diaminopropanoade (64 mg, 0.253 mmol) and PyBOP (131 mg,
0.253 mmol) in DMF (2 mL) was added DIPEA (81 mg, 0.65 mmol). The
reaction mixture was stirred at rt. overnight and diluted with
water (50 ml), extracted with EtOAc (50 ml.times.2). The combined
organic layers were washed with water (50 ml.times.2), brine (50
ml), dried (NaSO.sub.4) and concentrated under reduced pressure.
The crude product was purified by chromatography on silica gel
eluting with MeOH/CH.sub.2Cl.sub.2 (0-5%) to give product 7 (47 mg,
68.1%, MS.sup.+=548.1).
Step 9
##STR00057##
[1005] To a solution of compound (7) (48 mg, 0.08 mmol) in
CH.sub.2Cl.sub.2 (1 mL)/MeOH (2 mL) was added NH.sub.2OH.HCl (61
mg, 0.88 mmol) and NaOH (58 mg, 1.05 mmol). The reaction mixture
was stirred at rt for 3 days, and then diluted with
CH.sub.2Cl.sub.2 (20 mL), then treated with NH.sub.4Cl (saturated)
solution to adjust pH=7. The organic layer was separated, and the
aq. layer was extracted with CH.sub.2Cl.sub.2 (20 mL.times.2). The
combined CH.sub.2Cl.sub.2 layers were washed with brine (20 ml),
dried (NaSO.sub.4) and concentrated under reduced pressure. The
crude product was purified by chromatography on silica gel eluting
with CH.sub.2Cl.sub.21MeOH (0-10%) to give product (8) (10 mg,
22.8%. MS.sup.+=549.1)
Step 10
##STR00058##
[1007] The desired product (9a) (90 mg, 89.7%, MS.sup.+=463.1) was
prepared by the reaction of compound (6a) (100 mg, 0.217 mmol),
L-Threonine ethyl ester (75 mg, 0.434 mmol), HATU (165 mg, 0.434
mmol) and DIPEA (138 mg, 1.07 mmol) in DMF (3 mL) according to the
synthetic procedure for the preparation of compound (7).
Step 11
##STR00059##
[1009] The desired product (9b) (26 mg, 90%, MS.sup.+=463.1) was
prepared by the reaction of compound (6a) (30 mg, 0.065 mmol),
L-Threonine ethyl ester (22 mg, 0.13 mmol), HATU (49 mg, 0.138
mmol) and DIPEA (42 mg, 0.325 mmol) in DMF (1 mL) according to the
synthetic procedure for the preparation of compound (7).
Step 12
##STR00060##
[1011] The desired product (10) (36 mg, 46.0%, MS.sup.+=461.1) was
prepared by the reaction of compound (6) (60 mg, 0.17 mmol), valine
methyl ester (54 mg, 0.323 mmol), HATU (128 mg, 0.338 mmol) and
DIPEA (104 mg, 0.81 mmol) in DMF (3 mL) according to the synthetic
procedure for the preparation of compound (7).
Step 13
##STR00061##
[1013] To a solution of compound (8) (48 mg, 0.088 mmol) in
CH.sub.2Cl.sub.2 (1 ml) was added HCl (1 ml, 4 N in dioxane). The
reaction mixture was stirred at rt. for 2 hrs. and concentrated
under reduced pressure. The solid residue was purified by prep.
HPLC to give compound (30-11a) (53 mg, 90% yield) and (30-11b) (0.3
mg, 0.5% yield) as double TFA salt.
Step 14
##STR00062##
[1015] The desired product (30-12a) (53.8 mg, 14.9%,
MS.sup.+=464.1) was prepared by the reaction of compound (9a) (90
mg, 0.195 mmol) and NH.sub.2OH.HCl (134 mg, 1.95 mmol) and NaOMe
(128.7 mg, 2.34 mmol) in MeOH (5 ml) according to the synthetic
procedure for the preparation of compound (8).
Step 15
##STR00063##
[1017] Compound (30-12b) (6.2 mg, 24% yield) was prepared by the
reaction of compound (9b) (26 mg, 0.056 mmol) and NH.sub.2OH.HCl
(38.7 mg, 0.56 mmol) and NaOMe (37 mg, 0.672 mmol) in MeOH (3 ml)
according to the synthetic procedure for the preparation of
compound (8).
Step 16
##STR00064##
[1019] The desired product (13) is prepared by the reaction of
compound (10), NH.sub.2OH.HCl and NaOH in CH.sub.2Cl.sub.2/MeOH
according to the synthetic procedure for the preparation of
compound (8).
Step 17
##STR00065##
[1021] The desired product (14) is prepared by the reaction of
compound (6) and (2S,3R)-2-amino-3-Fmoc-butyric acid methyl ester
hydrochloride according to the synthetic procedure for the
preparation of compound (7). The desired product (15) is prepared
by the reaction of compound (14), NH.sub.2OH.HCl and NaOMe in
CH.sub.2Cl.sub.2/MeOH according to the synthetic procedures for the
preparation of compound (8).
Synthesis of (2S,3R)-2-amino-3-Fmoc-butyric acid methyl ester
hydrochloride
##STR00066##
[1022] (2S,3S)-methyl-3-hydroxy-2-(tritylamino)butanoate (14-2)
[1023] To a solution of H-allo-Thr-OMe.HCl (compound 14-1) (CAS
79617-27-9, Chem-Impex, 5 g, 29.5 mmoL) in CH.sub.2Cl.sub.2 (30 mL)
and DIEA (15 mL, 88.5 mmol) was added trityl bromide (10 g, 32.4
mmol) in CHCl.sub.3 (30 mL) dropwise through an addition funnel at
0.degree. C. The reaction mixture was warmed to rt slowly and
stirred overnight, and washed with water (2.times.10 mL) and brine,
dried (Na.sub.2SO.sub.4), filtered and concentrated to give the
desired product as a thick oil, which was solidified to a white
crystalline material in vacuo. The solid was treated with ethyl
ether and sonicated for 30 min, filtered and washed with ethyl
ether to give the pure product (14-2) (8 g, 21.3 mmol, 72% yield,
mw 375.5) as a white solid.
(2S,3R)-methyl 3-azido-2-(tritylamino)butanoate (14-3)
[1024] To a mixture of compound (14-2) (6 g, 16 mmol), PPh.sub.3
(4.2 g, 16 mmol) in CH.sub.2Cl.sub.2 (30 mL) at 0.degree. C. with
stirring under nitrogen was added diethyl azodicarboxylate (DIAD)
(5.2 g, 25.6 mmol) in CH.sub.2Cl.sub.2 (5 mL) slowly, followed by
diphenylphosphonic azide (DPPA) in CH.sub.2Cl.sub.2 (5 mL). The
reaction mixture was allowed to warm to rt. After stirring at rt
overnight, the reaction was concentrated under reduced pressure.
The residue was purified by chromatography on silica gel on an ISCO
system eluting with hexane/EtOAc to give the desired product (14-3)
(2.9 g, .about.7.2 mmol, 45% mw 400.5) as a yellow oil (NMR shows
there is DIAD in the product).
(2S,3R)-methyl 2-amino-3-azidobutanoate (14-4)
[1025] A mixture of compound (14-3) (2.9 g) in CH.sub.2Cl.sub.2 (10
mL) and HCl (5 mL, 4 M in dioxane) was stirred overnight. The
reaction mixture was concentrated and the residue was treated with
hexane. The suspension formed was filtered to give the desired
product (14-4) (600 mg, 52%) as a white solid. (Alternately,
compound (14-3) can be dissolved in THF (1 g: 8 mL), HCl 2M (3 eq.)
in ether can be added at 0.degree. C. The reaction is allowed to
warm and is complete after .about.3 h. The reaction mixture can be
diluted with ether to precipitate the product as an HCl salt which
is filtered and washed with ether. The resulting white powder,
after drying in vacuo, is highly pure and gives about 86% yield, mw
158.2 free base and 194.2 with 1 HCl salt. No further purification
is needed.)
(2S,3R)-3-Azido-2-Boc-amino-butyric acid methyl ester (14-5)
[1026] A solution of di-tert-butyl dicarbonate (810 mg, 3.7 mmol),
(2S,3R)-2-amino-3-azido-butyric acid methylester hydrochloride
(compound 14-4) (660 mg, 3.38 mmol) and DIEA (645 .mu.l, 3.7 mmol)
in i-PrOH (10 ml) was maintained at ambient temperature for 10 h.
The reaction mixture was evaporated in vacuum. The residue was
dissolved in water (4 mL) and extracted with hexane/ether (1:1)
(4.times.10 mL). The combined organic layers were dried
(Na.sub.2SO.sub.4) and concentrated under reduced pressure. The
residue was subjected to flash chromatography on CombiFlash.RTM.
Companion unit equipped with RediSep.RTM. flash column (normal
phase, 35-60 micron average particle size silicagel, 40 g, Teledyne
Isco); flow rate=35 ml/min; injection volume 2 ml (EtOAc); mobile
phase A: hexane; mobile phase B: EtOAc; gradient 0-50% B in 1 h.
Fractions containing the desired product were combined and
concentrated under reduced pressure to provide compound (14-5) (564
mg, 2.2 mmol, 65% yield, mw 258.3) as colorless oil. (Alternately,
the reaction can be run using 1.2 eq Boc.sub.2O and 2.5 eq DIEA in
ACN (1 g (14-5) in 30 mL ACN). After stirring overnight, the
reaction was concentrated and purified by silica chromatography
eluting with 10-15% EtOAc/Hexane. The product fractions were
collected to give 98% yield, >98% purity as a clear oil.
(2S,3R)-3-Amino-2-tert-butoxycarbonylamino-butyric acid methyl
ester (14-6)
[1027] Compound (14-5) (786 mg, 3.05 mmol) was dissolved in
methanol (20 ml) followed by the addition of Pd/C (5% wt, 200 mg).
The reaction mixture was subjected to hydrogenation (Parr
apparatus, 80 psi) at ambient temperature for 40 min. The solid
catalyst was filtered and washed with methanol. The filtrate was
evaporated under reduced pressure to provide compound (14-6) (682
mg, 96% yield, mw 232.3) as colorless oil.
(2S,3R)-2-Boc-amino-3-Fmoc-aminobutyric acid methyl ester
(14-7)
[1028] A mixture of compound (14-6) (682 mg, 2.94 mmol) and
Fmoc-OSu (1.04 g, 3.08 mmol) in acetone (5 ml) was stirred at rt
for 2 h. The solvent was evaporated under reduced pressure. The
residue was dissolved in EtOAc (50 ml) and washed with 5%
NaHCO.sub.3 (10 ml) and brine (10 ml). Organic layer was dried
(Na.sub.2SO.sub.4) and evaporated under reduced pressure. The
residue was subjected to flash chromatography on CombiFlash.RTM.
Companion unit equipped with RediSep.RTM. flash column (normal
phase, 35-60 micron average particle size silicagel, 40 g, Teledyne
Isco); flow rate=35 ml/min; injection volume 2 ml (EtOAc); mobile
phase A: hexane; mobile phase B: EtOAc; gradient 0-45% B in 1 h.
Fractions containing the desired product were combined and
concentrated in vacuum to provide compound (14-7) (1.10 g, 2.4
mmol, 82% yield, mw 454.5) as colorless oil. The oil solidified
while under vacuum. (Alternatively, THF may be used as the solvent
instead of acetone. It is also recommended to use 1 eq. of DIEA to
accelerate the reaction. Add the DIEA to the reaction after the
Fmoc reagent. The reaction can be concentrated, dissolved in EtOAc,
washed with 1 M citrate or 5% NaHSO.sub.4, water, 5% NaHCO.sub.3,
water, brine, dried (Na.sub.2SO.sub.4) and evaporated under reduced
pressure. A standard silica column purification can be accomplished
eluting with 25% EtOAc in Hexane to give 99% purity and 91%
yield.)
(2S,3R)-2-Amino-3-Fmoc-aminobutyric acid methyl ester hydrochloride
(14)
[1029] Compound (14-7) (1.10 g, 2.42 mmol) was dissolved in 4 N
HCl/dioxane (8 ml) at ambient temperature for 20 min. with stirring
under nitrogen. The resulting suspension was diluted with ether and
the precipitate was filtered and washed with ether (3.times.10 mL).
The compound (14) was dried in vacuo to provide the hydrochloric
salt (840 mg, 2.15 mmol, 89%, mw 354.4 free base, HCl salt 390.4)
as white solid. [M+H]=355.0. Retention time: 4.11 min [Chromolith
SpeedRod RP-18e C18 column (4.6.times.50 mm); flow rate 1.5 ml/min;
mobile phase A: 0.1% TFA/water; mobile phase B 0.1% TFA/ACN;
gradient elution from 5% B to 100% B over 12 min, detection 254
nm]
Synthesis of Alternate Intermediate 009
##STR00067##
[1030] (E)-methyl 4-(2-iodovinyl)benzoate (1)
[1031] Chromium chloride anhydrous (8.9 g, 73 mmol, 8 equiv) was
dissolved in 100 mL THF under nitrogen at 0.degree. C.
Triiodomethane (14.4 g, 37 mmol, 4 equiv) in 150 mL THF was added
dropwise in 10 min. Then compound (1S) (1.5 g, 9.1 mmol, 1 equiv)
in 20 mL THF was added dropwise. The mixture was stirred at
0.degree. C. for 2 hours and then at room temperature for 1 more
hour. The mixture was poured into iced water then extracted with
EtOAc (100 mL.times.2). The organic phase was washed with 20% aq.
Na.sub.2S.sub.2O.sub.3 (100 mL), brine (100 mL) and dried
(Na.sub.2SO.sub.4). The crude product was purified by
chromatography on silica gel eluting with EtOAc/petroleum ether
(0-2%) to give the title compound (1) (2.2 g, 85%). MS (m/z):
[M+H].sup.+=289.7. .sup.1H NMR (300 MHz, d.sub.6-DMSO): 3.92 (s,
3H), 7.01.about.7.05 (d, 1H), 7.33=7.34 (d, 1H), 7.35.about.7.36
(d, 1H), 7.44.about.7.49 (d. 1H), 7.97.about.7.98 (d, 1H),
7.99=8.00 (d, 1H).
(E)-methyl
4-(4-(4-(morpholinomethyl)phenyl)but-1-en-3-ynyl)benzoate (2)
[1032] Compound (1) (2 g, 6.9 mmol, 1 equiv), diisopropylamine (0.7
g, 6.9 mmol, 1 equiv) and PdCl.sub.2(PPh.sub.3).sub.2 (0.24 g, 0.34
mmol, 0.05 equiv) was dissolved in 20 mL triethylamine at room
temperature under nitrogen. The mixture was stirred for 15 min
followed by addition of compound (004) (1.4 g, 6.9 mmol, 1 equiv).
The mixture was stirred at room temperature for 12 hours. The
reaction mixture was diluted with 50 mL EtOAc, filtered and
concentrated. Then, the residue was diluted with 100 ml EtOAc and
washed with water (100 mL) and brine (100 mL), dried
(Na.sub.2SO.sub.4) and concentrated under reduced pressure. The
crude product was purified by chromatography on silica gel eluting
with EtOAc/petroleum ether (0-10%) to give the title compound (2)
(1.5 g, 60%). MS (m/z): [M+H].sup.+=362. .sup.1H NMR (300 MHz,
d.sub.6- DMSO): 2.3.about.22.34 (d, 4H), 3.46 (s, 1H),
3.5.about.43.57 (t, 4H), 3.83 (s, 3H), 6.77=6.82 (d. 1H), 7.13=7.18
(d, 1H), 7.32=7.34 (d, 2H), 7.4.about.37.45 (d, 2H),
7.68.about.7.71 (d, 2H), 7.90=7.93 (d, 2H).
(E)-4-(4-(4-(morpholinomethyl)phenyl)but-1-en-3-ynyl)benzoic acid
(009)
[1033] Compound (2) (1.5 g, 4.2 mmol, 1 equiv) was dissolved in a
solvent of (THF:MeOH:H.sub.2O=1:1:1, 20 mL) at room temperature.
Then, lithium hydroxide (0.35 g, 6.4 mmol, 2 equiv) was added. The
mixture was stirred for 12 hours at room temperature. The pH was
adjusted to 7 by acetic acid. The mixture was stirred for 1 hour.
The solid was filtered and washed with water (20 mL), ether 20 mL
and dried in vacuo to give the target product (009) (0.9 g, 62%).
MS (m/z): [M+H].sup.+=348. .sup.1H NMR (300 MHz, d.sub.6-DMSO):
2.3.about.22.35 (t, 4H), 3.47 (s, 2H), 3.54.about.3.57 (t, 4H),
6.75.about.6.80 (d. 1H), 7.1.about.27.18 (d, 1H), 7.3.about.27.35
(d, 2H), 7.43=7.45 (d, 2H), 7.66=7.68 (d, 2H), 7.88.about.7.91 (d,
2H).
Synthesis of Alternate Intermediate (011)
##STR00068##
[1034] (4-Iodophenyl)methanol (2)
[1035] To a solution of compound (1) (50 g, 0.21 mol, 1.0 equiv) in
methanol (500 mL) was added with NaBH.sub.4 (20.5 g, 0.5 mol, 2.5
equiv) slowly under 10.degree. C. for 1 h and stirred for 2 h. The
reaction mixture was concentrated under reduced pressure, quenched
with water (300 mL), and extracted with EtOAc (300 mL.times.3). The
organic layer was dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The residue was dried in vacuo
overnight to provide the title compound (2) (49 g, 97%).
Tert-butyl(4-iodobenzyloxy)dimethylsilane (3)
[1036] To a solution of compound (2) (9 g, 38.5 mmol, 1.0 equiv),
TBSCl (5.8 g, 38.5 mmol, 1.0 equiv) and imidazole (5.3 g, 77 mmol,
2.0 equiv) in DMF (18 mL) was stirred for 2 h at 45.degree. C. The
reaction mixture was diluted with CH.sub.2Cl.sub.2 (200 mL) and
washed with water (200 mL.times.3). The organic layer was dried
over Na.sub.2SO.sub.4, filtered and concentrated under reduced
pressure. The residue was dried under high vacuum overnight to
produce the title compound (3) (11.6 g, 87%). .sup.1H NMR (300 MHz,
d.sub.6-DMSO): 0.05 (s, 6H), 0.88 (s, 9H), 4.64 (s, 2H),
7.09.about.7.11 (d. 2H), 7.66.about.7.69 (d, 2H).
Tert-butyldimethyl(4-((trimethylsilyl)ethynyl)benzyloxy)silane
(4)
[1037] Under nitrogen, ethynyltrimethylsilane (3.929 g, 37 mmol,
1.1 equiv) was added to a solution of compound (3) (11.6 g, 33.4
mmol 1.0 equiv), PdCl.sub.2(PPh.sub.3).sub.2 (2.345 g, 3.34 mmol,
0.1 equiv), CuI (0.636 g, 3.34 mmol, 0.1 equiv) and i-Pr.sub.2NH
(10.05 mL) in THF (anhydrous, 200 ml) at room temperature. The
mixture was allowed to reaction at ambient temperature for 3 h.
Then, the precipitate was isolated. The filter cake was washed with
EtOAc (50 mL). The filtrate was concentrated under reduced
pressure. The residue was dissolved in EtOAc (300 mL) and washed
with water (50 ml), 1M HCl aq. (50 ml), water (50 ml.times.2) and
brine (50 ml). The organic layer was separated, dried
(Na.sub.2SO.sub.4) and the filtrate was concentrated under reduced
pressure. The residue was purified by chromatography
(EtOAc/petroleum ether 0-2%) on silica gel to give the title
compound (4) (9.2 g, 87%). .sup.1H NMR (300 MHz, d.sub.6-DMSO):
0.10 (s, 6H), 0.26 (s, 9H), 0.93 (s, 9H), 4.73 (s, 2H),
7.23.about.7.26 (d. 2H), 7.42.about.7.44 (d, 2H).
Tert-butyl(4-ethynylbenzyloxy)dimethylsilane (5)
[1038] To a solution of compound (4) (5.2 g, 16.4 mmol, 1.0 equiv)
in methanol (100 mL) was treated with KOH/methanol (0.457 g/5 mL)
slowly below 10.degree. C., then the mixture was allowed to react
at ambient temperature for 5 min. The reaction mixture was
neutralized with acetic acid and concentrated under reduced
pressure. The residue was dissolved in EtOAc (100 mL). The organic
layer was washed with 5% aq. Na.sub.2CO.sub.3 (50 ml.times.2),
dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. The residue was dried in vacuo overnight to
provide the title compound (5) (4 g, 99%). .sup.1H NMR (300 MHz,
d.sub.6-DMSO): 0.04 (s, 6H), 0.87 (s, 9H), 4.09 (s, 1H), 4.68 (s,
2H), 7.26.about.7.29 (d. 2H), 7.4.about.17.43 (d, 2H).
(E)-methyl
4-(4-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)but-1-en-3-y-
nyl) benzoate (010)
[1039] Under nitrogen, (E)-methyl 4-(2-iodovinyl)benzoate (1 g,
3.47 mmol, 1.0 equiv) was added to a solution of compound (5)
(0.855 g, 3.47 mmol, 1.0 equiv), PdCl.sub.2(PPh.sub.3).sub.2 (0.244
g, 0.347 mmol, 0.1 equiv), CuI (0.066 g, 0.347 mmol, 0.1 equiv) and
i-Pr.sub.2NH (2 mL) in THF (anhydrous, 10 mL) at room temperature.
The mixture was allowed to reaction at ambient temperature for 3 h.
Then, the precipitate was filtered. The filter cake was washed with
EtOAc. The filtrate and wash liquid were combined and concentrated
under reduced pressure. The residue was dissolved in EtOAc (30 ml)
and washed with water (10 ml), 1M HCl aq. (10 ml), water (10
ml.times.2) and brine (10 ml). The organic layer was separated,
dried (Na.sub.2SO.sub.4), filtered and concentrated under reduced
pressure. The residue was purified by chromatography
(EtOAc/petroleum ether 0-3%) on silica gel to give the target
compound (010) (9.2 g, 86.6%). .sup.1H NMR (300 MHz,
d.sub.6-CDCl.sub.3): 0.10 (s, 6H), 0.94 (s, 9H), 3.91 (s, 3H), 4.74
(s, 2H), 6.46.about.6.52 (d. 1H), 7.01.about.7.07 (d, 1H),
7.26.about.7.31 (t, 2H), 7.43.about.7.49 (m, 4H), 7.99.about.8.02
(t, 2H).
Example 31
Step 1
##STR00069##
[1041] A solution of ethyl 4-iodo-benzoate (2.43 g, 8.81 mmol) and
propargyl alcohol (543.3 mg, 9.69 mmol) in THF (35 mL) was purged
by nitrogen for 30 min, followed by addition of
PdCl.sub.2(PPh.sub.3).sub.2 (74 mg, 0.106 mmol) and CuI (40 mg,
0.212 mmol). The reaction mixture was cooled to 0.degree. C. and
triethyl amine (1.34 g, 13.22 mmol) was added. The reaction mixture
was warmed to rt and stirred overnight under N.sub.2. The reaction
mixture was filtered through a plug of celite and the filtrate was
concentrated. The residue was treated with water (200 mL) and
extracted with EtOAc (200 mL.times.2). The combined organic layers
were washed with water (200 mL.times.2), brine (200 mL) and dried
(NaSO.sub.4). The crude product was purified by chromatography on
silica gel eluting with EtOAc/Hexane (0-50%) to give 1.53 g, 85%
yield) of the product (20).
[1042] Dess-Martin reagent (4.78 g, 11.25 mmol) was added to a
solution of compound (20) (1.53 g, 7.5 mmol) in CH.sub.2Cl.sub.2
(20 mL) at 0.degree. C. The reaction mixture was warmed to rt and
stirred overnight. The reaction mixture was diluted with
CH.sub.2Cl.sub.2 (200 mL), basified with NaHCO.sub.3 (saturated) to
pH=7 and then washed with water (200 mL) and brine (200 mL), dried
(NaSO.sub.4) and concentrated under reduced pressure. The crude
product was purified by chromatography on silica gel eluting with
EtOAc/Hexane (0-40%) to give the desired product (21) (1.24 g,
81.8%).
Step 2
##STR00070##
[1044] p-Toluenesulfonic acid (721 mg, 12% HOAc solution) was added
to a benzene (30 ml) solution of 4-bromomethyl-benzaldhyde (1 g,
5.03 mmol) and ethylene glycol (623 mg, 10.06 mmol). The reaction
was heated under refluxing overnight. After cooled to room temp,
the reaction mixture was concentrated under reduced pressure. The
crude product was purified by chromatography on silica gel eluting
with EtOAc/Hexane (0-20%) to give the desired product (22) (1.13 g,
92.8%).
[1045] Triphenylphosphine (1.34 g, 5.11 mmol) was added to a
1,2-dichloroethane (10 ml) solution of compound (22) (1.13 g, 4.65
mmol). The reaction was heated to 70.degree. C. for 4 hours. After
cooling to room temp., the organic solution was concentrated with
rotavap. Diethyl ether (50 ml) was added to the residue with
vigorous stirring to precipitated the wittig salt. After
filtration, the collected solid was washed with ether (3.times.50
ml) and dried under high vacuum to give compound (23) (2 g, 85%
yield).
Step 3
##STR00071##
[1047] To a solution of compound (23) (1.36 g, 2.69 mmol) in DCM
(10 ml) was added DIPEA (694 mg, 5.38 mmol). The reaction mixture
was stirred at rt for 10 min., followed by addition of compound
(21) (544 mg, 2.69 mmol) in DCM (10 ml) solution.
[1048] The resulting mixture was stirred at rt overnight and
concentrated under reduced pressure. The residue was treated with
EtOAc (100 ml), washed with water (2.times.100 ml) and brine (100
ml), dried (NaSO.sub.4) and concentrated under reduced pressure.
The crude product was purified by chromatography on silica gel
(0-20% EtOAc/Hexane) to give compound (24) (600 mg, 63.9%).
Step 4
##STR00072##
[1050] To a solution of compound (24) (718 mg, 2.35 mmol) in THF (6
ml) and HOAc (6 ml) was added NaBH.sub.3CN (211 mg, 3.55 mmol). The
reaction was stirred at room temp. for 30 min. The reaction mixture
was then concentrated under reduced pressure. The residue was
diluted with EtOAc (200 ml) and treated with NaHCO.sub.3 (sat'd) to
pH=8. After separation, the aqueous layer was extracted with EtOAc
(2.times.200 ml). The combined organic layers was washed with
H.sub.2O (2.times.100 ml), brine (100 ml) and dried with
Na.sub.2SO.sub.4. Concentrated by ratovap, the residue was purified
by chromatography on silica gel (0-50% EtOAc/Hexane) to give
compound (25a) (300 mg) and (25b) (187.5 mg) with 67% total
yield.
Step 5
##STR00073##
[1052] A DCM solution (5 ml) of compound 25 (300 mg, 0.98 mmol) and
DIPEA (158 mg, 1.23 mmol) was cooled to 0.degree. C., followed by
the addition MsCl (124 mg, 1.08 mmol). The reaction was warmed to
rt and stirred for 30 min. Morphline (171 mg, 1.96 mmol) was added
to reaction and stirred for 2 hours at rt. Diluted with EtOAc (200
ml), reaction mixture was washed with H.sub.2O (2.times.100 ml),
brine (100 ml) and dried with Na.sub.2SO.sub.4. Concentrated under
reduced pressure, the crude product was purified by chromatography
on silica gel (0-50% EtOAc/Hexane) to give compound (27) (345 mg)
in 94% yield.
Step 6
##STR00074##
[1054] The desired product (28) (284 mg, 95%) was prepared with
compound (26) (244 mg, 0.8 mmol), MsCl (80.5 mg, 0.88 mmol),
morphline (106 mg, 1.22 mmol) and DIPEA (100 mg, 0.88 mmol)
according to the synthetic procedure for the preparation of
compound (27).
Step 7
##STR00075##
[1056] To a mix solution (6 ml) of THF/MeOH/H.sub.2O (1:1:1) of
compound (27) (345 mg, 0.92 mmol) was added LiOH (44 mg, 1.84
mmol). Reaction was stirred over at rt. HOAc was added to the
reaction to pH=7. The reaction was concentrated under reduced
pressure. The residue was re-dissolved in CH.sub.3CN (1 ml) and
H.sub.2O (2 ml) and dried with lyophlizer to give crude product
(29) (482 mg, 66% pure, 100% yield).
Step 8
##STR00076##
[1058] The desired product (30) (374 mg, 76% pure, 100% yield) was
prepared with compound (28) (284 mg, 0.76 mmol), LiOH (36 mg, 1.52
mmol) according to the synthetic procedure for the preparation of
compound (29).
Step 9
##STR00077##
[1060] The desired product (31) (65 mg, 48%, MS.sup.+=463.1) was
prepared by the reaction of compound (29) (100 mg, 0.29 mmol),
L-Threonine methyl ester (88 mg, 0.44 mmol), HATU (176 mg, 0.46
mmol) and DIPEA (187 mg, 1.45 mmol) in DMF (2 mL) according to the
synthetic procedure for the preparation of compound (7).
Step 10
##STR00078##
[1062] The desired product (32) (100 mg, 63%, MS.sup.+=548.1) was
prepared by the reaction of compound (29) (100 mg, 0.29 mmol),
methyl 3-Boc-2, 3-diaminopropanoade (112 mg, 0.44 mmol), HATU (176
mg, 0.46 mmol) and DIPEA (187 mg, 1.45 mmol) in DMF (12 mL)
according to the synthetic procedure for the preparation of
compound (7).
Step 11
##STR00079##
[1064] The desired product (33) (70 mg, 52%, MS.sup.+=463.1) was
prepared by the reaction of compound (30) (100 mg, 0.29 mmol),
L-Threonine methyl ester (88 mg, 0.44 mmol), HATU (176 mg, 0.46
mmol) and DIPEA (187 mg, 1.45 mmol) in DMF (2 mL) according to the
synthetic procedure for the preparation of compound (7).
Step 12
##STR00080##
[1066] The desired product (34) (90 mg, 56.7%, MS.sup.+=548.1) was
prepared by the reaction of compound (30) (100 mg, 0.29 mmol),
Methyl 3-Boc-2, 3-diaminopropanoade (112 mg, 0.44 mmol), HATU (176
mg, 0.46 mmol) and DIPEA (187 mg, 1.45 mmol) in DMF (12 mL)
according to the synthetic procedure for the preparation of
compound (7).
Step 13
##STR00081##
[1068] The desired product (35) (20 mg, 14.9%, MS.sup.+=464.1) was
prepared by the reaction of compound (31) (65 mg, 0.14 mmol) and
NH.sub.2OH.HCl (96.6 mg, 1.4 mmol) and NaOMe (115 mg, 2.1 mmol) in
MeOH (5 ml) according to the synthetic procedure for the
preparation of compound (8).
Step 14
##STR00082##
[1070] The desired product (36) (30 mg, 30%, MS.sup.+=464.1) was
prepared by the reaction of compound (32) (100 mg, 0.182 mmol) and
NH.sub.2OH.HCl (126 mg, 1.8 mmol) and NaOMe (148.5 mg, 2.7 mmol) in
MeOH (5 ml) according to the synthetic procedure for the
preparation of compound (8).
Step 15
##STR00083##
[1072] The desired product (37a) (20 mg, 28.4%, MS.sup.+=464.1) was
prepared by the reaction of compound (33) (70 mg, 0.152 mmol) and
NH.sub.2OH.HCl (104 mg, 1.52 mmol) and NaOMe (125 mg, 2.28 mmol) in
MeOH (5 ml) according to the synthetic procedure for the
preparation of compound (8).
Step 16
##STR00084##
[1074] The desired product (37b) (40 mg, 44.5%, MS.sup.+=548.1) was
prepared by the reaction of compound (34) (90 mg, 0.164 mmol) and
NH.sub.2OH.HCl (114 mg, 1.65 mmol) and NaOMe (136.1 mg, 2.47 mmol)
in MeOH (5 ml) according to the synthetic procedure for the
preparation of compound (8).
Step 17
##STR00085##
[1076] To a solution of compound (36) (30 mg, 0.055 mmol) in
CH.sub.2Cl.sub.2 (1 ml) was added HCl (1 ml, 4 N in dioxane). The
reaction mixture was stirred at rt. for 2 hrs. and concentrated
under reduced pressure. The solid residue was purified by prep.
HPLC to give compound (38) (10 mg, 40% yield, MS.sup.+=449.1) as
double TFA salt.
Step 18
##STR00086##
[1078] To a solution of compound (37b) (40 mg, 0.073 mmol) in
CH.sub.2Cl.sub.2 (1 ml) was added HCl (1 ml, 4 N in dioxane). The
reaction mixture was stirred at rt. for 2 hrs. and concentrated
under reduced pressure. The solid residue was purified by prep.
HPLC to give compound (39) (15 mg, 45.8% yield, MS.sup.+=449.1) as
double TFA salt.
Step 19
##STR00087##
[1080] The desired products (40) and (41) may be prepared according
to the foregoing synthetic procedures.
Example 32
##STR00088##
[1081] Step 1
##STR00089##
[1083] NaBH(OAc).sub.3 (2.28 g, 0.76 mmol) was added at 0.degree.
C. to a solution of 4-ethylnyl-benzylaldehyde (1.0 g, 7.69 mmol)
and morpholine (462 mg, 5.37 mmol) in THF (20 mL). The reaction
mixture was then warmed to rt and stirred overnight. The solvent
was removed (RV) and the residue was extracted with EtOAc
(2.times.) from aqueous NaHCO.sub.3 (pH=8.about.9). The combined
organic extracts were dried (Na.sub.2SO.sub.4) and concentrated to
dryness (RV). Column chromatography (silica gel, EtOAc/DCM 0-50%)
yielded compound (40) (1.31 g, 84.8% yield, M+H.sup.+=202.0).
Step 2
##STR00090##
[1085] A solution of methyl 4-formylbenzoate (1 g, 6.09 mmol) and
p-TSA (12% in AcOH, 104 mg, 0.609 mmol) in benzene solution (50 mL)
was heated at reflux for 3 hours. The reaction mixture was cooled
to rt, diluted with EtOAc (200 ml) and washed with water (200
mL.times.2) and brine (200 mL). The crude product was purified by
chromatography on silica gel eluting with EtOAc/Hexane (0-50%) to
give compound (41) (1.1 g, 87%)
Step 3
##STR00091##
[1087] NaHMDS was added to a solution of compound (40) in THF at
0.degree. C. The reaction was stirred for 1 hour, followed by
addition of compound (41) in THF at 0.degree. C. The reaction
mixture was warmed to rt and stirred overnight. The reaction
mixture was treated with NH.sub.4Cl (saturated) and extracted with
EtOAc. The combined organic layers were washed with brine (20 ml),
dried (NaSO.sub.4) and concentrated under reduced pressure. The
crude product was purified by chromatography on silica gel.
Further Steps
##STR00092##
[1088] Example 33
##STR00093##
[1089] Example 34
##STR00094##
[1090] Example 35
##STR00095##
[1091] Example 36
##STR00096##
[1092] The following compounds may be synthesized as described in
this, and the foregoing, Example.
##STR00097##
Examples 37A and 37B
##STR00098## ##STR00099##
[1093] Example 38
##STR00100##
[1094] Example 39
##STR00101##
[1095] The following compound may be synthesized as described in
this Example.
##STR00102##
Example 40
##STR00103##
[1096] Example 41
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-[1-(4-morpholin-4-ylmeth-
yl-phenyl)-piperidin-4-yl]-benzamide
##STR00104##
[1097] Synthesis of 4-[1-(4-formyl-phenyl)-piperidin-4-yl]-benzoic
acid methyl ester (U
[1098] A mixture of 4-(4-methoxycarboxyphenyl) piperidine HCl (256
mg, 1.0 mmol), 4-fluoro-benzaldehyde (105 .mu.l, 1.0 mmol) and
K.sub.2CO.sub.3 (250 mg, 1.8 mmol) in DMF (5 ml) was stirred at
ambient temperature overnight. Reaction was diluted with water (30
ml). Formed precipitate was filtrated, washed with water (20 ml)
and ether (20 ml), and dried in vacuum overnight to provide target
compound (1) (203 mg, 63%) as white solid. LC-MS [M+H] 324.3
(C.sub.20H.sub.21NO.sub.3+H, requires 324.41).
Synthesis of
4-[1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl]-benzoic acid
methyl ester (2)
[1099] A mixture of compound (1) (200 mg, 0.62 mmol),
NaBH(OAc).sub.3 (158 mg, 0.75 mmol) and morpholine (60 .mu.l, 0.68
mmol) in DCM (5 ml) was stirred at ambient temperature overnight.
Reaction was quenched with 5% aq. NaHCO.sub.3 (15 ml) and extracted
with EtOAc (30 ml.times.2). Organic layer was washed with brine (20
ml) and dried over MgSO.sub.4 (anh.). Solvent was evaporated in
vacuum. Residue was dried in vacuum overnight to provide target
compound (2) (225 mg, 92%) as yellowish solid. LC-MS [M+H] 308.1
(C.sub.24H.sub.30N.sub.2O.sub.3+H, requires 395.53).
Synthesis of
4-[1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl]-benzoic acid
(3)
[1100] A solution of compound (2) (225 mg, 0.57 mmol) and 1 M aq.
NaOH (10 ml, 10 mmol) in dioxane (6 ml) was stirred at ambient
temperature overnight. Reaction mixture was acidified with 1 M aq.
HCl to pH.about.6. Volatile solvent was evaporated in vacuum.
Formed precipitate was filtrated and washed with water (10 ml) and
cold ether (5 ml) and dried in vacuum overnight to provide
di-hydrochloric salt of target material (3) (211 mg, 89%) as
off-white solid. LC-MS [M+H] 381.4
(C.sub.23H.sub.28N.sub.2O.sub.3+H, requires 381.50).
Synthesis of
(2S,3R)-3-hydroxy-2-{4-[1-(4-morpholin-4-ylmethyl-phenyl)-piperidin-4-yl]-
-benzoylamino}-butyric acid methyl ester (4)
[1101] A solution of compound (3) (70 mg, 0.15 mmol), HATU (63 g,
0.17 mmol) and DIEA (131 .mu.l, 0.75 mmol) in DMF (800 .mu.l) was
maintained at ambient temperature for 10 min followed by the
addition of H-Thr-OMe hydrochloride (37 mg, 0.22 mmol). Reaction
mixture was stirred at ambient temperature overnight followed by
the dilution with EtOAc (100 ml). Solution was extracted with water
(20 ml.times.2) and brine (20 ml). Organic layer was dried over
MgSO.sub.4 and evaporated. Residue was dried in vacuum to provide
target compound (4) (73 mg, 99%) as yellow solid. LC-MS [M+H] 496.3
(C.sub.28H.sub.37N.sub.3O.sub.5+H, requires 496.63).
Synthesis of
N-((1S,2R)-2-hydroxy-1-hydroxycarbamoyl-propyl)-4-[1-(4-morpholin-4-ylmet-
hyl-phenyl)-piperidin-4-yl]-benzamide (41-5)
[1102] A solution of hydroxylamine hydrochloride (63 mg, 0.9 mmol)
in MeOH (2 ml) was cooled to -5.degree. C. followed by the addition
of 25% NaOMe/MeOH (308 .mu.l, 4.5 mmol) under nitrogen. Reaction
mixture was stirred at -5.degree. C. for additional 5 min, cooled
to -20.degree. C., and solution of compound 4 (73 mg, 0.15 mmol) in
THF/MeOH (1:1, 2 ml) was added dropwise over the period of 5 min.
Temperature of reaction mixture was raised to ambient. Completion
of the reaction was monitored by LC-MS. Reaction mixture was
acidified with 1 N aq. HCl to pH.about.7 and evaporated in vacuum.
Residue was dissolved in DMSO (500 .mu.l) and subjected to HPLC
purification. [Phenomenex Gemini C-18 column, 110 .ANG.
(30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100% water,
0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient elution from
8% B to 28% B in 60 min., detection 254 nm]. Fractions containing
the desired product were combined and lyophilized to provide
di-trifluoroacetic salt of target product (41-5) as white solid.
LC-MS [M+H] 497.7 (C.sub.27H.sub.36N.sub.4O.sub.5+H, requires
497.62).
TABLE-US-00003 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (41-5) 0.15 76 70 100 497.7 1.97
*[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm); flow
rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase B
0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 min,
detection 254 nm]
Example 42
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-[4-(4-morpholin-4-ylmeth-
yl-phenyl)-piperidin-1-yl]-benzamide
##STR00105##
[1103] Synthesis of 4-(4-hydroxymethyl)-piperidine-1-carboxylicacid
tert-butyl ester (1)
[1104] A solution of N-Boc-4-(4-carboxyphenyl) piperidine (305 mg,
1.0 mmol) and 1 M BH.sub.3 THF (3.1 ml, 3.1 mmol) in THF (3 ml) was
maintained under nitrogen at ambient temperature overnight.
Reaction was quenched with 5% aq. NH.sub.4Cl (5 ml) and extracted
with EtOAc (30 ml.times.2). Organic layer was washed with 5%
NaHCO.sub.3 (20 ml) and brine (20 ml) and dried over MgSO.sub.4.
Solvent was evaporated in vacuum. Residue was dried in vacuum
overnight to provide target compound (1) (272 mg, 93%) as white
solid. LC-MS [M+H] 292.3 (C.sub.17H.sub.25NO.sub.3+H, requires
292.40).
Synthesis of
4(4-Morpholin-4-ylmethyl-phenyl)-piperidine-1-carboxylic acid
tert-butyl ester (2)
[1105] A solution of compound (1) (272 mg, 0.93 mmol) and DIEA (198
.mu.l, 1.14 mmol) in DCM (5 ml) was cooled to 0.degree. C. followed
by the addition of MsCl (87 .mu.l, 1.12 mmol). Reaction mixture was
maintained at 0.degree. C. for 10 min followed by the addition of
mixture of DIEA (179 .mu.l, 1.1 mmol) and morpholine (90 .mu.l, 1.1
mmol). Temperature of the reaction mixture was allowed to rise to
ambient. Reaction mixture was maintained at ambient temperature
overnight and diluted with EtOAc (80 ml). Organic layer was washed
with 5% NaHCO.sub.3 (20 ml) and brine (20 ml) and dried over
MgSO.sub.4 (anh.). Solvent was evaporated in vacuum. Residue was
dried in vacuum overnight to provide target compound (2) (315 mg,
94%) as brownish oil. LC-MS [M+H] 361.4
(C.sub.21H.sub.32N.sub.2O.sub.3+H, requires 361.51).
Synthesis of 4-(4-piperidin-4-yl-benzyl)-morpholine (3)
[1106] A solution of compound (2) (315 mg, 1.13 mmol), TFA (3 ml,
40 mmol) in DCM (3 ml) was maintained at ambient temperature for 3
h. Solvents were evaporated in vacuum. Residue was dissolved in DCM
(1 ml) and 1 M HCl/ether (50 ml) was added. Formed precipitate was
filtrated, washed with ether and dried in vacuum overnight to
provide di-hydrochloric salt of target compound (3) (281 mg, 91%)
as off-white solid. LC-MS [M+H] 261.1 (C.sub.16H.sub.24N.sub.2O+H,
requires 261.39).
Synthesis of
4-[4-(4-morpholin-4-ylmethyl-phenyl)-piperidin-1-yl]-benzoic acid
methyl ester (4)
[1107] A mixture of compound (3) (261 mg, 0.78 mmol),
4-methoxycarbonylphenyl) boronic acid (388 mg, 2.16 mmol),
Cu(OAc).sub.2 (216 mg, 1.19 mmol), molecular sieves (4 .ANG., 200
mg) and Et.sub.3N (750 .mu.l, 5.6 mmol) in DCE (5 ml) was stirred
at ambient temperature overnight under nitrogen. Formed precipitate
was filtrated. Filtrate was diluted with EtOAc (100 ml) and
extracted with water (20 ml.times.2) and brine (20 ml). Solvent was
evaporated in vacuum. Residue was dissolved in DMSO (1 ml) and
subjected to HPLC purification. [YMC-Pack ODS-A C-18 column
(30.times.100 mm); flow rate=10 ml/min; injection volume 1.0 ml;
mobile phase A: 100% water, 0.1% TFA; mobile phase B: 100% ACN,
0.1% TFA; gradient elution from 10% B to 60% B in 70 min.,
detection 254 nm]. Fractions containing the desired product were
combined and concentrated in vacuum. The residue was dissolved in
EtOAc (25 ml), extracted with 5% aq. NaHCO.sub.3 (20 ml) and brine
(20 ml) and dried over MgSO.sub.4 (anh.). Solvent was evaporated in
vacuum. Residue was dried in vacuum overnight to provide target
product (4) (24 mg, 6%) as white solid. LC-MS [M+H] 394.8
(C.sub.24H.sub.30N.sub.2O.sub.3+H, requires 395.53).
Synthesis of
4-[4-(4-morpholin-4-ylmethyl-phenyl)-piperidin-1-yl]-benzoic acid
(5)
[1108] A solution of compound (4) (24 mg, 0.06 mmol) and 1 M aq.
NaOH (500 .mu.l, 0.5 mmol) in dioxane (500 .mu.l) was stirred at
ambient temperature overnight. Reaction mixture was acidified with
1 M aq. HCl to pH.about.2. Formed precipitate was filtrated and
washed with water (10 ml) and dried in vacuum overnight to provide
di-hydrochloric salt of target material (5) (24 mg, 88%) as
off-white solid. LC-MS [M+H] 381.4
(C.sub.23H.sub.28N.sub.2O.sub.3+H, requires 381.50).
Synthesis of
(2S,3R)-3-hydroxy-2-{4-[4-(4-morpholin-4-ylmethyl-phenyl)-piperidin-1-yl]-
-benzoylamino}-butyric acid methyl ester (6)
[1109] A solution of compound (5) (24 mg, 0.053 mmol), HATU (25 g,
0.066 mmol) and DIEA (52 .mu.l, 0.3 mmol) in DMF (600 .mu.l) was
maintained at ambient temperature for 10 min followed by the
addition of H-Thr-OMe hydrochloride (14 mg, 0.08 mmol). Reaction
mixture was stirred at ambient temperature overnight followed by
the dilution with EtOAc (100 ml). Solution was extracted with water
(20 ml.times.2) and brine (20 ml). Organic layer was dried over
MgSO.sub.4 and evaporated. Residue was dried in vacuum to provide
target compound (6) (26 mg, 99%) as yellow solid. LC-MS [M+H] 496.4
(C.sub.28H.sub.37H.sub.3O.sub.5+H, requires 496.63).
Synthesis of
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-[4-(4-morpholin-4-ylmet-
hyl-phenyl)-piperidin-1-yl]-benzamide (42-7)
[1110] A solution of hydroxylamine hydrochloride (24 mg, 0.34 mmol)
in MeOH (2 ml) was cooled to -5.degree. C. followed by the addition
of 25% NaOMe/MeOH (117 .mu.l, 0.51 mmol) under nitrogen. Reaction
mixture was stirred at -5.degree. C. for additional 5 min, cooled
to -20.degree. C., and solution of compound (6) (26 mg, 0.053 mmol)
in THF/MeOH (1:1, 2 ml) was added dropwise over the period of 5
min. Temperature of reaction mixture was raised to ambient.
Completion of the reaction was monitored by LC-MS. Reaction mixture
was acidified with 1 N aq. HCl to pH.about.7 and evaporated in
vacuum. Residue was dissolved in DMSO (500 .mu.l) and subjected to
HPLC purification. [Phenomenex Gemini C-18 column, 110 .ANG.
(30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100% water,
0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient elution from
8% B to 28% B in 60 min., detection 254 nm]. Fractions containing
the desired product were combined and lyophilized to provide
di-trifluoroacetic salt of target product 42-7 as white solid.
LC-MS [M+H] 497.5 (C.sub.27H.sub.36N.sub.4O.sub.5+H, requires
497.62).
TABLE-US-00004 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (42-7) 0.053 17.5 46 99.8 497.5
2.22 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 mm,
detection 254 nm]
Example 43
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-[4-(4-morpholin-4-ylmeth-
yl-phenyl)-piperazin-1-yl]-benzamide
##STR00106##
[1111] Synthesis of 4-(4-formyl-phenyl)-piperazine-1-carboxylic
acid tert-butyl ester (1)
[1112] A mixture of 4-(tert-butyl-1-piperazinecarboxylate (556 mg,
3.0 mmol), 4-fluoro-benzaldehyde (315 .mu.l, 3.0 mmol) and
K.sub.2CO.sub.3 (514 mg, 3.7 mmol) in DMF (5 ml) was stirred at
ambient temperature overnight. Reaction was diluted with water (30
ml) and extracted with EtOAc (50 ml.times.2). Organic layer was
washed with water (20 ml), 1 M aq. HCl (20 ml), water (20
ml.times.2) and brine (20 ml) and dried over MgSO.sub.4 (anh.).
Solvent was evaporated in vacuum. Residue was triturated with
hexane. Formed precipitate was filtrated and dried in vacuum
overnight to provide target compound (1) (342 mg, 39%) as off-white
solid. LC-MS [M+H] 291.2 (C.sub.16H.sub.22N.sub.2O.sub.3+H,
requires 291.38).
Synthesis of
4-(4-morpholin-4-ylmethyl-phenyl)-piperazine-1-carboxylic acid
tert-butyl ester (2)
[1113] A mixture of compound (1) (342 mg, 1.18 mmol),
NaBH(OAc).sub.3 (300 mg, 1.42 mmol) and morpholine (113 .mu.l, 1.3
mmol) in DCM (5 ml) was stirred at ambient temperature overnight.
Reaction was quenched with 5% aq. NaHCO.sub.3 (15 ml) and extracted
with EtOAc (30 ml.times.2). Organic layer was washed with brine (20
ml) and dried over MgSO.sub.4 (anh.). Solvent was evaporated in
vacuum. Residue was dried in vacuum overnight to provide target
compound (2) (408 mg, 96%) as white solid. LC-MS [M+H] 361.9
(C.sub.20H.sub.31N.sub.3O.sub.3+H, requires 362.50).
Synthesis of 4-(4-piperazin-1-yl-benzyl)-morpholine (3)
[1114] A solution of compound (2) (408 mg, 1.13 mmol), TFA (5 ml,
68 mmol) in DCM (5 ml) was maintained at ambient temperature for 40
min. Solvents were evaporated in vacuum. Residue was dissolved in 1
M aq. NaOH (10 ml) and extracted with EtOAc (30 ml.times.2).
Organic layer was washed with brine (20 ml) and dried over
MgSO.sub.4 (anh.). Solvent was evaporated in vacuum. Residue was
dried in vacuum overnight to provide target compound (3) (212 mg,
72%) as yellowish solid. LC-MS [M+H] 262.3
(C.sub.15H.sub.23N.sub.3O+H, requires 262.38).
Synthesis of
4-[4-(4-morpholin-4-ylmethyl-phenyl)-piperazin-1-yl]-benzoic acid
methyl ester (4)
[1115] A mixture of compound (3) (140 mg, 0.54 mmol), methyl
4-fluorobenzoate (76 .mu.l, 0.59 mmol) and DIEA (141 .mu.l 1, 0.81
mmol) in DMSO (2 ml) was irradiated in microwave oven (max. power
250 W, 160.degree. C.) for 2 h and cooled to ambient temperature.
Reaction mixture was diluted with water (30 ml). Formed precipitate
was filtrated and dissolved in EtOAc (100 ml). Solution was washed
with 5% aq. NaHCO.sub.3 (20 ml) and brine (20 ml) and dried over
MgSO.sub.4 (anh.). Solvent was evaporated in vacuum. Residue was
dried in vacuum overnight to provide target compound (4) (98 mg,
46%) as yellowish solid. LC-MS [M+H] 396.2
(C.sub.23H.sub.29N.sub.3O.sub.3+H, requires 396.52).
Synthesis of
4-[4-(4-morpholin-4-ylmethyl-phenyl)-piperazin-1-yl]-benzoic acid
(5)
[1116] A solution of compound (4) (98 mg, 0.57 mmol) and 1 M aq.
NaOH (2 ml, 2 mmol) in dioxane (2 ml) was stirred at ambient
temperature overnight. Reaction mixture was acidified with 1 M aq.
HCl to pH.about.6 and evaporated in vacuum. Residue was dissolved
in DMSO (1 ml) and subjected to HPLC purification. [YMC-Pack ODS-A
C-18 column (30.times.100 mm); flow rate=10 ml/min; injection
volume 1.0 ml; mobile phase A: 100% water, 0.1% TFA; mobile phase
B: 100% ACN, 0.1% TFA; gradient elution from 0% B to 45% B in 72
min., detection 254 nm]. Fractions containing the desired product
were combined and concentrated in vacuum. The residue was dissolved
in i-PrOH (15 ml) and evaporated in vacuum. Obtained residue was
dissolved in i-PrOH (5 ml) and 1 M HO/ether (50 ml) was added.
Precipitate was filtrated and dried in vacuum to provide
tri-hydrochloric salt of target product (5) (30 mg, 24%) as
off-white solid. LC-MS [M+H] 382.6
(C.sub.22H.sub.27N.sub.3O.sub.3+H, requires 382.49).
Synthesis of
(2S,3R)-3-hydroxy-2-{4-[4-(4-morpholin-4-ylmethyl-phenyl)-piperazin-1-yl]-
-benzoylamino}-butyric acid methyl ester (6)
[1117] A solution of compound (5) (30 mg, 0.06 mmol), HATU (25 g,
0.066 mmol) and DIEA (63 .mu.l, 0.36 mmol) in DMF (500 .mu.l) was
maintained at ambient temperature for 10 min followed by the
addition of H-Thr-OMe hydrochloride (14 mg, 0.084 mmol). Reaction
mixture was stirred at ambient temperature overnight followed by
the dilution with EtOAc (100 ml). Solution was extracted with water
(20 ml.times.2) and brine (20 ml). Organic layer was dried over
MgSO.sub.4 and evaporated. Residue was dried in vacuum to provide
target compound (6) (30 mg, 99%) as yellow solid. LC-MS [M+H] 479.0
(C.sub.27H.sub.36N.sub.4O.sub.5+H, requires 497.62).
Synthesis of
N-((1S,2R)-2-hydroxy-1-hydroxycarbamoyl-propyl)-4-[4-(4-morpholin-4-ylmet-
hyl-phenyl)-piperazin-1-yl]-benzamide (43-7)
[1118] A solution of hydroxylamine hydrochloride (63 mg, 0.36 mmol)
in MeOH (2 ml) was cooled to -5.degree. C. followed by the addition
of 25% NaOMe/MeOH (123 .mu.l, 0.36 mmol) under nitrogen. Reaction
mixture was stirred at -5.degree. C. for additional 5 min, cooled
to -20.degree. C., and solution of compound (6) (30 mg, 0.06 mmol)
in THF/MeOH (1:1, 2 ml) was added dropwise over the period of 5
min. Temperature of reaction mixture was raised to ambient.
Completion of the reaction was monitored by LC-MS. Reaction mixture
was acidified with 1 N aq. HCl to pH.about.7 and evaporated in
vacuum. Residue was dissolved in DMSO (500 .mu.l) and subjected to
HPLC purification. [Phenomenex Gemini C-18 column, 110 .ANG.
(30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100% water,
0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient elution from
8% B to 28% B in 60 min., detection 254 nm]. Fractions containing
the desired product were combined and lyophilized to provide
tri-trifluoroacetic salt of target product (43-7) as white solid.
LC-MS [M+H] 498.3 (C.sub.26H.sub.35N.sub.5O.sub.5+H, requires
498.61).
TABLE-US-00005 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (43-7) 0.06 15.3 31 100 498.61
2.64 *[Chromolith SpeedRod RP-18e C18 column (4.6 x 50 mm); flow
rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase B
0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 min,
detection 254 nm]
The following compounds may be synthesized as described in this
Example.
##STR00107##
Example 44
##STR00108##
[1119] Example 45
##STR00109##
[1120] Example 46
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-(4-morpholin-4-ylmethyl--
benzylsulfanyl)-benzamide
##STR00110##
[1121] Synthesis of
4-(4-morpholin-4-ylmethyl-benzylsulfanyl)-benzoic acid methyl ester
(1)
[1122] A solution of (4-(morpholinomethyl)phenyl)methanol (207 mg,
1.0 mmol) and DIEA (192 .mu.l, 1.1 mmol) in DCM (3 ml) was cooled
to 0.degree. C. followed by the addition of MsCl (94 .mu.l, 1.2
mmol). Reaction mixture was maintained at 0.degree. C. for 1 h
followed by the addition of mixture of DIEA (192 .mu.l, 1.1 mmol)
and methyl-4-mercaptobenzoate (185 mg, 1.1 mmol). Temperature of
the reaction mixture was allowed to rise to ambient. Reaction
mixture was maintained at ambient temperature 40 min and diluted
with EtOAc (80 ml). Organic layer was washed with 5% NaHCO.sub.3
(20 ml) and brine (20 ml) and dried over MgSO.sub.4 (anh.). Solvent
was evaporated in vacuum. Residue (1) was used as is for the next
transformation. LC-MS [M+H] 358.1 (C.sub.20H.sub.23NO.sub.3S+H,
requires 358.49).
Synthesis of 4-(4-morpholin-4-ylmethyl-benzylsulfanyl)-benzoic acid
(2)
[1123] To a solution of compound (1) (1.0 mmol) in dioxane (1 ml) 1
M aq. NaOH (1.5 ml, 1.5 mmol) was added. Reaction mixture was
maintained at ambient temperature overnight and acidified with 1 M
aq. HCl to pH.about.5. Solvents were evaporated. Residue was
dissolved in DMSO (1 ml) and subjected to HPLC purification.
[YMC-Pack ODS-A C-18 column (30.times.100 mm); flow rate=10 ml/min;
injection volume 1.5 ml; mobile phase A: 100% water, 0.1% TFA;
mobile phase B: 100% ACN, 0.1% TFA; gradient elution from 5% B to
50% B in 70 min., detection 254 nm]. Fractions containing the
desired product were combined and concentrated in vacuum. The
residue was dissolved in i-PrOH (15 ml) and evaporated in vacuum.
Obtained residue was dissolved in i-PrOH (5 ml) and 1 M HCl/ether
(50 ml) was added. Precipitate was filtrated and dried in vacuum to
provide hydrochloric salt of target product (2) (161 mg, 54%) as
white solid. LC-MS [M+H] 344.1 (C.sub.19H.sub.21NO.sub.3S+H,
requires 344.46).
Synthesis of
(2S,3R)-3-hydroxy-2-[4-(4-morpholin-4-ylmethyl-benzylsulfanyl)-benzoyl
amino]-butyric acid methyl ester (3)
[1124] A solution of compound (2) (34 mg, 0.09 mmol), HATU (34 g,
0.09 mmol) and DIEA (63 .mu.l, 0.36 mmol) in DMF (800 .mu.l) was
maintained at ambient temperature for 10 min followed by the
addition of H-Thr-OMe hydrochloride (18 mg, 0.11 mmol). Reaction
mixture was stirred at ambient temperature overnight followed by
the dilution with EtOAc (100 ml). Solution was extracted with water
(20 ml.times.2) and brine (20 ml). Organic layer was dried over
MgSO.sub.4 and evaporated. Residue was dried in vacuum to provide
target compound (3) (40 mg, 98%) as yellow solid. LC-MS [M+H] 459.2
(C.sub.24H.sub.30N.sub.2O.sub.5S+H, requires 459.59).
Synthesis of
N-((1S,2R)-2-hydroxy-1-hydroxycarbamoyl-propyl)-4-(4-morpholin-4-ylmethyl-
-benzylsulfanyl)-benzamide (46-4)
[1125] A solution of hydroxylamine hydrochloride (19 mg, 0.27 mmol)
in MeOH (2 ml) was cooled to -5.degree. C. followed by the addition
of 25% NaOMe/MeOH (94 .mu.l, 0.41 mmol) under nitrogen. Reaction
mixture was stirred at -5.degree. C. for additional 5 min, cooled
to -20.degree. C., and solution of compound (3) (40 mg, 0.09 mmol)
in THF/MeOH (1:1, 2 ml) was added dropwise over the period of 5
min. Temperature of reaction mixture was raised to ambient.
Completion of the reaction was monitored by LC-MS. Reaction mixture
was acidified with 1 N aq. HCl to pH.about.7 and evaporated in
vacuum. Residue was dissolved in DMSO (500 W) and subjected to HPLC
purification. [Phenomenex Gemini C-18 column, 110 .ANG.
(30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100% water,
0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient elution from
8% B to 28% B in 60 min., detection 254 nm]. Fractions containing
the desired product were combined and lyophylised to provide
trifluoroacetic salt of target product (46-4) (25.8 mg, 50%) as
white solid. LC-MS [M+H] 460.2 (C.sub.23H.sub.29N.sub.3O.sub.5S+H,
requires 460.58).
TABLE-US-00006 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (46-4) 0.09 25.8 50 98.7 460.2
3.11 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 mm,
detection 254 nm]
Compounds (5) and (6)
[1126] Compounds (5) and (6) may be synthesized from compound 4
using OXONE oxidation in dichloromethane.
Example 47
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-(4-morpholin-4-ylmethyl--
phenylsulfanyl)-benzamide-4-ylmethyl-phenylethynyl)-benzamide
##STR00111##
[1127] Synthesis of 4-(4-iodo-benzyl)-morpholine (1)
[1128] To a solution of morpholine (353 .mu.l, 4.06 mmol) in DMSO
(5 ml) was added 4-iodobenzylbromide (402 mg, 1.35 mmol). Reaction
mixture was stirred at ambient temperature overnight. Reaction
mixture was diluted with 5% NaHCO.sub.3 (100 ml) and extracted with
EtOAc (50 ml.times.2). Organic layer was washed with brine (30 ml),
dried over MgSO.sub.4 (anh.) and evaporated in vacuum. Residue was
dried in vacuum overnight at ambient temperature to provide target
material (1) (344 g, 84%) as white solid. LC-MS [M+H] 304.1
(C.sub.11H.sub.14INO+H, requires 304.15).
Synthesis of 4-(4-morpholin-4-ylmethyl-phenylsulfanyl)-benzoic acid
methyl ester (2)
[1129] A mixture of compound (1) (260 mg, 0.86 mmol),
methyl-4-mercaptobenzoate (159 mg, 0.94 mmol), CuI (16.3 mg, 0.086
mmol and K.sub.2CO.sub.3 (237 mg, 1.72 mmol) in NMP (2 ml) was
stirred was irradiated in microwave oven (max. power 250 W,
160.degree. C.) for 40 min and cooled to ambient temperature.
Reaction mixture was diluted with EtOAc (80 ml) and extracted with
5% aq. NaHCO.sub.3 (20 ml) and brine (20 ml) and dried over
MgSO.sub.4 (anh.). Solvent was evaporated in vacuum. Residue was
dried in vacuum overnight to provide target compound (2) (289 mg,
98%) as yellowish solid. LC-MS [M+H] 344.3
(C.sub.19H.sub.21NO.sub.3S+H, requires 344.46).
Synthesis of 4-(4-morpholin-4-ylmethyl-phenylsulfanyl)-benzoic acid
(3)
[1130] To a solution of compound (2) (289 mg, 0.84 mmol) in dioxane
(500 .mu.l) 1 M aq. NaOH (1 ml) was added. Reaction mixture was
maintained at ambient temperature for 1.5 h, acidified with 1 M aq.
HCl to pH.about.5 and evaporated in vacuum. Residue was dissolved
in DMSO (1 ml) and subjected to HPLC purification. [YMC-Pack ODS-A
C-18 column (30.times.100 mm); flow rate=10 ml/min; injection
volume 1.0 ml; mobile phase A: 100% water, 0.1% TFA; mobile phase
B: 100% ACN, 0.1% TFA; gradient elution from 5% B to 50% B in 72
min., detection 254 nm]. Fractions containing the desired product
were combined and concentrated in vacuum. The residue was dissolved
in i-PrOH (15 ml) and evaporated in vacuum. Obtained residue was
dissolved in i-PrOH (5 ml) and 1 M HCl/ether (50 ml) was added.
Precipitate was filtrated and dried in vacuum to provide
hydrochloric salt of target product (3) (77 mg, 25%) as yellowish
solid. LC-MS [M+H] 330.1 (C.sub.18H.sub.19NO.sub.3S+H, requires
330.43).
Synthesis of
(2S,3R)-3-hydroxy-2-[4-(4-morpholin-4-ylmethyl-phenylsulfanyl)-benzoyl
amino]-butyric acid methyl ester (4)
[1131] A solution of compound (3) (33 mg, 0.09 mmol), HATU (34 g,
0.09 mmol) and DIEA (63 .mu.l, 0.36 mmol) in DMF (800 .mu.l) was
maintained at ambient temperature for 10 min followed by the
addition of compound H-Thr-OMe hydrochloride (18 mg, 0.11 mmol).
Reaction mixture was stirred at ambient temperature overnight
followed by the dilution with EtOAc (80 ml). Solution was extracted
with water (20 ml.times.2) and brine (20 ml). Organic layer was
dried over MgSO.sub.4 and evaporated. Residue was dried in vacuum
to provide target compound (4) (39 mg, 98%) as brown solid. LC-MS
[M+H] 445.3 (C.sub.23H.sub.28N.sub.2O.sub.5S+H, requires
445.56).
Synthesis of
N-((1S,2R)-2-hydroxy-1-hydroxycarbamoyl-propyl)-4-(4-morpholin-4-ylmethyl-
-phenylsulfanyl)-benzamide (47-5)
[1132] A solution of hydroxylamine hydrochloride (39 mg, 0.54 mmol)
in MeOH (anh, 2 ml) was cooled to -5.degree. C. followed by the
addition of 25% NaOMe/MeOH (188 .mu.l, 0.81 mmol) under nitrogen.
Reaction mixture was stirred at -5.degree. C. for additional 5 min,
cooled to -20.degree. C., and solution of compound (4) (0.09 mmol)
in THF/MeOH (1:1, 2 ml) was added dropwise over the period of 5
min. Temperature of reaction mixture was raised to ambient.
Completion of the reaction was monitored by LC-MS. After completion
reaction mixture was acidified with 1 N aq. HCl to pH.about.7 and
evaporated in vacuum. Residue was dissolved in DMSO (600 .mu.l) and
subjected to HPLC purification. [Phenomenex Gemini C-18 column, 110
.ANG. (30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100%
water, 0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient
elution from 8% B to 28% B in 60 min., detection 254 nm]. Fractions
containing the desired product were combined and lyophylised to
provide trifluoroacetic salt of target product (47-5) (25.8 mg,
52%) as white solid. LC-MS [M+H] 446.2
(C.sub.22H.sub.27N.sub.3O.sub.5S+H, requires 446.55).
TABLE-US-00007 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (47-5) 0.09 25.8 52 98.7 446.2
3.11 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 min,
detection 254 nm
Compound (6)
[1133] Compound (6) may be synthesized from compound (5) using
OXONE oxidation in dichloromethane.
Example 48
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-(4-morpholin-4-ylmethyl--
benzyl)-benzamide
##STR00112##
[1134] Synthesis of 4-(4-hydroxymethyl-benzyl)-benzoic acid methyl
ester (1)
[1135] A mixture of 4-(hydroxymethyl)phenylboronic acid (304 mg,
2.0 mmol), methyl 4-(bromomethyl)-benzoate (229 mg, 1.0 mmol),
Pd(PPh.sub.3).sub.4 (12 mg, 0.01 mmol) and 1 M aq. K.sub.2CO.sub.3
(400 .mu.l) in ACN (800 .mu.l) was irradiated in microwave oven
(max. power 250 W, 160.degree. C.) for 7 min and cooled to ambient
temperature. Reaction mixture was diluted with EtOAc (100 ml) and
extracted with 5% aq. NaHCO.sub.3 (30 ml) and brine (30 ml).
Organic layer was dried over MgSO.sub.4 (anh.). Solvent was
evaporated in vacuum. Residue was dried in vacuum overnight to
provide target product (1) (224 mg, 88%) as yellow oil.
Synthesis of 4-(4-morpholin-4-ylmethyl-benzyl)-benzoic acid methyl
ester (2)
[1136] A solution of compound (1) (204 mg, 0.8 mmol) and DIEA (191
.mu.l, 1.1 mmol) in DCM (2 ml) was cooled to 0.degree. C. followed
by the addition of MsCl (86 .mu.l, 1.1 mmol). Reaction mixture was
maintained at 0.degree. C. for 1 h followed by the addition of
mixture of DIEA (191 .mu.l, 1.1 mmol) and morpholine (131 .mu.l,
1.5 mmol). Temperature of the reaction mixture was allowed to rise
to ambient. Reaction mixture was maintained at ambient temperature
overnight and diluted with EtOAc (80 ml). Organic layer was washed
with 5% NaHCO.sub.3 (20 ml) and brine (20 ml) and dried over
MgSO.sub.4 (anh.). Solvent was evaporated in vacuum. Residue was
dissolved in DMSO (1 ml) and subjected to HPLC purification.
[YMC-Pack ODS-A C-18 column (30.times.100 mm); flow rate=15 ml/min;
injection volume 1.0 ml; mobile phase A: 100% water, 0.1% TFA;
mobile phase B: 100% ACN, 0.1% TFA; gradient elution from 15% B to
70% B in 70 min., detection 254 nm]. Fractions containing the
desired product were combined and concentrated in vacuum. The
residue was dissolved in EtOAc (25 ml), extracted with 5% aq.
NaHCO.sub.3 (20 ml) and brine (20 ml) and dried over MgSO.sub.4
(anh.). Solvent was evaporated in vacuum. Residue was dried in
vacuum overnight to provide target product (2) (73 mg, 28%) as
white solid. LC-MS [M+H] 326.3 (C.sub.20H.sub.23NO.sub.3+H,
requires 326.42).
Synthesis of 4-(4-morpholin-4-ylmethyl-benzyl)-benzoic acid (3)
[1137] To a solution of compound (2) (73 mg, 0.22 mmol) in dioxane
(500 .mu.l) 1 M aq. NaOH (1.5 ml, 1.5 mmol) was added. Reaction
mixture was maintained at ambient temperature overnight and
acidified with 1 M aq. HCl to pH.about.5. Solvents were evaporated.
Residue was dissolved in DMSO (1 ml) and subjected to HPLC
purification. [YMC-Pack ODS-A C-18 column (30.times.100 mm); flow
rate=15 ml/min; injection volume 1 ml; mobile phase A: 100% water,
0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient elution from
5% B to 50% B in 70 min., detection 254 nm]. Fractions containing
the desired product were combined and concentrated in vacuum. The
residue was dissolved in i-PrOH (15 ml) and evaporated in vacuum.
Obtained residue was dissolved in i-PrOH (5 ml) and 1 M HCl/ether
(50 ml) was added. Precipitate was filtrated and dried in vacuum to
provide hydrochloric salt of target product (3) (38 mg, 50%) as
white solid. LC-MS [M+H] 312.4 (C.sub.19H.sub.21NO.sub.3+H,
requires 312.39).
Synthesis of
(2S,3R)-3-hydroxy-2-[4-(4-morpholin-4-ylmethyl-benzyl)-benzoylamino]-buty-
ric acid methyl ester (4)
[1138] A solution of compound (3) (31 mg, 0.09 mmol), HATU (34 g,
0.09 mmol) and DIEA (63 .mu.l, 0.36 mmol) in DMF (800 .mu.l) was
maintained at ambient temperature for 10 min followed by the
addition of H-Thr-OMe hydrochloride (18 mg, 0.11 mmol). Reaction
mixture was stirred at ambient temperature overnight followed by
the dilution with EtOAc (100 ml). Solution was extracted with water
(20 ml.times.2) and brine (20 ml). Organic layer was dried over
MgSO.sub.4 and evaporated. Residue was dried in vacuum to provide
target compound (4) (31 mg, 82%) as yellow solid. LC-MS [M+H] 427.1
(C.sub.24H.sub.30N.sub.2O.sub.5+H, requires 427.53).
Synthesis of
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-(4-morpholin-4-ylmethyl-
-benzyl)-benzamide (48-5)
[1139] A solution of hydroxylamine hydrochloride (15 mg, 0.22 mmol)
in MeOH (2 ml) was cooled to -5.degree. C. followed by the addition
of 25% NaOMe/MeOH (75 .mu.l, 0.33 mmol) under nitrogen. Reaction
mixture was stirred at -5.degree. C. for additional 5 min, cooled
to -20.degree. C., and solution of compound 4 (31 mg, 0.07 mmol) in
THF/MeOH (1:1, 2 ml) was added dropwise over the period of 5 min.
Temperature of reaction mixture was raised to ambient. Completion
of the reaction was monitored by LC-MS. Reaction mixture was
acidified with 1 N aq. HCl to pH.about.7 and evaporated in vacuum.
Residue was dissolved in DMSO (500 .mu.l) and subjected to HPLC
purification. [Phenomenex Gemini C-18 column, 110 .ANG.
(30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100% water,
0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient elution from
8% B to 28% B in 60 min., detection 254 nm]. Fractions containing
the desired product were combined and lyophylised to provide
trifluoroacetic salt of target product (48-5) (18.8 mg, 50%) as
white solid. LC-MS [M+H] 428.1 (C.sub.23H.sub.29N.sub.3O.sub.5+H,
requires 428.51).
TABLE-US-00008 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (48-5) 0.07 18.8 50 99.3 428.1
2.73 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 mm,
detection 254 nm]
Example 49
##STR00113##
[1140] Examples 50A and 50B
##STR00114##
[1141] Example 51
##STR00115##
[1142] Example 52
##STR00116##
[1143] Example 53
##STR00117##
[1144] Example 54
##STR00118## ##STR00119##
[1145] Example 55
##STR00120## ##STR00121##
[1146] Example 56
##STR00122##
[1147] Example 57
##STR00123##
[1148] Example 58
##STR00124##
[1149] Example 59
(S)-3-amino-N-hydroxy-2-(7-((4-(morpholinomethyl)phenyl)ethynyl)-4-oxoquin-
azolin-3(4H)-yl)propanamide (59-8)
##STR00125##
[1150] 2-amino-4-iodobenzoic acid (2)
[1151] A solution of 2-amino-4-bromobenzoic acid (1) (2.15 g, 10
mmol) in degassed DMF (25 ml), CuI (3.80 g, 20 mmol) and KI (8.8 g,
50 mmol) was heated in a sealed tube at 130.degree. C. for 18 h.
The reaction mixture was cooled to room temperature and solid was
filtered off. The filtrate was concentrated to dryness and the
residue was stirred in ethyl acetate (400 ml) and water (100 ml)
and the organic layer was separated and concentrated. The crude
product was then purified over a silica gel column to give (2)
(0.98 g).
(S)-methyl
2-(2-amino-4-iodobenzamido)-3-(tert-butoxycarbonylamino)propano-
ate (4)
[1152] To a solution of 2-amino-4-iodobenzoic acid (2) (0.98 g,
3.37 mmol), DAP hydrochloride methyl ester (compound 3) (0.952 g,
3.74 mmol), DIEA (2 mL, excess) in acetonitrile (26 mL) was added
HATU (1.42 g, 3.74 mmol). The reaction mixture was stirred for 30
min and concentrated. The crude product extracted with ethyl
acetate (200 mL) and concentrated to give (4) and used as such in
the next step.
(S)-methyl-3-(tert-butoxycarbonylamino)-2-(7-iodo-4-oxoquinazolin-3(4H)-yl-
)propanoate (5)
[1153] Compound (4) (1.42 g) was heated in neat trietyl
orthoformate (18 mL) at 120.degree. C. for 24 h. Excess triethyl
orthoformate was removed under reduced pressure and crude product
was purified on silica gel column to give compound (5) (0.48
g).
(S)-methyl-3-(tert-butoxycarbonylamino)-2-(7-((4-(morpholinomethyl)phenyl)-
ethynyl)-4-oxoquinazolin-3(4H)-yl)propanoate (7)
[1154] CuI (15 mg) and PdCl.sub.2(PPh.sub.3).sub.2 (21 mg) was
added to a degassed THF (10 ml) solution of
(S)-methyl-3-(tert-butoxycarbonylamino)-2-(7-iodo-4-oxoquinazolin-3(4H)-y-
l)propanoate (5) (0.48 g, 1.01 mmol), diisopropyl amine (2 mL) and
4-(4-ethynylbenzyl)morpholine (6) (0.21 g, 1.05 mmol) and stirred
for 1 h. The solvent was removed and extracted with ethyl acetate
(2.times.100 ml), dried over Na.sub.2SO.sub.4, and concentrated to
give compound (7) (0.521 g).
(S)-3-amino-N-hydroxy-2-(7-((4-(morpholinomethyl)phenyl)ethynyl)-4-oxoquin-
azolin-3(4H)-yl)propanamide (59-8)
[1155] To a stirred solution of compound (7) (0.18 g, 0.338 mmol)
and hydroxylamine hydrochloride (118 mg, 1.69 mmol) in methanol (10
ml), KOH (113 mg, 2 mmol) was added and stirred for 30 min. Excess
solvent was removed and crude product was acidified with dilute
AcOH (10%) and extracted with ethyl acetate (2.times.50 ml), dried
and concentrated. After deprotection of BOC group using HCl gas in
ethyl acetate, crude product was purified using HPLC to give
compound (59-8). [M+H.sup.+]=448
Example 60
N-Hydroxy-2-isopropyl-N'-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-phenyl]-
-malonamide
##STR00126## ##STR00127##
[1156] Synthesis of 2-(4-Iodo-phenylcarbamoyl)-3-methyl-butyric
acid (1)
[1157] A solution of isopropylmalonic acid (613 mg, 4.2 mmol) and
DIC (330 .mu.l, 2.1 mmol) in chloroform (2 ml) was maintained at
ambient temperature for 10 min followed by the addition of
4-iodoaniline (438 mg, 2.0 mmol). Reaction mixture was stirred at
ambient temperature for additional 2 h and diluted with EtOAc (150
ml). Solution was extracted with water (30 ml.times.2) and brine
(30 ml), and dried over MgSO.sub.4 (anh). Solvent was evaporated in
vacuum. Residue was dissolved in DCM (2 ml) and subjected to flash
chromatography on CombiFlash.RTM. Companion unit equipped with
RediSep.RTM. flash column (normal phase, 35-60 micron average
particle size silicagel, 80 g, Teledyne Isco); flow rate=60 ml/min;
injection volume 2.5 ml; mobile phase A: DCM; mobile phase B: MeOH;
gradient 0-60% B in 60 min. Fractions containing the desired
product were combined and concentrated in vacuum. Residue was dried
in vacuum overnight to obtain target product (1) (89 mg, 13%) as
white solid. LC-MS [M+H] 348.1 (C.sub.12H.sub.141 NO.sub.3+H,
requires 348.16).
Synthesis of 2-(4-iodo-phenylcarbamoyl)-3-methyl-butyric acid
methyl ester (2)
[1158] A solution of compound (1) (89 g, 0.26 mmol) and HCl (conc.,
500 .mu.l) in 2,2-dimethoxypropane (2.0 ml, 16 mmol) was maintained
at ambient temperature overnight. Reaction mixture was evaporated
in vacuum. Residue was dissolved in i-PrOH (10 ml) and evaporated
in vacuum. The aforementioned procedure was repeated twice. Residue
was triturated with ether, filtrated, washed with ether and dried
in vacuum overnight to obtained hydrochloric salt of target product
(2) (84 mg, 99%) as white amorphous solid. LC-MS [M+H] 361.9
(C.sub.13H.sub.161 NO.sub.3+H, requires 362.19).
Synthesis of
2-[4-(4-formyl-phenylethynyl)-phenylcarbamoyl]-3-methyl-butyric
acid methyl ester (3)
[1159] A solution of compound (2) (84 mg, 0.23 mmol),
4-ethynylbenzaldehyde (36 mg, 0.28), Ph.sub.3P (6 mg, 0.23 mmol)
and di-isopropylamine (400 in THF (anh., 800 .mu.l) was purged with
dry nitrogen for 2 min followed by the addition of mixture of
PdCl.sub.2(PPh.sub.3).sub.2 (5 mg, 0.007 mmol) and CuI (3 mg, 0.014
mmol). Reaction mixture was irradiated in microwave oven (max.
power 250 W, 120.degree. C.) for 10 min and cooled to ambient
temperature. Solvents were evaporated in vacuum. Residue was
dissolved in EtOAc (80 ml) and extracted with 5% aq. NaHCO.sub.3
(20 ml.times.2) and brine (20 ml). The organic layer was dried over
anh. MgSO.sub.4 and evaporated in vacuum. Residue was dried in
vacuum overnight at ambient temperature to provide target material
(3) (82 mg, 99%) as brown solid. LC-MS [M+H] 364.2
(C.sub.22H.sub.21NO.sub.4+H, requires 364.43).
Synthesis of
3-methyl-2-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-phenylcarbamoyl]-but-
yric acid methyl ester (4)
[1160] A solution of compound (3) (82 mg, 0.23 mmol), AcOH (52
.mu.l, 0.92 mmol) and morpholine (30 .mu.l, 0.35 mmol) in DCE (1
ml) was maintained at ambient temperature for 10 min followed by
the addition of sodium triacetoxyborohydride (98 mg, 0.46 mmol).
Reaction mixture was stirred for 2 h at ambient temperature.
Reaction was quenched with 5% aq. NaHCO.sub.3 (20 ml) and extracted
with EtOAc (50 ml.times.2). Organic layer was washed with brine (20
ml), dried over anh. MgSO.sub.4 and evaporated in vacuum. Residue
was dried in vacuum overnight to provide target material (4) (98 g,
98%) as yellowish solid. LC-MS [M+H] 435.0
(C.sub.26H.sub.30N.sub.2O.sub.4+H, requires 435.55).
Synthesis of
N-hydroxy-2-isopropyl-N'-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-phenyl-
]-malonamide (60-5)
[1161] A solution of hydroxylamine hydrochloride (97 mg, 1.38 mmol)
in MeOH (anh, 2 ml) was cooled to -5.degree. C. followed by the
addition of 25% NaOMe/MeOH (473 .mu.l, 1.8 mmol) under nitrogen.
Reaction mixture was stirred at -5.degree. C. for additional 5 min,
cooled to -20.degree. C., and solution of compound (4) (98 mg, 0.23
mmol) in THF/MeOH (1:1, 2 ml) was added dropwise over the period of
5 min. Temperature of reaction mixture was raised to ambient.
Completion of the reaction was monitored by LC-MS. After completion
reaction mixture was acidified with 1 N aq. HCl to pH.about.7 and
evaporated in vacuum. Residue was dissolved in DMSO (600 .mu.l) and
subjected to HPLC purification. [Phenomenex Gemini C-18 column, 110
.ANG. (30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100%
water, 0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient
elution from 8% B to 28% B in 60 min., detection 254 nm]. Fractions
containing the desired product were combined and lyophylised to
provide trifluoroacetic salt of target product (60-5) (12 mg, 9.4%)
as white solid. LC-MS [M+H] 436.0
(C.sub.25H.sub.29N.sub.3O.sub.4+H, requires 436.54).
TABLE-US-00009 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (60-5) 0.23 12 9.4 99.8 436.0
3.31 *[Chromolith SpeedRod RP-18e C18 column (4.6 x 50 mm); flow
rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase B
0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 min,
detection 254 nm]
Example 61
##STR00128##
[1162] Example 62
Synthesis of
(R)--N-Hydroxy-2-[4-(4-morpholin-4-yl-methyl-phenylethynyl)-benzenesulfon-
ylamino]-3-phenylpropionamide
##STR00129##
[1163] Synthesis of 4-(4-bromo-benzyl)-morpholine (1)
[1164] To a solution of morpholine (2.61 ml, 30 mmol) in DMSO (25
ml) was added 4-bromobenzylbromide (2.5 g, 10 mmol). Reaction
mixture was stirred at ambient temperature for 30 min. Solvents
were evaporated in vacuum. Residue was dissolved in EtOAc (150 ml)
and extracted with 5% aq. NaHCO.sub.3 (50 ml.times.2) and brine (50
ml). The organic layer was dried over anh. MgSO.sub.4 and
evaporated in vacuum. Residue was dried in vacuum overnight at
ambient temperature to provide target material (1) (2.27 g, 87%) as
a white solid.
Synthesis of 4-(4-trimethylsilanylethynyl-benzyl)-morpholine
(2)
[1165] To a solution of compound (1) (2.27 g, 8.9 mmol),
ethynyltrimethylsilane (1.0 g, 10 mmol), PPh.sub.3 (262 mg, 1 mmol)
and dipropylamine (5 ml, 36.5 mmol) in DMF (10 ml) was added a
mixture of PdCl.sub.2(PPh.sub.3).sub.2 (130 mg, 0.18 mmol) and CuI
(100 mg, 0.5 mmol). Reaction mixture was irradiated in microwave
oven (max. power 250 W, 120.degree. C.) for 25 min and cooled to
ambient temperature. Reaction mixture was diluted with water (100
ml) and extracted with EtOAc (50 ml.times.2). Organic layer was
washed with 5% aq. NaHCO.sub.3 (50 ml) and brine (50 ml), and dried
over MgSO.sub.4 (anh). Solvent was evaporated in vacuum. Residue
was dried in vacuum overnight to produce target material (2) (2.36
g, 97%) as brown oil. LC-MS [M+H] 274.1 (C.sub.16H.sub.23NOSi+H,
requires 274.46).
4-(4-Ethynyl-benzyl)-morpholine (3)
[1166] To a solution of compound (2) (2.36 g, 8.6 mmol) in DCM (3
ml) was added TFA (10 ml, 135 mmol). Reaction mixture was
maintained at ambient temperature for 1.5 h. Solvent was evaporated
in vacuum. Residue was dissolved in DMSO (15 ml) and subjected to
HPLC purification. [Nanosyn-Pack Microsorb 100-10 C-18 column
(50.times.300 mm); flow rate=50 ml/min; injection volume 18 ml;
mobile phase A: 100% water, 0.1% TFA; mobile phase B: 100% ACN,
0.1% TFA; gradient elution from 5% B to 20% B in 60 min., detection
254 nm]. Fractions containing the desired product were combined and
concentrated in vacuum. Residue was dissolved in ether (100 ml) and
washed with 1 M aq. NaOH (50 ml), and brine (50 ml). Organic layer
was dried over MgSO.sub.4 (anh). Solvent was evaporated in vacuum.
Residue was dried in vacuum overnight to produce target material
(3) (687 mg, 40%) as off-white solid. LC-MS [M+H] 202.4
(C.sub.13H.sub.15NO+H, requires 202.28).
Synthesis of
(R)--N-Hydroxy-2-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzenesulfony-
l amino]-3-phenyl-propionamide (62-4)
[1167] 2-Chlorotrityl-N-Fmoc-hydroxylamine resin (50 mg, 0.03 mmol)
was placed in 3 cc plastic syringe equipped with plunger and
plastic frit. Resin was swelled in DCM (2 ml) at ambient
temperature for 10 min. DCM was discharged followed by the
treatment with 20% piperidine/DMF (2 ml.times.2.times.10 min).
Solvents were discharged and resin was washed with DCM (2
ml.times.6.times.5 min) followed by the addition of mixture of
Fmoc-D-Phe-OH (47 mg, 0.12 mmol), HATU (46 mg, 0.12 mmol) and DIEA
(42 .mu.l, 0.24 mmol) in DMF (500 .mu.l). Syringe was agitating at
85 rpm on orbital shaker at ambient temperature overnight. Solution
was discharged and resin was washed with DMF (2 ml.times.6.times.5
min) followed by the treatment with 20% piperidine/DMF (2
ml.times.2.times.10 min). Solvents were discharged and resin was
washed with DCM (2 ml.times.6.times.5 min) followed by the addition
of mixture of compound (3) (48 mg, 0.24 mmol),
PdCl.sub.2(PPh.sub.3).sub.2 (20 mg, 0.03 mmol), CuI (10 mg, 0.05
mmol) and di-propylamine (200 .mu.l) in DMF (400 .mu.l). Syringe
was agitating at 85 rpm on orbital shaker at ambient temperature
overnight. Solution was discharged and resin was washed with DMF (3
ml.times.4.times.5 min) and DCM (3 ml.times.4.times.5 min) followed
by the addition of 80% aq. TFA (2 ml). Syringe was agitating at 85
rpm on orbital shaker at ambient temperature for 3 min. Solution
was collected and evaporated in vacuum. Residue was dissolved in
DMSO (500 .mu.l) and subjected to HPLC purification. [Phenomenex
Gemini C-18 column, 110 .ANG. (30.times.100 mm); flow rate=20
ml/min; mobile phase A: 100% water, 0.1% TFA; mobile phase B: 100%
ACN, 0.1% TFA; gradient elution from 8% B to 28% B in 60 min.,
detection 254 nm]. Fractions containing the desired product were
combined and lyophylised to provide trifluoroacetic salt of target
product (62-4) as white solid. LC-MS [M+H] 520.5
(C.sub.28H.sub.29N.sub.3O.sub.5S+H requires 520.63).
TABLE-US-00010 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (62-4) 0.03 4.04 21 100 520.5
3.70 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.5 min,
detection 254 nm]
The following compounds were synthesized as described in this
Example.
TABLE-US-00011 Compound # Structure [M + H] (62-5) ##STR00130## 550
(62-6) ##STR00131## 520 (62-7) ##STR00132## 474 (62-8) ##STR00133##
484 (62-9) ##STR00134## 490 (62-10) ##STR00135## 470 (62-11)
##STR00136## 456
Example 63
(2S,3R)-3,N-Dihydroxy-2-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzenes-
ulfinylamino]-butyramide
##STR00137##
[1168] Synthesis of
(2S,3R)-2-(4-bromo-benzenesulfinylamino)-3-hydroxy-butyric acid
methyl ester (1)
[1169] A solution of 4-Bromobenzenesulfinic acid sodium salt
dihydrate (250 mg, 0.9 mmol) in SOCl.sub.2 (3 ml, 41.1 mmol) was
maintained at ambient temperature for 3 h. Solvent was evaporated.
Residue was dissolved in DCM (8 ml) and combined with H-Thr-OMe
hydrochloride (253 mg, 1.5 mmol) followed by the dropwise addition
of DIEA (500 .mu.l, 3.0 mmol) over the period of 5 min. After
stirring at ambient temperature for additional hour reaction
mixture was subjected to flash chromatography on CombiFlash.RTM.
Companion unit equipped with RediSep.RTM. flash column (normal
phase, 35-60 micron average particle size silicagel, 4 g, Teledyne
Isco); flow rate=18 ml/min; injection volume 10 ml; mobile phase A:
hexane; mobile phase B: EtOAc; gradient 0-100% B in 40 min.
Fractions containing the desired product were combined and
concentrated in vacuum. Residue was dried in vacuum overnight to
provide target product (1) (100 mg, 33%) as white solid. LC-MS
[M+H] 337.8 (C.sub.11H.sub.14BrNO.sub.4S+H, requires 337.22).
Synthesis of
(2S,3R)-2-[4-(4-Formyl-phenylethynyl)-benzenesulfinylamino]-3-hydroxy-but-
yric acid methyl ester (2)
[1170] A solution of compound (1) (100 mg, 0.30 mmol),
4-ethynylbenzaldehyde (43 mg, 0.32 mmol), Ph.sub.3P (123 mg, 0.34)
and di-propylamine (1 ml) in DMF (2 ml) was purged for 5 min with
dry nitrogen. Catalysts PdCl.sub.2(PPh.sub.3).sub.2 (30 mg, 0.043
mmol), and CuI (15 mg, 0.079 mmol) were added and reaction mixture
was subjected to microwave irradiation (max. power 250 W,
120.degree. C.) for 15 min. Reaction mixture was cooled to ambient
temperature, diluted with EtOAc (100 ml) and extracted with water
(30 ml), 2% aq. H.sub.2SO.sub.4 (30 ml), water (30 ml.times.2) and
brine (30 ml). Organic layer was dried over Na.sub.2SO.sub.4 and
evaporated. Residue was dried in vacuum to provide target compound
(2) as brownish amorphous solid. LC-MS [M+H] 385.6
(C.sub.20H.sub.19NO.sub.5S+H, requires 386.45). Compound (2) was
used as is for the next transformation.
Synthesis of
(2S,3R)-3-Hydroxy-2-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzenesulf-
inylamino]-butyric acid methyl ester (3)
[1171] A solution of compound (2) (0.30 mmol) and morpholine (52
.mu.l, 0.6 mmol) in chloroform (10 ml) was treated with
NaBH(OAc).sub.3 (100 mg, 0.47 mmol) for 5 h at ambient temperature
under nitrogen. Reaction was quenched with 5% aq. NaHCO.sub.3 (20
ml) and extracted with EtOAc (50 ml.times.2). Organic layer was
dried over anhydrous Na.sub.2SO.sub.4 and evaporated in vacuum.
Residue was dissolved in DCM (2 ml) and subjected to flash
chromatography on CombiFlash.RTM. Companion unit equipped with
RediSep.RTM. flash column (normal phase, 35-60 micron average
particle size silicagel, 12 g, Teledyne Isco); flow rate=30 ml/min;
injection volume 3 ml; mobile phase A: DCM; mobile phase B: MeOH;
gradient 0-5% B in 15 min. Fractions containing the desired product
were combined and concentrated in vacuum. Residue was dried in
vacuum overnight to provide target product (3) (92 mg, 33%) as
colorless oil. LC-MS [M+H] 457.3
(C.sub.24H.sub.28N.sub.2O.sub.5S+H, requires 457.58).
Synthesis of
(2S,3R)-3,N-dihydroxy-2-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzene-
sulfinylamino]-butyramide (4)
[1172] A solution of hydroxylamine hydrochloride (84 mg, 1.2 mmol)
in MeOH (anh., 2 ml) was cooled to -5.degree. C. followed by the
addition of 25% NaOMe/MeOH (411 .mu.l, 3.15 mmol) under nitrogen.
Reaction mixture was stirred at -5.degree. C. for additional 5 min,
cooled to -20.degree. C., and solution of compound (3) (92 mg, 0.20
mmol) in THF/MeOH (1:1, 2 ml) was added dropwise over the period of
5 min. Temperature of reaction mixture was raised to ambient.
Completion of the reaction was monitored by LC-MS. After completion
reaction mixture was acidified with 1 N aq. HCl to pH.about.7 and
evaporated in vacuum. Residue was dissolved in DMSO (800 .mu.l) and
subjected to HPLC purification. [Phenomenex Gemini C-18 column, 110
.ANG. (30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100%
water, 0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient
elution from 8% B to 28% B in 60 min., detection 254 nm]. Fractions
containing the desired product were combined and neutralized with 1
N aq. NaOH. Organics were evaporated in vacuum. Water layer was
extracted with EtOAc (10 ml), dried over Na.sub.2SO.sub.4 and
evaporated in vacuum. Residue was dried in vacuum overnight to
provide free base of target product (4) (4 mg, 4.4%) as white
solid. LC-MS [M+H] 458.1 (C.sub.23H.sub.27N.sub.3O.sub.5S+H,
requires 458.56).
TABLE-US-00012 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (4) 0.2 4 4.4 98.5 475.1 2.96
*[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm); flow
rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase B
0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.5 min,
detection 254 nm
Example 64
N-(Hydroxycarbamoyl-pyrrolidin-3-yl-methyl)-4-(4-morpholin-4-ylmethyl-phen-
ylethynyl)-benzamide
##STR00138##
[1173] Synthesis of 4-(4-formyl-phenylethynyl)-benzonitrile (1)
[1174] To a solution of 4-ethynylbenzonitrile (2.27 g, 17.9 mmol),
4-iodobenzaldehyde (5.40 g, 23.3) and triethylamine (7.0 ml, 2.3
mmol) in THF (anh., 360 ml) was added mixture of
PdCl.sub.2(PPh.sub.3).sub.2 (400 mg, 0.6 mmol) and CuI (216 mg, 1.1
mmol). Reaction mixture was stirred at ambient temperature
overnight. Solvents were evaporated in vacuum. Residue was
dissolved in EtOAc (150 ml) and extracted with 5% aq. NaHCO.sub.3
(50 ml.times.2) and brine (50 ml). The organic layer was dried over
anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was dried
in vacuum overnight at ambient temperature to provide target
material (1) (3.75 g, 90%) as yellow solid.
Synthesis of 4-(4-morpholin-4-ylmethylphenylethynyl)-benzonitrile
(2)
[1175] To a solution of compound (1) (2.0 g, 8.6 mmol) and
morpholine (1.08 ml, 12.4 mmol) in chloroform (30 ml) was added
sodium triacetoxyborohydride (2.80 g, 13.2 mmol). Reaction mixture
was stirred for 4 h at ambient temperature. Reaction was quenched
with 5% aq. NaHCO.sub.3 (50 ml) and extracted with EtOAc (150
ml.times.2). Organic layer was washed with brine (50 ml), dried
over anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was
dried in vacuum overnight to provide target material (2)(2.65 g,
97%) as off-white solid. LC-MS [M+H] 303.2
(C.sub.20H.sub.18N.sub.2O+H, requires 303.39).
Synthesis of 4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoic acid
(3)
[1176] A mixture of compound (2) (2.65 g, 8.8 mmol) and 2M aq. LiOH
(22 ml, 44 mmol) in dioxane (20 ml) was irradiated in microwave
oven (max. power 250 W, 130.degree. C.) for 45 min and cooled to
ambient temperature. Reaction mixture was diluted with water (300
ml) and extracted with EtOAc (100 ml.times.2). Water layer was
acidified with 1 M HCl to pH.about.3 and extracted with EtOAc (300
ml.times.3). Organic layer was washed with water (50 ml.times.2)
and brine (50 ml), and dried over MgSO.sub.4 (anh). Solvent was
evaporated in vacuum. Residue was dried in vacuum overnight to
produce hydrochloric salt of target material (3) (2.23 g, 71%) as
yellowish solid. LC-MS [M+H] 322.1 (C.sub.20H.sub.19NO.sub.3+H,
requires 322.39).
Synthesis of
3-(tert-butoxycarbonylamino-carboxy-methyl)-pyrrolidine-1-carboxylic
acid 9H-fluoren-9-ylmethyl ester (4)
[1177] To a solution of Boc-DL-pyrrolidin-3-yl-acetic acid (2.0 g,
8.6 mmol) in water (2 ml) was added solution of Fmoc-OSu (621 mg,
1.84 mmol) in ACN (5 ml). Reaction mixture was stirred for 2 h at
ambient temperature. Reaction was diluted with EtOAc (50 ml).
Organic layer was washed with water (30 ml.times.2) and brine (30
ml), dried over anh. Na.sub.2SO.sub.4 and evaporated in vacuum.
Residue was dried in vacuum overnight to provide target material
(4) (500 mg, 58%) as white solid. LC-MS [M+H] 467.2
(C.sub.26H.sub.30H.sub.2O.sub.6+H, requires 467.55).
Synthesis of
3-(amino-methoxycarbonyl-methyl)-pyrrolidine-1-carboxylic acid
9H-fluoren-9-ylmethyl ester (5)
[1178] A solution of compound (4) (500 mg, 1.07 mmol) and HCl
(conc., 100 .mu.l) in 2,2-dimethoxypropane (3 ml, 24 mmol) was
maintained at ambient temperature overnight. Reaction mixture was
evaporated in vacuum. Residue was dissolved in DCM (1 ml) and
subjected to flash chromatography on CombiFlash.RTM. Companion unit
equipped with RediSep.RTM. flash column (normal phase, 35-60 micron
average particle size silicagel, 12 g, Teledyne Isco); flow rate=30
ml/min; injection volume 1.5 ml; mobile phase A: DCM; mobile phase
B: MeOH; gradient 0-30% B in 43 min. Fractions containing the
desired product were combined and concentrated in vacuum. Residue
was triturated with ether, filtrated, washed with ether and dried
in vacuum overnight to obtained hydrochloric salt of target product
(5) (300 mg, 67%) as off-white powder. LC-MS [M+H] 381.1
(C.sub.22H.sub.24N.sub.2O.sub.4+H, requires 381.46).
Synthesis of
3-{methoxycarbonyl-[4-(4-morpholin-4-ylmethyl-phenylethynyl)benzoylamino]-
-methyl}-pyrrolidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester
(6)
[1179] A solution of compound (3) hydrochloride (110 mg, 0.34
mmol), HATU (136 mg, 0.36 mmol) and DIEA (330 .mu.l, 1.9 mmol) in
DMF (1.5 ml) was maintained at ambient temperature for 10 min
followed by the addition of compound 5 hydrochloride (150 mg, 0.36
mmol). Reaction mixture was stirred at ambient temperature
overnight, diluted with EtOAc (80 ml) and extracted with water (20
ml.times.2) and brine (20 ml). Organic layer was dried over anh.
MgSO.sub.4, evaporated in vacuum and dried in vacuum overnight to
provide target product (6) (228 mg, 99%) as brown solid. LC-MS
[M+H] 684.6 (C.sub.42H.sub.41N.sub.3O.sub.6+H, requires
684.82).
Synthesis of
N-(hydroxycarbamoyl-pyrrolidin-3-yl-methyl)-4-(4-morpholin-4-ylmethyl-phe-
nylethynyl)-benzamide (64-7)
[1180] A solution of hydroxylamine hydrochloride (140 mg, 0.33
mmol) in MeOH (anh, 2 ml) was cooled to -5.degree. C. followed by
the addition of 25% NaOMe/MeOH (678 .mu.l, 2.0 mmol) under
nitrogen. Reaction mixture was stirred at -5.degree. C. for
additional 5 min, cooled to -20.degree. C., and solution of
compound (6) (228 mg, 0.33 mmol) in THF/MeOH (1:1, 2 ml) was added
dropwise over the period of 5 min. Temperature of reaction mixture
was raised to ambient. Completion of the reaction was monitored by
LC-MS. After completion reaction mixture was acidified with 1 N aq.
HCl to pH.about.7 and evaporated in vacuum. Residue was dissolved
in DMSO (600 .mu.l) and subjected to HPLC purification. [Phenomenex
Gemini C-18 column, 110 .ANG. (30.times.100 mm); flow rate=20
ml/min; mobile phase A: 100% water, 0.1% TFA; mobile phase B: 100%
ACN, 0.1% TFA; gradient elution from 8% B to 28% B in 60 min.,
detection 254 nm]. Fractions containing the desired product were
combined and lyophylised to provide di-trifluoroacetic salt of
target product (64-7) (4.8 mg, 2.1%) as white solid. LC-MS [M+H]
463.2 (C.sub.26H.sub.30N.sub.4O.sub.4+H, requires 463.56).
TABLE-US-00013 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (64-7) 0.33 4.8 2.1 97.4 463.2
2.31 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 min,
detection 254 nm]
Example 65
N--((S)-Hydroxycarbamoyl-piperidin-4-yl-methyl)-4-(4-morpholin-4-ylmethyl--
phenylethynyl)-benzamide
##STR00139##
[1181] Synthesis of 4-(4-formyl-phenylethynyl)-benzonitrile (1)
[1182] To a solution of 4-ethynylbenzonitrile (2.27 g, 17.9 mmol),
4-iodobenzaldehyde (5.40 g, 23.3) and triethylamine (7.0 ml, 2.3
mmol) in THF (anh., 360 ml) was added mixture of
PdCl.sub.2(PPh.sub.3).sub.2 (400 mg, 0.6 mmol) and CuI (216 mg, 1.1
mmol). Reaction mixture was stirred at ambient temperature
overnight. Solvents were evaporated in vacuum. Residue was
dissolved in EtOAc (150 ml) and extracted with 5% aq. NaHCO.sub.3
(50 ml.times.2) and brine (50 ml). The organic layer was dried over
anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was dried
in vacuum overnight at ambient temperature to provide target
material (1) (3.75 g, 90%) as yellow solid.
Synthesis of 4-(4-morpholin-4-ylmethylphenylethynyl)-benzonitrile
(2)
[1183] To a solution of compound (1) (2.0 g, 8.6 mmol) and
morpholine (1.08 ml, 12.4 mmol) in chloroform (30 ml) was added
sodium triacetoxyborohydride (2.80 g, 13.2 mmol). Reaction mixture
was stirred for 4 h at ambient temperature. Reaction was quenched
with 5% aq. NaHCO.sub.3 (50 ml) and extracted with EtOAc (150
ml.times.2). Organic layer was washed with brine (50 ml), dried
over anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was
dried in vacuum overnight to provide target material (2) (2.65 g,
97%) as off-white solid. LC-MS [M+H] 303.2
(C.sub.20H.sub.18N.sub.2O+H, requires 303.39).
Synthesis of 4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoic acid
(3)
[1184] A mixture of compound (2) (2.65 g, 8.8 mmol) and 2M aq. LiOH
(22 ml, 44 mmol) in dioxane (20 ml) was irradiated in microwave
oven (max. power 250 W, 130.degree. C.) for 45 min and cooled to
ambient temperature. Reaction mixture was diluted with water (300
ml) and extracted with EtOAc (100 ml.times.2). Water layer was
acidified with 1 M HCl to pH.about.3 and extracted with EtOAc (300
ml.times.3). Organic layer was washed with water (50 ml.times.2)
and brine (50 ml), and dried over MgSO.sub.4 (anh). Solvent was
evaporated in vacuum. Residue was dried in vacuum overnight to
produce hydrochloric salt of target material (3) (2.23 g, 71%) as
yellowish solid. LC-MS [M+H] 322.1 (C.sub.20H.sub.19NO.sub.3+H,
requires 322.39).
Synthesis of
4-{(S)-carboxy-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoylamino]-me-
thyl}-piperidine-1-carboxylic acid tert-butyl ester (4)
[1185] A solution of compound (3) (110 mg, 0.31 mmol), HATU (136
mg, 0.36 mmol) and DIEA (330 .mu.l, 1.9 mmol) in DMF (1.5 ml) was
maintained at ambient temperature for 30 min. A mixture of
H-Gly[4-Pip(Boc)]-OH (150 mg, 0.36 mmol) and BSA (170 .mu.l, 0.7
mmol) in dioxane (1.5 ml) was stirred at 100.degree. C. for 10 min
and cooled to the ambient temperature. Reaction mixtures were
combined and stirred at ambient temperature overnight followed by
the dilution with EtOAc (100 ml). Solution was extracted with water
(20 ml), 2% aq. H.sub.2SO.sub.4 (20 ml), water (20 ml.times.2) and
brine (20 ml). Organic layer was dried over MgSO.sub.4 and
evaporated. Residue was dried in vacuum to provide target compound
(4) (172 mg, 99%) as yellow solid. LC-MS [M+H] 562.2
(C.sub.32H.sub.39N.sub.3O.sub.6+H, requires 562.69).
Synthesis of
(S)-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoylamino]-piperidin-4-y-
l-acetic acid methyl ester (5)
[1186] A solution of compound (4) (172 mg, 0.31 mmol) and HCl
(conc., 1 ml) in 2,2-dimethoxypropane (5 ml, 40 mmol) was
maintained at 60.degree. C. for 3 h. Reaction mixture was cooled to
ambient temperature and evaporated in vacuum. Residue was dissolved
in DCM (1 ml) and subjected to flash chromatography on
CombiFlash.RTM. Companion unit equipped with RediSep flash column
(normal phase, 35-60 micron average particle size silicagel, 4 g,
Teledyne Isco); flow rate=18 ml/min; injection volume 1.5 ml;
mobile phase A: hexane; mobile phase B: EtOAc; gradient 0-20% B in
30 min. Fractions containing the desired product were combined and
concentrated in vacuum. Residue was dried in vacuum overnight to
obtained hydrochloric salt of target product (5) (44 mg, 91%) as
off-white powder. LC-MS [M+H] 476.4
(C.sub.28H.sub.33N.sub.3O.sub.4+H, requires 476.60).
Synthesis of
N--((S)-hydroxycarbamoyl-piperidin-4-yl-methyl)-4-(4-morpholin-4-ylmethyl-
-phenylethynyl)-benzamide (65-6)
[1187] A solution of hydroxylamine hydrochloride (118 mg, 0.28
mmol) in MeOH (anh, 2 ml) was cooled to -5.degree. C. followed by
the addition of 25% NaOMe/MeOH (575 .mu.l, 2.52 mmol) under
nitrogen. Reaction mixture was stirred at -5.degree. C. for
additional 5 min, cooled to -20.degree. C., and solution of
compound (5) (144 mg, 0.28 mmol) in THF/MeOH (1:1, 2 ml) was added
dropwise over the period of 5 min. Temperature of reaction mixture
was raised to ambient. Completion of the reaction was monitored by
LC-MS. After completion reaction mixture was acidified with 1 N aq.
HCl to pH.about.7 and evaporated in vacuum. Residue was dissolved
in DMSO (600 .mu.l) and subjected to HPLC purification. [Phenomenex
Gemini C-18 column, 110 .ANG. (30.times.100 mm); flow rate=20
ml/min; mobile phase A: 100% water, 0.1% TFA; mobile phase B: 100%
ACN, 0.1% TFA; gradient elution from 8% B to 28% B in 60 min.,
detection 254 nm]. Fractions containing the desired product were
combined and lyophylised to provide di-trifluoroacetic salt of
target product (65-6) (11.1 mg, 5.6%) as white solid. LC-MS [M+H]
477.5 (C.sub.26H.sub.30N.sub.4O.sub.4+H, requires 463.56).
TABLE-US-00014 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (65-6) 0.28 11.1 5.6 99.5 477.5
2.36 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 min,
detection 254 nm]
Example 66
N--((S)-Hydroxycarbamoyl-phenyl-methyl)-4-(4-morpholin-4-ylmethyl-phenylet-
hynyl)-benzamide
##STR00140##
[1188] Synthesis of 4-(4-formyl-phenylethynyl)-benzonitrile (1)
[1189] To a solution of 4-ethynylbenzonitrile (2.27 g, 17.9 mmol),
4-iodobenzaldehyde (5.40 g, 23.3) and triethylamine (7.0 ml, 2.3
mmol) in THF (anh., 360 ml) was added mixture of
PdCl.sub.2(PPh.sub.3).sub.2 (400 mg, 0.6 mmol) and CuI (216 mg, 1.1
mmol). Reaction mixture was stirred at ambient temperature
overnight. Solvents were evaporated in vacuum. Residue was
dissolved in EtOAc (150 ml) and extracted with 5% aq. NaHCO.sub.3
(50 ml.times.2) and brine (50 ml). The organic layer was dried over
anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was dried
in vacuum overnight at ambient temperature to provide target
material (1) (3.75 g, 90%) as yellow solid.
Synthesis of 4-(4-morpholin-4-ylmethylphenylethynyl)-benzonitrile
(2)
[1190] To a solution of compound (1) (2.0 g, 8.6 mmol) and
morpholine (1.08 ml, 12.4 mmol) in chloroform (30 ml) was added
sodium triacetoxyborohydride (2.80 g, 13.2 mmol). Reaction mixture
was stirred for 4 h at ambient temperature. Reaction was quenched
with 5% aq. NaHCO.sub.3 (50 ml) and extracted with EtOAc (150
ml.times.2). Organic layer was washed with brine (50 ml), dried
over anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was
dried in vacuum overnight to provide target material (2) (2.65 g,
97%) as off-white solid. LC-MS [M+H] 303.2
(C.sub.20H.sub.18N.sub.2O+H, requires 303.39).
Synthesis of 4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoic
acid
[1191] A mixture of compound (2) (2.65 g, 8.8 mmol) and 2M aq. LiOH
(22 ml, 44 mmol) in dioxane (20 ml) was irradiated in microwave
oven (max. power 250 W, 130.degree. C.) for 45 min and cooled to
ambient temperature. Reaction mixture was diluted with water (300
ml) and extracted with EtOAc (100 ml.times.2). Water layer was
acidified with 1 M HCl to pH.about.3 and extracted with EtOAc (300
ml.times.3). Organic layer was washed with water (50 ml.times.2)
and brine (50 ml), and dried over MgSO.sub.4 (anh). Solvent was
evaporated in vacuum. Residue was dried in vacuum overnight to
produce hydrochloric salt of target material (3) (2.23 g, 71%) as
yellowish solid. LC-MS [M+H] 322.1 (C.sub.20H.sub.19NO.sub.3+H,
requires 322.39).
Synthesis of
S)-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoylamino]-phenyl-acetic
acid methyl ester (4)
[1192] A solution of compound (3) hydrochloride (143 mg, 0.4 mmol),
HATU (152 mg, 0.4 mmol) and DIEA (278 .mu.l, 1.6 mmol) in DMF (1.5
ml) was maintained at ambient temperature for 10 min followed by
the addition of H-Phg-OMe hydrochloride (89 mg, 0.44 mmol).
Reaction mixture was stirred at ambient temperature overnight,
diluted with EtOAc (80 ml) and extracted with water (20 ml.times.2)
and brine (20 ml). Organic layer was dried over anh. MgSO.sub.4,
evaporated in vacuum and dried in vacuum overnight to provide
target product (4) (181 mg, 97%) as brown amorphous solid. LC-MS
[M+H] 469.2 (C.sub.29H.sub.28N.sub.2O.sub.4+H, requires
469.57).
Synthesis of
N--((S)-hydroxycarbamoyl-phenyl-methyl)-4-(4-morpholin-4-ylmethyl-phenyle-
thynyl)-benzamide (66-5)
[1193] A solution of hydroxylamine hydrochloride (168 mg, 2.4 mmol)
in MeOH (anh, 2 ml) was cooled to -5.degree. C. followed by the
addition of 25% NaOMe/MeOH (832 .mu.l, 3.78 mmol) under nitrogen.
Reaction mixture was stirred at -5.degree. C. for additional 5 min,
cooled to -20.degree. C., and solution of compound (4) (181 mg, 0.4
mmol) in THF/MeOH (1:1, 2 ml) was added dropwise over the period of
5 min. Temperature of reaction mixture was raised to ambient.
Completion of the reaction was monitored by LC-MS. After completion
reaction mixture was acidified with 1 N aq. HCl to pH.about.7 and
evaporated in vacuum. Residue was dissolved in DMSO (600 .mu.l) and
subjected to HPLC purification. [Phenomenex Gemini C-18 column, 110
.ANG. (30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100%
water, 0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient
elution from 8% B to 28% B in 60 min., detection 254 nm]. Fractions
containing the desired product were combined and lyophylised to
provide trifluoroacetic salt of target product (66-5) (143 mg,
8.3%) as white solid. LC-MS [M+H] 470.2
(C.sub.28H.sub.27N.sub.3O.sub.4+H, requires 470.56).
TABLE-US-00015 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (66-5) 0.4 143 61 99.4 470.2
3.46 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1 %TFA/ACN; gradient elution from 5% B to 100% B over 9.6 min,
detection 254 nm]
The following compounds were synthesized as described in this
Example.
TABLE-US-00016 Compound # Structure [M + H] (66-6) ##STR00141##
Example 67
N-[Hydroxycarbamoyl-(tetrahydro-pyran-4-yl)-methyl]-4-(4-morpholin-4-ylmet-
hyl-phenylethynyl)-benzamide
##STR00142##
[1194] Synthesis of 4-(4-formyl-phenylethynyl)-benzonitrile (1)
[1195] To a solution of 4-ethynylbenzonitrile (2.27 g, 17.9 mmol),
4-iodobenzaldehyde (5.40 g, 23.3) and triethylamine (7.0 ml, 2.3
mmol) in THF (anh., 360 ml) was added mixture of
PdCl.sub.2(PPh.sub.3).sub.2 (400 mg, 0.6 mmol) and CuI (216 mg, 1.1
mmol). Reaction mixture was stirred at ambient temperature
overnight. Solvents were evaporated in vacuum. Residue was
dissolved in EtOAc (150 ml) and extracted with 5% aq. NaHCO.sub.3
(50 ml.times.2) and brine (50 ml). The organic layer was dried over
anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was dried
in vacuum overnight at ambient temperature to provide target
material (1) (3.75 g, 90%) as yellow solid.
Synthesis of 4-(4-morpholin-4-ylmethylphenylethynyl)-benzonitrile
(2)
[1196] To a solution of compound (1) (2.0 g, 8.6 mmol) and
morpholine (1.08 ml, 12.4 mmol) in chloroform (30 ml) was added
sodium triacetoxyborohydride (2.80 g, 13.2 mmol). Reaction mixture
was stirred for 4 h at ambient temperature. Reaction was quenched
with 5% aq. NaHCO.sub.3 (50 ml) and extracted with EtOAc (150
ml.times.2). Organic layer was washed with brine (50 ml), dried
over anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was
dried in vacuum overnight to provide target material (2) (2.65 g,
97%) as off-white solid. LC-MS [M+H] 303.2
(C.sub.20H.sub.18N.sub.2O+H, requires 303.39).
Synthesis of 4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoic acid
(3)
[1197] A mixture of compound (2) (2.65 g, 8.8 mmol) and 2M aq. LiOH
(22 ml, 44 mmol) in dioxane (20 ml) was irradiated in microwave
oven (max. power 250 W, 130.degree. C.) for 45 min and cooled to
ambient temperature. Reaction mixture was diluted with water (300
ml) and extracted with EtOAc (100 ml.times.2). Water layer was
acidified with 1 M HCl to pH.about.3 and extracted with EtOAc (300
ml.times.3). Organic layer was washed with water (50 ml.times.2)
and brine (50 ml), and dried over MgSO.sub.4 (anh). Solvent was
evaporated in vacuum. Residue was dried in vacuum overnight to
produce hydrochloric salt of target material (3) (2.23 g, 71%) as
yellowish solid. LC-MS [M+H] 322.1 (C.sub.20H.sub.19NO.sub.3+H,
requires 322.39).
Synthesis of
[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoylamino]-(tetrahydro-pyran-
-4-yl)-acetic acid methyl ester (4)
[1198] A solution of compound (3) hydrochloride (110 mg, 0.31
mmol), HATU (167 mg, 0.44 mmol) and DIEA (330 .mu.l, 2.0 mmol) in
DMF (3 ml) was maintained at ambient temperature for 10 min
followed by the addition of DL-(4-tetrahydropyranyl)Ala-OMe
hydrochloride (84 mg, 0.4 mmol). Reaction mixture was stirred at
ambient temperature overnight, diluted with EtOAc (100 ml) and
extracted with water (30 ml.times.2) and brine (30 ml). Organic
layer was dried over anh. MgSO.sub.4, evaporated in vacuum and
dried in vacuum overnight to provide target product (4) (144 mg,
98%) as brown solid. LC-MS [M+H] 477.2
(C.sub.28H.sub.32N.sub.2O.sub.5+H, requires 477.59).
Synthesis of
N-[hydroxycarbamoyl-(tetrahydro-pyran-4-yl)-methyl]-4-(4-morpholin-4-ylme-
thyl-phenylethynyl)-benzamide (67-5)
[1199] A solution of hydroxylamine hydrochloride (126 mg, 1.8 mmol)
in MeOH (anh, 2 ml) was cooled to -5.degree. C. followed by the
addition of 25% NaOMe/MeOH (616 .mu.l, 2.7 mmol) under nitrogen.
Reaction mixture was stirred at -5.degree. C. for additional 5 min,
cooled to -20.degree. C., and solution of compound (4) (144 mg,
0.30 mmol) in THF/MeOH (1:1, 2 ml) was added dropwise over the
period of 5 min. Temperature of reaction mixture was raised to
ambient. Completion of the reaction was monitored by LC-MS. After
completion reaction mixture was acidified with 1 N aq. HCl to
pH.about.7 and evaporated in vacuum. Residue was dissolved in DMSO
(600 .mu.l) and subjected to HPLC purification. [Phenomenex Gemini
C-18 column, 110 .ANG. (30.times.100 mm); flow rate=20 ml/min;
mobile phase A: 100% water, 0.1% TFA; mobile phase B: 100% ACN,
0.1% TFA; gradient elution from 8% B to 28% B in 60 min., detection
254 nm]. Fractions containing the desired product were combined and
lyophylised to provide trifluoroacetic salt of target product
(67-5) (65.7 mg, 37%) as white solid. LC-MS [M+H] 408.2
(C.sub.27H.sub.31H.sub.3O.sub.5+H, requires 478.58).
TABLE-US-00017 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (67-5) 0.30 65.7 37 99.9 478.3
2.85 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 mm,
detection 254 nm]
The following compounds were synthesized as described in this
Example.
TABLE-US-00018 Compound # Structure [M + H] (67-7) ##STR00143##
476.3 (67-8) ##STR00144## 476.2 (67-9) ##STR00145## 526.2
Example 68
N--((S)-Cyclopropyl-hydroxycarbamoyl-methyl)-4-(4-morpholin-4-ylmethyl-phe-
nylethynyl)-benzamide
##STR00146##
[1200] Synthesis of 4-(4-formyl-phenylethynyl)-benzonitrile (1)
[1201] To a solution of 4-ethynylbenzonitrile (2.27 g, 17.9 mmol),
4-iodobenzaldehyde (5.40 g, 23.3) and triethylamine (7.0 ml, 2.3
mmol) in THF (anh., 360 ml) was added mixture of
PdCl.sub.2(PPh.sub.3).sub.2 (400 mg, 0.6 mmol) and CuI (216 mg, 1.1
mmol). Reaction mixture was stirred at ambient temperature
overnight. Solvents were evaporated in vacuum. Residue was
dissolved in EtOAc (150 ml) and extracted with 5% aq. NaHCO.sub.3
(50 ml.times.2) and brine (50 ml). The organic layer was dried over
anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was dried
in vacuum overnight at ambient temperature to provide target
material (1) (3.75 g, 90%) as yellow solid.
Synthesis of 4-(4-morpholin-4-ylmethylphenylethynyl)-benzonitrile
(2)
[1202] To a solution of compound (1) (2.0 g, 8.6 mmol) and
morpholine (1.08 ml, 12.4 mmol) in chloroform (30 ml) was added
sodium triacetoxyborohydride (2.80 g, 13.2 mmol). Reaction mixture
was stirred for 4 h at ambient temperature. Reaction was quenched
with 5% aq. NaHCO.sub.3 (50 ml) and extracted with EtOAc (150
ml.times.2). Organic layer was washed with brine (50 ml), dried
over anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was
dried in vacuum overnight to provide target material (2) (2.65 g,
97%) as off-white solid. LC-MS [M+H] 303.2
(C.sub.20H.sub.18N.sub.2O+H, requires 303.39).
Synthesis of 4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoic acid
(3)
[1203] A mixture of compound (2) (2.65 g, 8.8 mmol) and 2M aq. LiOH
(22 ml, 44 mmol) in dioxane (20 ml) was irradiated in microwave
oven (max. power 250 W, 130.degree. C.) for 45 min and cooled to
ambient temperature. Reaction mixture was diluted with water (300
ml) and extracted with EtOAc (100 ml.times.2). Water layer was
acidified with 1 M HCl to pH.about.3 and extracted with EtOAc (300
ml.times.3). Organic layer was washed with water (50 ml.times.2)
and brine (50 ml), and dried over MgSO.sub.4 (anh). Solvent was
evaporated in vacuum. Residue was dried in vacuum overnight to
produce hydrochloric salt of target material (3) (2.23 g, 71%) as
yellowish solid. LC-MS [M+H] 322.1 (C.sub.20H.sub.19NO.sub.3+H,
requires 322.39).
Synthesis of (S)-amino-cyclopropyl-acetic acid methyl ester (4)
[1204] A solution of Boc-L-cyclopropylglycine (97 mg, 0.45 mmol)
and HCl (conc., 500 .mu.l) in 2,2-dimethoxypropane (5 ml, 40 mmol)
was maintained at 40.degree. C. overnight. Reaction mixture was
evaporated in vacuum. Residue was dissolved in i-PrOH (10 ml) and
evaporated in vacuum. The aforementioned procedure was repeated
twice. Residue was triturated with ether, filtrated, washed with
ether and dried in vacuum overnight to obtained hydrochloric salt
of target product (4) (73 mg, 98%) as off-white powder. LC-MS [M+H]
130.0 (C.sub.6H.sub.11NO.sub.2+H, requires 130.17).
Synthesis of
(S)-cyclopropyl-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoylamino]-a-
cetic acid methyl ester (5)
[1205] A solution of compound (3) hydrochloride (143 mg, 0.4 mmol),
HATU (176 mg, 0.44 mmol) and DIEA (313 .mu.l, 1.8 mmol) in DMF (1
ml) was maintained at ambient temperature for 10 min followed by
the addition of compound (4) hydrochloride (73 mg, 0.44 mmol).
Reaction mixture was stirred at ambient temperature overnight,
diluted with EtOAc (80 ml) and extracted with water (20 ml.times.2)
and brine (20 ml). Organic layer was dried over anh. MgSO.sub.4 and
evaporated in vacuum. Residue was dissolved in DCM (1 ml) and
subjected to flash chromatography on CombiFlash.RTM. Companion unit
equipped with RediSep.RTM. flash column (normal phase, 35-60 micron
average particle size silicagel, 4 g, Teledyne Isco); flow rate=18
ml/min; injection volume 1.5 ml; mobile phase A: DCM; mobile phase
B: MeOH; gradient 0-30% B in 38 min. Fractions containing the
desired product were combined and concentrated in vacuum. Residue
was dried in vacuum overnight to obtain target product 5 (112 mg,
65%) as off-white powder. LC-MS [M+H] 433.2
(C.sub.26H.sub.28N.sub.2O.sub.4+H, requires 433.53).
Synthesis of
N--((S)-cyclopropyl-hydroxycarbamoyl-methyl)-4-(4-morpholin-4-ylmethyl-ph-
enylethynyl)-benzamide (68-6)
[1206] A solution of hydroxylamine hydrochloride (107 mg, 1.6 mmol)
in MeOH (anh, 2 ml) was cooled to -5.degree. C. followed by the
addition of 25% NaOMe/MeOH (534 .mu.l, 2.34 mmol) under nitrogen.
Reaction mixture was stirred at -5.degree. C. for additional 5 min,
cooled to -20.degree. C., and solution of compound (5) (122 mg,
0.26 mmol) in THF/MeOH (1:1, 2 ml) was added dropwise over the
period of 5 min. Temperature of reaction mixture was raised to
ambient. Completion of the reaction was monitored by LC-MS. After
completion reaction mixture was acidified with 1 N aq. HCl to
pH.about.7 and evaporated in vacuum. Residue was dissolved in DMSO
(600 .mu.l) and subjected to HPLC purification. [Phenomenex Gemini
C-18 column, 110 .ANG. (30.times.100 mm); flow rate=20 ml/min;
mobile phase A: 100% water, 0.1% TFA; mobile phase B: 100% ACN,
0.1% TFA; gradient elution from 8% B to 28% B in 60 min., detection
254 nm]. Fractions containing the desired product were combined and
lyophylised to provide trifluoroacetic salt of target product
(68-6) (39.5 mg, 28%) as white solid. LC-MS [M+H] 434.3
(C.sub.25H.sub.27N.sub.3O.sub.4+H, requires 434.52).
TABLE-US-00019 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* (68-6) 0.26 39.5 28 100 434.3
2.98 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 min,
detection 254 nm]
Example 69
##STR00147##
[1207] Example 70
##STR00148##
[1208] Example 71
##STR00149##
[1209] Example 72
##STR00150##
[1210] Example 73
##STR00151##
[1211] Example 74
##STR00152##
[1212] Example 75
##STR00153##
[1213] Example 76
##STR00154##
[1214] Example 77
##STR00155##
[1215] Example 78
##STR00156##
[1216] Example 79
##STR00157##
[1217] Example 80
##STR00158##
[1218] Example 81
##STR00159##
[1219] General Procedures for Following Examples
[1220] Method 1-A (1-Bromo-1-alkyne/Alkyne Coupling)
[1221] A solution of the 1-bromo-1-alkyne (0.35 mmol, 1.0 equiv),
alkyne (0.35 mmol, 1.0 equiv), PdCl.sub.2(PPh.sub.3).sub.2 (0.0035
mmol, 0.01 equiv), P(tBu).sub.3 HBF.sub.4 (0.007 mmol, 0.02 equiv),
Cu(I)I (0.0018 mmol, 0.005 equiv) and Et.sub.3N (1.05 mmol, 3.0
equiv) in deoxygenated THF (5 mL) was allowed to stir at ambient
temperature under N.sub.2 until the starting material was consumed
as determined by TLC or LC-MS analysis. The solution was
concentrated in vacuo and purified by normal phase flash
chromatography to provide the desired compound.
Method 1-B (Vinyldibromide/Alkyne Coupling)
[1222] A solution of vinyldibromide (2.0 mmol, 1.0 equiv), alkyne*
(2.8 mmol, 1.4 equiv), Pd.sub.2(dba).sub.3 (0.02 mmol, 0.01 equiv),
tri(4-methoxyphenyl)phosphine (0.08 mmol, 0.04 equiv) and Et.sub.3N
(6.0 mmol, 3.0 equiv) in deoxygenated DMF (5 mL) was heated at
80.degree. C. for 2-6 h under nitrogen. The reaction was monitored
by LC-MS until disappearance of the vinyldibromide. The reaction
mixture was diluted with EtOAc (120-150 mL), washed with water
(2.times.50 mL), brine (1.times.50 mL) dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The crude material was purified by normal
phase flash chromatography to provide the desired compound. * In
the case of a volatile alkyl- or cycloalkyl acetylene, amount of
the acetylene was increased to 2-3 equivalents, and the reaction
vessel was sealed before heating.
Method 1-C (Cadiot-Chodkiewicz Coupling)
[1223] To a solution of the alkyne (8.37 mmol, 1.0 equiv) in MeOH
(25 mL) at 0.degree. C. was added aqueous EtNH.sub.2 (70%, 35 mL)
and Cu(I)Cl (0.419 mmol, 0.05 equiv). The this solution at
0.degree. C. was then added a solution of the 1-bromo- 1-alkyne
(8.37 mmol, 1.0 equiv) in THF (25 mL). Solid NH.sub.2OH HCl (8.37
mmol, 1.0 equiv) was then added in one portion and the solution was
allowed to stir at 0.degree. C. until starting material was
consumed as determined by TLC or LC-MS analysis. The solution was
then diluted with EtOAc (50 mL) and deionized water (50 mL). The
layers were separated and the organic layer was washed with aqueous
HCl (0.1 N, 2.times.25 mL) and brine (1.times.25 mL). The organics
were then dried (Na.sub.2SO.sub.4), filtered and concentrated in
vacuo. Crude material was then purified by flash chromatography to
provide the desired compound.
Method 2-A (Basic Hydrolysis)
[1224] To a solution of the methyl ester (1.0-1.5 mmol, 1.0 equiv)
in 1,4-dioxane* (2-4 mL) was added 1.5 N NaOH (aq) (4-6 mL, 6.0
equiv) and the mixture was heated at 70-90.degree. C. for 1-4 h,
monitored by LC-MS until starting material was consumed. After
cooling to ambient temperature, the reaction mixture was acidified
with 2 N HCl (aq)**, and the solid was collected by filtration,
washed with water (2.times.) and dried under high vacuum to give
the desired compound. The product was used without further
purification in the next synthetic step. * Alternatively, THF or
EtOH can be used.** Alternatively, 10% H.sub.3PO.sub.4 (aq) or AcOH
can be used.
Method 2-B (Acidic Hydrolysis)
[1225] A solution of the methyl ester (1-2 mmol, 1.0 equiv) in 2 N
HCl (aq) (8 mL, 8-16 equiv) was heated at 80.degree. C. for 6-10
min, monitored by LC-MS until starting material was consumed. The
reaction mixture was cooled to 5.degree. C. and the solid was
collected by filtration, washed with water and dried under high
vacuum to give the desired compound. The product was used without
further purification in the next synthetic step.
Method 3-A (HATU Coupling)
[1226] To a solution of the acid (0.50 mmol, 1.0 equiv) and DIEA
(1.5 mmol, 3.0 equiv) in DMF (0.1-0.5 M) was added HATU (0.60 mmol,
1.2 equiv), and the mixture was stirred at ambient temperature* for
5 min. The amine (0.55 mmol, 1.1 eq) was then added and the mixture
was stirred at ambient temperature for 18 h or until the starting
material was consumed as determined by TLC or LC-MS analysis. The
mixture was then added to aqueous HCl (0.1 N, 50 mL) and extracted
with EtOAc (3.times.25 mL). Combined organic layers were washed
with water (1.times.25 mL) and brine (1.times.25 mL), dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo to give the
desired compound. Crude product may be used in next synthetic step
without additional purification or purified by normal phase flash
chromatography. * An ice/water bath should be used if scale more 2
mmol.
Method 3-B (EDC/HOBT Coupling)
[1227] The carboxylic acid (1.15 mmol, 1.0 equiv), amine (1.27
mmol, 1.1 equiv), EDC (2.30 mmol, 2.0 euiv) and HOBT (2.30 mmol,
2.0 equiv) were slurried in anhydrous CH.sub.2Cl.sub.2 (12 mL). To
this slurry was added N,N-diisopropylethylamine (5.40 mmol, 4.0
equiv) in one portion. The solution was then allowed to stir at
ambient temperature until complete conversion is observed by LCMS
analysis. The solution was then concentrated in vacuo and the crude
solid was purified by normal phase flash chromatography to provide
the desired compound.
Method 4-A (Boc Deprotection)
[1228] To the Boc protected amine (0.5 mmol, 1.0 equiv) was added 4
M HCl/dioxane (3-6 mL), and the mixture was stirred at ambient
temperature for 0.5-2 h, or until complete as determined by TLC or
LC-MS analysis. Volatiles were removed in vacuo or under a stream
of nitrogen to give the desired compound as the hydrochloride
salt.
Method 4-B (Boc Deprotection)
[1229] To Boc protected amine (0.50 mmol, 1.0 equiv) in
CH.sub.2Cl.sub.2 (10 mL) was added TFA (2 mL) and the mixture was
stirred at ambient temperature until complete as determined by TLC
or LC-MS analysis. Volatiles were removed in vacuo or under a
stream of nitrogen to give the desired compound as the TFA
salt.
Method 4-C(Fmoc Deprotection)
[1230] To Fmoc protected amine (13.5 mmol, 1.0 equiv) in DMF (135
mL) at 0.degree. C. was added morpholine (25 mL). The solution was
allowed to stir at 0.degree. C. until complete as determined by TLC
or LC-MS analysis. The solution was then vacuum filtered through a
pad of Celite and diluted with EtOAc (400 mL). The organics were
then washed with deionized water (3.times.100 mL), dried
(MgSO.sub.4), filtered and concentrated in vacuo. The crude
material was then purified by normal phase flash
chromatography.
Method 5-A (Hydroxamate Formation, Aqueous)
[1231] Isopropyl alcohol (1-4 mL) was added to a corresponding
methyl ester (.about.0.5 mmol, 1.0 eq) and the mixture was
optionally cooled in an ice/water bath for 5 min. NH.sub.2OH (50%
aq) (1-4 mL) was added to the mixture, dropwise for the first 1/2
vol. After 5 min, the ice bath was removed and the reaction mixture
was stirred for 6-24 h, or until complete as determined by LC-MS
analysis of the reaction mixture. Solvent volume was reduced by
half using a nitrogen stream and water (10-15 mL) was added. The
suspension was thoroughly agitated (vibro mixer and sonication),
centrifuged and the supernatant was discarded. Water (10-15 mL) was
added to the solid and the suspension was thoroughly agitated,
centrifuged and the supernatant was discarded. Wet solid was
optionally dried by lyophilization to give the crude corresponding
hydroxamate.
Method 5-B (Hydroxamate Formation and Fmoc Deprotection,
Anhydrous)
[1232] To a stirred suspension of a corresponding methyl ester
(.about.0.5 mmol, 1.0 eq) and hydroxylamine hydrochloride (5 mmol,
10 eq) in anhydrous MeOH (2 mL) and optionally anhyd THF (2 mL)
cooled at -5.degree. C. in a ice/salt/water bath, was added
dropwise 25% NaOMe/MeOH (1.2 mL, 10 mmol) under nitrogen. The
reaction mixture was stirred at -5.degree. C. for an additional 5
min then stirred for 0.5-2 h or until complete as determined by
LC-MS analysis.sup.2 of the reaction mixture. Reaction mixture was
cooled, acidified to pH.about.6 with 1 M HCl, and concentrated in
vacuo or under a stream of nitrogen to give the crude corresponding
hydroxamate.
Method 6 (DAST Fluorination)
[1233] To a stirred solution of the corresponding alcohol (2.8
mmol, 1.0 equiv) in anhydrous CH.sub.2Cl.sub.2 (50 mL) was slowly
added diethylamino sulfur trifluoride (2.8 mmol, 1.0 equiv) at
0.degree. C. The solution was allowed to stir at 0.degree. C. for 1
h or until complete as determined by TLC or LC-MS analysis.
Solution was then diluted with aqueous, saturated NaHCO.sub.3 (50
mL) and the layers were separated. The aqueous layer was extracted
with CH.sub.2Cl.sub.2 (1.times.25 mL) and the combined organics
were dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo.
Crude material was used as is or purified by normal phase flash
chromatography.
Purification A (1-200 mg Scale)
[1234] Crude product was purified by preparative scale
reverse-phase HPLC (Phenomenex Gemini C-18 column, 110 .ANG.,
30.times.100 mm, flow rate: 20 mL/min, mobile phase A: 0.1%
TFA/water, mobile phase B: 0.1% TFA/ACN, gradient elution from 0% B
to 100% B, UV (254 nm) and MS detection). Fractions containing the
desired product were combined and lyophilized to provide the
trifluoroacetate salt of target compound as a white solid.
Purification B (200-2500 mg Scale).
[1235] [Varian L/L 4002-2 column (5.times.50 cm.; Microsorb 100-10
C-18), flow rate=50 ml/min; mobile phase A: 100% water, 0.1% TFA;
mobile phase B: 100% ACN, 0.1% TFA; gradient elution from 20% B to
95% B in 90 min., detection 254 nm].
Synthesis of (2S,3R)-2-amino-3-(Fmoc-amino)-butyric acid methyl
ester hydrochloride (6)
##STR00160##
[1236] Step 1: (2S,3S)-3-hydroxy-2-(trityl-amino)-butyric acid
methyl ester (2)
[1237] A suspension of H-allo-Thr-OMe.HCl (1, 45.8 g, 270 mmol) in
anhydrous CH.sub.2Cl.sub.2 (225 ml) was ice cooled. Anhydrous
NEt.sub.3 (85 ml, 610 mmol) was added, followed by a solution of
trityl chloride (79 g, 284 mmol) in anhydrous CH.sub.2Cl.sub.2 (225
ml) (dropwise over 30 min). The reaction mixture was allowed to
warm to room temperature and stirred overnight. The resulting
suspension was filtered and the white solid was washed with
CH.sub.2Cl.sub.2 (2.times.450 ml). The filtrate was combined with
the first CH.sub.2Cl.sub.2 washing and was washed with sat.
NaHCO.sub.3 (225 ml) and brine (225 ml). The second
CH.sub.2Cl.sub.2 washing was used to back extract the aqueous
extracts. The combined CH.sub.2Cl.sub.2 solutions were dried
(Na.sub.2SO.sub.4), filtered, and concentrated. Hexane (450 ml) was
added and the resulting mixture was concentrated. The resulting
solid was triturated with hexane (600 ml), filtered, and washed
with hexane to provide 2 (102.5 g, 100% yield, 98% pure by NMR) as
a white solid.
Step 2: (2S,3R)-3-azido-2-(trityl-amino)-butyric acid methyl ester
(3)
[1238] A solution of 2 (98.4 g, 262 mmol) and PPh.sub.3 (68.7 g,
262 mmol) in anhydrous CH.sub.2Cl.sub.2 (1.7 l) was ice cooled.
Diisopropyl azodicarboxylate (DIAD, 78 ml, 396 mmol) was added
dropwise over 20 min, followed by diphenylphosphoric azide (DPPA,
93 ml, 432 mmol) added dropwise over 20 min. The resulting solution
was allowed to warm to room temperature and stirred for two days.
Solvent was evaporated and the residue was purified twice by flash
chromatography (2 kg of SiO.sub.2 each, eluting with 30%
CH.sub.2Cl.sub.2 in hexanes, containing 1% NEt.sub.3) to provide 3
(46.7 g, 45% yield) as a clear oil.
Step 3A: (2S,3R)-3-amino-2-(trityl-amino)-butyric acid methyl ester
(4A)
[1239] To a solution of 3 (10 g, 25 mmol) in EtOAc (200 ml) was
added Pd/C (5% wt, 2.5 g) and the resulting mixture was stirred
under an H.sub.2 balloon at room temperature for two days. The
reaction mixture was filtered through Celite and the filtrate was
concentrated to provide the desired compound 4A (9.2 g, 99% yield)
which was used directly in the next step.
Step 4A: (2S,3R)-3-(Fmoc-amino)-2-(trityl-amino)-butyric acid
methyl ester (5A)
[1240] A solution of 4A (0.94 g, 2.5 mmol) and Fmoc-OSu (0.89 g,
2.63 mmol) in anhydrous THF (5 ml) was stirred at room temperature
for 3.5 h. Solvent was evaporated and the resulting residue was
purified by flash chromatography (CombiFlash, 40 g silica gel
column, 35 ml/min, 10-30% EtOAc in hexane) to provide 5A (1.2 g,
81% yield) as a white solid.
Step 5A: (2S,3R)-2-amino-3-(Fmoc-amino)-butyric acid methyl ester
(6)
[1241] To a solution of 5A (1.2 g, 2 mmol) in anhydrous THF (6 ml)
was added 2 M HO/ether (3 ml, 6 mmol) and the resulting solution
was stirred at room temperature. A precipitate slowly begun
forming. Anhydrous ether (9 ml) was added after 3.5 h and the
resulting mixture was stirred at room temperature overnight. The
solid was collected by filtration and was washed with ether (15 ml)
to provide 6 (0.7 g, ca. 90% yield). NMR showed that this material
contains about 4% of trityl alcohol. Trituration in ether is in
progress.
Synthesis of (2S,3R)-2-amino-3-(Boc-amino)-butyric acid methyl
ester hydrochloride (6A-HCl)
##STR00161##
[1242] Note: Steps 1, 2 and 3A were described in the experimentals
for (6) above.
Step 4B: (2S,3R)-3-(Boc-amino)-2-(trityl-amino)-butyric acid methyl
ester (5B)
[1243] A solution of 4A (137 g, 366 mmol) and Boc anhydride (96 g,
438 mmol) in anhydrous CH.sub.2Cl.sub.2 (350 ml) was stirred at
room temperature overnight. Solvent was evaporated and the
resulting residue was purified by flash chromatography (SiO.sub.2,
10-30% EtOAc/hexane) to provide 5B (111.8 g, 64% yield) as a white
solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6) .delta. 7.42 (bd, J=7.2
Hz, 6H), 7.26 (bt, J=7.2 Hz, 6H), 7.18 (bt, J=7.2 Hz, 3H), 6.98
(bd, J=8.8 Hz, 1H), 3.9-3.75 (m, 1H), 3.24 (dd, J=11.3, 5.8 Hz,
1H), 3.01 (s, 3H), 2.66 (d, J=11.3 Hz, 1H), 1.37 (s, 9H), 1.09 (d,
J=6.9 Hz, 3H).
Step 5B: (2S,3R)-2-amino-3-(Boc-amino)-butyric acid methyl ester
(6A)
[1244] To a solution of 5B (126.8 g, 267 mmol) in anhydrous MeOH
(1.4 l) was added Pd/C (10%, wet, 19.5 g) and the resulting mixture
was hydrogenated in a Parr apparatus (50 psi pressure) over two
days. The reaction mixture was filtered through Celite and solvent
was evaporated. The residue was purified by flash chromatography
(SiO.sub.2, 50-100% EtOAc/hexane, then 0-10% MeOH/EtOAc) to provide
6A (57.6 g, 92% yield) as an oil. .sup.1H-NMR (300 MHz,
DMSO-d.sub.6) .delta. 6.62 (bd, J=9.1 Hz, 1H), 3.9-3.75 (m, 1H),
3.57 (s, 3H), 3.28 (d, J=4.1 Hz, 1H), 1.69 (bs, 2H), 1.36 (s, 9H),
1.03 (d, J=6.9 Hz, 3H)
Step 5C: (2S,3R)-2-amino-3-(Boc-amino)-butyric acid methyl ester
HCl salt (6A-HCl)
[1245] A solution of 6A (57.6 g, 248 mmol) in anhydrous ether (300
ml) was ice cooled. A solution of HCl in ether (2 M, 124 ml, 248
mmol) was added dropwise over 15 minutes. The resulting solution
was stirred for 5 minutes, hexane (900 ml) was added, and the
resulting solid was collected by filtration. The solid was washed
with hexane and was dried under high vacuum to provide 6A-HCl (63.3
g, 95% yield) as a white solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.53 (bs, 3H), 6.96 (d, J=8.3 Hz, 1H), 4.15-4.05 (m, 2H),
3.70 (s, 3H), 1.38 (s, 9H), 1.13 (d, J=6.9 Hz, 3H). MS (APCI, pos):
233 (M+1, 20%), 177 (233-CH.sub.2.dbd.CMe.sub.2, 100%), 133
(177-CO.sub.2). Elemental Analysis: Found: C, 44.16; H, 7.90; N,
10.06; Cl, 13.03. Calc.: C, 44.10; H, 7.92; N, 10.29; Cl, 13.02
(C.sub.10H.sub.21N.sub.2O.sub.4Cl.0.2H.sub.2O). LC purity: 100%
(MS, TIC).
(2S, 3S)-methyl
3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-aminobutanoate
hydrochloride (7)
(2R,3S)-methyl
3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-aminobutanoate
hydrochloride (8)
(2R,3R)-methyl
3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-aminobutanoate
hydrochloride (9)
##STR00162##
[1247] (7), (8) and (9) were prepared using the same method as
described in the synthesis of compound (6).
Synthesis of 2-amino-3-(Boc-amino)-3-methyl-butyric acid methyl
ester (C001)
##STR00163##
[1248] Synthesis of 2-amino-3-nitro-3-methyl-butyric acid methyl
ester (1)
[1249] Reference: J. Chem. Soc. Perkin Trans. 1, 2659-2660
(1999).
[1250] 2-Nitropropane (4.1 mL, 46 mmol, 2 eq) was taken up in 60 mL
water containing KOH (3 g, 54 mmol, 2.3 eq). A solution of
glyoxylic acid hydrate (2.15 g, 23 mmol, 1 eq) was treated with 30
mL of ammonia water (28-30%, ca. 10 eq), and this was added to the
mixture containing the nitropropane. The clear, colorless reaction
mixture was stirred vigorously for three hours at room temperature.
The reaction mixture was cooled in ice water and treated with conc.
HCl (aq) to pH=1-2. The reaction mixture attained a blue color at
ca. pH 4 but remained homogeneous. The blue color was removed by
washing sequentially with 2.times.50 mL and 1.times.25 mL
chloroform, then the aqueous layer was stripped to yield a white
solid. The solid was then taken up in one liter of absolute
ethanol. Insoluble material was removed by filtration and
discarded, and the filtrate was stripped to give
2-amino-3-methyl-3-nitrobutanoic acid (1) as a white solid, which
was used without further purification.
[1251] This material was taken up in methanol and cooled in ice.
HCl gas was bubbled through for ca. one hour, and the reaction
mixture was stirred at room temperature overnight. A white solid
formed, which was removed by filtration and deemed not to be
product by .sup.1H NMR. The methanol was removed in vacuo and the
resulting slightly greasy off-white solid taken up in 750 mL of
chloroform and stirred with 500 mL of sat. NaHCO.sub.3 (aq.) to
remove HCl. The layers were separated and the chloroform layer
dried over Na.sub.2SO.sub.4, then stripped to an oil. Pure product
was obtained via chromatography on silica gel using 5% ethyl
acetate/hexanes. After removal of solvent, the resulting yellow oil
was dried under vacuum for no more than one hour to avoid loss of
material. No solvents were detected in the .sup.1H NMR. Yield: 24 g
(50%). TLC Rf=0.31 (40% ethyl acetate/hexanes). APCI(+) m/z=177,
130 amu (the latter peak is the most prominent, and is due to loss
of HNO.sub.2 occurring in the mass spectrometer). .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta. 4.15 (s, 1H), 3.74 (s, 3H), 1.59 (s,
1H), 1.58 (s, 1H). C.sub.6H.sub.12N.sub.2O.sub.4 requires C, 40.91;
H, 6.87; N, 15.90. Found C, 41.50; H, 6.99; N, 15.34.
2-(Z-amino)-3-methyl-3-nitro-butyric acid methyl ester (2)
[1252] To a solution of 2-Amino-3-nitro-3-methyl-butyric acid
methyl ester 1 (5.37 g, 30.5 mmol) in 60 mL of THF and DIEA (6.6
mL, 40 mmol) Z--OSu (7.23 g, 29 mmol) was added and the reaction
mixture was stirred 4 h at r.t. THF was removed under reduced
pressure, the residue was taken in EtOAc (200 mL). Organics was
washed with water (50 mL.times.2), brine (50 mL) and dried over
Na.sub.2SO.sub.4. The solvent was removed by rotary evaporation and
colorless oil 2 (5.9 g, 62%), which was used on next step without
purification.
2-(Z-amino)-3-amino-3-methyl-butyric acid methyl ester (3)
[1253] To a cold (ice bath) solution of compound 2 (5.9 g, 19 mmol)
in 10 mL of AcOH and 40 ml of THF, Zn dust (16.5 g, 250 mmol, 13
eq) was added over 2 min. After adding of zinc dust, the
temperature of the reaction mixture was allowed to rise to ambient.
Reaction was monitored by LCMS. After 2-3 hrs, LCMS showed the
major peak of amine along with a small peak of acid (.about.5%).
The reaction mixture was filtered through Celite using THF to
rinse, and the filtrate was concentrated by rotary evaporation to
give thick syrup. (Note: this syrup contained some amount of
Zn(OAc).sub.2, but it would not affect next reaction).
2-(Z-amino)-3-(Boc-amino)-3-methyl-butyric acid methyl ester
(4)
[1254] The above syrup was re-dissolved in 40 ml THF. Boc.sub.2O
(9.1 g, 41.8 mmol, 2.2 eq) was added, followed by addition of DIEA
(10 ml, 57 mmol, 3 eq). The reaction mixture was stirred for 3 hr
at ambient temperature. When LC-MS indicated the completion of
reaction, solvent was evaporated and the resulting residue was
purified by flash chromatography (Combiflash, 80 g Si gel column,
40 ml/min, 0-30% EtOAc in Hexanes) to provide the desired compound
(5.3 g, 74% on two steps) as white crystal.
2-Amino-3-(Boc-amino)-3-methyl-butyric acid methyl ester (C001)
[1255] To a solution of compound 4 (5.2 g, 14 mmol) in 70 ml of
MeOH was added Pd/C (5% wt, 800 mg) and the resulting mixture was
hydrogenated using a Parr shaker (50 psi H.sub.2) for 30 min.
Catalyst was removed by filtration and the filtrate was
concentrated to give target compound C001 (3.3 g, as white crystal,
97.3%).
(2S)-2-Amino-3-(tert-butoxycarbonylamino)-3-methyl-butyric acid
methyl ester HCl salt Via S-alpha-Methylbenzylamine
(E-(S)--HCl)
##STR00164## ##STR00165##
[1256] Synthesis of
3-Methyl-3-nitro-(2(S)-(1(S)-phenylethyl-amino))-butyric acid
(A-(S))
[1257] The 2-nitropropane (90.87 g, 1.02 mol, 1.02 eq) and water
(1.0 L) were placed under nitrogen in a 2 L Erlenmeyer flask with a
large stirbar (2''.times.3/8''). With good stirring, the potassium
hydroxide (.about.90%; 74.81 g, 1.20 mol, 1.2 eq) was added all at
once (solution warms to .about.40.degree. C.). The flask was placed
in a regulated water or oil bath heated to 45.degree. C. The
(S)-alpha-methylbenzylamine (130 mL, 1.02 mol, 1.02 eq) was
measured and added very quickly (very fast CO.sub.2 absorption).
The reaction mixture was maintained at .about.44-46.degree. C. and
stirred swiftly as the glyoxylic acid (50% aq, 112 mL, 1.00 mol,
1.00 eq) was added slowly dropwise (60 min, slowest for the last
one-third) via a dropping funnel. The reaction mixture becomes
cloudy, then clear, and when the solids begin forming again the
addition was slowed down. After complete addition, the reaction was
stirred for an additional 2-4 h under nitrogen as the temperature
cools to 25-30.degree. C. Additional water (200 mL) was added and
the reaction mixture warmed to 34.degree. C. (internal) and stirred
swiftly as the 3.00 M aq hydrochloric acid (610 mL, 1.83 mol, 1.83
eq) was warmed in a dropping funnel and added as a stream over
20-30 min. The thick slightly off-white suspension was stirred for
0-16 h at room temperature (and if necessary, then placed in a
-10.degree. C. bath to cool to .about.18-20.degree. C. internally).
The cooled suspension was then filtered with suction through paper
and rinsed with dilute aq hydrochloric acid (0.2 M, 2 L), water (2
L) and ethyl ether (500 mL). The filtercake was then suctioned to
compact "dryness" over 30-60 min. The filtercake was then
transferred to a 20.degree. C. desiccator or vacuum oven and dried
under full vacuum for 2-6 h. The solids were then ground and placed
in the vacuum oven for 2-4 h at 50-60.degree. C., and 2-4 h at
90.degree. C. to yield A-(S) as a slightly off-white powder (127.0
g, 47.7% yield). Check of a sample by HPLC-MS* showed a 4.5:95.5
ratio of diastereomers (2.13 min (minor), 2.30 min (major)) of the
product with an overall purity of 94%. Both peaks show the same
molecular weight (MH.sup.+=266.7). LC-MS [M+H] 267.7 (C13H18N2O4+H,
requires 267.30). *[Common HPLC method: Onyx monolithic C18 column,
50.times.4.6 mm; 1.5 mL/min; 9.10 min gradient of 5%-60% MeCN in
H.sub.2O with 0.1% TFA; UV (254 nm); MS; ELSD. Retention times are
reported for UV (254 nm) unless otherwise noted.]
Purification of
3-Methyl-3-nitro-(2(S)-(1(S)-phenylethyl-amino))-butyric acid
(A-(S))
[1258] A solution of dilute aq hydrochloric acid (3.0 M, 250 mL),
water (3.0 L) and acetic acid (350 mL) was placed in a 4 L
Erlenmeyer flask and stirred well as it was immersed in a
45-60.degree. C. bath and warmed to 40.degree. C. (internal). Once
the solution was up to temperature, dissolve the amino-acid A-(S)
(.about.10:90 d.r., 33.03 g) in stirred warm DMSO (50.degree. C.,
dry, 150 mL) and add 100 mL of acetic acid to form a clear
solution. Pour the solution into a separatory (dropping) funnel
that was warmed and contains 150 mL of warm acetic acid and 100 mL
of warm DMSO and mix. Suspend the dropping funnel over a fast
vortex in the Erlenmeyer flask and add the warm DMSO solution to
the Erlenmeyer flask at an even dropwise rate (.about.5-10 mL/min,
.about.45-60 min addition). The suspension was then filtered
through paper by suction and rinsed with dilute aq hydrochloric
acid (0.2 M, 2 L), water (4 L), isopropanol (150 mL) and ethyl
ether (500 mL). The filtercake was then suctioned to compact
"dryness" over 20-40 min. The filtercake was then transferred to a
20.degree. C. vacuum oven and dried under full vacuum for 3-12 h.
The solids are then ground and placed in the vacuum oven for 2 h at
50-60.degree. C., and 2-4 h at 90-95.degree. C. to yield A-(S) as a
pale tan-white powder (29.66 g, 89.8% yield). Check of a sample by
HPLC-MS showed a 1.2:98.8 ratio of diastereomers (HPLC-MS: 2.12 min
(minor), 2.29 min (major); both MH.sup.+=267.6) of the product with
an overall purity >99%.
Second Purification of
3-Methyl-3-nitro-(2(S)-(1(S)-phenylethyl-amino))-butyric acid
(A-(S))
[1259] (Procedure was similar to the first precipitation above.) A
solution of dilute aq hydrochloric acid (3.0 M, 250 mL), water (3.0
L) and acetic acid (450 mL) was placed in a 4 L Erlenmeyer flask
and stirred well as it was immersed in a 45-60.degree. C. bath and
warmed to 40.degree. C. (internal). Once the solution was up to
temperature, dissolve the amino-acid A-(S) (1.2:98.8 d.r., 31.05 g)
in stirred warm DMSO (50.degree. C., dry, 175 mL) and add 100 mL of
acetic acid to form a clear solution. Pour the solution into a
separatory (dropping) funnel that was warmed and contains 100 mL of
warm acetic acid and 75 mL of warm DMSO and mix. Suspend the
dropping funnel over a fast vortex in the Erlenmeyer flask and add
the warm DMSO solution to the Erlenmeyer flask at an even dropwise
rate (.about.5-10 mL/min, .about.45-60 min addition). Upon complete
addition, the suspension was stirred and placed in a -10.degree. C.
bath to cool to .about.20-22.degree. C. internally. The suspension
was then filtered through paper by suction and rinsed with dilute
aq hydrochloric acid (0.2 M, 2 L), water (4 L), isopropanol (150
mL) and ethyl ether (500 mL). The filtercake was then suctioned to
compact "dryness" over 20-40 min. The filtercake was then
transferred to a 20.degree. C. vacuum oven and dried under full
vacuum for 3-12 h. The solids are then ground and placed in the
vacuum oven for 2 h at 50-60.degree. C., and 2-4 h at 90-95.degree.
C. to yield A-(S) as a slightly off-white powder (29.6 g, 95%
yield). Check of a sample by HPLC-MS showed a 0.15:99.85 ratio of
diastereomers (2.12 min (minor), 2.31 min (major)) of the product
with an overall purity >99%.
Synthesis of 3-Methyl-3-nitro-2(S)-(1(S)-phenylethyl-amino)-butyric
acid methyl ester (B--(S))
[1260] Into a dry 100 mL flask with a stirbar was placed the
amino-acid A-(S) (9.77 g, 36.7 mmol) and cesium carbonate (12.55 g,
38.05 mmol, 1.05 eq.) under nitrogen. With rapid stirring the
dimethylformamide (37 mL) was added rapidly and stirred for 10 min,
with sonication for 1 min. The reaction mixture was then cooled in
a 10-15.degree. C. water bath as the first portion of iodomethane
(1.75 mL, two-thirds of the 2.63 mL) was added dropwise over 15
min. The bath was removed and the reaction was brought to room
temperature over 20 min. The second portion of iodomethane (0.88
mL, one-third of the 2.63 mL) was added dropwise more slowly over
30 min. After the reaction was stirred for an additional 20 min,
check of a sample by HPLC-MS showed a major product peak (5.89 min,
MH.sup.+=281.7; 99.2% convn) with of a small amount of the SM (2.64
min, .about.0.75%). After the reaction was stirred for an
additional 60 min, check of a sample by HPLC-MS showed complete
conversion to the product peak. The reaction was then washed with
EtOAc and water into a separatory funnel containing EtOAc (250 mL),
water (70 mL) and 3 M aq HCl (12.8 mL, 38.4 mmol). The phases were
shaken and the aqueous layer was adjusted to pH.about.7-8 and
separated. The organic phase was washed with 3% aq Li.sub.2SO.sub.4
(3.times.100 mL), half-saturated aq NaHCO.sub.3 (50 mL) and satd aq
NaCl (2.times.100 mL), dried (Na.sub.2SO.sub.4), filtered and
evaporated under reduced pressure with a heptane chaser to an amber
oil. After placing under full vacuum for >4 h, the amino-ester
B--(S) (9.88 g, 96% yield) was obtained. Check of a sample by
HPLC-MS showed a major product peak (3.32 min, MH.sup.+=281.7).
LC-MS [M+H] 281.7 (C14H20N2O4+H, requires 281.33).
Synthesis of
3-Amino-3-methyl-(2(5)-(1(S)-phenylethyl-amino))-butyric acid
methyl ester (C--(S))
[1261] The amino-ester B--(S) (9.88 g, 35.24 mmol) was dissolved in
dry THF (100 mL) and glacial acetic acid (150 mL) along with
activated powdered molecular sieves (4 A, 12 g) and stirred mildly
for 2-4 h under nitrogen. The flask was then immersed in a
0.degree. C. bath and stirred well for 20 min. To the cooled
reaction mixture was then added the zinc dust (20.74 g, 317 mmol, 9
eq) portionwise: 1 eq of zinc dust (2.30 g) was added and the flask
removed from the bath and stirred for 10 min, and then immersed in
a 20.degree. C. bath, stirred for 20 min. Another 2 eq portion of
zinc dust (4.61 g) was added and the mixture stirred .about.20-30
min until slight venting through a bubbler ceased. The last
sequence was repeated 3 more times to finish the addition of zinc
dust (9 eq total). After stirring a total of 18 h, a check of a
sample by HPLC-MS showed a major product peak (3.36 min,
MH.sup.+=251.7) with a minor diamino-acid peak (1.38 min,
MH.sup.+=237.6). This mixture was then diluted with THF (.about.150
mL) and filtered through a celite pad with additional THF
(.about.300 mL) washing. This slightly cloudy solution was rotary
evaporated under full vacuum to yield a slightly yellow oily solid
(32.6 g). This material was dissolved in 3:1 chloroform/isopropanol
(200 mL) and poured into a separatory funnel containing 3:1
chloroform/isopropanol (500 mL) and 0.25 MEDTA solution at pH
10.5-11 (275 mL). Aqueous 4 MNaOH soln (18 mL) was added and the
mixture was shaken and the pH of the aqueous checked. Additional 4
M NaOH soln was added in portions to reach pH 10.5-11.0. The funnel
contents were thoroughly shaken, and the aqueous phase separated.
The organic phase was then thoroughly shaken with 0.25 MEDTA
solution at pH 10.5-11 (1.times.200 mL, 1.times.50 mL), and
separated. The organic phase was then washed with satd aq NaCl
(3.times.150 mL), dried (Na.sub.2SO.sub.4), filtered and evaporated
under reduced pressure, followed with addition of heptane
(3.times.100 mL) and evaporation to yield a light-amber oil. After
placing under full vacuum for .about.1-2 h, the diamino-ester
C--(S) (7.62 g, 86.4% yield) was obtained. Check of a sample by
HPLC-MS showed a major product peak (3.32 min, MH.sup.+=251.7).
LC-MS [M+H] 251.7 (C14H22N2O2+H, requires 251.34).
Synthesis of 3-(tert-Butoxycarbonylamino)-3-methyl-(2(S)-(1
(S)-phenylethyl- amino))-butyric acid methyl ester (D-(S))
[1262] The diamino-ester C--(S) (7.62 g, 30.44 mmol, 1.0 eq) was
dissolved in THF (150 mL) under nitrogen and diisopropylethylamine
(5.8 mL, 33.5 mmol, 1.10 eq) was added to this solution. The
tert-butylpyrocarbonate (9.96 g, 45.66 mmol, 1.50 eq) was added in
two portions: the first portion (7.97 g, 1.20 eq) was followed by
the second portion (1.99 g, 0.30 eq) 1 h later. After stirring for
10 h, a check of a sample by HPLC-MS showed a major product peak
(4.94 min, MH.sup.+=351.7) with a minor SM peak (3.59 min,
.about.2%). After stirring for 16 h, a check of a sample by HPLC-MS
showed complete reaction. The reaction mixture was then dissolved
in EtOAc (.about.300 mL) and washed with water containing 1 eq HCl
(0.3 M HCl, 100 mL), half saturated NaHCO.sub.3 soln (100 mL),
.about.14% aq NH.sub.4OH (2.times.75 mL), satd aq NaCl (2.times.70
mL), dried (Na.sub.2SO.sub.4), filtered and concentrated under
reduced pressure to yield the BOC-diamino-ester D-(S) (10.5 g) as
an oily part crystalline residue. This material was dissolved in a
minimum of DCM and loaded onto a Combiflash column (silica gel,
230-400 mesh, 400 g) and chromatographed using DCM (85 mL/min) as
eluant for 10 min, followed with a gradient of EtOAc (0-10% over 40
min) in DCM. The pure fractions eluted between 0.6% and 5% EtOAc in
DCM. Evaporation gave 6.30 g of pure BOC-diamino-ester D-(S) as a
slightly crystalline viscous oil. Check of a sample by HPLC-MS
showed a major product peak (4.85 min, MH.sup.+=351.7). LC-MS [M+H]
351.7 (C19H30N2O4+H, requires 351.46).
Synthesis of
(2S)-2-Amino-3-(tert-butoxycarbonylamino)-3-methyl-butyric acid
methyl ester (E-(S))
[1263] The combined BOC-diamino-ester D-(S) (6.30 g, 17.98 mmol)
was dissolved in THF (5% soln, 125 mL) in Parr shaker bottle and
placed under nitrogen. The palladium hydroxide catalyst (2.27 g, 18
wt %) was rapidly weighed and added to the shaker flask with a
following flush with nitrogen. The shaker flask was then connected
to hydrogen and evacuated and refilled 3 times. The flask was then
filled with hydrogen (70 psi) and shaking was commenced. The
pressure was kept above 60 psi as the hydrogen was consumed. After
1 h, check of a sample by HPLC-MS showed incomplete deprotection.
After 11 h, check of a sample by HPLC-MS showed a major product
peak (2.55 min (MS-TIC), 2.59 (ELSD), MH.sup.+=247.5) with no other
peaks visible by UV (254 nm), MS, or ELSD. This mixture was then
carefully flushed with nitrogen and filtered through a celite pad
with additional MeOH (.about.250 mL) washing. This clear solution
was rotary evaporated under reduced pressure (to 35.degree. C.)
followed with addition of heptane (50 mL) and evaporation to yield
a "water" clear oil (4.2 g) that was kept under vacuum. LC-MS [M+H]
247.5 (C11H22N2O4+H, requires 247.31).
Synthesis of
(2S)-2-Amino-3-(tert-butoxycarbonylamino)-3-methyl-butyric acid
methyl ester HCl salt (E-(S)--HCl)
[1264] The BOC-Me.sub.2DAP methyl ester (E-(S)) (506 mg, 2.05 mmol)
under nitrogen was dissolved in diethyl ether (3 mL), cooled in a
0.degree. C. bath and rapidly stirred as a 2 M in Et.sub.2O
hydrochloric acid soln (1.05 mL, 2.10 mmol, 1.02 eq) was added over
1 min. After stirring an additional 4 min, hexanes (25 mL) was
added, and the suspension shaken, centrifuged and decanted.
Additional hexanes (.about.20 mL) was added and the suspension
shaken, cooled in a 0.degree. C. bath, centrifuged and decanted.
The white precipitate was dried under full vacuum to yield the
BOC-diamino-ester hydrochloride salt (E-(S)--HCl) (592 mg, 101.9%
yield). Check of the sample by HPLC-MS showed the major product
peak (2.89 min (MS-TIC), 2.92 (ELSD), MH.sup.+=247.5) with no other
peaks visible by UV (254 nm), MS, or ELSD. LC-MS [M+H] 247.5
(C11H22N2O4+H, requires 247.31).
TABLE-US-00020 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* E-(S)-HCl 2.05 592 100 100 247.5
2.89 *[HPLC method: Onyx monolithic C18 column, 50 .times. 4.6 mm;
1.5 mL/min; 9.10 min gradient of 5%-60% MeCN in H.sub.2O with 0.1%
TFA; UV (254 nm); MS; ELSD. Retention times reported for UV (254
nm).]
Synthesis of (2R)-2-Amino-3-(Boc-amino)-3-methyl-butyric acid
methyl ester (C002)
##STR00166##
[1266] (C002) was prepared using the same method described in the
synthesis of compound (E-(S)--HCl) by R-alpha-Methylbenzylamine
instead.
Synthesis of di-Me-(S)-Ser methyl ester
##STR00167##
[1268] Thionyl chloride (0.34 ml, 4.7 mmol) was added dropwise to a
suspension of H--(S)-di-Me-Ser-OH (250 mg, 1.88 mmol) in MeOH (4
ml) at -10.degree. C. Reaction mixture was stirred at low
temperature for 30 min and then temperature of reaction was raised
to ambient. After the reaction mixture was heated at 50.degree. C.
for 2 days. Then, additional amount of thionyl chloride (0.34 ml,
4.7 mmol) was added to the reaction mixture at low temperature.
Stirring was continued at 50.degree. C. for 3 days. Completion of
the reaction was monitored by TLC (in order to check a starting
amino acid) and LCMS. After completion (5-6 days) solvent was
evaporated in vacuum and residue was dried in vacuum overnight to
provide target compound hydrochloride (343 mg, 100%) as white
solid. Compound was used as is for the next step transformation
with no additional purification.
Example 82
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(4-methoxy-phenyl)-buta-
-1,3-diynyl]-benzamide (82-1)
##STR00168##
[1269] Synthesis of 1-ethoxymethyl-4-ethynyl-benzene (1a)
[1270] To a cold solution of 4-ethynyl benzyl alcohol (500 mg, 3.8
mmol) and iodoethane (336 mL, 4.2 mmol) in anhydrous THF (3 mL) at
0.degree. C. was added NaH (212 mg, 5.3 mmol). The reaction mixture
was stirred at 25.degree. C. for 30-60 min, monitored by LC-MS
until there was no starting material remained. The solution was
quenched with MeOH (1 mL) and volatiles were removed in vacuo. The
crude mixture was partitioned in aqueous HCl (1 N, 10 mL) and EtOAc
(10 mL), the aqueous layer was extracted with ethyl acetate and the
combined organics were washed with brine, dried (Na.sub.2SO.sub.4),
filtered and concentrated in vacuo. Crude material was purified by
flash chromatography (20 g SiO.sub.2, EtOAc/Hex) to give the
desired compound (300 mg, 61%) as light yellow oil.
Synthesis of 1-(Fmoc-amino)-4-ethynyl-benzene (1b)
[1271] To a cold solution of 4-ethynyl aniline (1.4 g, 11.9 mmol)
and DIEA (33 mL, 20 mmol) in CH.sub.2Cl.sub.2 (20 mL) at 0.degree.
C. was added Fmoc-Cl (3.25 g, 5.3 mmol) over 2 min. The solution
was stirred at ambient temperature overnight. Solution was
concentrated in vacuo and the crude material was redissolved in
EtOAc (200 mL) and washed with water (2.times.70 mL) and brine
(1.times.100 mL), dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to provide the desired compound as a brown
solid (3.35 g, 83%). [M+H].sup.+=439.1; Ret. Time (Method A)=6.78
min.
Synthesis of 4-[4-(4-Methoxy-phenyl)-buta-1,3-diynyl]-benzoic acid
methyl ester (2)
[1272] Prepared as described in Method 1-B using 1c (2.0 g, 15.1
mmol) and methyl 4-(2,2-dibromovinyl)benzoate (4.00 g, 12.5 mmol).
Purified by normal phase flash chromatography (80 g SiO.sub.2,
0-50% EtOAc/Hex) to provide the desired compound 2 (940 mg, 26%) as
an off-white solid. LC-MS: [M+H].sup.+=Not observed; Ret. Time
(Method A) 7.76 min; .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 3.8
(3H, s), 3.9 (3H, s), 6.8 (2H, d), 7.45 (2H, d), 7.6 (2H, d), 8.0
(2H, d).
Synthesis of 4-[4-(4-Methoxy-phenyl)-buta-1,3-diynyl]-benzoic acid
(3)
[1273] Prepared as described in Method 2-A using compound 2 (470
mg, 1.62 mmol) to provide the desired compound 3 (412 mg, 92%) as
an off-white solid. LC-MS: [M+H].sup.+=Not observed; Ret. Time
(Method A) 6.34 min.
Synthesis of (2S,3R)-3-tert-Butoxycarbonylamino-2-
{4-[4-(4-methoxy-phenyl)-buta-1,3-diynyl]-benzoylamino}-butyric
acid methyl ester (4)
[1274] Prepared as described in Method 3-A using compound 3 (150
mg, 0.543 mmol) and (2S,3R)-3-methyl Dap.HCl (160 mg, 0.598 mmol)
to provide the desired compound 4 (448 mg, 168%) as a viscous amber
oil. LC-MS: [M+H].sup.+=491.2; Ret. Time (Method A) 6.99 min.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(4-methoxy-phenyl)-but-
a-1,3-diynyl]-benzamide (82-1)
[1275] Prepared as described in Method 5-A using compound 4 (266
mg, 0.543 mmol) to provide the crude product (119 mg, 56%) as an
off-white solid. Crude product was purified by Purification Method
A to provide the TFA salt of desired compound 82-1 (9 mg, 3%) as a
white solid. LC-MS: [M+H].sup.+=392.4; Ret. Time (Method A) 4.34
min.
TABLE-US-00021 Scale Yield Yield Purity [M + Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 H] time (min).sup.2 82-1
0.543 8.5 3.1 99.1 392.4 4.34 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
Each of the following compounds was synthesized as described above
using the appropriate phenyl acetylene (all commercially available
with the exception of 1a and 1b), amino acid and deprotection.
TABLE-US-00022 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 82-2 ##STR00169## 4.79 378.3 A 82-3 ##STR00170##
4.95 392.3 A 82-4 ##STR00171## 6.67 362.3 A 82-5 ##STR00172## 6.87
380.3 A 82-6 ##STR00173## 7.78 430.3 A 82-7 ##STR00174## 6.58 380.3
A 82-8 ##STR00175## 7.47 395.9 A 82-9 ##STR00176## 7.36 395.9 A
82-10 ##STR00177## 6.97 396.3 A 82-11 ##STR00178## 7.90 446.3 A
82-12 ##STR00179## 6.79 380.3 A 82-13 ##STR00180## 6.48 377.1 A
82-14 ##STR00181## 5.60 393.1 A 82-15 ##STR00182## 5.89 407.1 A
82-16 ##STR00183## 4.10 377.1 A 82-17 ##STR00184## 4.90 392.3 A
82-18 ##STR00185## 7.55 381.1 A 82-19 ##STR00186## 7.78 395.1 A
82-20 ##STR00187## 7.71 421.1 A 82-21 ##STR00188## 8.03 435.1 A
82-22 ##STR00189## 5.70 431.1 A 82-23 ##STR00190## 5.13 381.1 A
82-24 ##STR00191## A 82-25 ##STR00192## A 82-26 ##STR00193## A
82-27 ##STR00194## 7.05 394.3 A 82-28 ##STR00195## 7.01 394.3 A
82-29 ##STR00196## 6.83 394.3 A
Example 83
N--((S)-2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-[4-(4-hydroxy-phenyl-
)-buta-1,3-diynyl]-benzamide (83-1)
##STR00197##
[1276] Synthesis of (4-tert-butoxy-phenylethynyl)-trimethyl-silane
(2)
[1277] A 20 mL microwave tube was charged with a mixture of
1-bromo-4-tert-butoxybenzene 1 (1.0 g, 4.36 mmol), PdCl.sub.2(dppf)
(71 mg, 0.087 mmol), CuI (33 mg, 0.174 mmol), DIPA (0.924 mL, 6.55
mmol), and THF (15 mL). Tube was backfilled with nitrogen, sealed,
and irradiated in a microwave reactor (max. power 250 W) at
100.degree. C. for 5 min. Solution was diluted with water (200 mL)
and extracted with EtOAc (3.times.80 mL). Combined organic layers
were washed with water (1.times.100 mL) and brine (1.times.80 mL),
dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo. Crude
product was purified by normal phase flash chromatography (40 g
SiO.sub.2, 0-30% EtOAc/Hex) to provide the desired compound 2 (488
mg, 45%) as a clear colorless oil. LC-MS: [M+H].sup.+=Not observed;
Ret. Time (Method A) 7.87 min; .sup.1H NMR (250 MHz, CDCl.sub.3)
.delta. 0.2 (s, 9H), 1.3 (s, 9H), 6.9 (d, 2H), 7.4 (d, 2H).
Synthesis of 1-tert-Butoxy-4-ethynyl-benzene (3)
[1278] Prepared as described in Method 3-A using compound 2 (488
mg, 1.98 mmol) to provide the desired compound 3 (373 mg, 108%) as
a clear colorless oil. LC-MS: [M+H].sup.+=Not observed; Ret. Time
(Method A) 5.87 min; .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 1.3
(s, 9H), 3.0 (s, 1H), 6.9 (d, 2H), 7.4 (d, 2H).
Synthesis of 4-[4-(4-t-Butoxy-phenyl)-buta-1,3-diynyl]-benzoic acid
methyl ester (4)
[1279] Prepared as described in Method 1-B using compound 3 (373
mg, 2.14 mmol) and methyl 4-(2,2-dibromovinyl)benzoate (822 mg,
2.57 mmol) to provide the desired compound 4 (160 mg, 23%) as an
off-white solid. LC-MS: [M+H].sup.+=Not observed; Ret. Time (Method
A) 8.28 min; .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 1.35 (s,
9H), 3.9 (s, 3H), 6.9 (d, 2H), 7.45 (d, 2H), 7.6 (d, 2H), 8.0 (d,
2H).
Synthesis of 4-[4-(4-tert-Butoxy-phenyl)-buta-1,3-diynyl]-benzoic
acid (5)
[1280] Prepared as described in Method 2-A using compound 4 (160
mg, 0.482 mmol) to provide the desired compound 5 (130 mg, 85%) as
a slightly off-white solid. LC-MS: [M+H].sup.+=Not observed; Ret.
Time (Method A) 7.10 min.
Synthesis of (S)-3-tert-Butoxycarbonylamino-2-
{4-[4-(4-tert-butoxy-phenyl)-buta-1,3-diynyl]-benzoylamino}-3-methyl-buty-
ric acid methyl ester (6)
[1281] Prepared as described in Method 3-A using compound 5 (65 mg,
0.205 mmol) and (2S,3R)-3-methyl Dap (56 mg, 0.227 mmol) to provide
the desired compound 6 (117 mg, 104%) as a light amber solid.
LC-MS: [M+H].sup.+=547.2; Ret. Time (Method A) 8.23 min.
Synthesis of
N--((S)-2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-[4-(4-hydroxy-pheny-
l)-buta-1,3-diynyl]-benzamide (83-1)
[1282] Prepared as described in Method 5-A using compound 6 (112
mg, 0.205 mmol) to provide the desired compound 83-1. Crude
material was purified by Purification Method A to provide the TFA
salt of the desired compound 83-1 (36 mg, 35%) as a white solid.
LC-MS: [M+H].sup.+=391.8; Ret. Time (Method A) 3.65 min.
TABLE-US-00023 Scale Yield Yield Purity [M + Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 H] time (min).sup.2 83-1
0.205 36.2 34.9 99.2 391.8 3.65 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
The following compound was synthesized as described above.
TABLE-US-00024 Compound # Structure RT.sup.1 (min) [M + H] 83-2
##STR00198## 3.53 378.4 .sup.1Using LC-MS Analytical Method A.
Example 84
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(4-cyclopropoxy-phenyl)-
-buta-1,3-diynyl]-benzamide (84-1)
##STR00199##
[1283] Synthesis of 1-Bromo-4-(2-chloro-ethoxy)-benzene (1)
[1284] To a mixture of 4-bromophenol (2.0 g, 11.6 mmol) and
K.sub.2CO.sub.3 (3.20 g, 23.2 mmol) in DMF (50 mL) was added
3-chloroethyl p-toluenesulfonate (2.52 mL, 13.9 mmol) and the
mixture was stirred at 60.degree. C. for 16 h. Reaction mixture was
concentrated in vacuo, and the residue was partitioned between
water (200 mL) and CH.sub.2Cl.sub.2 (50 mL). Aqueous layer was
further extracted with CH.sub.2Cl.sub.2 (3.times.20 mL). Combined
organic layers were washed with water (30 mL) and brine (30 mL),
dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo to
provide the desired compound 1 (3.12 g, 115%) as a light amber oil.
LC-MS: [M+H.sup.+]=Not observed; Ret. Time (Method A) 5.83 min;
.sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 3.8 (t, 2H), 4.2 (t, 2H),
6.8 (d, 2H), 7.4 (d, 2H).
Synthesis of 1-Bromo-4-vinyloxy-benzene (2)
[1285] To a stirred solution of compound 1 (2.7 g, 11.6 mmol) in
THF (30 mL), at 0.degree. C., was added potassium tert-butoxide
(1.95 g, 17.3 mmol) in three portions. After 10 min the solution
was allowed to warm to ambient temperature and stirred for 16 h.
The solution was then concentrated in vacuo and partitioned between
water (150 mL) and CH.sub.2Cl.sub.2 (50 mL). Aqueous layer was
further extracted with CH.sub.2Cl.sub.2 (3.times.30 mL). Combined
organic layers were washed with water (40 mL) and brine (40 mL),
dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo. Crude
material was purified by normal phase flash chromatography (40 g
SiO.sub.2, 100% Hex) to provide the desired compound 2 (1.70 g,
74%) as a clear oil. LC-MS: [M+H].sup.+=Not observed; Ret. Time
(Method A) 5.95 min; .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 4.45
(dd, 1H), 4.75 (dd, 1H), 6.6 (dd, 1H), 6.85 (d, 2H), 7.4 (d,
2H).
Synthesis of 1-Bromo-4-cyclopropoxy-benzene (3)
[1286] To a stirred solution of compound 2 (1.70 g, 8.55 mmol) and
CH.sub.2I.sub.2 (5.52 mL, 68.4 mmol) in anhydrous
1,2-dichloroethane (75 mL), under N.sub.2 at 0.degree. C. was
cautiously added a solution of diethylzinc (1.0 M, 68.4 mL) in
hexanes. After 30 min the solution was allowed to warm to ambient
temperature and stirred for 64 h. Solution was then added
cautiously to saturated, aqueous NH.sub.4Cl (200 mL). The mixture
was shaken and layers separated, and aqueous layer was extracted
with CH.sub.2Cl.sub.2 (3.times.30 mL). Combined organic layers were
washed with aqueous HCl (1.0 N, 1.times.100 mL), water (1.times.100
mL), saturated NaHCO.sub.3 (aq) (1.times.100 mL) and brine
(1.times.80 mL), dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to. Crude product was purified by normal
phase flash chromatography (40 g SiO.sub.2, 100% Hex) to provide
the desired compound 3 (1.31 g, 72%) as a clear oil. LC-MS:
[M+H].sup.+=Not observed; Ret. Time (Method A) 5.87 min; .sup.1H
NMR (250 MHz, CDCl.sub.3) .delta. 0.75 (m, 4H), 3.7 (m, 1H), 6.9
(d, 2H), 7.4 (d, 2H).
Synthesis of (4-Cyclopropoxy-phenylethynyl)-trimethyl-silane
(4)
[1287] To a mixture of compound 3 (900 mg, 4.22 mmol),
PdCl.sub.2(Ph.sub.3P).sub.2 (150 mg, 0.211 mmol), CuI (80 mg, 0.420
mmol), Ph.sub.3P (1.44 g, 5.49 mmol), and DIPA (5 mL, 35.4 mmol) in
DMF (10 mL), in a 20 mL microwave tube, was added
ethynyltrimethylsilane (0.716 mL, 5.07 mmol). Tube was backfilled
with N.sub.2, sealed, and irradiated in a microwave reactor (max.
power 250 W) at 120.degree. C. for 15 min. Solution was diluted
with water (200 mL) and extracted with EtOAc (3.times.60 mL).
Combined organic layers were washed with water (1.times.100 mL) and
brine (1.times.60 mL), dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo. Crude product was purified by normal phase
flash chromatography (40 g silica gel, 0-10% EtOAc/Hex) to provide
a mixture of target compound 4 (840 mg) and triphenylphosphine.
LC-MS: [M+H].sup.+=Not observed; Ret. Time (Method A) 7.52 min.
Synthesis of 1-Cyclopropoxy-4-ethynyl-benzene (5)
[1288] To a solution of compound 4 (972 mg, 4.22 mmol) in MeOH (15
mL) was added NaOH (400 mg, 10 mmol) and the mixture was stirred at
ambient temperature for 20 min. Solution was diluted with water
(150 mL), cooled to 0.degree. C., neutralized with aqueous HCl (1.0
N), and extracted with CH.sub.2Cl.sub.2 (4.times.40 mL). Combined
organic layers were washed with water (1.times.80 mL) and brine
(1.times.80 mL), dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo. Crude material was purified by preparative
scale reverse-phase HPLC (Varian Microsorb 100-10 C-18 column
(50.times.300 mm), flow rate: 50 mL/min, mobile phase A: 0.1%
TFA/water, mobile phase B: 0.1% TFA/ACN, gradient elution from 10%
B to 80% B over 90 min, UV 254 nm monitor). Fractions containing
the desired product were combined and neutralized with NaHCO.sub.3
(aq). Acetonitrile was removed by evaporation in vacuo, and the
residual aqueous solution was extracted with EtOAc (3.times.40 mL).
The combined organic layers were washed with water (1.times.60 mL)
and brine (1.times.60 mL), dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to provide the desired compound 5 (34 mg, 5%)
as a clear oil. LC-MS: [M+H].sup.+=Not observed; Ret. Time (Method
A) 5.55 min; .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 0.75 (m,
4H), 3.0 (s, 1H), 3.7 (m, 1H), 7.0 (d, 2H), 7.4 (d, 2H).
Synthesis of 4-[4-(4-Cyclopropoxy-phenyl)-buta-1,3-diynyl]-benzoic
acid methyl ester (6)
[1289] Prepared as described in Method 1-B using compound 5 (34 mg,
0.216 mmol) and methyl 4-(2,2-dibromovinyl)benzoate (83 mg, 0.259
mmol) to provide the desired compound 6 (40 mg, 59%) as an
off-white solid. LC-MS: [M+H].sup.+=Not observed; Ret. Time (Method
A) 8.03 min.
Synthesis of 4-[4-(4-Cyclopropoxy-phenyl)-buta-1,3-diynyl]-benzoic
acid (7)
[1290] Prepared as described in Method 2-A using compound 6 (40 mg,
0.127 mmol) to provide the desired compound 7 (33 mg, 86%) as an
off-white solid. LC-MS: [M+H].sup.+=Not observed; Ret. Time (Method
A) 6.81 min.
Synthesis of (2S,3R)-3-tert-Butoxycarbonylamino-2-
{4-[4-(4-cyclopropoxy-phenyl)-buta-1,3-diynyl]-benzoylamino}-butyric
acid methyl ester (8)
[1291] Prepared as described in Method 3-A using compound 7 (33 mg,
0.109 mmol) and (2S,3R)-3-methyl Dap (32 mg, 0.120 mmol) to provide
the desired compound 8 (89 mg, 158%) as a viscous amber oil. LC-MS:
[M+H].sup.+=517.4; Ret. Time (Method A) 7.55 min.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(4-cyclopropoxy-phenyl-
)-buta-1,3-diynyl]-benzamide (84-1)
[1292] Prepared as described in Method 4-A followed by Method 5-A
using compound 8 (56 mg, 0.109 mmol) to provide the desired
compound 84-1. Crude material was purified by Purification Method A
to provide the TFA salt of the desired compound 84-1 (25 mg, 44%)
as a white solid. LC-MS: [M+H].sup.+=418.4; Ret. Time (Method A)
4.84 min.
TABLE-US-00025 Scale Yield Yield Purity [M + Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 H] time (min).sup.2 84-1
0.109 25.3 43.6 95.1 418.4 4.84 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
Example 85
Synthesis of
N--[(S)-2-(2-Cyclopropylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-(4-
-phenyl-buta-1,3-diynyl)-benzamide (85-1)
##STR00200## ##STR00201##
[1293] Synthesis of 4-(4-Phenyl-buta-1,3-diynyl)-benzoic acid
methyl ester (1)
[1294] Prepared as described in Method 1-B using phenylacetylene
(760 mg, 7.44 mmol) and methyl 4-(2,2-dibromovinyl)benzoate (1.70
g, 5.31 mmol) to provide the desired compound 1 (1.14 g, 82%) as an
off-white solid.
Synthesis of 4-(4-Phenyl-buta-1,3-diynyl)-benzoic acid (2)
[1295] Prepared as described in Method 2-A using compound 1 (1.14
g, 4.37 mmol) to provide the desired compound 2 (995 mg, 92%) as a
white solid.
Synthesis of
(S)-3-tert-Butoxycarbonylamino-2-[4-(4-phenyl-buta-1,3-diynyl)-benzoyl
amino]-propionic acid methyl ester (3)
[1296] Prepared as described in Method 3-A using compound 2 (100
mg, 0.40 mmol) and (2S) (Boc)Dap.HCl (111 mg, 0.42 mmol) to provide
the desired compound 3 (127 mg, 70%) as a white solid. LC-MS:
[M+H].sup.+=447.3; Ret. Time (Method A) 6.87 min.
Synthesis of
(S)-3-Amino-2-[4-(4-phenyl-buta-1,3-diynyl)-benzoylamino]-propionic
acid methyl ester (4)
[1297] Prepared as described in Method 4-A using compound 3 (127
mg, 0.28 mmol) to provide the desired compound 4 (100 mg, 95%).
LC-MS: [M+H].sup.+=347.4; Ret. Time (Method A) 4.82 min.
Synthesis of
(S)-3-[2-(tert-Butoxycarbonyl-cyclopropyl-amino)-acetylamino]-2-[4-(4-phe-
nyl-buta-1,3-diynyl)-benzoylamino]-propionic acid methyl ester
(5)
[1298] Prepared as described in Method 3-A using compound 4 (100
mg, 0.40 mmol) and N-cyclopropyl-N-Boc-glycine.HCl (111 mg, 0.42
mmol) to provide the desired compound 3 (127 mg, 70%). LC-MS: Ret.
Time (Method A) 5.34 min.
Synthesis of (S)-3-(2-Cyclopropyl
amino-acetylamino)-2-[4-(4-phenyl-buta-1,3-diynyl)-benzoylamino]-propioni-
c acid methyl ester (6)
[1299] Prepared as described in Method 4-A using compound 5 (127
mg, 0.23 mmol) to provide the desired compound 6. LC-MS:
[M+H].sup.+=444.5; Ret. Time (Method A) 4.99 min.
Synthesis of
N--[(S)-2-(2-Cyclopropylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-(4-
-phenyl-buta-1,3-diynyl)-benzamide (85-1)
[1300] Prepared as described in Method 5-B using compound 6 (235
mg, 0.40 mmol) to provide the desired compound 85-1. Crude material
was purified by Purification Method A to provide the TFA salt of
the desired compound 85-1 (16 mg, 7% yield) as a white solid.
LC-MS: [M+H].sup.+=445.1; Ret. Time (Method A) 6.75 min.
TABLE-US-00026 Retention Scale Yield Yield Purity [M + time
Compound (mmol).sup.1 (mg) (%).sup.1 (%).sup.2 H] (min).sup.2 85-1
0.4 15.5 6.9 98.4 445.1 6.75 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
The following compound was synthesized as described above using the
appropriate amino acid and deprotection.
TABLE-US-00027 HPLC- MH.sup.+ Ret. Time MS Compound # Structure
(m/z) (min) Method 85-2 ##STR00202## 459.1 6.84 A
Example 86
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-{4-[(2,2-difluoro-ethy-
lamino)-methyl]-phenyl}-buta-1,3-diynyl)-benzamide (86-1)
##STR00203## ##STR00204##
[1301] Synthesis of
(2S,3R)-3-tert-Butoxycarbonylamino-2-{4-[4-(4-hydroxymethyl-phenyl)-buta--
1,3-diynyl]-benzoylamino}-butyric acid methyl ester (2)
[1302] Prepared as described in Method 3-A using compound 1 (390
mg, 1.4 mmol) and (S)-Boc-Me-Dap-OMe.HCl (403 mg, 1.5 mmol) to
provide the desired compound 2 (660 mg, 96%). LC-MS:
[M+H].sup.+=491.2; Ret. Time (Method A) 5.98 min.
Synthesis of
(2S,3R)-3-tert-Butoxycarbonylamino-2-[4-(4-{4-[(2,2-difluoro-ethylamino)--
methyl]-henyl}-buta-1,3-diynyl)-benzoylamino]-butyric acid methyl
ester (4)
[1303] To a solution of compound 2 (660 mg, 1.35 mmol) and TEA
(0.42 mL, 3.0 mmol) in CH.sub.2Cl.sub.2 (6 mL) at 0.degree. C.,
methanesulfonyl chloride (113 mg, 1.45 mmol) was added. The
solution was then allowed to warm to ambient temperature and
stirred for 1 h. To this solution containing compound 3 was added
2,2-difluoroethylamine (273 mg, 3.37 mmol) dropwise and stirred
overnight at 50.degree. C. All volatiles were removed in vacuo and
the crude material was diluted with EtOAc (100 mL) and washed with
water (2.times.40 mL), brine (1.times.40 mL), dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo to provide
the desired compound 4. LC-MS: [M+H].sup.+=554.5; Ret. Time (Method
A) 4.81 min.
Synthesis of (2S,3R)-3-Amino-2-
[4-(4-{4-[(2,2-difluoro-ethylamino)-methyl]-phenyl}-buta-1,3-diynyl)-benz-
oylamino]-butyric acid methyl ester (5)
[1304] Prepared as described in Method 4-A using compound 4 (374
mg, 0.68 mmol) to provide the desired compound 5. LC-MS:
[M+H].sup.+=454.8; Ret. Time (Method A) 3.07 min.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-{4-[(2,2-difluoro-ethy-
l amino)-methyl]-phenyl}-buta-1,3-diynyl)-benzamide (86-1)
[1305] Prepared as described in Method 5-A using compound 5 (355
mg, 0.675 mmol) to provide the desired compound 86-1. Crude
material was purified by Purification Method A to provide the TFA
salt of the desired compound 86-1 (76 mg, 16%) as a white solid.
LC-MS: [M+H].sup.+=455.8; Ret. Time (Method A) 3.79 min.
TABLE-US-00028 Retention Scale Yield Yield Purity [M + time
Compound (mmol).sup.1 (mg) (%).sup.1 (%).sup.2 H] (min).sup.2 86-1
0.7 75.7 18 98.6 455.8 3.79 .sup.1Based on the amount of carboxylic
acid used in the coupling reaction. .sup.2Using LC-MS Analytical
Method A.
Each of the following compounds was synthesized as described above
using the appropriate amine and amino acid.
TABLE-US-00029 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 86-2 ##STR00205## 3.71 461.1 A 86-3 ##STR00206##
4.01 431.5 A 86-4 ##STR00207## 3.38 475.9 A 86-5 ##STR00208## 3.75
437.1 A 86-6 ##STR00209## 4.22 509.1 A 86-7 ##STR00210## 4.42 523.5
A
Example 87
Synthesis of
N-(2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-[4-(4-cyclopropylaminome-
thyl-phenyl)-buta-1,3-diynyl]-benzamide (87-1)
##STR00211## ##STR00212##
[1306] Synthesis of
Cyclopropyl-(4-trimethylsilanylethynyl-benzyl)-amine (2)
[1307] To a solution of compound 1 (10 g, 48.9 mmol) and DIEA (16
mL, 96.5 mmol) in CH.sub.2Cl.sub.2 (25 mL) at 0.degree. C., was
added methanesulfonyl chloride (4.56 mL, 58.7 mmol) dropwise. The
solution was allowed to warm to ambient temperature and stirred for
1 h. Cyclopropyl amine (25.69 g, 450 mmol) was added dropwise and
resulting solution was stirred overnight at ambient temperature.
The solution was concentrated in vacuo and the crude material was
diluted with EtOAc (200 mL), washed with water (2.times.70 mL),
brine (1.times.100 mL) and dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo. The crude material was purified by normal
phase chromatography (120 g SiO.sub.2, CHCl.sub.3/MeOH) to provide
the desired compound 2 (3.6 g, 30%) as brown liquid. LC-MS:
[M+H].sup.+=244.2; Ret. Time (Method A) 4.86 min.
Synthesis of
Cyclopropyl-(4-trimethylsilanylethynyl-benzyl)-carbamic acid
tert-butyl ester (3)
[1308] To a solution of compound 2 (3.6 g, 14.8 mmol) and Et.sub.3N
(4.17 mL, 30 mmol) in CH.sub.2Cl.sub.2 (15 mL), was added
Boc.sub.2O (3.55 g, 16.26 mmol) and the resulting mixture was
stirred for 2 h at ambient temperature. The solution was
concentrated in vacuo and the crude material was diluted with EtOAc
(150 mL), washed with water (2.times.70 mL), brine (1.times.80 mL)
and dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo to
provide the desired compound 3 (4.32 g) as a brown oil. LC-MS:
[M+H].sup.+=Not observed; Ret. Time (Method A) 8.31 min.
Synthesis of Cyclopropyl-(4-ethynyl-benzyl)-carbamic acid
tert-butyl ester (4)
[1309] To a solution of NaOH (0.20 g, 5.0 mmol) in MeOH (75 mL),
was added compound 3 (4.32 g, 12.6 mmol) and resulting mixture was
stirred for 1 h at ambient temperature. The solution was
concentrated in vacuo. and the crude material was diluted with
EtOAc (120 mL), washed with water (2.times.30 mL), brine
(1.times.50 mL), dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo. The crude material was purified by normal
phase flash chromatography (40 g SiO.sub.2, EtOAc/Hex) to provide
the desired compound 4 (1.58 g, 47%) as white solid. LC-MS:
[M+H].sup.+=Not observed; Ret. Time (Method A) 6.38 min.
Synthesis of
4-(4-{4-[(tert-Butoxycarbonyl-cyclopropyl-amino)-methyl]-phenyl}-buta-1,3-
-diynyl)-benzoic acid methyl ester (5)
[1310] Prepared as described in Method 1-B using 4 (1.07 g, 3.94
mmol) and methyl 4-(2,2-dibromovinyl)benzoate (1.38 g, 4.33 mmol)
to provide the desired compound 5 (615 mg, 36%) as a white solid.
LC-MS: [M+H].sup.+=430.4; Ret. Time (Method A) 8.73 min.
Synthesis of 4-(4-
{4-[(tert-Butoxycarbonyl-cyclopropyl-amino)-methyl]-phenyl}-buta-1,3-diyn-
yl)-benzoic acid (6)
[1311] Prepared as described in Method 2-A using compound 5 (615
mg, 1.4 mmol) to provide the desired compound 6 (509 mg, 88%) as a
white solid. LC-MS: [M+H].sup.+=416.5; Ret. Time (Method A) 7.44
min.
Synthesis of 3-tert-Butoxycarbonylamino-2-[4-(4-
{4-[(tert-butoxycarbonyl-cyclopropyl-amino)-methyl]-phenyl}-buta-1,3-diyn-
yl)-benzoylamino]-3-methyl-butyric acid methyl ester (7)
[1312] Prepared as described in Method 3-A using compound 6 (400
mg, 0.96 mmol) and (25)-3-dimethylDap-(OMe) (249 mg, 1.01 mmol) to
provide the desired compound 6 (585 mg, 96%) as a white solid.
LC-MS: [M+H].sup.+=644.5; Ret. Time (Method A) 8.47 min.
Synthesis of
3-Amino-2-{4-[4-(4-cyclopropylaminomethyl-phenyl)-buta-1,3-diynyl]-benzoy-
lamino}-3-methyl-butyric acid methyl ester (8)
[1313] Prepared as described in Method 4-A using compound 7 (585
mg, 0.91 mmol) to provide the desired compound 8 (407 mg). LC-MS:
[M+H].sup.+=444.5; Ret. Time (Method A) 3.42 min.
Synthesis of
N-(2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-[4-(4-cyclopropylaminome-
thyl-phenyl)-buta-1,3-diynyl]-benzamide (87-1)
[1314] Prepared as described in Method 5-A using compound 8 (407
mg, 0.91 mmol) to provide the crude compound 87-1. Crude product
was purified by Purification Method A to provide the TFA salt of
desired compound 87-1 (266 mg, 18%) as a white solid. LC-MS:
[M+H].sup.+=445.5; Ret. Time (Method A) 3.10 min.
TABLE-US-00030 Retention Scale Yield Yield Purity [M + time
Compound (mmol).sup.1 (mg) (%).sup.1 (%).sup.2 H] (min).sup.2 87-1
0.96 266 53.3 99.6 445.1 3.10 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
Each of the following compounds was synthesized as described above
using the appropriate amino acid.
TABLE-US-00031 Ret. HPLC- Compound [MH.sup.+] Time Ms # Structure
(m/z) (min) Method 87-2 ##STR00213## 432.3 4.64 A 87-3 ##STR00214##
446.3 4.90 A 87-4 ##STR00215## 4.07 445.5 A
Example 88
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(3-methyl-3H-imidazol--
4-yl)-buta-1,3-diynyl]-benzamide (88-1)
##STR00216## ##STR00217##
[1315] Synthesis of
4-[4-(3-Methyl-3H-imidazol-4-yl)-buta-1,3-diynyl]-benzoic acid
methyl ester (2)
[1316] Prepared as described in Method 1-B using
5-ethynyl-1-methyl-1H-imidazole (220 mg, 2.10 mmol) and methyl
4-(2,2-dibromovinyl)benzoate (700 mg, 2.18 mmol) and purified by
Purification Method B to provide the TFA salt of the desired
compound 2 (482 mg, 59%) as a yellow solid. LC-MS:
[M+H].sup.+=265.1; Ret. Time (Method A) 3.97 min.
Synthesis of
4-[4-(3-Methyl-3H-imidazol-4-yl)-buta-1,3-diynyl]-benzoic acid
(3)
[1317] Prepared as described in Method 2-A (Method 2-B for pyridyl
derivatives) using compound 2 (482 mg, 1.83 mmol) to provide the
desired compound 3 (334 mg, 73%) as an off-white solid. LC-MS:
[M+H].sup.+=250.9; Ret. Time (Method A) 3.13 min.
Synthesis of
(2S,3R)-3-(9H-Fluoren-9-ylmethoxycarbonylamino)-2-{4-[4-(3-methyl-3H-imid-
azol-4-yl)-buta-1,3-diynyl]-benzoylamino}-butyric acid methyl ester
(4)
[1318] Prepared as described in Method 3-A using compound 3 (100
mg, 0.40 mmol) and (2S,3R)Fmoc-3-Me-Dap(OMe) HCl (164 mg, 0.67
mmol) to provide the desired compound 4 (235 mg). LC-MS:
[M+H].sup.+=586.7; Ret. Time (Method A) 5.21 min.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(3-methyl-3H-imidazol--
4-yl)-buta-1,3-diynyl]-benzamide (88-1)
TABLE-US-00032 [1319] Reagent MW, d Eq. mmol mg, ml Compound 4
586.65 1.0 0.4 235 mg NH2OH .times. HCl 69.49 6.14 1.72 120 mg 25%
MeONa in MeOH 0.5 mL THF 1 mL MeOH 2.5 mL
[1320] The Compound 88-1 was made using the General Method for
hydroxamate formation. Check of a sample by HPLC-MS showed a major
product peak (Ret. time (Method A) 2.03 min, MH.sup.+=366.2). Crude
product was purified by preparative scale reverse-phase HPLC
(Phenomenex Gemini C-18 column, 110 .ANG., 30.times.100 mm, flow
rate: 20 mL/min, mobile phase A: 0.1% TFA/water, mobile phase B:
0.1% TFA/ACN, gradient elution from 15% B to 40% B over 60 min, MS
detection). Fractions containing the desired product were combined
and lyophilized to provide the trifluoroacetate salt of target
compound 88-1 (112.4 mg, 47.3% yield) as a white solid. LC-MS: RT
(Method A) 2.13 min; [M+H] 366.3 (C.sub.19H.sub.19N.sub.5O.sub.3+H,
requires 366.4).
TABLE-US-00033 Retention Scale Yield Yield Purity [M + time
Compound (mmol).sup.1 (mg) (%).sup.1 (%).sup.2 H] (min).sup.2 88-1
0.4 112.4 47.3 98.8 366.2 2.13 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
##STR00218##
tert-Butyl thiazol-2-ylcarbamate 2
[1321] A solution of thiazol-2-amine (10.0 g, 0.10 mol, 1.0 equiv),
(Boc.sub.2)O (26.2 g, 0.12 mol, 1.2 equiv), and DIPEA (25.8 g, 0.20
mol, 2.0 equiv) in THF (150 mL) was stirred at 50.degree. C. for 12
hours. The reaction mixture was concentrated in vacuum and EtOAc
(300 mL) was added. Then, the organic layer was washed by water
(250 mL.times.2) and brine (250 mL.times.2), dried (MgSO.sub.4),
filtrated, concentrated in vacuum to give target product (6.3 g,
31.5%). [M+1]: 201.1
tert-Butyl 5-bromothiazol-2-ylcarbamate 3
[1322] A suspension of NBS (6.2 g, 34.6 mmol, 1.1 equiv) and
tert-butyl thiazol-2-ylcarbamate (6.3 g, 31.5 mmol, 1.0 equiv) in
THF (100 mL) was stirred at room temperature for 12 hours. Then,
the reaction mixture was filtrated and purified by column
chromatography to give target compound (6.5 g, 73.9%)
tert-Butyl 5-((trimethylsilyl)ethynyl)thiazol-2-ylcarbamate 4
[1323] A mixture of tert-butyl 5-bromothiazol-2-ylcarbamate (6.5 g,
23.3 mmol, 1.0 equiv), ethynyltrimethylsilane (3.4 g, 34.9 mmol,
1.5 equiv), PdCl.sub.2(PPh.sub.3).sub.2 (0.16 g, 0.23 mmol, 0.01
equiv), CuI (0.14 mg, 0.84 mmol, 0.03 equiv) in TEA (50 mL) was
stirred at 80.degree. C. for 4 hours under nitrogen. The reaction
mixture was extracted with EtOAc (500 ml) and organics was washed
with water (200 mL.times.2) and brine (200 mL) Organic layer was
dried over Na.sub.2SO.sub.4 and evaporated. The residue was
purified by column chromatography to give target compound (1.5 g,
30%).
tert-Butyl 5-ethynylthiazol-2-ylcarbamate 5
[1324] To a solution of tert-butyl
5-((trimethylsilyl)ethynyl)thiazol-2-ylcarbamate (1.50 g, 5.1 mmol,
1.0 equiv) in THF (50 mL) was treated with KOH/methanol (10.2 mmol,
0.57 g/10 mL, 2 equiv) slowly below 10.degree. C., then the mixture
was allowed to react at ambient temperature for 1 hours. Then, the
reaction mixture concentrated in vacuum. The residue was dissolved
in EtOAc (100 mL). The organic layer was washed with water (50
mL.times.2) and brine (50 mL), dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuum. The residue was dried in
vacuum overnight to provide the title compound (1.1 g, 96%)
Methyl
4-((2-(tert-butoxycarbonylamino)thiazol-5-yl)buta-1,3-diynyl)benzoa-
te 6
[1325] A mixture of methyl 4-(2,2-dibromovinyl)benzoate (1.10 g,
5.4 mmol, 1.1 equiv), tert-butyl 5-ethynylthiazol-2-ylcarbamate
(1.70 g, 4.9 mmol, 1.0 equiv), Pd.sub.2(dba).sub.3 (9 mg, 0.01
mmol, 0.02 equiv), TMPP (14 mg, 0.02 mmol, 0.04 equiv) and TEA (97
mg, 9.8 mmol, 2 equiv) in DMF (20 ml) was stirred at 45.degree. C.
for 12 hours under nitrogen. The reaction mixture was extracted
with EtOAc (100 ml) and organics was washed with water (100
ml.times.2) and brine (50 ml). Organic layer was dried over
Na.sub.2SO.sub.4 and evaporated. The residue was purified by column
chromatography to give target compound (0.9 g, 46%). .sup.1H-NMR:
(400 MHz, DMSO-d.sub.6): .delta. 1.50 (s, 9H), 3.87 (s, 3H), 7.74
(dd, J=2.4 Hz, 6.4 Hz), 7.93 (s, 1H), 7.99 (dd, J=2.0 Hz, 6.0 Hz),
12.09 (s, 1H).
4-((2-(tert-Butoxycarbonylamino)thiazol-5-yl)buta-1,3-diynyl)benzoic
acid 7
[1326] To a solution of
methyl-4-((2-(tert-butoxycarbonylamino)thiazol-5-yl)buta-1,3-diynyl)
benzoate (0.9 g, 2.4 mmol, 1 equiv) in THF (10 mL) and MeOH (10
mL), 2 M NaOH aq. (2.0 ml) was added and the reaction was stirred
at room temperature for 1 h. After cooling the reaction mixture was
acidified to a pH of 1-2 with 10% HCl. The formed solid was
collected by filtration, washed with water (2.times.10 ml) and
ice-cold MeOH (10 ml). The filtration was dried in vacuum overnight
to give the final product (650 mg, 71%). [M+1]: 369.0; .sup.1H-NMR:
(400 MHz, DMSO-d.sub.6): .delta. 1.50 (s, 9H), 7.68 (d, J=6.0 Hz),
7.91 (s, 1H), 7.97 (d, J=6.4 Hz). Compound 7 was used for synthesis
of compound 88-17 and 88-18 using the appropriate amino acids.
Each of the following compounds was synthesized as described above
using the appropriate amino acid and deprotection.
TABLE-US-00034 Ret. HPLC- Compound Time MH.sup.+ MS # Structure
(min) (m/z) Method 88-2 ##STR00219## 2.67 363.5 A 88-3 ##STR00220##
3.44 363.5 A 88-4 ##STR00221## 3.77 363.5 A 88-5 ##STR00222## 4.30
378.3 A 88-6 ##STR00223## 2.36 377.1 A 88-7 ##STR00224## 3.41 378.3
A 88-8 ##STR00225## 3.71 377.8 A 88-9 ##STR00226## 2.84 367.1 A
88-10 ##STR00227## 3.13 381.1 A 88-11 ##STR00228## .sup. 4.82.sup.1
383.3 A 88-12 ##STR00229## .sup. 6.22.sup.2 367.9 B 88-13
##STR00230## .sup. 4.36.sup.2 382.0 B 88-14 ##STR00231## 4.77 383.2
A 88-15 ##STR00232## 4.31 382.0 B 88-16 ##STR00233## 4.95 383.1 A
88-17 ##STR00234## 3.08 383.9 A 88-18 ##STR00235## 3.08 383.9 A
88-19 ##STR00236## 401.4 88-20 ##STR00237## 405 expted 88-21
##STR00238## 366.1 expted A 88-22 ##STR00239## 382 expted A 88-23
##STR00240## 366.1 expted 88-24 ##STR00241## 382 expted
Example 89
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-methyl-1H-pyraz-
ol-4-yl)buta-1,3-diynyl)benzamide
##STR00242##
[1327] Synthesis of 4-(2,2-dibromovinyl)-1-methyl-1H-pyrazole
(1)
[1328] The 1-methyl-1H-pyrazole-4-carbaldehyde (1.00 g, 9.08 mmol)
and carbon tetrabromide (3.16 g, 9.54 mmol) were dissolved in
CH.sub.2Cl.sub.2 (27 mL) and the solution was cooled to 0.degree.
C. To this chilled solution was then added PPh.sub.3 (5.01 g, 19.1
mmol) in four portions over 5 min. The solution was then allowed to
warm to ambient temperature for 18 h. The solution was diluted with
hexanes (30 mL) and stirred for 15 min. The slurry was filtered and
the filtrate was concentrated in vacuo and was purified by flash
chromatography (50% EtOAc/Hex) to provide the desired product 1 as
a white solid (1.72 g, 71%). LC-MS [M+H].sup.+=266.8 (Theoretical,
C.sub.6H.sub.7Br.sub.2N.sub.2.sup.+=266.9).
Synthesis of methyl
4-((1-methyl-1H-pyrazol-4-yl)buta-1,3-diynyl)benzoate (2)
[1329] The methyl 4-ethynylbenzoate (1.09 g, 6.79 mmol) and
compound 1 (1.72 g, 6.47 mmol) were dissolved in DMF (65 mL) and
this solution was deoxygenated by bubbling N.sub.2 through for 10
min. To this deoxygenated solution was then added Et.sub.3N (1.3
mL, 9.39 mmol). N.sub.2 was then bubbled through for an additional
5 min followed by addition of Pd.sub.2(dba).sub.3 (0.060 g, 0.065
mmol) and tri(4-methoxyphenyl)phosphine (0.091 g, 0.259 mmol). The
dark brown solution was then allowed to stir at 80.degree. C. for
18 h then cooled to ambient temperature. The solution was diluted
with EtOAc (100 mL), washed with deionized water (3.times.50 mL)
and brine (1.times.50 mL), dried (MgSO.sub.4), filtered and
concentrated in vacuo. The crude oil was purified by flash
chromatography (0-50% EtOAc/CH.sub.2Cl.sub.2) to provide the
desired product 2 as a yellow solid (1.03 g, 60%). LC-MS
[M+H].sup.+=265.0 (Theoretical,
C.sub.16H.sub.13N.sub.2O.sub.2.sup.+=265.1).
Synthesis of 4-((1-methyl-1H-pyrazol-4-yl)buta-1,3-diynyl)benzoic
acid (3)
[1330] To a solution of compound 2 (1.03 g, 3.90 mmol) in a mixture
of THF (13 mL), MeOH (13 mL), and water (13 mL) was added LiOH
monohydrate (0.491 g, 11.7 mmol) in one portion. The solution was
allowed to stir at ambient temperature for 18 h. The pH of the
solution was adjusted with aqueous HCl (1.0 N) and aqueous
NaHCO.sub.3 (sat.) to pH.about.7.5. The resulting solution was then
extracted with EtOAc (3.times.100 mL), dried (MgSO.sub.4), filtered
and concentrated in vacuo to provide the desired product 3 (0.400
g, 41%) as an off white solid. LC-MS [M+H].sup.+=251.0
(Theoretical, C.sub.15H.sub.11N.sub.2O.sub.2.sup.+=251.1).
Synthesis of (2S,3R)-methyl
3-(tert-butoxycarbonylamino)-2-(4-((1-methyl-1H-pyrazol-4-yl)buta-1,3-diy-
nyl)benzamido)butanoate (4)
[1331] Compound 3 (0.400 g, 1.60 mmol), (2S,3R)-methyl
3-(Boc)-2-aminobutanoate HCl (0.473 g, 1.76 mmol), EDC (0.613 g,
3.20 mmol) and HOBT (0.432 g, 3.20 mmol) were slurried in anhydrous
CH.sub.2Cl.sub.2 (16 mL). To this slurry was added
N,N-diisopropylethylamine (1.04 mL, 6.40 mmol) in one portion. The
solution was then allowed to stir at ambient temperature for 18 h.
The solution was then concentrated in vacuo and the crude solid was
purified by flash chromatography (0-50% EtOAc/CH.sub.2Cl.sub.2) to
provide the desired product 4 (0.785 g, 81%) as an off white solid.
.sup.1H NMR (DMSO) .delta. 8.43 (d, J=8.4, 1H), 8.22 (s, 1H), 7.91
(d, J=7.9, 2H) 7.80 (s, 1H), 7.72 (d, J=7.3, 2H) 7.00 (d, J=9.7,
1H), 4.62 (dd, J=4.2, 8.2, 1H) 4.22-4.27 (m, 1H) 3.86 (s, 3H), 3.61
(s, 3H), 1.36 (s, 9H), 1.11 (d, J=7.0, 3H).
Synthesis of (2S,3R)-methyl
3-amino-2-(4-((1-methyl-1H-pyrazol-4-yl)buta-1,3-diynyl)benzamido)butanoa-
te (5)
[1332] To a solution of compound 4 (0.286 g, 0.616 mmol) in of
CH.sub.2Cl.sub.2 (10 mL) was added TFA (2 mL) slowly. The solution
was allowed to stir at ambient temperature for 1 h then
concentrated in vacuo. The thick oil was then azeotroped with
CH.sub.2Cl.sub.2 (3.times.) to provide the TFA salt of the desired
product 5 (0.284 g, 100%) as an off white solid. LC-MS
[M+H].sup.+=365.1 (Theoretical,
C.sub.20H.sub.21N.sub.4O.sub.3.sup.+=365.2).
Synthesis of
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((1-methyl-1H-pyra-
zol-4-yl)buta-1,3-diynyl)benzamide (89-1)
[1333] The TFA salt of 5 (0.284 g, 0.616 mmol) was dissolved in
isopropyl alcohol (6 mL) and the hydroxylamine solution (0.81 mL,
12.3 mmol) was added in one portion at ambient temperature and the
solution was allowed to stir for 18 h at ambient temperature. The
volatiles were removed in vacuo and the resulting crude material
was purified by reverse phase HPLC (5-30% MeCN/H.sub.2O, w/0.1%
TFA) then lyophilized to dryness to provide the desired product
(89-1) (0.090 g, 40%) as a white solid; LC-MS [M+H].sup.+=366.1
(Theoretical, C.sub.19H.sub.20N.sub.5O.sub.3.sup.+=366.2).
Each of the following compounds was synthesized as described
above.
TABLE-US-00035 Ret. HPLC- Time MH.sup.+ MS Compound # Structure
(min) (m/z) Method 89-2 ##STR00243## 4.71 380.3 A 89-3 ##STR00244##
5.43 381.1 A 89-4 ##STR00245## 3.99 364.3 A 89-5 ##STR00246## 2.46
380.3 A 89-6 ##STR00247## 4.26 378.3 A 89-7 ##STR00248## 4.96 379.1
A
Example 90
Synthesis of
(S)-4-((1H-pyrazol-4-yl)buta-1,3-diynyl)-N-(3-amino-1-(hydroxyamino)-3-me-
thyl-1-oxobutan-2-yl)benzamide (90-1)
##STR00249##
[1334] Synthesis of tert-butyl 4-iodo-1H-pyrazole-1-carboxylate
(1)
[1335] NaH (247 mg, 6.18 mmol) was added to the DMF (50 ml)
solution of 4-iodo-1H-pyrazole (1.0 g, 5.15 mmol) at 0.degree. C.
The reaction was stirred at 0.degree. C. in 30 min. (Boc).sub.2O
(1.68 g, 7.76 mmol) was added to the reaction at 0.degree. C. The
reaction was warmed to r.t. nd stirred overnight. H.sub.2O (200 ml)
was added to quench the reaction. The mixture was extracted with
EtOAc (3.times.200 ml). The combined EtOAc extracts was washed with
H.sub.2O (2.times.200 ml), brine (200 ml) and dried with
Na.sub.2SO.sub.4 the crude product was purified with ISCO normal
phase column (0-20% EtOAc/DCM). Compound 20 (1.3 g) was obtained in
the yield of 86%.
Synthesis of tert-butyl
4-((trimethylsilyl)ethynyl)-1H-pyrazole-1-carboxylate (2)
[1336] THF was degassed by passing through N.sub.2 gas for 30 min.
TEA (6.0 ml, 11.5 mmol) was added to the THF solution (20 ml) of
Compound 1 (1.69 g, 5.75 mmol), Trimethylsilylethyne (845 mg, 8.63
mml), PdCl.sub.2 (PPh.sub.3).sub.2 (404 mg, 0575 mmol) and CuI (109
mg, 0.575 mmol). The reaction was stirred overnight. The reaction
was diluted with EtOAc and filtered through celite. The organic
solution was washed with H.sub.2O, brine and dried with
Na.sub.2SO.sub.4. The crude product was purified with ISCO normal
phase column The crude product was purified with ISCO normal phase
column (0-2% EtOAc/DCM). Compound 21 (1.02 g, 67.2%) was
obtained
Synthesis of tert-butyl 4-ethynyl-1H-pyrazole-1-carboxylate (3)
[1337] TBAF (5.2 ml, 1.0M in THF) was added to the THF solution (10
ml) of Compound 2 (1.02 g, 3.46 mmol) at 0.degree. C. The reaction
was stirred at 0.degree. C. for 10 min. The THF was removed and the
residue was dissolved in EtOAc. The EtOAc solution was washed with
H.sub.2O, brine and dried with Na.sub.2SO.sub.2. The crude produce
was purified with ISCO normal phase column. The crude product was
purified with ISCO normal phase column (0-30% EtOAc/hexane).
Compound 3 (362.3 mg, 54.5%) was obtained.
Synthesis of methyl 4-(bromoethynyl)benzoate (4)
[1338] NBS (13.4 g, 75 mmol) was added to the acetone solution (250
ml) of 4-ethynyl-benzoic methyl ester (8 g, 50 mmol) and
CF.sub.3COOAg (850 mg, 5 mmol). The reaction was stirred at r.t for
2 hrs. The reaction was poured into ice-water (500 ml) and stirred
for 30 min. After separation, the H.sub.2O layer was extracted with
EtOAc (300 ml.times.3). The combined EtOAc layers was washed with
H.sub.2O (2.times.200 ml) and brine (200 ml) and dried with
Na.sub.2SO.sub.4. The crude product was purified with ISCO normal
phase column (0-50% EtOAc/hexane). Compound 27 (12.0 g, 100%) was
obtained.
Synthesis of methyl
4-((1-methyl-1H-pyrazol-4-yl)buta-1,3-diynyl)benzoate (5)
[1339] THF was degassed by passing through N.sub.2 gas for 30 min.
TEA was added to the THF solution (10 ml) of Compound 3 (362 mg,
1.89 mmol), Compound 4 (666 mg, 2.27 mmol), PdCl.sub.2
(PPh.sub.2).sub.2 (133 mg, 0.189 mmol), PPh.sub.3 (25 mg, 0.095
mmol) and CuI (36 mg, 0.189 mmol). The reaction was stirred at r.t.
for 30 min followed by the addition of CuI. The reaction was heated
to 45.degree. C. overnight. The reaction was diluted with EtOAc and
filtered through celite. The organic solution was washed with
H.sub.2O, brine and dried with Na.sub.2SO.sub.4. The crude product
was purified with ISCO normal phase column. The crude product was
purified with ISCO normal phase column (0-50% EtOAc/hexane).
Compound 28 (150 mg, 19.7%) was obtained
Synthesis of
4-((1-(tert-butoxycarbonyl)-1H-pyrazol-4-yl)buta-1,3-diynyl)benzoic
acid (6)
[1340] Compound 6 (120 mg, 94%) was made using the General Method
for basic hydrolysis used to the next step without further
purification.
Synthesis of methyl
3-(tert-butoxycarbonylamino)-2-(4-(imidazo[1,2-a]pyridin-6-ylbuta-1,3-diy-
nyl)benzamido)-3-methylbutanoate (7)
[1341] Compound 7 (100 mg, 48%) was coupled to BocDAP-OMe using the
General Method for HATU coupling used in the next step without
purification.
Synthesis of (S)-methyl
2-(4-((1H-pyrazol-4-yl)buta-1,3-diynyl)benzamido)-3-amino-3-methylbutanoa-
te (8)
[1342] The Compound 8 was made using the General Method for Boc
deprotection and used on next step without purification. Compound 8
(65 mg, 100%)
Synthesis of
(S)-4-((1H-pyrazol-4-yl)buta-1,3-diynyl)-N-(3-amino-1-(hydroxyamino)-3-me-
thyl-1-oxobutan-2-yl)benzamide (90-1)
[1343] The target product (33 mg, 50%, m+z=366.66) was prepared by
following General Method 3-A for hydroxamate Method (Hydroxyamide
formation, aqueous).
The following compounds were synthesized by using above procedure
with corresponding acid and amine.
TABLE-US-00036 Ret. HPLC- Compound Time MH.sup.+ MS # Structure
(min) (m/z) Method 90-2 ##STR00250## 393.7 A 90-3 ##STR00251##
416.6 A
Example 91
N--((S)-2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-hexa-1,3-diynyl-benz-
amide (91-1)
##STR00252##
[1344] Synthesis of 4-Hexa-1,3-diynyl-benzoic acid methyl ester
(2)
[1345] To a solution of 4-(2,2-Dibromo-vinyl)-benzoic acid methyl
ester (1) (1.5 g, 4.69 mmol), Pd.sub.2dba.sub.3 (45 mg, 1 mol %),
TMPP (60 mg, 4 mol %), and TEA (1.94 mL, 14.1 mmol) in DMF (15 mL),
cooled in a dry ice/acetonitrile bath, was introduced 1-butyne
(0.75 mL, 9.4 mmol) via condensation on a -78.degree. C. cold
finger under a nitrogen atmosphere. Reaction vessel was sealed and
heated at 80.degree. C. for 16 h. Reaction mixture was diluted with
water (200 mL) and extracted with EtOAc (3.times.80 mL). Combined
organic layers were washed with water (100 mL) and brine (80 mL),
dried over anhydrous Na.sub.2SO.sub.4, and concentrated in vacuo to
give a sticky brown solid. Crude product was purified by normal
phase flash chromatography on a CombiFlash.RTM. Companion.TM. unit
equipped with Luknova flash column (40 g silica gel, 40-60 .mu.m
average particle size, 60 .ANG. pore size); flow rate: 40 mL/min;
mobile phase A: hexane; mobile phase B: EtOAc; gradient elution
from 0% B to 30% B over 70 min. Fractions containing the desired
product were combined and concentrated in vacuo to give target
compound 2 (1.093 mg, 110%) as a slightly sticky light brown solid.
LC-MS: RT (Method A) 6.67 min; compound not significantly
ionizable. .sup.1H NMR (250 MHz, CDCl.sub.3) .delta. 1.15 (3H, t),
2.35 (2H, q), 3.9 (3H, s), 7.6 (2H, d), 8.0 (2H, d).
Synthesis of 4-Hexa-1,3-diynyl-benzoic acid (3)
[1346] To compound 2 (4.69 mmol) were added THF (8 mL) and 3 M NaOH
(aq) (12 mL, 36 mmol). Reaction mixture was heated at 80.degree. C.
for 1 h. Reaction mixture was diluted with water (150 mL), cooled
in ice/water bath, acidified to pH 3 with 10% H.sub.3PO.sub.4 (aq),
and filtered. Solids were washed with water (3.times.50 mL) and
dried by lyophilization to give target compound 3 (766.9 mg, 83.4%
from 1) as an off-white solid. LC-MS: RT (Method A) 5.38 min;
compound not significantly ionizable.
Synthesis of
(S)-3-tert-Butoxycarbonylamino-2-(4-hexa-1,3-diynyl-benzoylamino)-3-methy-
l-butyric acid methyl ester (4)
TABLE-US-00037 [1347] Reagent MW Eq. mg/mL mmol Compound 3 198.22
1.0 96.1 mg 0.485 Chiral dimethyl DAP 246.31 1.1 133 mg 0.540 HATU
380.2 1.2 224 mg 0.589 DIEA 129.25 3.0 0.256 mL 1.47 DMF 4 mL
[1348] Compound 4 (231.6 mg, 112%) as a sticky amber solid prepared
using the General Method for HATU coupling and used on next step
without purification. LC-MS: RT (Method A) 6.90 min; [M+H] 427.1
(C.sub.24H.sub.30H.sub.2O.sub.5+H, requires 427.53).
Synthesis of
N--((S)-2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-hexa-1,3-diynyl-ben-
zamide (91-1)
[1349] To compound 4 (.about.0.485 mmol) was added 4 M HCl/dioxane
(4 mL), and the mixture was stirred at ambient temperature for 1 h.
Volatiles were removed in vacuo to give a sticky amber solid.
LC-MS: RT (Method A) 4.31 min; [M+H] 327.1
(C.sub.19H.sub.22N.sub.2O.sub.3+H, requires 327.41). Isopropyl
alcohol (4 mL) was added to the solid and the mixture was cooled in
an ice/water bath for 5 min. NH.sub.2OH (50%, aq) (4 mL) was added
to the mixture, dropwise for the first 2 mL. Reaction mixture was
allowed to stir in ice bath for 5 min, and then allowed to stir at
ambient temperature for 16 h. Solvent volume was reduced
approximately by half under a stream of nitrogen, and water (10 mL)
was added. The suspension was thoroughly agitated (vibro mixer and
sonication), centrifuged and the supernatant was discarded. Water
(10 mL) was added to the solid and the suspension was thoroughly
agitated, centrifuged and the supernatant was discarded. Wet solid
was dried by lyophilization to give crude product (127 mg, 80.3%
crude yield from 3) as an off-white solid. Crude product was
purified by preparative scale reverse-phase HPLC (Phenomenex Gemini
C-18 column, 110 .ANG., 30.times.100 mm, flow rate: 20 mL/min,
mobile phase A: 0.1% TFA/water, mobile phase B: 0.1% TFA/ACN,
gradient elution from 15% B to 40% B over 60 min, MS detection).
Fractions containing the desired product were combined and
lyophilized to provide the trifluoroacetate salt of target compound
91-1 (64.8 mg, 30.3% yield from 3, 37.8% recovery from crude
product) as a white solid. LC-MS: RT (Method A) 3.77 min; [M+H]
328.3 (C.sub.18H.sub.21N.sub.3O.sub.3+H, requires 328.40).
TABLE-US-00038 Retention Scale Yield Yield Purity [M + time
Compound (mmol).sup.1 (mg) (%).sup.1 (%).sup.2 H] (min).sup.2 91-1
0.485 64.8 30.3 98.5 328.3 3.77 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
Intermediate Acid IC-1
##STR00253##
[1350] Synthesis of cyclobutylacetylene (2)
[1351] The synthesis was done according to U.S. Pat. No. 6,303,057
entitled "Preparation of cycloalkylacetylene compounds".
[1352] Into a 0.5 liter round bottom flask equipped with an
addition funnel and a reflux condenser were placed),
diisopropylamine (10.1 g, 0.1 mol) and THF (250 ml). Bromoethane
(59.9 g, 0.55 mol) was added dropwise to this mixture via the
addition funnel at such a rate as to maintain a refluxing solution.
Ethane was evolved during the addition. The reaction was determined
to be complete once all of the magnesium was consumed. This process
produced a solution containing EtMgBr and (iPr).sub.2NMgBr.
6-Chlorohexyne (23.32 g, 0.2 mol) was added dropwise and the
resulting reaction mixture was stirred at 65.degree. C. for 36 h.
The cooled reaction mixture was poured onto crashed ice. Organic
upper layer was separated, washed 3 times with water (3.times.100
mL) and dried over Na.sub.2SO.sub.4. Na.sub.2SO.sub.4 was separated
by filtration to give 21.7 g of yellow liquid, which was used on
next step without purification.
Synthesis of 4-(4-Cyclobutyl-buta-1,3-diynyl)-benzoic acid
(IC-1)
TABLE-US-00039 [1353] Reagent MW Eq. mmol g, ml Methyl
4-(2,2-dibromovinyl)- 319.98 1.0 7.8 2.5 g benzoate
Cyclobutylacetylene (2) 80.13 1.4 10.93 0.88 g Tris(dibenzyllidene-
915.72 0.08 0.065 60 mg acetone)dipalladium(0)
Tris(4-methoxyphenyl)phosphine 352.36 0.03 0.24 85 mg TEA 101.19
3.2 25 3.47 mL DMF(anhydrous) 10 mL
[1354] The 4-(4-Cyclobutyl-buta-1,3-diynyl)-benzoic acid methyl
ester (4) was made and separated using the General Method for
Sonogashira coupling*. Yield: 11.3%. (Yellow solid). Check of a
sample by HPLC-MS showed a major product peak (Ret. time (Method A)
7.58 min, [MH+]=239.2). This product was subject to basic
hydrolysis to give the desired acid IC-1, used to prepare compound
10-16 and 10-17.
For syntheses of the following alkyl- and cycloalkyl diacetylenes,
commercially available acetylenes were used.
TABLE-US-00040 Ret. HPLC- Compound Time MH.sup.+ MS # Structure
(min) (m/z) Method 91-2 ##STR00254## 5.46 326.3 A 91-3 ##STR00255##
6.79 354.3 A 91-4 ##STR00256## 7.35 368.3 A 91-5 ##STR00257## 6.12
327.1 A 91-6 ##STR00258## 6.50 341.1 A 91-7 ##STR00259## 3.64 314.1
A 91-8 ##STR00260## 4.04 328.3 A 91-9 ##STR00261## 4.14 342.2 A
Each of the following compounds was synthesized as described above
using the Boc protected amino acid and HCl deprotection.
TABLE-US-00041 Ret. HPLC- Time MH.sup.+ MS Compound # Structure
(min) (m/z) Method 91-10 ##STR00262## 4.01 340.3 A 91-11
##STR00263## 3.97 339.9 A 91-12 ##STR00264## 3.95 340.3 A 91-13
##STR00265## 4.16 328.3 A 91-14 ##STR00266## 6.95 368.3 A 91-15
##STR00267## 6.08 342.6 A 91-16 ##STR00268## 6.32 354.3 A 91-17
##STR00269## 3.18 340.2 A
Intermediate Acid IC-2
##STR00270##
[1355] Methyl 4-(7-methylocta-1,3-diynyl)benzoate (2)
[1356] To a degassed solution of compound 1 (2.8 g, 11 mmol),
Pd(PPh.sub.3).sub.2Cl.sub.2 (0.411 g, 0.58 mmol) and CuI (0.11 g,
0.58 mmol) in dried THF (50 mL) was added 5-methylhex-1-yne (1.35
g, 1.86 mL, 14 mmol), followed by diisopropylamine (3.56 g, 4.9 ml,
35.1 mmol) dropwise. After the addition of diisopropylamine, the
reaction mixture was stirred overnight at room temperature. The
suspension was filtered and washed the cake with CH.sub.2Cl.sub.2.
The filtrate was concentrated in vacuo. The residue was purified by
silica-gel column chromatography (PE: EA=100:1) to give compound 2
(2.25 g, 75%) as a brown solid.
4-(7-Methylocta-1,3-diynyl)benzoic acid (3)
TABLE-US-00042 [1357] Reagent MW Eq. mmol g, mL Compound 2 254.32 1
8.6 2.15 g 2N NaOH 40 2.3 20 10 mL THF 30 mL MeOH 10 mL
[1358] Compound 3 (1.5 g, 70%) as a white solid made and separated
using the General Method for basic hydrolysis. .sup.1H-NMR (400
MHz, DMSO-d.sub.6): 0.89 (d, J=6.4, 6H), 1.39-1.45 (m, 2H),
1.61-1.70 (m, 1H), 2.44-2.51 (m, 2H), 7.65 (d, J=8.4 Hz, 2H), 7.93
(d, J=8.8 Hz, 2H), 13.24 (s, 1H).
The intermediate acids for making the following analogues were
synthesized by using the same synthetic method for compound 10-18.
Each of the following compounds of was synthesized as described
above using the Boc protected amino acid and HCl deprotection.
TABLE-US-00043 Ret. HPLC- Compound Time MH.sup.+ MS # Structure
(min) (m/z) Method 91-18 ##STR00271## 8.55 371.1 A 91-19
##STR00272## 7.84 357.1 A 91-20 ##STR00273## 8.73 383.1 A 91-21
##STR00274## 7.50 370.3 A 91-22 ##STR00275## 6.90 356.3 A 91-23
##STR00276## 7.69 382.3 A 91-24 ##STR00277## 6.67 342.3 A 91-25
##STR00278## 7.64 368.3 A 91-26 ##STR00279## 6.43 354.3 A 91-27
##STR00280## 6.22 340.3 A 91-28 ##STR00281## 7.31 356.3 A 91-29
##STR00282## 355.2 91-30 ##STR00283## 344.1
Example 92
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((R)-5-morpholinohe-
xa-1,3-diynyl)benzamide AND
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((S)-5-morpholinoh-
exa-1,3-diynyl)benzamide (92-1 and 92-2)
##STR00284##
[1359] Synthesis of (rac)-methyl
4-(5-hydroxyhexa-1,3-diynyl)benzoate (1)
[1360] The methyl 4-(2,2-dibromovinyl)benzoate (3.00 g, 9.38 mmol)
was dissolved in DMF (50 mL) and this solution was deoxygenated by
bubbling N.sub.2 through for 10 min. To this deoxygenated solution
was then added Et.sub.3N (1.3 mL, 9.39 mmol) and
2-methyl-3-butyn-2-ol (0.342 g, 4.07 mmol). N.sub.2 was then
bubbled through for an additional 5 min followed by addition of
PdCl.sub.2(PPh.sub.3).sub.2 (0.022 g, 0.031 mmol) and P(tBu).sub.3
HBF.sub.4 (0.036 g, 0.125 mmol). The dark brown solution was then
allowed to stir at 85.degree. C. for 3 h then cooled to ambient
temperature. The solution was diluted with EtOAc (100 mL), washed
with deionized water (3.times.50 mL) and brine (1.times.50 mL),
dried (MgSO.sub.4), filtered and concentrated in vacuo. The crude
oil was purified by flash chromatography (0-50% EtOAc/Hex) to
provide the desired product 1 as a brown solid (1.10 g, 71%). LC-MS
[M+H].sup.+=229.1 (Theoretical,
C.sub.15H.sub.13O.sub.2.sup.+=229.1).
Synthesis of (rac)-methyl 4-(5-morpholinohexa-1,3-diynyl)benzoate
(2)
[1361] Compound 1 (0.400 g, 1.75 mmol) was dissolved in anhydrous
CH.sub.2Cl.sub.2 (20 mL) under N.sub.2 and cooled to 0.degree. C.
To this chilled solution was added methanesulfonic anhydride (0.336
g, 1.93 mmol) in one portion followed by slow addition of Et.sub.3N
(0.37 mL, 2.63 mmol). The solution was allowed to stir at 0.degree.
C. for 30 min then morpholine (5 mL) was added and the solution was
heated to 50.degree. C. for 30 min. The solution was then removed
from heat and allowed to stir at ambient temperature for 18 h. The
solution was concentrated in vacuo and the crude oil was purified
by flash chromatography (0-50% EtOAc/CH.sub.2Cl.sub.2) to provide
the desired product 2 (0.468 g, 90%) as a solid. LC-MS
[M+H].sup.+=298.1 (Theoretical,
C.sub.18H.sub.20NO.sub.3.sup.+=298.1).
Synthesis of (racy-4-(5-morpholinohexa-1,3-diynyl)benzoic acid
(3)
[1362] To a solution of compound 2 (0.468 g, 1.57 mmol) in a
mixture of THF (5 mL), MeOH (5 mL), and water (5 mL) was added LiOH
monohydrate (0.198 g, 4.71 mmol) in one portion. The solution was
allowed to stir at ambient temperature for 4 h. The volatile
organics were then carefully removed and the pH of the resulting
aqueous solution was adjusted with NaHSO.sub.4 (1.0 N) to .about.2.
The resulting slurry was vacuum filtered and the solid was washed
with deionized water (1.times.20 mL) to provide the desired product
3 (0.445 g, 99%) as an offwhite solid. LC-MS [M+H].sup.+=284.1
(Theoretical, C.sub.17H.sub.18NO.sub.3.sup.+=284.1).
Synthesis of (2S,3R)-methyl
3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-(4-((R)-5-morpholinohexa-1,-
3-diynyl)benzamido)butanoate and (2S,3R)-methyl
3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-2-(4-((S)-5-morpholinohexa-1,-
3-diynyl)benzamido) butanoate (4)
[1363] Compound 3 (0.445 g, 1.57 mmol), (2S,3R)-methyl
3-(Fmoc)-2-aminobutanoate (0.676 g, 1.73 mmol), EDC (0.602 g, 3.14
mmol) and HOBT (0.424 g, 3.14 mmol) were slurried in anhydrous
CH.sub.2Cl.sub.2 (15 mL). To this slurry was added
N,N-diisopropylethylamine (1.02 mL, 6.28 mmol) in one portion. The
solution was then allowed to stir at ambient temperature for 18 h.
The solution was then diluted with water (20 mL) and
CH.sub.2Cl.sub.2 (15 mL), then the layers were separated. The
aqueous layer was extracted with CH.sub.2Cl.sub.2 (3.times.10 mL)
and the combined organics were dried (MgSO.sub.4), filtered and
concentrated in vacuo. The crude solid was purified by flash
chromatography (0-10% MeOH/CH.sub.2Cl.sub.2) to provide the desired
mixture of diastereomers 4 (0.785 g, 81%) as an oil. LC-MS
[M+H].sup.+=620.3 (Theoretical,
C.sub.37H.sub.38N.sub.3O.sub.6.sup.+=620.2).
Synthesis of (2S,3R)-methyl
3-amino-2-(4-((R)-5-morpholinohexa-1,3-diynyl) benzamido)butanoate
and (2S,3R)-methyl
3-amino-2-(4-((S)-5-morpholinohexa-1,3-diynyl)benzamido)butanoate
(5)
[1364] The mixture of diastereomers 4 (0.785 g, 1.27 mmol) was
dissolved in DMF (13 mL) and morpholine (2.2 mL, 25.4 mmol) was
added in one portion at ambient temperature and allowed to stir for
18 h. The resultant slurry was vacuum filtered and the filtrate was
concentrated in vacuo. The crude solid was purified by flash
chromatography (0-10% MeOH/CH.sub.2Cl.sub.2) to provide the desired
mixture of diastereomers 5 (0.307 g, 61%) as a pale yellow oil.
LC-MS [M+H].sup.+=398.2 (Theoretical,
C.sub.22H.sub.28N.sub.3O.sub.4.sup.+=398.2).
Synthesis of
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((R)-5-morpholinoh-
exa-1,3-diynyl)benzamide (92-1) and
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-44(S)-5-morpholinohe-
xa-1,3-diynyl)benzamide (92-2)
[1365] The mixture of diastereomers 5 (0.307 g, 0.722 mmol) was
dissolved in isopropyl alcohol (8 mL) and the hydroxylamine
solution (1.02 mL, 15.4 mmol) was added in one portion at ambient
temperature. To this was then added solid potassium hydroxide
(0.130 g, 2.31 mmol) in one portion and the solution was allowed to
stir for 18 h at ambient temperature. The volatiles were removed in
vacuo and the resulting crude material was purified by reverse
phase HPLC (5-40% MeCN/H.sub.2O, w/0.1% TFA) then lyophilized to
dryness to provide both of the desired products 92-1 (0.0xx g, xx
%) as a white solid; LC-MS [M+H].sup.+=399.1 (Theoretical,
C.sub.21H.sub.27N.sub.4O.sub.4.sup.+=399.2). .sup.1H NMR (DMSO)
.delta. 11.31 (s, 1H), 9.42 (br s, 1H), 8.60 (d, J=8.3, 1H), 8.36
(br s, 3H), 7.91 (d, J=8.2, 2H), 7.71 (d, J=8.0, 2H), 4.33 (q,
J=6.6, 1H), 3.60-3.70 (m, 6H), 2.55-2.65 (m, 4H), 1.37 (d, J=6.7,
3H), 1.15 (d, J=8.3, 3H) and 92-2 (0.0xx g, xx %) as a white solid;
LC-MS [M+H].sup.+=399.0 (Theoretical,
C.sub.21H.sub.27N.sub.4O.sub.4.sup.+=399.2). .sup.1H NMR (DMSO)
.delta. 11.15 (s, 1H), 8.87 (d, J=8.6, 1H), 8.05 (br s, 3H), 7.96
(d, J=8.3, 2H) 7.72 (d, J=8.0, 2H) 4.39-5.41 (m, 2H), 3.78 (br s,
4H), 3.56-3.59 (m, 1H) 2.97-3.09 (m, 4H), 1.49 (d, J=5.9, 3H), 1.20
(d, 6.4, 3H).
Example 93
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(methylsulfonam-
ido)phenyl)buta-1,3-diynyl)benzamide (93-1)
##STR00285##
[1366] Synthesis of methyl
4-((4-aminophenyl)buta-1,3-diynyl)benzoate (1)
[1367] The methyl 4-(2,2-dibromovinyl)benzoate (2.73 g, 8.54 mmol)
and 4-ethynylaniline (1.00 g, 8.54 mmol) were dissolved in DMF (40
mL) and this solution was deoxygenated by bubbling N.sub.2 through
for 10 min. To this deoxygenated solution was then added Et.sub.3N
(3.6 mL, 25.6 mmol). N.sub.2 was then bubbled through for an
additional 5 min followed by addition of Pd.sub.2(dba).sub.3 (0.078
g, 0.085 mmol) and tri(4-methoxyphenyl)phosphine (0.121 g, 0.342
mmol). The dark brown solution was then allowed to stir at
80.degree. C. for 18 h then cooled to ambient temperature. The
solution was diluted with EtOAc (100 mL), washed with deionized
water (3.times.50 mL) and brine (1.times.50 mL), dried
(MgSO.sub.4), filtered and concentrated in vacuo. The crude oil was
purified by flash chromatography (0-50% EtOAc/CH.sub.2Cl.sub.2) to
provide the desired product 1 as a yellow solid (0.671 g, 29%).
LC-MS [M+H].sup.+=276.0 (Theoretical,
C.sub.18H.sub.14NO.sub.2.sup.+=276.1).
Synthesis of methyl
4-((4-(methylsulfonamido)phenyl)buta-1,3-diynyl)benzoate (2)
[1368] To a solution of compound 2 (0.370 g, 1.34 mmol) in
CH.sub.2Cl.sub.2 (13 mL) was added methanesulfonyl chloride (0.11
mL, 1.47 mmol) slowly, followed by dropwise addition of Et.sub.3N
(0.21 mL, 1.47 mmol). The solution was allowed to stir at ambient
temperature for 3 h. The solution was diluted with EtOAc (50 mL)
and washed with aqueous HCl (1.0 N, 1.times.25 mL), aqueous
NaHCO.sub.3 (sat., 1.times.25 mL) and brine (1.times.25 mL). The
organics were then dried (MgSO.sub.4), filtered and concentrated in
vacuo to provide the desired product 2 (0.345 g, 73%) as an orange
solid. .sup.1H NMR (DMSO) .delta. 7.99 (d, J=7.3, 2H), 7.72-7.80
(m, 4H), 7.62 (d, J=7.5, 2H), 3.87 (s, 3H), 2.40 (s, 3H).
Synthesis of
4-((4-(methylsulfonamido)phenyl)buta-1,3-diynyl)benzoic acid
(3)
[1369] To a solution of compound 2 (0.345 g, 0.976 mmol) in a
mixture of THF (3 mL), MeOH (3 mL), and water (3 mL) was added LiOH
monohydrate (0.123 g, 2.93 mmol) in one portion. The solution was
allowed to stir at ambient temperature for 90 min. The pH of the
solution was adjusted with aqueous HCl (1.0 N) to pH.about.1. The
resulting solution was then extracted with EtOAc (3.times.20 mL),
dried (MgSO.sub.4), filtered and concentrated in vacuo the desired
product 3 (0.176 g, 53%) as a yellow solid. .sup.1H NMR (DMSO)
.delta. 10.24 (s, 1H), 7.96 (d, J=7.9, 2H), 7.71 (d, J=8.0, 2H),
7.60 (d, J=8.4, 2H), 7.23 (d, J=8.5, 2H), 3.09 (s, 3H).
Synthesis of (2S,3R)-methyl
3-(tert-butoxycarbonylamino)-2-(4-((4-(methylsulfonamido)
phenyl)buta-1,3-diynyl)benzamido)butanoate (4)
TABLE-US-00044 [1370] Reagent MW Eq. g/mL mmol Compound 3 339.37
1.0 0.176 g 0.518 (2S,3R)-methyl 3-(Boc)-2- 268.74 1.1 0.153 g
0.570 aminobutanoate EDC 191.70 2.0 0.199 g 1.04 HOBT 135.12 2.0
0.141 g 1.04 N,N-Diisopropylethylamine 129.24 4.0 0.34 mL 2.08
CH.sub.2Cl.sub.2 5 mL
[1371] Compound 4 (0.285 g, 99%) as a yellow solid was prepared
using General EDC coupling. .sup.1H NMR (DMSO) .delta. 10.23 (s,
1H), 8.44 (d, J=8.2, 1H), 7.92 (d, J=8.4, 2H) 7.74 (d, J=8.4, 2H),
7.60 (d, J=8.6, 2H), 7.23 (d, J=8.6, 2H) 7.00 (d, J=9.7, 1H), 4.62
(dd, J=4.1, 8.5, 1H) 4.22-4.25 (m, 1H) 3.61 (s, 3H), 3.09 (s, 3H),
1.19 (s, 9H), 1.11 (d, J=6.8, 3H).
Synthesis of (2S,3R)-methyl
3-amino-2-(4-((4-(methylsulfonamido)phenyl)buta-1,3-diynyl)benzamido)buta-
noate (5)
[1372] To a solution of compound 4 (0.285 g, 0.515 mmol) in of
CH.sub.2Cl.sub.2 (10 mL) was added TFA (2 mL) slowly. The solution
was allowed to stir at ambient temperature for 1 h then
concentrated in vacuo. The thick oil was then azeotroped with
CH.sub.2Cl.sub.2 (3.times.) to provide the TFA salt of the desired
product 5 (0.284 g, 100%) as an off white solid. LC-MS
[M+H].sup.+=454.1 (Theoretical,
C.sub.23H.sub.24N.sub.3O.sub.5S.sup.+=454.1).
Synthesis of
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(methyl
sulfonamido)phenyl)buta-1,3-diynyl)benzamide 93-1
[1373] The TFA salt of 5 (0.284 g, 0.515 mmol) was dissolved in
isopropyl alcohol (6 mL) and the hydroxylamine solution (0.68 mL,
10.3 mmol) was added in one portion at ambient temperature and the
solution was allowed to stir for 18 h at ambient temperature. The
volatiles were removed in vacuo and the resulting crude material
was purified by reverse phase HPLC (5-40% MeCN/H.sub.2O, w/0.1%
TFA) then lyophilized to dryness to provide the desired product
(93-1) (0.067 g, 29%) as a white solid; LC-MS [M+H].sup.+=455.1
(Theoretical, C.sub.22H.sub.23N.sub.4O.sub.5S.sup.+=455.1).
Example 94
Synthesis of
4-(cyclopropylbuta-1,3-diynyl)-N-(2-(hydroxyamino)-1-(1-hydroxycyclopropy-
l)-2-oxoethyl)benzamide 94-1
##STR00286##
[1374] Synthesis of 1-(2,2-dimethoxyethyl)cyclopropanol (1)
[1375] A solution of methyl 3,3-dimethoxypropanoate (28.2 g, 190
mmol) in a three-neck flask equipped with a overhead stirrer was
cooled to 0.degree. C. under N.sub.2. The Ti(OiPr).sub.4 (11.3 mL,
38.1 mmol) was then slowly added and the solution was allowed to
stir for 10 min at 0.degree. C. To this cooled solution with
vigorous stirring was then added the EtMgBr solution (158 mL, 475
mmol) via syringe pump at .about.3 mL/min. After the addition was
complete, the solution was allowed to slowly warm to ambient
temperature and stirred for an additional 18 h. The solution was
then cooled to 0.degree. C. and deionized water (45 mL) was slowly
added with vigorous stirring. After stirring for 20 min at
0.degree. C. the mixture vacuum filtered through a pad of anhydrous
MgSO.sub.4. The clear, colorless solution was the concentrated in
vacuo and purified by flash chromatography (0-50% EtOAc/Hex) to
provide the desired product (1) as a clear, colorless oil (8.60 g,
31%). .sup.1H NMR (DMSO) .delta. 5.04 (s, 1H), 4.62 (t, J=5.3, 1H),
3.22 (s, 6H), 1.69 (d, J=5.3, 2H) 0.50 (dd, J=4.9, 6.9, 2H), 0.37
(dd, J=4.2, 6.2, 2H).
Synthesis of 1-(2,2-dimethoxyethyl)cyclopropyl acetate (2)
[1376] To a solution of compound 1 (8.60 g, 58.8 mmol) in
CH.sub.2Cl.sub.2 was added DMAP (0.718 g, 5.88 mmol) and pyridine
(7.13 mL, 88.2 mmol) sequentially. The solution was then cooled to
0.degree. C. and acetic anhydride was added dropwise. After the
addition was complete, the solution was stirred at 0.degree. C. for
10 min then allowed to warm to ambient temperature and stirred for
18 h. The solution was then washed with aqueous NaHSO.sub.4 (1.0 N,
2.times.100 mL), aqueous NaHCO.sub.3 (sat., 2.times.100 mL), dried
(MgSO.sub.4), filtered and concentrated in vacuo. Isolated the
desired product, (2) as a clear, colorless oil (11.1 g, 99%).
.sup.1H NMR (DMSO) .delta. 4.50 (t, J=5.5, 1H), 3.21 (2, 6H), 1.95
(d, J 5.3, 2H), 1.92 (s, 3H), 0.73-0.78 (m, 2H), 0.66-0.71 (m,
2H).
Synthesis of 2-(1-acetoxycyclopropyl)acetic acid (3)
[1377] Compound 2 (11.1 g, 58.8 mmol) was dissolved in THF (50 mL)
and water (100 mL) and cooled to 0.degree. C. To this cooled
solution was added Oxone.RTM. in portions. After complete addition
the slurry was allowed to stir at 0.degree. C. for 10 min the
warmed to ambient temperature. After 8 h at ambient temperature the
slurry was diluted with deionized H2O (100 mL) and extracted with
EtOAc (3.times.150 mL). The combined organics were dried
(MgSO.sub.4), filtered and concentrated in vacuo. The product (3)
was isolated as a thick, colorless oil (9.1 g, 98%). .sup.1H NMR
(DMSO) .delta. 2.66 (s, 2H), 1.92 (s, 3H), 0.77-0.85 (m, 4H).
Synthesis of methyl 2-(1-acetoxycyclopropyl)-2-bromoacetate (4)
[1378] Compound 3 (3.35 g, 21.2 mmol) was dissolved in anhydrous
DCE (60 ml) under N.sub.2 and cooled to 0.degree. C. Thionyl
chloride (3.5 g, 30 mmol) was then added slowly and the solution
was refluxed for 30 min. At ambient temperature, were added NBS
(4.78 g, 26 mmol) and 4 drops of concentrated HBr and the solution
was heated under reflux for 4 h. MeOH (50 ml) was added at room
temperature and the solution was stirred at rt for 3 h. The solvent
were removed under reduced pressure, water (100 ml) was added and
product was extracted with ethyl acetate, dried (Na2SO4), and
concentrated to give 3.8 g of 4.
Synthesis of methyl 2-amino-2-(1-hydroxycyclopropyl)acetate (5)
[1379] The bromide product 4 was redessolved in dry DMF (20 ml),
NaN.sub.3 (2.05 g, 30 mmol) was added and heated at 85.degree. C.
for 4 h. The reaction mixture was diluted with ethyl acetate (100
ml) and water 5 ml was added. The organic layer was separated,
dried and concentrated. The product (2.6 g) was the hydrogenated
Pd--C (1.2 g) (40 psi) for 2 h. The catalyst was filtered off and
ethanol solution were concentrated to give 5 (2.42 g)
Synthesis of methyl
2-(4-(cyclopropylbuta-1,3-diynyl)benzamido)-2-(1-hydroxycyclopropyl)aceta-
te (7)
TABLE-US-00045 [1380] Reagent MW Eq. g/ml mmol
4-(cyclopropylbuta-1,3- 201 1 210 mg 1 diynyl)benzoic acid methyl
2-amino-2-(1-hydroxy- 145 2 300 mg 2.06 cyclopropyl)acetate HATU
380.23 1.0 395 mg 1.05 DIEA 129.24 4 1.2 mL excess CH3CN 10 ml
[1381] Compound (7) (172 mg) was prepared using the General Method
for HATU coupling and used on next step without purification. LC-Ms
(M+1) 338.
Synthesis of
4-(cyclopropylbuta-1,3-diynyl)-N-(2-(hydroxyamino)-1-(1-hydroxycyclopropy-
l)-2-oxoethyl)benzamide (94-1)
[1382] Aq. Hydroxylamine (2 ml, 50% aq.) was added to a stirred
solution of ester 7, (0.17 g, 0.51 mmol) in isopropanol (15 ml),
stirred for 18 h. Excess solvent was removed and the product was
purified on a reverse phase HPLC to give compound (94-1) (42 mg)
LC-MS (M+1) 339: Chemical Formula: C19H18N2O4, MW: 338.36.
Example 95
##STR00287##
[1383] Example 95 was prepared by using the General Method for HATU
coupling, General Method for Boc deprotection and General Method
for hydroxamate formation
Synthesis of Intermediate Acid IC-3
##STR00288##
[1384] (1s, 4s)-methyl 4-hydroxycyclohexanecarboxylate 2
[1385] Methanol (104 mL) was cooled in an ice-NaCl bath and
SOCl.sub.2 (15.2 mL) was added dropwise. To the resultant solution
of HCl in methanol, compound 1 (15 g, 0.1042 mol, 1.0 equiv) was
added and the reaction mixture was refluxed for 1 h. After that
time, Methanol was evaporated and another 104 mL of a 2M solution
of HCl in MeOH, prepared in the same way as before, was added and
the reaction mixture was refluxed for another hour. Methanol was
evaporated again to give compound 2 (16.3 g, 99%) as a light yellow
liquid. .sup.1H NMR (400 MHz, DMSO-d.sub.6): 1.47-1.83 (m, 9H),
2.36-2.51 (m, 1H), 3.63 (s, 3H), 4.26 (s, 1H)
(1s,4s)-Methyl 4-(tert-butyldimethylsilyloxy)
cyclohexanecarboxylate (3)
[1386] To a solution of compound 2 (16.3 g, 0.1032 mol, 1.0 equiv)
and imidazole (14.03 g, 0.206 mol, 2.0 equiv) in dried DMF (100 mL)
was added TBSCl (17.1 g, 0.114 mol, 1.1 equiv) in eight portions at
0.degree. C., then the reaction mixture was warmed to 30.degree. C.
and reacted at this temperature for 2 h. DMF was evaporated, DCM
(150 mL) was added, washed with water (80 mL.times.2) and brine
(100 mL), dried over anhydrous sodium sulfate, evaporated the DCM
and purified by silica-gel column (EA:PE, 1:50) to give compound 3
(17 g, 61%) as a colorless liquid. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 0.032 (s, 6H), 0.88 (s, 9H), 1.45-1.51 (m,
2H), 1.61-1.68 (m, 4H), 1.90-1.98 (m, 2H), 2.29-2.34 (m, 1H), 3.67
(s, 3H), 3.89 (s, 1H)
(1s, 4s)-4-(tert-butyldimethylsilyloxy) cyclohexyl) methanol
(4)
[1387] To a stirred suspension of LiAlH.sub.4 (1.9 g, 0.05 mol) in
dried THF (50 mL), under N.sub.2, cooled to 0.degree. C., a
solution of compound 3 (17 g, 0.0625 mol) in dried THF (20 mL) was
added dropwise. The reaction mixture was stirred for 1.5 h at
0.degree. C., then quenched by the addition of
Na.sub.2SO.sub.4.10H.sub.2O (5 g), filtered and evaporated the
solvent, purified by silica-gel column (EA: PE, 1:20) to give
compound 4 (10.5 g, 69%) as a thick oil. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 0.02 (s, 6H), 0.86 (s, 9H), 1.14-1.41 (m,
7H), 1.51-1.55 (m, 2H), 3.17 (t, J=10.8 Hz, 2H), 3.94 (s, 1H), 4.36
(t, J=10.8 Hz, 1H)
(1s, 4s)-4-(tert-butyldimethylsilyloxy) cyclohexanecarbaldehyde
(5)
[1388] IBX (14.45 g, 0.052 mol) was dissolved in DMSO (50 mL)
completely, then compound 4 (10.5 g. 0.043 mol) was added in one
portion and reacted at 30.degree. C. for 3 h. Water (60 mL) was
added to quench the reaction, filtered, EA (100 mL) was added,
washed with water (80 mL.times.2), brine (100 mL), dried over
anhydrous sodium sulfate, evaporated EA and the residue was
purified by silica-gel column (EA:PE, 1:50) to give compound 5
(6.29 g, 50%) as a colorless liquid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): 0.021 (s, 6H), 0.84 (s, 9H), 1.43-1.48 (m, 2H),
1.51-1.60 (M, 4H), 1.67-1.76 (m, 2H), 2.27-2.33 (m, 1H), 3.86 (s,
1H), 9.56 (s, 1H)
Tert-butyl ((1s, 4s)-4-ethynylcyclohexyloxy) dimethylsilane (6)
[1389] To a solution of compound 5 (6.29 g, 0.026 mol) and
K.sub.2CO.sub.3 (7.18 g, 0.052 mol) in methanol (50 mL) was added
dimethyl-1-diazo-2-oxopropylphosphonate (5.99 g, 0.031 mol) and
stirred overnight. The reaction mixture was diluted with Et.sub.2O
(50 mL), washed with an aqueous solution (5%) of NaHCO.sub.3 (30
mL) and dried over anhydrous sodium sulfate, after filtration and
evaporation of the solvent in cacuo to give compound 6 (3.09 g,
50%) as a light yellow liquid. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
0.025 (s, 6H), 0.85 (s, 9H), 1.16-1.36 (m, 3H), 1.51 (d, J=4.8 Hz,
2H), 1.74-1.87 (m, 3H), 2.26-2.30 (m, 1H), 2.83-2.86 (m, 1H),
3.6-3.74 (m, 1H)
Methyl 4-(((1s, 4s)-4-(tert-butyldimethylsilyloxy) cyclohexyl)
buta-1, 3-diynyl) benzoate (7)
TABLE-US-00046 [1390] Reagent MW Eq. mmol g, mL Compound 6 238.44
1.3 13 3.09 g Methyl 4-(bromoethynyl)benzoate 239.07 1.0 10 2.58 g
Pd(PPh.sub.3).sub.2Cl.sub.2 701.9 0.05 0.5 0.38 g CuI 190.45 0.05
0.5 0.1 g Diisopropylamine 101.19 3 30 4.54 mL THF 50 mL
[1391] Compound 7 (2.9 g, 58%) as a light yellow solid was prepared
using the same method for making IC-2. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): 0.032 (s, 6H), 0.85 (s, 9H), 1.23-1.95 (m, 8H),
2.57-2.73 (m, 1H), 3.59-3.77 (m, 1H), 3.86 (s, 3H), 7.67 (d, J=8
Hz, 2H), 7.95 (d, J=8.4 Hz, 2H).
4-(((1s, 4s)-4-(tert-butyldimethylsilyloxy)
cyclohexyl)buta-1,3-diynyl)benzoic acid (8)
TABLE-US-00047 [1392] Reagent MW Eq. mmol g, mL Compound 7 396.59
1.0 7.32 2.9 g NaOH (2N solution) 7 mL THF 7 mL Methanol 7 mL
[1393] Compound 8 (2.0 g, 71%) as a white solid made and separated
using the General Method for basic hydrolysis. .sup.1H NMR (400
MHz, DMSO-d.sub.6): 0.036 (s, 6H), 0.85 (s, 9H), 1.28-1.95 (m, 8H),
2.57-2.77 (m, 1H), 3.65-3.78 (m, 1H), 7.64 (d, J=8 Hz, 2H), 7.93
(d, J=8.4 Hz, 2H), 13.23 (s, 1H)
Synthesis of Intermediate Acid IC-4
##STR00289##
[1394] Diethyl tetrahydropyran-4,4-dicarboxylate (1)
[1395] Under ice bath, a three-necked flask was added 600 mL EtOH,
then 23 g (l mmol) Na was added. After Na was almost dissolved,
diethyl malonate 160 ml (1 mol) and
1-chloro-2-(2-chloroethoxy)ethane (118 ml,1.2 mol) were added
dropwise sequently to the solution at R.T. and stirred for another
half hour. Then the mixture was heated to reflux for 1 h and cooled
to r.t., then the other part of NaOEt (25 g Na dissolved in 600 mL
EtOH) solution (1.2 mol) was poured into the mixture and refluxed
overnight. The next day, the solvent was evaporated. The residue
was dissolved in water and extracted the product with EtOAc three
times. The organic layer was washed with brine, dried on
Na.sub.2SO.sub.4 and evaporated to give the crude product, which
gave the pure product (120 g, Y=52%) by distillation. .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. ppm 4.2 (q, 4H), 3.68 (m, 4H), 2.12
(m, 4H), 1.26 (t, 6H).
Tetrahydropyran-4,4-dicarboxylic acid (2)
[1396] To a solution of compound 1 (40.0 g, 1.0 equiv) in
CH.sub.3OH/THF/H.sub.2O=5/5/1 (600 mL) was added NaOH (27.8 g, 4.0
equiv) and the mixture reacted at 25.degree. C. overnight. Then,
the reaction solvents was removed and neutralized with 1 N HCl to
PH=3-5. The product was extracted with EtOAc and concentrated under
reduced pressure to give the desired product 2 (27.3 g 91%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. ppm 12.84 (S, 2H),
3.53 (M, 4H), 1.89 (m, 4H).
Tetrahydro-2H-pyran-4-carboxylic acid (3)
[1397] 2 (27.3 g) was placed in a bottle and gradually heated to
170.degree. C. over a period of 1 h until gas was ceased. The left
solid was the desired product 3 (20.4 g, Y=100%). .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. ppm 12.19 (s, 1H), 3.80 (m, 2H), 3.28
(m, 2H), 2.47 (m, 1H), 1.69 (m, 2H), 1.53 (m, 2H).
(Tetrahydro-2H-pyran-4-yl)methanol (4)
[1398] 3 (6.5 g, 50 mmol. 1 eq.) was dissolved in dry THF (150 mL)
and added BF.sub.3.Et.sub.2O (7.0 mL, 50 mmol, 1.0 eq.) dropwise.
The mixture was heated to reflux. While at this temperature 1M/L
BH.sub.3.THF (55 mL, 55 mmol, 1.1 eq.) was added dropwise. When the
addition finished, the mixture was left refluxing overnight. The
next day 3M/L NaOH solution .quadrature.970 mL. 4.0 eq.) was added
while the mixture was cooled to r.t. and reheated to reflux for 1.5
h. Later, solvents were removed and the product was extracted with
EtOAc three times. The organic layer was washed with brine dried
and evaporated to give the crude product which purified by column
chromatography (PE/EA=6:1-2:1) to obtain the pure desired product 1
4 (4.8 g, Y=83%). .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. ppm
4.31 (m, 1H), 3.71 (m, 2H), 3.09 (m, 4H), 1.40 (m, 3H), 0.98 (m,
2H).
Tetrahydro-2H-pyran-4-carbaldehyde (5)
[1399] IBX (5.8 g, 1.2 eq.) were dissolved in 30 mL DMSO at
40.degree. C. and 4 (2.0 g, 1.0 eq.) was added to the mixture and
left stirring overnight. The next day, filtrated the solid, the
filtrate was diluted with 80 mL water, and extracted the product
with ether four times. The ether layer was washed with brine dried
and evaporated the solvents under ice bath to give the crude
product 1.3 g (the product was broken up under the air). .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. ppm 9.62 (s, 1H), 3.81 (m,
2H), 3.34 (m, 2H), 2.56 (m, 1H), 1.75 (m, 2H), 1.50 (m, 2H).
4-(2,2-Dibromovinyl)-tetrahydro-2H-pyran (6)
[1400] To a 0.degree. C. solution of compound 18-5 (1.3 g, 11.4
mmol, 1.0 eq.) and carbon tetrabromide (4.2 g, 12.5 mol, 1.1 eq.)
in dry CH.sub.2Cl.sub.2 (30 ml) was added triphenylphosphine (6.27
g, 24.0 mmol, 2.1 equiv.) in 4 portions at 3 min intervals. The
reaction was then stirred for 1 h at 25.degree. C. Hexane was added
to the reaction mixture with good stirring, and the resulting
slurry was filtered through silica gel and evaporated to give the
crude product, which purified by column chromatography
(PE/EA=0-10%) to obtain the pure product 6 (2.0 g, 65%). .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. ppm 6.20 (d, J=8.8 Hz), 3.87
(m, 2H), 3.37 (m, 2H), 2.47 (m, 1H), 1.57 (m, 2H), 1.42 (m,
2H).
Methyl 4-((tetrahydro-2H-pyran-4-yl)buta-1,3-diynyl)benzoate
(7)
[1401] A solution of 6 (2.0 g 7.4 mmol, 1 equiv), methyl
4-ethynylbenzoate (1.80 g 11.1 mmol, 1.5 equiv), Pd.sub.2dba.sub.3
(68 mg, 0.08 mmol, 0.01 equiv), TMPP (106 mg, 0.32 mmol, 0.04
equiv) and TEA (3 mL, 22.2 mmol, 3 equiv) in anhydrous DMF (30 ml)
was flushed with N.sub.2 and heated at 80.degree. C. for 10 hours.
Then, most DMF was evaporated under reduced pressure, the residue
was dissolved in EtOAc (500 ml) and washed with semi-saturated NaCl
solution (300 ml.times.4), dried on Na.sub.2SO.sub.4 and evaporated
to give a crude product, which was purified by chromatography
(EA/PE=1/20-1/5) to give the desired product 7 (360 mg, 30%). MS:
[M+1].sup.+269
4-((Tetrahydro-2H-pyran-4-yl)buta-1,3-diynyl)benzoic acid
(IC-4)
TABLE-US-00048 [1402] Reagent MW Eq. mmol g, mL Compound 7 268 1.0
1.3 360 mg NaOH 40 4.0 5.4 300 m CH.sub.3OH/THF/H.sub.2O = 5/5/1 50
mL
[1403] Compound IC-4 (310 mg, 98%) was made and separated using the
General Method for basic hydrolysis. MS: [M+1].sup.+255. .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. ppm 13.21 (s, 1H), 7.94 (d,
0.1=8.4 Hz, 2H), 7.66 (d, J=8.4 Hz, 2H), 3.77 (m, 2H), 3.44 (m,
2H0, 2.93 (m, 1H), 1.83 (m, 2H), 1.62 (m, 2H).
Synthesis of Intermediate Acid IC-5
##STR00290##
[1404] Methyl 4-(2,2-difluorocyclopropyl buta-1,3-diynyl)benzoate
(5)
[1405] IBX (2.8 g, 10 mmol) was added to DMSO (20 mL) in one
portion. After IBX was totally dissolved, compound 1 was added in
one portion and the mixture was stirred for 3 h at 25.degree. C.
Then, 80 mL water was added and the white precipitate was filtered
off without suction. The filtrate was extracted with toluene
(3.times.15 mL). Then the organic layer was washed with water
(5.times.10 mL), dried overnight with anhydrous MgSO.sub.4.
MgSO.sub.4 was filtered off and the solid was washed twice with
toluene. A 3-neck flask charged with K.sub.2CO.sub.3 (2.61 g, 18
mmol) was flushed with nitrogen 3 times. Then, MeOH (30 mL), the
toluene solution from the former step and
dimethyl-1-diazo-2-oxopropyl phosphonate (1.728 g, 9 mmol) were
added sequentially. The reaction mixture was stirred at r.t.
overnight and washed with distilled water (3.times.10 mL). Then,
the organic layer was dried over anhydrous MgSO.sub.4 for 4 hours.
Filtration without suction gave the toluene solution of compound 3
for the next step. Another 3-neck flask with methyl 4-ethynyl
benzoate (480 mg, 3 mmol), Pd(PPh.sub.3).sub.2Cl.sub.2 (105 mg,
0.15 mmol), CuI (57 mg, 0.3 mmol) was charged with N.sub.2. The
dried toluene solution with compound 3 in it was put into the flask
by a syringe. Diisopropylamine (909 mg, 9 mmol) was added dropwise.
The reaction mixture was stirred overnight and filtered. The solid
was washed with EtOAc (3.times.20 mL). The filtrate was
concentrated in vacuo and purified by flash chromatography
(PE:EA=50:1) to give compound 5 (262 mg, yield 11% from 3 steps) as
a yellow solid. .sup.1H NMR (500 MHz, CDCl.sub.3): .delta. ppm,
7.98 (d, J=8.0 Hz, 2H), 7.54 (d, J=8.0 Hz, 2H), 3.92 (s, 3H),
2.25-2.32 (m, 1H), 1.79-1.83 (m, 1H), 1.63-1.68 (m, 1H).
4-(2,2-Difluorocyclopropyl buta-1,3-diynyl)benzoic acid (IC-5)
[1406] To a solution of compound 5 (260 mg, 1 mmol) in THF (5 mL),
MeOH (5 mL) and a solution of NaOH (160 mg, 4 mmol) in water (2 mL)
was added at 0.degree. C. Then, the mixture was stirred at r.t. for
2 h as monitored by TLC. The solvent was evaporated and 20 mL water
was added. Then, the mixture PH value was adjusted to 2-3 and
extracted with EtOAc (3.times.15 mL). The organic layer was dried
over MgSO.sub.4, filtered and concentrated to give compound IC-5
(200 mg, 81%) as a light pink solid. .sup.1H NMR (500 MHz,
DMSO-d.sub.6): .delta. ppm, 7.94 (d, J=6.5 Hz, 2H), 7.69 (d, J=6.5
Hz, 2H), 2.90-2.94 (m, 1H), 2.15-2.19 (m, 1H), 1.90-1.97 (m,
1H).
Synthesis of Intermediate Acid IC-6
##STR00291##
[1407] Step 1: Trimethyl(4-methylpent-3-en-1-ynyl)silane 2
[1408] Under nitrogen, ethynyltrimethylsilane 1 (3.5 g, 0.036 mol,
1.2 equiv) was added to a solution of compound SM1 (4 g, 0.03 mol,
1.0 equiv), PdCl.sub.2(PPh.sub.3).sub.2 (1.05 g, 1.5 mmol, 0.05
equiv) and CuI (0.6 g, 0.003 mmol, 0.1 equiv) in TEA (50 mL) at
90.degree. C. The mixture was allowed to react overnight. Then, the
precipitate was isolated. The filter cake was washed with Et.sub.2O
(100 mL). The filtrate was concentrated under reduced pressure. The
residue was dissolved in Et.sub.2O (100 mL) and washed 1 M HCl aq.
(200 mL), water (200 mL.times.2) and brine (200 mL). The organic
layer was separated, dried (Na.sub.2SO.sub.4) and the filtered. The
filtrate was concentrated under reduced pressure to give the crude
product of title compound 2 as liquid (3 g, 65% yield). The purity
was about 70% from LCMS.
Step 2: Methyl 4-(6-methylhepta-5-en-1,3-diynyl)benzoate 3
[1409] To a solution of compound 2 (2 g, 0.02 mol, 1.0 equiv) in
DMF (50 mL) was treated with K.sub.2CO.sub.3 (16 g, 0.12 mol, 4
equiv) at r.t. Then, the mixture was stirred at room temperature
for 1 h. Then, the reactant methyl 4-(bromoethynyl)benzoate SM2 (5
g, 0.02 mol, 1.0 equiv), PdCl.sub.2(PPh.sub.3).sub.2 (0.7 g, 0.001
mol, 0.05 equiv) and CuI (0.38 g, 0.002 mmol, 0.1 equiv) and
diisopropylamine HN(i-Pr).sub.2 (4 g, 0.04 mol, 2.0 equiv) was
added in to the reaction mixture quickly under N.sub.2 protection.
The mixture was stirred for overnight. Then, the reaction mixture
was added EtOAc (200 mL) and washed with dilute HCl aqueous
(150.times.2), H.sub.2O (200.times.2). The organic layer was
washed, dried (Na.sub.2SO.sub.4), filtered and concentrated under
reduced pressure. The residue was purified by chromatography on
silica gel to give the desired product 3 (0.4 g, 10%). LCMS (m/z):
[M+H].sup.+=239.0. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta.
7.97-7.99 (m, 2H), 7.57-7.49 (m, 2H), 5.40 (s, 1H), 3.92 (s, 3H),
1.98 (s, 3H), 1.87 (s, 3H).
Step 3: 4-(6-Methylhepta-5-en-1,3-diynyl)benzoic acid 4
[1410] To a solution of compound 3 (0.25 g, 1.7 mmol, 1.0 equiv) in
methanol (5 mL) was treated with KOH/H.sub.2O (0.3 g/3 mL) at r.t.
The reaction mixture was neutralized with acetic acid and EtOAc
(100 mL). The organic layer was washed with 5% aq. Na.sub.2CO.sub.3
(50 mL.times.2), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure. The residue was dried in vacuo
overnight to provide the title compound IC-6 (0.2 g, 87%). LCMS
(m/z): [M+H].sup.+=225.0. .sup.1H NMR (300 MHz, DMSO): .delta.
7.93-7.95 (d, 2H), 7.66-7.68 (d, 2H), 5.58 (m, 1H), 1.93 (s, 3H),
1.87 (s, 3H).
Synthesis of Intermediate Acid IC-7
##STR00292##
[1411] Methyl 4-(5-(methylsulfonyloxy)penta-1,3-diynyl)benzoate
(2)
[1412] To a stirred solution of compound 1 (0.7 g, 3.27 mmol), TEA
(0.55 mL, 3.92 mmol) in dichloromethane (30 mL) and THF (10 mL) was
added methanesulfonyl chloride (0.56 g, 0.38 mL, 4.9 mmol) dropwise
under ice cooling. After addition cooling-bath was removed and
stirred continued for 2 hours. The mixture was diluted with
dichloromethane (100 mL) and washed successively with water (30
mL), saturated NH.sub.4Cl (20 mL), brine (50 mL), dried
(Na.sub.2SO.sub.4) and filtered. The residue was evaporated to give
the crude product as a dark brown solid. MS (m/z):
[M+H].sup.+=293
Methyl 4-(5-(dimethylamino)penta-1,3-diynyl)benzoate (3)
[1413] To a solution of compound 2 (0.533 g, 3.27 mmol) in DMF (20
mL), was added dimethylamine hydrochloride (3.2 g, 39 mmol),
followed by DIPEA (5.9 g, 7.9 mL, 45.8 mmol). After being stirred
at 65.degree. C. for 2 hours, cooled down to room temperature,
diluted with saturated NaHCO.sub.3 aqueous and extracted with
dichloromethane (3.times.100 mL). The combined organic layers was
washed (water, brine), dried (Na.sub.2SO.sub.4), filtered and
evaporated to dry. The crude product was purified by silica gel
column chromatography (PE/EA=20:1) to give the desired product (0.2
g, 25%). MS (m/z): [M+H].sup.+=242. .sup.1H-NMR (400 MHz,
DMSO-d.sub.6): 2.22 (s, 6H), 3.50 (s, 2H), 3.59 (s, 3H), 7.72 (d,
J=8.4 Hz, 2H), 7.96 (d, J=8.8 Hz, 2H).
4-(5-(Dimethylamino)penta-1,3-diynyl)benzoic acid (IC-7)
[1414] To a solution of compound 3 (0.2 g, 0.83 mmol) in a mixture
solution of THF (20 mL) and CH.sub.3OH (10 mL) was added 2N NaOH (5
mL) dropwise at ambient temperature. The mixture was allowed to
react at room temperature for 3 hours, distilled the solvent,
extracted with ether. The aqueous layer was adjusted the PH at 7
with 2 N HCl aqueous and filtered to give compound 4 (129 mg, 68%)
as a yellow solid. MS (m/z): [M+H].sup.+=228. .sup.1H-NMR (400 MHz,
DMSO-d.sub.6): 2.23 (s, 6H), 3.51 (s, 2H), 3.59 (s, 3H), 7.69 (d,
J=8 Hz, 2H), 7.94 (d, J=7.6 Hz, 2H).
Synthesis of Intermediate Acid IC-8
##STR00293##
[1415] 5-(5-Bromothiophen-2-yl)oxazole (2)
[1416] To a degassed solution of tosylmethyl isocyanide (0.56 g,
2.88 mmol), K.sub.2CO.sub.3 (0.4 g, 2.88 mmol) in dried CH.sub.3OH
(15 mL) was added compound 1 (0.5 g, 2.9 mL, 2.6 mmol). The
reaction mixture refluxed under nitrogen for 2 hours. Volatiles
were removed in vacuo and the residue was purified by silica gel
column (PE:EA=50:1) to give compound 2 (0.45 g, 75%) as a light
yellow solid. .sup.1H-NMR (400 MHz, CDCl.sub.3): 7.04 (d, J=4 Hz,
1H), 7.07 (d, J=4 Hz, 1H), 7.19 (s, 1H), 7.86 (s, 1H).
5-(5-((Trimethylsilyl)ethynyl)thiophen-2-yl)oxazole (3)
[1417] Under nitrogen ethynyltrimethylsilane (85 mg, 0.13 mL, 0.87
mmol) was added to a solution of compound 2 (0.1 g, 0.43 mmol),
Pd(PPh.sub.3).sub.2Cl.sub.2 (10 mg, 0.014 mmol), CuI (8 mg, 0.04
mmol) in TEA (5 mL) at 60.degree. C. The solution was heated to
90.degree. C. for 2 hours. The reaction was treated with EA (100
mL), washed with water (100 mL), brine (100 mL), dried
(Na.sub.2SO.sub.4), evaporated in vacuo. The residue product was
purified by silica gel column (PE: EA=50:1) to give desired product
(73 mg, 68%) as a light yellow solid.
5-(5-Ethynylthiophen-2-yl)oxazole (4)
[1418] To a solution of compound 3 (4.3 g, 17.4 mmol) in a mixture
solution of methanol (40 mL) and THF (50 mL) was treated with
KOH/CH.sub.3OH (0.49 g/10 mL) dropwise below 10.degree. C. The
reaction mixture was allowed to react at ambient temperature for
0.5 h. The reaction solution was neutralized with acetic acid to
PH=7 and concentrated under reduced pressure. The residue was
purified by silica gel column (PE: EA=50:1) to give desired product
(2.0 g, 67%) as a yellow solid. .sup.1H-NMR (400 MHz, CDCl.sub.3):
3.44 (s, 1H), 7.23 (d, J=2, 1H), 7.26 (d, J=1.6, 1H), 7.18 (s, 1H),
7.87 (s, 1H),
Methyl 4-((5-(oxazol-5-yl)thiophen-2-yl)buta-1,3-diynyl)benzoate
(5)
[1419] To a degassed solution of compound 4 (1.9 g, 10.8 mmol),
methyl 4-(bromoethynyl)benzoate (2.7 g, 11.4 mmol),
Pd(PPh.sub.3).sub.2Cl.sub.2 (0.38 g, 0.54 mmol), CuI (0.10 g, 0.54
mmol) in THF (90 mL) was added i-Pr.sub.2NH (3.29 g, 4.6 mL, 32.5
mmol) at room temperature. The mixture was allowed to react at this
temperature for 3 h. The mixture was treated with EA (300 mL),
washed with water (200 mL), saturated NH.sub.4Cl (100 mL), brine
(300 mL), dried (Na.sub.2SO.sub.4), concentrated in vacuo. The
residue was purified by silica gel column (PE/EA=1:1) to give
desired product (1.45 g, 40%) as a yellow solid.
4((5-(Oxazol-5-yl)thiophen-2-yl)buta-1,3-diynyl)benzoic acid
(IC-8)
[1420] To a solution of compound 5 (1.43 g, 4.3 mmol) in a mixture
solution of THF (300 mL) and CH.sub.3OH (50 mL) was added 2 N NaOH
(10 mL) at ambient temperature. The reaction solution was allowed
to react for 3 hours. Then evaporated the organic solvent, adjusted
the PH at 6 with 2 N HCl. Filtration gave crude product, which was
triturated in THF. The precipitate was collected by filtration to
give desired product (0.262 g, 20%) as a yellow solid. .sup.1H-NMR
(400 MHz, DMSO-d.sub.6): 7.52 (d, J=4, 1H), 7.6 6 (d, J=3.6, 1H),
7.72-7.74 (m, 3H), 7.98 (d, J=8, 2H), 8.51 (s, 1H).
Synthesis of Intermediate Acid IC-9
##STR00294##
[1421] Methyl 4-(bromobuta-1,3-diynyl)benzoate (1)
[1422] 0 (368 mg, 2 mmol, 1.0 eq.) and AgNO.sub.3 (40 mg, 0.1 eq.)
were dissolved in 50 mL acetone and stirring for 2 h at r. t. Then,
NBS (4 mmol, 2.0 eq.) was added to the mixture and stirred for 2 h.
TLC monitored the reaction. When the reaction was complete,
filtered the solid and the filtrate was evaporated and dissolved in
EtOAc. The organic layer was washed with sat. NaHCO.sub.3, H.sub.2O
and brine, dried, filtered and evaporated to give the desired
product 1 without purification (526 mg, Y=100%). .sup.1H NMR (400
MHz, CDCl3): .delta. ppm 8.00 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.4 Hz,
2H), 3.92 (s, 3H).
Methyl 4-(cyclopropylhexa-1,3,5-triynyl)benzoate (2)
[1423] Under nitrogen, diisopropylethylamine (DIPEA) (1 mL, 3.0
equiv) and ethynylcyclopropane (4 mmol, 2.0 equiv.) were added to a
solution of compound 1 (526 mg, 2 mmol 1.0 equiv),
PdCl.sub.2(PPh.sub.3).sub.2 (0.181 g, 0.05 mmol, 0.025 equiv) and
CuI (0.191 g, 0.1 mmol, 0.1 equiv) in dry THF (50 mL) in ice bath.
The mixture was allowed to react at r.t. overnight. Then, the
solvents were evaporated and the residue was purified by column
chromatography to get the pure desired product 2 (380 mg, 76.6%).
MS: [M+1].sup.+=249
4-(Cyclopropylhexa-1,3,5-triynyl)benzoic acid (IC-9)
[1424] To a solution of compound 2 (380 mg, 1.0 equiv) in
CH.sub.3OH/THF/H.sub.2O=5/5/1 (50 mL) was added NaOH (300 mg, 4.0
equiv). Then, the mixture was stirred at 25.degree. C. overnight.
Then, the solvent was removed and neutralized with 1 N HCl to
PH=3-5. The product was extracted with EtOAc and concentrated under
reduced pressure to give the desired product IC-9 (310 mg, 86.6%).
LC-MS: [M-H].sup.-=233. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. ppm 13.32 (s, 1H), 7.95 (d, J=8.4 Hz, 2H), 7.73 (d, J=8.4
Hz, 2H), 1.61 (m, 1H), 0.95 (m, 2H), 0.85 (m, 2H).
Synthesis of Intermediate Acid IC-10
##STR00295##
[1425] The target product was prepared by following the General
procedure for Method 1-C (Cadiot-Chodkiewicz Coupling), Method 6
(DAST Fluorination) and Method 2-A (Basic hydrolysis) The following
compounds were synthesized as described above.
TABLE-US-00049 MH.sup.+ Ret. HPLC- Compound (m/z) Time MS #
Structure theo (min) Method 95-1 ##STR00296## 397 95-2 ##STR00297##
397 95-3 ##STR00298## 383 95-4 ##STR00299## 396 95-5 ##STR00300##
382 95-6 ##STR00301## 398 95-7 ##STR00302## 356 95-8 ##STR00303##
368 95-9 ##STR00304## 410 95-10 ##STR00305## 369 95-11 ##STR00306##
343 95-12 ##STR00307## 357 95-13 ##STR00308## 367 95-14
##STR00309## 375 95-15 ##STR00310## 353 95-16 ##STR00311## 365
95-17 ##STR00312## 351 95-18 ##STR00313## 448 95-19 ##STR00314##
460 95-20 ##STR00315## 438 95-21 ##STR00316## 396 95-22
##STR00317## 332 95-23 ##STR00318## 346 95-24 ##STR00319## 364
95-25 ##STR00320## 346
Example 96
Synthesis of
(E)-4-[4-(4-morpholin-4-ylmethylphenyl)-but-3-en-1-ynyl]benzoic
acid (1)
##STR00321##
[1426] 4-Morpholin-4-ylmethylbenzaldehyde (2)
[1427] To a solution containing morpholine (5.25 mL, 60 mmol) in
dichloromethane (50 mL) was added HCl (5 mL, 20 mmol, 4 M in
dioxane) dropwise following by 4-diethoxymethylbenzaldehyde (1,
2.08 g, 10 mmol), NaBH.sub.3CN (0.44 g, 7 mmol) and Aliquat 336
(2.93 g, 7 mmol). Then 1 g of 4 A molecular sieves was added. The
mixture was stirred at room temperature overnight, filtered, and
the solvent removed in vacuo. Then 200 mL water was added to the
residue and the pH was adjusted to 4 by 0.5 M citric acid. The
mixture was stirred for 1 hour and then extracted with ether
(2.times.100 mL). The pH of the aqueous layer was adjusted to 9 by
1.0 M sodium hydroxide. It was extracted with ether (3.times.100
mL). The combined organic layers were washed with water (150 mL),
brine (50 mL) dried (MgSO.sub.4), filtered and concentrated under
reduced pressure to give the title compound 2 (1.0 g, 48%). MS
(m/z): [M+H].sup.+=206. .sup.1H NMR (300 MHz, CDCl.sub.3): in ppm,
2.48 (br s, 4H), 3.59 (s, 2H), 3.70-3.78 (m, 4H), 7.54 (d, J=8.0
Hz, 2H), 7.85 (d, J=8.3 Hz, 2H), 10.0 (s, 1H).
(E)-4-[4-(2-Iodovinyl)benzyl]morpholine (3)
[1428] Chromium chloride anhydrous (19.1 g, 155 mmol, 8 eq) was
added to THF (400 mL) under nitrogen. A solution of triiodomethane
(30.7 g, 78 mmol, 4 eq) in THF (500 mL) was added dropwise at
0.degree. C. under nitrogen. Then a solution of 2 (4.0 g, 19.5
mmol, 1 eq) in THF (100 mL) was added dropwise. The mixture was
stirred at 0.degree. C. for 2 h and then at room temperature for 2
h. The mixture was poured into iced water and extracted with EtOAc
(2.times.800 mL). The combined organic phase was washed with 20%
aq. Na.sub.2S.sub.2O.sub.3 (300 mL), brine (300 mL), dried
(MgSO.sub.4), filtered and concentrated under reduced pressure. The
residue was purified by chromatography on silica gel (0 to 5%
EtOAc/Hexanes) to give the title compound 3 (3.55 g, 55%). MS
(m/z): [M+H]+=330. .sup.1H NMR (300 MHz, CDCl.sub.3): in ppm, 2.44
(t, J=4.6 Hz, 4H), 3.47 (s, 2H), 3.70 (t, J=4.6 Hz, 4H), 6.80 (d,
J=15 Hz, 1H), 7.22-7.27 (m, 4H), 7.41 (d, J=15 Hz, 1H).
(E)-4-[4-(4-morpholin-4-yl-methyl-phenyl)-but-3-en-1-ynyl]-benzoic
acid methyl ester (5)
[1429] To a mixture of 3 (290 mg, 0.88 mmol, 1.0 eq), 4 (141 mg,
0.88 mmol, 1.0 eq.), diisopropylamine (0.125 mL, 0.88 mmol) and
PdCl.sub.2(PPh.sub.3).sub.2 (32 mg, 0.044 mmol, 0.05 eq) in
Et.sub.3N (15 mL) was added CuI (18 mg, 0.09 mmol, 0.1 eq) under
nitrogen at room temperature. The mixture was stirred at room
temperature for 12 h, diluted with EtOAc (40 mL), filtered and
concentrated. The residue was dissolved into EtOAc (50 mL) and
washed with water (50 mL) and brine (50 mL), and dried
(MgSO.sub.4). After filtration and concentration, the residue was
purified by chromatography on silica gel (0 to 30% EtOAc/Hexanes)
to give the title compound 5 (209 mg, 66%). MS (m/z): [M+H]+=362.
.sup.1H NMR (300 MHz, CDCl.sub.3): in ppm, 2.44 (t, J=4.6 Hz, 4H),
3.48 (s, 2H), 3.70 (t, J=4.6 Hz, 4H), 3.90 (s, 3H), 6.36 (d, J=16.2
Hz, 1H), 7.06 (d, J=16.2 Hz, 1H), 7.30 (d, J=8.4 Hz, 2H), 7.37 (d,
J=8.4 Hz, 2H), 7.50 (d, J=8.9 Hz, 2H), 7.99 (d, J=8.9 Hz, 2H).
(E)-4-[4-(4-Morpholin-4-ylmethylphenyl)-but-3-en-1-ynyl]benzoic
acid (1)
[1430] To a solution of 5 (4.3 g, 11.9 mmol, 1.0 eq) in
THF/MeOH/H.sub.2O (80 mL, 1/1/1) was added LiOH.H.sub.2O (1.0 g,
23.8 mmol, 2.0 eq). The mixture was stirred at room temperature for
24 h. The pH was adjusted to 7 by 1 M HCl. The mixture was stirred
for 1 h. The solid was filtered and washed with water (40 mL) and
ether (40 mL) and dried in vacuo. To a suspension of above solid in
ether (40 mL) was added HCl (24 mL, 48 mmol, 2 M in ether). The
mixture was stirred at room temperature for 1 h. The solid was
filtered and washed with ether (40 mL), and dried in vacuo at
45.degree. C. overnight to give the target product 1-HCl (3.0 g,
71%). MS (m/z): [M+H].sup.+=348. .sup.1H NMR (300 MHz, CDCl.sub.3):
in ppm, 2.95-3.20 (m, 4H), 3.75-4.00 (m, 4H), 4.29 (s, 2H), 6.78
(d, J=16.2 Hz, 1H), 7.22 (d, J=16.2 Hz, 1H), 7.61 (d, J=8.4 Hz,
2H), 7.67 (br, s, 4H), 7.96 (d, J=8.4 Hz, 2H), 11.7 (br s, 1H).
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-[(E)-4-(4-morpholin-4-yl-
methyl-phenyl)-but-3-en-1-ynyl]-benzamide (96-1)
##STR00322##
[1431] Synthesis of
(2S,3R)-3-hydroxy-2-{4-[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1--
ynyl]-benzoylamino}-butyric acid methyl ester (2)
[1432] To the mixture of compound 1 (70 mg, 0.20 mmol) and
H--(S)-Thr-OMe hydrochloride (41 mg, 0.24 mmol) in DMF (1.5 mL) was
added BOP (115 mg, 0.26 mmol) followed by DIEA (104 .mu.l, 0.6
mmol). Reaction mixture was stirred at ambient temperature for 20
min, diluted with EtOAc (50 mL), extracted with water (30
mL.times.2) and brine (30 mL). Organic layer was dried over anh.
Na.sub.2SO.sub.4, evaporated in vacuo and dried in vacuo overnight
to provide target product 2 (92 mg, 100%) as white solid. LC-MS
[M+H] 463.3 (C27H30N2O5+H, requires 463.55). Compound was used in
next synthetic step without additional purification.
Synthesis of
N-((1S,2R)-2-hydroxy-1-hydroxycarbamoyl-propyl)-4-[(E)-4-(4-morpholin-4-y-
lmethyl-phenyl)-but-3-en-1-ynyl]-benzamide (96-1)
[1433] To a stirred suspension of compound 2 (92 mg, 0.2 mmol) and
hydroxylamine hydrochloride (84 mg, 1.2 mmol) in MeOH (anh, 2 mL)
and THF (anh, 2 mL) was added NaOtBu (154 mg, 1.6 mmom) powder in
one portion at -5.degree. C. under nitrogen. Reaction mixture was
stirred at -5.degree. C. for additional 5 min. Temperature of
reaction mixture was raised to ambient. Completion of the reaction
was monitored by LC-MS. After completion (in 20 min) reaction
mixture was acidified with 1 N HCl in MeOH to pH.about.6 at low
temperature and evaporated in vacuo. Residue was dissolved in DMSO
(600 .mu.l) and subjected to HPLC purification. [Phenomenex Gemini
C-18 column, 110 .ANG. (30.times.100 mm); flow rate=20 mL/min;
mobile phase A: 100% water, 0.1% TFA; mobile phase B: 100% ACN,
0.1% TFA; gradient elution from 8% B to 28% B in 60 min., detection
254 nm]. Fractions containing the desired product were combined and
lyophilized to provide trifluoroacetate salt of target product
(15-1) (20.5 mg) as white solid. LC-MS [M+H] 464.3 (C26H29N3O5+H,
requires 464.54).
TABLE-US-00050 Retention Scale Yield Yield Purity [M + time
Compound (mmol)* (mg) (%)* (%) H] (min)** 96-1 0.2 20.5 17.8 97.7
464.3 4.06 *Based on the amount of carboxylic acid used in the
coupling reaction **HPLC-MS Method B
Each of the following compounds was synthesized as described
above.
TABLE-US-00051 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 96-2 ##STR00323## 464.4 4.08 B 96-3 ##STR00324##
462.4 5.01 B 96-4 ##STR00325## 463.3 3.57 B
Example 97
N-((1S,2R)-1-Hydroxycarbamoyl-2-methoxy-propyl)-4-[(E)-4-(4-morpholin-4-yl-
methyl-phenyl)-but-3-en-1-ynyl]-benzamide (97-1)
##STR00326##
[1434] Synthesis of
(2S,3R)-3-methoxy-2-{4-[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1--
ynyl]-benzoylamino}-butyric acid methyl ester (3)
TABLE-US-00052 [1435] Reagent MW Eq. mg/mL mmol Compound 1
(Ach-Tr-Db- 347.41 1.0 80 mg 0.23 (Morpholine)-OH
H-(S)-Thr(Me)-OTMS 133.15 1.2 37 mg 0.28 BSA 203.43 2.9 160 .mu.l
0.67 BOP 442.28 1.26 127 mg 0.29 DIEA 129.24 4.0 160 .mu.l 0.92 DMF
2 mL
[1436] Compound 3 (100 mg, 95%) as light yellow oil was prepared
using the BOP coupling described in Example 96 for compound 2.
LC-MS [M+H] 463.2 (C27H30N2O5+H, requires 463.5).
Synthesis of N
N-[(1S,2R)-2-methoxy-1-(tetrahydro-pyran-2-yloxycarbamoyl)-propyl]-4-[(E)-
-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzamide
(4)
[1437] A solution of compound 3 (100 mg, 0.22 mmol), DIC (51 .mu.l,
0.33 mmol) and HOAT (45 mg) in CHCl.sub.3 (1.67 mL) and DMF (0.33
mL) was stirred at 0.degree. C. for 10 min followed by addition of
THP--O--NH.sub.2 (52 mg, 0.44 mmol). Reaction mixture was stirred
at 0.degree. C. for additional 30 min. Then reaction mixture was
allowed to warm to ambient temperature, diluted with water (50 mL),
extracted with CHCl.sub.3 (50 mL.times.2). Combined organic phase
was washed with brine (30 mL), dried over anh. Na.sub.2SO.sub.4 and
concentrated in vacuo. Flash chromatography on silica gel of the
residue gave target product 4 (63 mg, 51%) as white solid. LC-MS
[M+H] 562.4 (C32H39N3O6+H, requires 562.7).
Synthesis of
N-((1S,2R)-1-hydroxycarbamoyl-2-methoxy-propyl)-4-[(E)-4-(4-morpholin-4-y-
lmethyl-phenyl)-but-3-en-1-ynyl]-benzamide (97-1)
[1438] A solution of compound 4 (63 mg, 0.11 mmol) in 0.5 mL of
dioxane was cooled to 0.degree. C. followed by 4 N HCl/dioxane (0.5
mL, 2 mmol). Reaction mixture was allowed to warm to ambient
temperature and stirred for 30 min. Solvent was evaporated in
vacuo. Residue was dissolved in DMSO (400 .mu.l) and subjected to
HPLC purification. [Phenomenex Gemini C-18 column, 110 .ANG.
(30.times.100 mm); flow rate=20 mL/min; mobile phase A: 100% water,
0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient elution from
8% B to 28% B in 60 min., detection 254 nm]. Fractions containing
the desired product were combined and lyophilized to provide
trifluoroacetate salt of target product 97-1 (12.8 mg) as white
solid. LC-MS [M+H] 478.2 (C27H31N3O5+H, requires 478.7).
TABLE-US-00053 Retention Compound Scale Yield Yield Purity [M +
time # (mmol)* (mg) (%)* (%) H] (min)** 97-1 0.23 12.8 9.4 95 478.2
4.8 *Based on the amount of carboxylic acid used in the coupling
reaction **HPLC-MS Method B
The following compound was synthesized as described above.
TABLE-US-00054 HPLC- Compound MH.sup.+ Ret. Time MS # Structure
(m/z) (min) Method 97-2 ##STR00327## 478.2 4.43 B
Example 98
Synthesis of
N--((S)-2-amino-1-hydroxycarbamoyl-ethyl)-4-[(E)-4-(4-morpholin-4-ylmethy-
l-phenyl)-but-3-en-1-ynyl]-benzamide (98-1)
N--[(S)-2-(2-dimethylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-[(E)-4-
-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzamide
(98-2)
N--((S)-2-acetylamino-1-hydroxycarbamoyl-ethyl)-4-[(E)-4-(4-morpholin-4-yl-
methyl-phenyl)-but-3-en-1-ynyl]-benzamide (98-3)
##STR00328##
[1439] Synthesis of (S)-3-tert-butoxycarbonylamino-2-
{4-[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzoylamino}--
propionic acid methyl ester (2)
TABLE-US-00055 [1440] Reagent MW Eq. mg/mL mmol Compound 1
(Ach-Tr-Db- 347.41 1.0 280 mg 0.80 (Morpholine)-OH
N-Boc-(S)-DAP-OMe .times. HCl 254.71 1.2 245 mg 0.96 BOP 442.28
1.25 442.3 mg 1.0 DIEA 129.24 3.0 418 .mu.l 2.4 DMF 5 mL
[1441] The product 2 (338 mg, 77%) as yellow solid was prepared
using the BOP coupling described in Example 96 for compound 2.
LC-MS [M+H] 548.4 (C31H37N3O6+H, requires 548.6). Compound was used
in next synthetic step without additional purification.
Synthesis of
(S)-3-amino-2-{4-[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]--
benzoylamino}-propionic acid methyl ester (3)
TABLE-US-00056 [1442] Reagent MW Eq. mg/mL mmol Compound 2 547.64
1.0 338 mg 0.62 4N HCl/dioxane 13 2 mL 8 Dioxane/MeOH (1:1) 2
mL
[1443] The product 3 (321 mg, 100%) as white solid was made using
the General Method for Boc deprotection. LC-MS [M+H] 448.4
(C26H29N3O4+H, requires 448.5).
Synthesis of
N--((S)-2-amino-1-hydroxycarbamoyl-ethyl)-4-[(E)-4-(4-morpholin-4-ylmethy-
l-phenyl)-but-3-en-1-ynyl]-benzamide (98-1)
TABLE-US-00057 [1444] Reagent MW Eq. mg/mL mmol Compound 3 .times.
2 HCl 518.5 1.0 104 mg 0.2 NH.sub.2OH .times. HCl 69.49 6.0 84 mg
1.2 NaOtBu 96.11 8.0 154 mg 1.6 MeOH 2 mL THF 2 mL
[1445] The product 4 (20.5 mg) as white solid was prepared using
the Hydoxyamide formation described in Example 96 for compound
96-1. LC-MS [M+H] 449.2 (C25H28N4O4+H, requires 449.5).
TABLE-US-00058 Retention Scale Yield Yield Purity [M + time
Compound (mmol)* (mg) (%)* (%) H] (min)* 98-1 0.2 20.5 18.3 97.5
449.2 3.48 *Based on the amount of compound 3. **HPLC-MS Method
B
Synthesis of (S)-3-(2-dimethylamino-acetylamino)-2- {4-
[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzoylamino}-pro-
pionic acid methyl ester (5)
[1446] To the mixture of compound 3 di-hydrochloride (104 mg, 0.20
mmol) and dimethylaminoacetyl chloride hydrochloride (41 mg, 0.26
mmol) in DMF (0.5 mL) and CHCl.sub.3 (1.5 mL) was added DIEA (210
.mu.l, 1.2 mmol). Reaction mixture was stirred at ambient
temperature overnight. Solvent was concentrated in vacuo. Residue
was dissolved in EtOAc (50 mL), washed with 5% solution of
NaHCO.sub.3 (50 mL) and brine (30 mL) Organic phase was dried over
anh. Na.sub.2SO.sub.4, evaporated in vacuo and dried in vacuo
overnight to provide target product 5 (75 mg, 71%) as white solid.
LC-MS [M+H] 533.5 (C30H36N4O5+H, requires 533.6). Compound was used
in next synthetic step without additional purification.
Synthesis of
N--[(S)-2-(2-dimethylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-[(E)--
4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzamide
(98-2)
TABLE-US-00059 [1447] Reagent MW Eq. mg/mL mmol Compound 5 532.6
1.0 75 mg 0.14 NH.sub.2OH .times. HCl 69.49 6.0 58 mg 0.84 NaOtBu
96.11 8.0 108 mg 1.12 MeOH 1.5 mL THF 1.5 mL
[1448] Compound was prepared using the same procedure as for
synthesis of compound (98-1). LC-MS [M+H] 534.4 (C29H35N5O5+H,
requires 534.6).
TABLE-US-00060 Retention Scale Yield Yield Purity [M + time
Compound (mmol)* (mg) (%)* (%) H] (min)* 98-2 0.2 25.8 20% 100
534.4 3.51 *Based on the amount of compound 3. **HPLC-MS Method
B
Synthesis of (S)-3-acetylamino-2- {4-
[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzoylamino}-pro-
pionic acid methyl esterster (7)
[1449] To the mixture of compound 3 di-hydrochloride (104 mg, 0.20
mmol) and acetic anhydride (36 .mu.l, 0.38 mmol) in DMF (0.5 mL)
and CHCl.sub.3 (1.5 mL) was added DIEA (210 .mu.l, 1.2 mmol).
Reaction mixture was stirred at ambient temperature overnight.
Solvent was concentrated in vacuo. Residue was dissolved in EtOAc
(50 mL), washed with 5% solution of NaHCO.sub.3 (30 mL) and brine
(30 mL). Organic phase was dried over anh. Na.sub.2SO.sub.4,
evaporated in vacuo and dried in vacuo overnight to provide target
product 7 (70 mg, 71%) as white solid. LC-MS [M+H] 490.3
(C28H31N3O5+H, requires 490.5). Compound was used in next synthetic
step without additional purification.
Synthesis of
N--((S)-2-acetylamino-1-hydroxycarbamoyl-ethyl)-4-[(E)-4-(4-morpholin-4-y-
lmethyl-phenyl)-but-3-en-1-ynyl]-benzamide (98-3)
TABLE-US-00061 [1450] Reagent MW Eq. mg/mL mmol Compound 7 489.6.6
1.0 70 mg 0.14 NH.sub.2OH .times. HCl 69.49 6.0 58 mg 0.84 NaOtBu
96.11 8.0 108 mg 1.12 MeOH 1.5 mL THF 1.5 mL
[1451] Compound was prepared using the same procedure as for
synthesis of compound (98-1). LC-MS [M+H] 491.2 (C27H30N4O5+H,
requires 491.5).
TABLE-US-00062 Retention Scale Yield Yield Purity [M + time
Compound (mmol)* (mg) (%)* (%) H] (min)** 98-3 0.2 22.4 18.6% 100
491.2 3.41 *Based on the amount of compound 3. **HPLC-MS Method
B
Example 99
4-[(E)-4-(4-{[Ethyl-(2-methoxy-ethyl)-amino]-methyl}-phenyl)-but-3-en-1-yn-
yl]-N--((S)-1-hydroxycarbamoyl-2-methylamino-ethyl)-benzamide
(99-1)
##STR00329##
[1452] Synthesis of (S)-3-hydroxy-2-
{4-[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzoylamino}--
propionic acid methyl ester (2)
TABLE-US-00063 [1453] Reagent MW Eq. mg/ml mmol Compound 1
(Ach-Tr-Db- 347.41 1.0 139 mg 0.40 (Morpholine)-OH H-(S)-Ser-OMe
.times. HCl 155.58 1.2 75 mg 0.48 BOP 442.28 1.25 223 mg 0.50 DIEA
129.24 3.0 210 .mu.l 1.20 DMF 4 ml
[1454] The product 2 (179 mg, 100%) as white solid was prepared
using the BOP coupling described in Example 96 for compound 2.
LC-MS [M+H] 449.4 (C26H28N2O5+H, requires 449.51). Compound was
used in next synthetic step without additional purification.
Synthesis of
(S)-3-methylamino-2-{4-[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1--
ynyl]-benzoylamino}-propionic acid methyl ester (3)
[1455] A solution of compound 2 (179 mg, 0.4 mmol) and DIEA (140
.mu.l, 0.8 mmol) in CH.sub.2Cl.sub.2 (5 ml) was cooled to 0.degree.
C. followed by the addition of MsCl (37 .mu.l, 0.48 mmol). Reaction
mixture was maintained at 0.degree. C. for 30 min followed by the
addition of 2 M solution of methylamine in THF (2 ml, 4 mmol).
Temperature of the reaction mixture was raised to ambient. Reaction
mixture was maintained at ambient temperature. After completion (in
30 min) solvent was removed in vacuo. Residue was dissolved in
EtOAc (50 ml), washed with water (30 ml.times.2), brine (50 ml) and
dried over anh. Na.sub.2SO.sub.4. Solvent was evaporated in vacuo
and dried in vacuo overnight to provide compound 3 (120 mg, 65%) as
light yellow solid. LC-MS [M+H] 462.4 (C27H31N3O4+H, requires
462.5).
Synthesis of 4- [(E)-4-(4-
{[ethyl-(2-methoxy-ethyl)-amino]-methyl}-phenyl)-but-3-en-1-ynyl]-N--((S)-
-1-hydroxycarbamoyl-2-methylamino-ethyl)-benzamide (99-1)
TABLE-US-00064 [1456] Reagent MW Eq. mg/ml mmol Compound 3 461.55
1.0 120 mg 0.26 NH.sub.2OH .times. HCl 69.49 6.0 110 mg 1.56 NaOtBu
96.11 8.0 200 mg 2.1 MeOH 2 ml THF 2 ml
[1457] The product 99-1 (11.2 mg) as white solid was prepared by
using the same procedure as for synthesis of compound (98-1). LC-MS
[M+H] 463.3 (C26H30N4O4+H, requires 463.5).
TABLE-US-00065 Retention Scale Yield Yield Purity [M + time
Compound (mmol)* (mg) (%)* (%) H] (min)** 99-1 0.4 11.2 4.1 92.2
463.3 3.48 *Based on the amount of carboxylic acid used in the
coupling reaction **HPLC-MS Method B
Example 100
N--[(S)-2-(2-Cyclopropylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-[(E-
)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzamide
(100-1)
##STR00330##
[1458] Synthesis of (S)-3-tert-butoxycarbonylamino-2-
{4-[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzoylamino}--
propionic acid methyl ester (2)
TABLE-US-00066 [1459] Reagent MW Eq. mg/mL mmol Compound 1
(Ach-Tr-Db- 347.41 1.0 139 mg 0.40 (Morpholine)-OH
N-Boc-(S)-DAP-OMe .times. HCl 254.71 1.2 122 mg 0.48 BOP 442.28
1.25 223 mg 0.50 DIEA 129.24 3.0 210 .mu.l 1.2 DMF 4 mL
[1460] The product 2 (207 mg, 94%) as yellow solid was prepared
using the BOP coupling described in Example 96 as for the synthesis
of the compound 2. LC-MS [M+H] 548.4 (C31H37N3O6+H, requires
548.6). Compound was used in next synthetic step without additional
purification.
Synthesis of
(S)-3-amino-2-{4-[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]--
benzoylamino}-propionic acid methyl ester (3)
TABLE-US-00067 [1461] Reagent MW Eq. mg/mL mmol Compound 2 547.64
1.0 207 mg 0.38 4N HCl/dioxane 21 2 mL 8 Dioxane/MeOH (1:1) 2
mL
[1462] The product 3 (208 mg, 100%) as white solid was made using
the General Method for Boc deprotection. LC-MS [M+H] 448.4
(C.sub.26H.sub.29N.sub.3O.sub.4+H, requires 448.5). Compound was
used in next synthetic step without additional purification.
Synthesis of
(S)-3-(2-bromo-acetylamino)-2-[4-((3E,5E,7E)-5,8-dimethyl-9-morpholin-4-y-
l-nona-3,5,7-trien-1-ynyl)-benzoylamino]-propionic acid methyl
ester (4)
[1463] To the mixture of compound 3 di-hydrochloride (207 mg, 0.40
mmol) and DIEA (180 .mu.l) in CH.sub.2Cl.sub.2 (4 mL) was added
bromoacetyl bromide (35 .mu.l, 0.4 mmol) at 0.degree. C. Reaction
mixture was allowed to warm to ambient temperature and stirred for
30 min. Solvent was evaporated in vacuo. Residue was dissolved in
EtOAc (50 mL), washed with 5% solution of NaHCO.sub.3 (50 mL) and
brine (50 mL.times.2). Organic phase was dried over anh.
Na.sub.2SO.sub.4, evaporated in vacuo and dried in vacuo overnight
to provide target product 4 (146 mg, 64%) as white solid. LC-MS
[M+H] 570.1 (C28H30BrN3O5+H, requires 569.5). Compound was used in
next synthetic step without additional purification.
Synthesis of (S)-3-(2-cyclopropylamino-acetylamino)-2-
{4-[(E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzoylamino}--
propionic acid methyl ester (5)
[1464] To a solution of compound 4 (146 mg, 0.26 mmol) in
CH.sub.2Cl.sub.2 (4 mL) was added cyclopropylamine (36 .mu.l, 0.52
mmol) at 0.degree. C. Reaction mixture was maintained at 0.degree.
C. for 10 min, then mixture was allowed to warm to ambient
temperature and stirred overnight. After completion the solvent was
removed in vacuo. Residue was dissolved in EtOAc (60 mL), washed
with water (50 mL.times.2), brine (50 mL), dried over anh.
Na.sub.2SO.sub.4 and concentrated in vacuum. Residue was dissolved
in DMSO (800 .mu.l) and subjected to HPLC purification. [YMC-Pack
ODS-AC-18 column (30.times.100 mm); flow rate=40 mL/min; mobile
phase A: 100% water, 0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA;
gradient elution from 10% B to 50% B in 50 min., detection 254 nm].
Fractions containing the desired product were combined and
evaporated in vacuo. Residue was dissolved in i-PrOH (10 mL),
evaporated in vacuum and dried in vacuo overnight to provide
di-trifluoroacetate salt of the target product 5 (70 mg, 36%) as
white solid. LC-MS [M+H] 545.0 (C.sub.31H.sub.36N.sub.4O.sub.5+H,
requires 545.6).
Synthesis of
N--[(S)-2-(2-cyclopropylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-[(-
E)-4-(4-morpholin-4-ylmethyl-phenyl)-but-3-en-1-ynyl]-benzamide
(100-1)
TABLE-US-00068 [1465] Reagent MW Eq. mg/mL mmol Compound 5 .times.
2 TFA 738.6 1.0 70 mg 0.095 NH.sub.2OH .times. HCl 69.49 6.0 40 mg
0.57 NaOtBu 96.11 8.0 73 mg 0.76 MeOH 1 mL THF 1 mL
[1466] The product 100-1 (18.4 mg) as white solid was prepared
using the same procedure as for synthesis of compound (98-1). LC-MS
[M+H] 546.6 (C30H35N5O5+H, requires 546.6).
TABLE-US-00069 Retention Scale Yield Yield Purity [M + time
Compound (mmol)* (mg) (%)* (%) H] (min)** 100-1 0.4 18.4 6.0% 95
546.6 3.68 *Based on the amount of carboxylic acid used in the
coupling reaction **HPLC-MS Method B
Example 101
Synthesis of
(E)-4-[4-(4-Hydroxymethylphenyl)but-3-en-1-ynyl]benzoic acid methyl
ester (1-2)
##STR00331##
[1467] Step 1: 4-Hydroxymethylbenzaldehyde (2)
[1468] A suspension of terephthaldehyde (200 g, 1.492 mol, 1.0 eq.)
in THF (1500 mL) was cooled to 0.degree. C. NaBH.sub.4 (16.94 g,
0.448 mol, 0.3 eq.) was added in one portion. The mixture was
stirred at 1020.degree. C. overnight. 800 mL 1 N HCl was added and
the mixture was stirred for 20 min and turned clear. Most THF was
removed in vacuum. Then, the residue was extracted by EtOAc (500
mL.times.3). The combined organic layer was washed with water
(2.times.400 mL), brine (400 mL) and dried (MgSO.sub.4), filtered
and concentrated to give the compound 2 (200 g, 98%) which was used
directly in next step without purification.
Step 2: 4-(tert-Butyldimethylsilanyloxymethyl)benzaldehyde (3)
[1469] A solution of compound 2 (200 g, 1.47 mol, 1.0 eq.), TBSCl
(220 g, 1.47 mol, 1.0 eq.) and imidazole (200 g, 2.94 mol, 2.0 eq.)
in DMF (1000 mL) was heated at 45.degree. C. for 2 hrs. The mixture
was concentrated to remove most DMF and DCM (2000 mL) was added.
The mixture was washed with water (500 mL.times.2), brine (500 mL)
and dried (MgSO.sub.4), filtered and concentrated under reduced
pressure. The residue was purified by chromatography on silica gel
(0 to 5% EtOAc/PE) to give the compound 3 (130 g, 35.4%).
.sup.1H-NMR (300 MHz, CDCl.sub.3): in ppm, 0.10 (s, 6H), 0.94 (s,
9H), 4.80 (s, 2H), 7.47 (d, J=8.7 Hz, 2H), 7.84 (d, J=8.1 Hz, 2H),
9.98 (s, 1H).
Step 3: (E)-tert-Butyl-[4-(2-iodo-vinyl)benzyloxy]dimethylsilane
(4)
[1470] Chromium chloride anhydrous (29.3 g, 240 mmol, 6 eq) was
added to THF (500 mL) under nitrogen. A solution of triiodomethane
(31.4 g, 80 mmol, 2 eq) in THF (200 mL) was added dropwise at
0.about.10.degree. C. under nitrogen. Then, a solution of compound
3 (10.0 g, 40 mmol, 1 eq) in THF (100 mL) was added dropwise. The
mixture was stirred at 0.about.10.degree. C. for 2 hrs and then at
10-20.degree. C. for 2 more hours. 400 mL iced water was added and
the mixture was stirred for 20 min, extracted with EtOAc (500
mL.times.3). The combined organic phase was washed with 20% aq.
Na.sub.2S.sub.2O.sub.3 aqueous (500 mL), water (500 mL), brine (500
mL) and dried (MgSO.sub.4), filtered and concentrated under reduced
pressure. The residue was purified by chromatography on silica gel
(0 to 2% EtOAc/PE) to give the title compound 4 (9 g, 60%).
.sup.1H-NMR (300 MHz, CDCl.sub.3): in ppm, 0.09 (s, 6H), 0.93 (s,
9H), 4.72 (s, 2H), 0.6.79 (d, J=15 Hz, 1H), 7.26 (s, 4H), 7.41 (d,
J=15 Hz, 1H).
Step 4: (E)-4-
{4-[4-(tert-Butyldimethylsilanyloxymethyl)phenyl]but-3-en-1-ynyl}benzoic
acid methyl ester (6)
[1471] To a mixture of compound 4 (1.02 g, 2.7 mmol, 1.0 eq), 5
(0.43 g, 2.7 mmol, 1.0 eq), PdCl.sub.2(PPh.sub.3).sub.2 (190 mg,
0.27 mmol, 0.1 eq) and Et.sub.3N (5 mL) in THF (50 mL) was added
CuI (51 mg, 0.27 mmol, 0.1 eq) under nitrogen. The mixture was
stirred at 10-20.degree. C. for 12 hrs. The reaction mixture was
diluted with EtOAc (50 mL), filtered and concentrated. The residue
was dissolved into EtOAc (100 mL) and washed with water (100 mL)
and brine (50 mL), and dried (MgSO.sub.4). After filtration and
concentration, the residue was purified by chromatography on silica
gel (0 to 2% EtOAc/PE) to give the title compound 6 (0.625 g, 57%).
.sup.1H-NMR (300 MHz, CDCl.sub.3): in ppm, 0.10 (s, 6H), 0.94 (s,
9H), 3.92 (s, 3H), 4.76 (s, 2H), 6.36 (d, J=18 Hz, 1H), 7.08 (d,
J=18 Hz, 1H), 7.31 (d, J=9.0 Hz, 2H), 7.40 (d, J=9.0 Hz, 2H), 7.52
(d, J=8.5 Hz, 2H), 7.99 (d, J=8.5 Hz, 2H).
Step 5: (E)-4-[4-(4-Hydroxymethylphenyl)but-3-en-1-ynyl]benzoic
acid methyl ester (I-2)
[1472] To a solution of compound 6 (5.65 g, 13.9 mmol, 1 eq) in THF
(50 mL) was added Et.sub.3N-3HF (6.72 g, 21.7 mmol, 3 eq) at room
temperature. The mixture was stirred at 10.about.20.degree. C. for
10 hrs. The mixture was concentrated to remove solvent and EtOAc
(100 mL), NaHCO.sub.3 (50 mL) was added. The mixture was filtered
and the organic of filtrate was separated, washed with brine
(2.times.100 mL) and dried by MgSO.sub.4, filtered. The filtrate
was concentrated to 10 mL and filtered. The combined filter cake
was dried in vacuum to give the target compound I-2 (3.25 g, 80%).
.sup.1H-NMR (300 MHz, DMSO-d.sub.6): in ppm, 3.86 (s, 3H), 4.51 (d,
J=5.76 Hz, 2H), 5.25 (t, J=5.76 Hz, 1H) 6.65 (d, J=16.5 Hz, 1H),
7.17 (d, J=16.2 Hz, 1H), 7.33 (d, J=8.0 Hz, 2H), 7.55 (d, J=8.2 Hz,
2H), 7.61 (d, J=8.25 Hz, 2H), 7.97 (d, J=8.52 Hz, 2H).
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-[(E)-4-(4-hydroxymethyl--
phenyl)-but-3-en-1-ynyl]-benzamide (101-1)
##STR00332##
[1473] Synthesis of
4-[(E)-4-(4-hydroxymethyl-phenyl)-but-3-en-1-ynyl]-benzoic acid
(2)
TABLE-US-00070 [1474] Reagent MW Eq. g/mL mmol Compound 1 293.33
1.0 780 mg 2.63 (Ach-Triple-Double(OH)--OMe) 1N NaOH 2.5 6.5 mL
6.57 THF 4 mL MeOH 4 mL
[1475] The compound 2 (710 mg, 90%) as white solid was made and
separated using the General Method for basic hydrolysis.
Synthesis of (2S,3R)-3-hydroxy-2-
{4-[(E)-4-(4-hydroxymethyl-phenyl)-but-3-en-1-ynyl]-benzoylamino}-butyric
acid methyl ester (3)
TABLE-US-00071 [1476] Reagent MW Eq. mg/mL mmol Compound 2 .times.
sodium salt 300.28 1.0 99 mg 0.33 H-(S)-Thr-OMe .times. HCl 169.6
1.2 66 mg 0.39 BOP 442.28 1.3 184 mg 0.42 DIEA 129.24 3.0 172 .mu.l
0.99 DMF 2 mL
[1477] The compound 3 (120 mg, 92%) as off-white solid was prepared
using the BOP coupling described in Example 96 as for the synthesis
of the compound 2. LC-MS [M+H] 394.3 (C23H23NO5+H, requires 394.4).
Compound was used in next synthetic step without additional
purification.
Synthesis of 4
N-((1S,2R)-2-hydroxy-1-hydroxycarbamoyl-propyl)-4-[(E)-4-(4-hydroxymethyl-
-phenyl)-but-3-en-1-ynyl]-benzamide (101-1)
TABLE-US-00072 [1478] Reagent MW Eq. mg/mL mmol Compound 3 393.4
1.1 120 mg 0.30 NH.sub.2OH .times. HCl 69.49 6.5 135 mg 1.94 25%
NaOMe/MeOH 8.8 600 .mu.l 2.64 MeOH 4 mL THF 1.5 mL
[1479] The target product 101-1 (20.7 mg) as white solid made using
the General Method for hydroxamate formation. LC-MS [M+H] 395.2
(C22H22N2O5+H, requires 395.4).
TABLE-US-00073 Com- Scale Yield Yield Purity Retention pound
(mmol)* (mg) (%)* (%) [M + H] time (min)** 101-1 0.33 20.7 16.0
90.0 395.2 5.31 *Based on the amount of carboxylic acid used in the
coupling reaction **HPLC-MS Method B
Each of the following compounds was synthesized as described
above.
TABLE-US-00074 Ret. Compound MH.sup.+ Time HPLC-MS # Structure
(m/z) (min) Method 101-2* ##STR00333## 380.5 4.56 B 101-3
##STR00334## 394.2 4.65 B 101-4 ##STR00335## 395.3 5.36 B 101-5**
##STR00336## 409.2 5.61 B 101-6* ##STR00337## 421.1 2.52 A
*Boc-protecting group from intermediate was removed by 4M
HCl/dioxane. **Methyl ester of diMeSer was prepared according to
general procedure.
Example 102
4-[(E)-4-(4-Cyclopropylaminomethyl-phenyl)-but-3-en-1-ynyl]-N-((1S,2R)-2-h-
ydroxy-1-hydroxycarbamoyl-propyl)-benzamide (102-1)
##STR00338##
[1480] Synthesis of
4-[(E)-4-(4-cyclopropylaminomethyl-phenyl)-but-3-en-1-ynyl]-benzoic
acid methyl ester (2)
[1481] A solution of compound 1 (750 mg, 2.56 mmol) and DIEA (1.1
mL, 6.40 mmol) in CH.sub.2Cl.sub.2 (15 mL) was cooled to 0.degree.
C. followed by the addition of MSCl (0.22 mL, 2.82 mmol) dropwise
over the period of 5 min. Reaction mixture was maintained at
0.degree. C. for 10 min followed by the addition of
cyclopropylamine (0.89 mL, 12.8 mmol). Temperature of the reaction
mixture was allowed to rise to ambient. Reaction mixture was
maintained at ambient temperature overnight. After completion
solvent was removed in vacuo. Residue was dissolved in EtOAc (150
mL), washed with water (150 mL.times.2), brine (150 mL) and dried
over anh. Na.sub.2SO.sub.4. Solvent was evaporated in vacuo to
provide compound 2 (848 mg, 100%) as light yellow oil. LC-MS [M+H]
332.2 (C22H21NO2+H, requires 332.41). Compound was used in next
synthetic step without additional purification.
Synthesis of 4-((E)-4-
{4-[(tert-butoxycarbonyl-cyclopropyl-amino)-methyl]-phenyl}-but-3-en-1-yn-
yl)-benzoic acid (3)
TABLE-US-00075 [1482] Reagent MW Eq. g/mL mmol Compound 2 331.41
1.0 848 mg 2.56 1N aq NaOH 3.1 8 mL 8.0 Di-tert-butyl dicarbonate
218.2 1.1 615 mg 2.82 THF 8 mL dioxane 5 mL
[1483] The compound 3 (795 mg, 75%) as white solid was made and
separated using the General Method for Boc protection. LC-MS [M+H]
418.3 (C26H27NO4+H, requires 418.5).
Synthesis of (2S,3R)-2-[4-((E)-4-
{4-[(tert-butoxycarbonyl-cyclopropyl-amino)-methyl]-phenyl}-but-3-en-1-yn-
yl)-benzoylamino]-3-hydroxy-butyric acid methyl ester (4)
TABLE-US-00076 [1484] Reagent MW Eq. mg/mL mmol Compound 3 417.5
1.0 155 mg 0.37 H-(S)-Thr-OMe .times. HCl 169.6 1.2 75 mg 0.44 BOP
442.28 1.3 212 mg 0.48 DIEA 129.24 3.0 190 .mu.l 1.10 DMF 2.5
mL
[1485] The product 4 (140 mg, 71%) as light yellow oil was prepared
using the BOP coupling described in Example 96 as for the synthesis
of the compound 2. LC-MS [M+H] 533.4 (C31H36N2O6+H, requires
533.6). Compound was used in next synthetic step without additional
purification.
Synthesis of
(2S,3R)-2-{4-[(E)-4-(4-cyclopropylaminomethyl-phenyl)-but-3-en-1-ynyl]-be-
nzoylamino}-3-hydroxy-butyric acid methyl ester (5)
TABLE-US-00077 [1486] Reagent MW Eq. mg/mL mmol Compound 4 532.6
1.0 140 mg 0.26 4N HCl/dioxane 23.0 1.5 mL 6.0 dioxane 1.5 mL
[1487] The product 5 (121 mg, 100%) as white solid was made using
the General Method for Boc deprotection. LC-MS [M+H] 433.4
(C26H28N2O4+H, requires 433.5). Compound was used in next synthetic
step without additional purification.
Synthesis of
4-[(E)-4-(4-cyclopropylaminomethyl-phenyl)-but-3-en-1-ynyl]-N-((1S,2R)-2--
hydroxy-1-hydroxycarbamoyl-propyl)-benzamide (102-1)
TABLE-US-00078 [1488] Reagent MW Eq. mg/mL mmol Compound 5 .times.
HCl 468.97 1.0 121 mg 0.26 NH.sub.2OH .times. HCl 69.49 7.4 135 mg
1.94 25% NaOMe/MeOH 10.0 600 .mu.l 2.64 MeOH 4 mL THF 1.5 mL
[1489] The product 102-1 (57.6 mg) as white solid was made using
the General Method for hydroxamate formation. LC-MS [M+H] 434.4
(C25H27N3O4+H, requires 434.5).
TABLE-US-00079 Com- Scale Yield Yield Purity Retention pound
(mmol)* (mg) (%)* (%) [M + H] time (min)** 102-1 0.37 57.6 28.5
90.1 434.3 4.41 *Based on the amount of carboxylic acid used in the
coupling reaction **HPLC-MS Method B
Each of the following compounds was synthesized as described
above.
TABLE-US-00080 Ret. Compound MH.sup.+ Time HPLC-MS # Structure
(m/z) (min) Method 102-2 ##STR00339## 433.2 3.86 B 102-3
##STR00340## 419.6 3.69 B 102-4 ##STR00341## 434.3 4.44 B 102-5*
##STR00342## 448.5 4.69 B 102-6 ##STR00343## 447.9 2.74 A *Methyl
ester of di-Me-Ser was prepared according to general procedure.
**Boc-protecting group before hydroxamate formation was removed by
2N HCl/dioxane
Example 103
N--[(S)-2-(2-Cyclopropylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-[(E-
)-4-(4-hydroxymethyl-phenyl)-but-3-en-1-ynyl]-benzamide (103-1)
##STR00344##
[1490] Synthesis of
(S)-3-tert-butoxycarbonylamino-2-{4-[(E)-4-(4-hydroxymethyl-phenyl)-but-3-
-en-1-ynyl]-benzoylamino}-propionic acid methyl ester (2)
TABLE-US-00081 [1491] Reagent MW Eq. mg/mL mmol Compound 1 .times.
sodium salt 300.28 1.0 120 mg 0.40 H-(S)-DAP(Boc)-OMe .times. HCl
254.7 1.2 122 mg 0.48 BOP 442.28 1.3 230 mg 0.52 DIEA 129.24 3.0
210 .mu.l 1.2 DMF 3 mL
[1492] The compound 2 (191 mg, 100%) as off-white solid was
prepared using procedure of the BOP coupling described in Example
96 as for the synthesis of the compound 2. LC-MS [M+H] 479.3
(C27H30N2O6+H, requires 479.5). Compound was used in next synthetic
step without additional purification.
Synthesis of
(S)-3-amino-2-{4-[(E)-4-(4-hydroxymethyl-phenyl)-but-3-en-1-ynyl]-benzoyl-
amino}-propionic acid methyl ester (3)
TABLE-US-00082 [1493] Reagent MW Eq. mg/mL mmol Compound 2 478.5
1.0 191 mg 0.4 4N HCl/dioxane 30 3 mL 12 Dioxane/MeOH (1:1) 3
mL
[1494] The product 3 (165 mg, 100%) as white solid was made using
the General Method for Boc deprotection. LC-MS [M+H] 379.1
(C22H22N2O4+H, requires 379.4).
Synthesis of ((S)-3-(2-bromo-acetylamino)-2-
{4-[(E)-4-(4-hydroxymethyl-phenyl)-but-3-en-1-ynyl]-benzoylamino}-propion-
ic acid methyl ester (4)
TABLE-US-00083 [1495] Reagent MW Eq. mg/mL mmol Compound 3 .times.
HCl 414.9 1.0 165 mg 0.40 Bromoacetyl bromide 201.86 1.0 35 .mu.l
0.40 DIEA 129.24 2.5 180 .mu.l 1.0 CH.sub.2Cl.sub.2 4 mL DMF 1
mL
[1496] The target product 4 (199 mg, 100%), as yellow solid, was
prepared using the method described in compound 4 of Example 100.
LC-MS [M+H] 501.3 (C24H23BrN2O5+H, requires 500.4). Compound was
used in next synthetic step without additional purification.
Synthesis of
(S)-3-(2-cyclopropylamino-acetylamino)-2-{4-[(E)-4-(4-hydroxymethyl-pheny-
l)-but-3-en-1-ynyl]-benzoylamino}-propionic acid methyl ester
(5)
TABLE-US-00084 [1497] Reagent MW Eq. g/mL mmol Compound 4 499.35
1.0 199 mg 0.40 Cyclopropylamine 57.09 3.7 100 .mu.l 1.48
CH.sub.2Cl.sub.2 4 mL
[1498] The target compound 5 (124 mg, 65%) as solid was prepared
using the method described in compound 5 of Example 100. LC-MS
[M+H] 476.3 (C27H29N3O5+H, requires 476.6).
Synthesis of
N--[(S)-2-(2-cyclopropylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-[(-
E)-4-(4-hydroxymethyl-phenyl)-but-3-en-1-ynyl]-benzamide
(103-1)
TABLE-US-00085 [1499] Reagent MW Eq. mg/mL mmol Compound 5 475.6
1.0 124 mg 0.26 NH.sub.2OH .times. HCl 69.49 7.4 135 mg 1.94 25%
NaOMe/MeOH 10.0 600 .mu.l 2.64 MeOH 4 mL THF 1.5 mL
[1500] The product 6 (12.2 mg) as white solid was made using the
General Method for hydroxamate formation. LC-MS [M+H] 477.3
(C26H28N4O5+H, requires 477.5).
TABLE-US-00086 Retention Scale Yield Yield Purity time Compound
(mmol)* (mg) (%)* (%) [M + H] (min)** 103-1 0.4 12.2 5.2 98.9 477.3
4.8 *Based on the amount of carboxylic acid used in the coupling
reaction **HPLC-MS Method B
Example 104
Synthesis of (E)-4-(4-Phenylbut-3-en-1-ynyl)benzoic acid (I-3)
##STR00345##
[1501] (E)-(2-Iodovinyl)benzene (2)
[1502] Chromium chloride anhydrous (37.1 g, 302 mmol, 8 eq) was
added to THF (400 mL) under nitrogen at room temperature. A
solution of triiodomethane (59.7 g, 151 mmol, 4 eq) in THF (500 mL)
was added dropwise at 0.degree. C. under nitrogen. Then a solution
of benzaldehyde 1 (4.0 g, 37.7 mmol, 1 eq) in THF (100 mL) was
added dropwise. The mixture was stirred at 0.degree. C. for 2 hrs
and then at room temperature for 2 more hours. The mixture was
poured into ice water and extracted with EtOAc (800 mL.times.2).
The organic phase was washed with 20% aq. Na.sub.2S.sub.2O.sub.3
(300 mL), water (800 mL), brine (300 mL) dried (MgSO.sub.4),
filtered and concentrated under reduced pressure. The residue was
triturated with EtOAc and hexanes. After filtration, the filtrates
were concentrated to give the title compound 2 (7.2 g, 83%).
.sup.1H NMR (300 MHz, CDCl.sub.3): .delta. ppm, 6.83 (d, J=15.1 Hz,
1H), 7.29-7.32 (m, 5H), 7.43 (d, J=14.8 Hz, 1H).
(E)-4-(4-Phenylbut-3-en-1-ynyl)benzoic acid methyl ester (3)
[1503] To a mixture of compound 2 (3.77 g, 16.4 mmol, 1.0 eq), 4
(2.62 g, 16.4 mmol, 1.0 eq), PdCl.sub.2(PPh.sub.3).sub.2 (0.58 mg,
0.82 mmol, 0.05 eq) and Et.sub.3N (10 mL) in THF (100 mL) was added
CuI (0.32 g, 1.64 mmol, 0.1 eq) under nitrogen at room temperature.
The mixture was stirred at room temperature for 12 hrs. The
reaction mixture was diluted with EtOAc (50 mL), filtered and
concentrated. The residue was dissolved into EtOAc (300 mL) washed
with water (300 mL) and brine (150 mL), and dried (MgSO.sub.4).
After filtration and concentration, the residue was purified by
chromatography on silica gel (0 to 15% EtOAc/Hexanes) to give the
title compound 3 (2.56 g, 60%). .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. ppm, 3.87 (s, 3H), 6.70 (d, J=16.2 Hz, 1H),
7.19 (d, J=16.2 Hz, 1H), 7.35-7.43 (m, 3H), 7.59-7.64 (m, 4H), 7.97
(d, J=8.22 Hz, 2H)
(E)-4-(4-Phenylbut-3-en-1-ynyl)benzoic acid (1-3)
[1504] The product I-3 (1.45 g, 61%) was made and separated using
the General Method for basic hydrolysis. MS (m/z): [M-H]+=247,
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm, 6.70 (d, J=16.2
Hz, 1H), 7.19 (d, J=16.2 Hz, 1H), 7.32-7.42 (m, 3H), 7.58-7.61 (m,
4H), 7.95 (d, J=8.5 Hz, 2H).
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-((E)-4-phenyl-but-3-en-1-
-ynyl)-benzamide (104-1)
##STR00346##
[1505] Synthesis of
(2S,3R)-3-hydroxy-2-[4-((E)-4-phenyl-but-3-en-1-ynyl)-benzoylamino]-butyr-
ic acid methyl ester (2)
TABLE-US-00087 [1506] Reagent MW Eq. mg/mL mmol Compound 1
(Ach-Tr-Db-OH) 248.28 1.0 85 mg 0.34 H-(S)-Thr-OMe .times. HCl
169.6 1.1 63 mg 0.37 HATU 380.2 1.2 155 mg 0.41 DIEA 129.24 3.0 178
.mu.l 1.0 DMF 2 mL
[1507] The product 2 (123 mg, 100%) as white solid was prepared
using the General Method for HATU coupling. LC-MS [M+H] 364.7
(C22H21NO4+H, requires 364.42). Compound was used in next synthetic
step without additional purification.
Synthesis of
N-((1S,2R)-2-hydroxy-1-hydroxycarbamoyl-propyl)-4-((E)-4-phenyl-but-3-en--
1-ynyl)-benzamide (23)
TABLE-US-00088 [1508] Reagent MW Eq. mg/mL mmol Compound 2 363.4
1.0 123 mg 0.34 NH.sub.2OH .times. HCl 69.49 8.0 188 mg 2.7 25%
NaOMe/MeOH 10.0 777 .mu.l 3.4 MeOH 4 mL THF 1.5 mL
[1509] The product 104-1 (58.7 mg, 48%) as white solid was made
using the General Method for hydroxamate formation. LC-MS [M+H]
365.4 (C21H20N2O4+H, requires 365.4).
TABLE-US-00089 Retention Scale Yield Yield Purity time Compound
(mmol)* (mg) (%)* (%) [M + H] (min)** 104-1 0.34 58.7 48 98.0 365.4
7.28 *Based on the amount of carboxylic acid used in the coupling
reaction **HPLC-MS Method B
Each of the following compounds was synthesized as described
above.
TABLE-US-00090 HPLC- Compound MH.sup.+ Ret. Time MS # Structure
(m/z) (min) Method 104-2 ##STR00347## 350.7 6.38 B 104-3*
##STR00348## 379.7 7.58 B 104-4 ##STR00349## 364.7 6.46 B 104-5**
##STR00350## 378.5 4.55 A *Methyl ester of diMeSer was prepared
according to general procedure. **Boc-protecting group before
hydroxamate formation was removed by 4N HCl/dioxane
Example 105
N--[(S)-2-(2-Cyclopropylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-((E-
)-4-phenyl-but-3-en-1-ynyl)-benzamide (105-1)
N--{(S)-1-Hydroxycarbamoyl-2-[2-((S)-1-phenyl-ethylamino)-acetylamino]-eth-
yl}-4-((E)-4-phenyl-but-3-en-1-ynyl)-benzamide (105-2)
##STR00351## ##STR00352##
[1510] Synthesis of
(S)-3-tert-butoxycarbonylamino-2-[4-((E)-4-phenyl-but-3-en-1-ynyl)-benzoy-
lamino]-propionic acid methyl ester (2)
TABLE-US-00091 [1511] Reagent MW Eq. mg/mL mmol Compound 1
(Ach-Tr-Db-OH) 248.3 1.0 189 mg 0.76 H-(S)-DAP(Boc)-OMe .times. HCl
254.7 1.2 232 mg 0.91 HATU 380.2 1.2 346 mg 0.91 DIEA 129.2 3.0 397
.mu.l 2.28 DMF 4 mL
[1512] The product 2 (328 mg, 100%) as off-white solid was prepared
using the General Method for HATU coupling. LC-MS [M+H] 433.8
(C26H28N2O4+H, requires 433.52). Compound was used in next
synthetic step without additional purification.
Synthesis of
((S)-3-amino-2-[4-((E)-4-phenyl-but-3-en-1-ynyl)-benzoylamino]-propionic
acid methyl ester (3)
TABLE-US-00092 [1513] Reagent MW Eq. mg/mL mmol Compound 2 432.5
1.0 328 mg 0.76 4N HCl/dioxane 31.6 6 mL 24.0
[1514] The product 3 (292 mg, 100%) as white solid was made using
the General Method for Boc deprotection. LC-MS [M+H] 349.7
(C21H20N2O3+H, requires 349.41).
Synthesis of
(S)-3-[2-(tert-butoxycarbonyl-cyclopropyl-amino)-acetylamino]-2-[4-((E)-4-
-phenyl-but-3-en-1-ynyl)-benzoylamino]-propionic acid methyl ester
(4)
TABLE-US-00093 [1515] Reagent MW Eq. mg/mL mmol Compound 3 .times.
HCl 384.9 1.0 146 mg 0.38 N-Boc-N-Cyclopropyl-Gly-OH 215.25 1.1 90
mg 0.42 HATU 380.2 1.2 175 mg 0.46 DIEA 129.2 3.0 198 .mu.l 1.14
DMF 3 mL
[1516] The product 4 (207 mg, 100%) as light yellow oil was
prepared using the General Method for HATU coupling. LC-MS [M+H]
546.4 (C31H35N3O6+H, requires 546.64). Compound was used in next
synthetic step without additional purification.
Synthesis of
(S)-3-(2-cyclopropylamino-acetylamino)-2-[4-((E)-4-phenyl-but-3-en-1-ynyl-
)-benzoylamino]-propionic acid methyl ester (5)
TABLE-US-00094 [1517] Reagent MW Eq. mg/mL mmol Compound 4 545.6
1.0 207 mg 0.38 4N HCl/dioxane 31.6 3 mL 12.0
[1518] The product 5 (183 mg, 100%) as white solid was made using
the General Method for Boc deprotection. LC-MS [M+H] 446.3
(C.sub.26H.sub.27N.sub.3O.sub.4+H, requires 446.52).
Synthesis of
N--[(S)-2-(2-cyclopropylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-((-
E)-4-phenyl-but-3-en-1-ynyl)-benzamide (105-1)
TABLE-US-00095 [1519] Reagent MW Eq. mg/mL mmol Compound 5 .times.
HCl 481.97 1.0 183 mg 0.38 NH.sub.2OH .times. HCl 69.49 8.0 211 mg
3.0 25% NaOMe/MeOH 10.0 868 .mu.l 3.8 MeOH 4 mL THF 1.5 mL
[1520] The product 105-1 (21.7 mg, 10%) as white solid was made
using the General Method for hydroxamate formation. LC-MS [M+H]
447.3 (C25H26N4O4+H, requires 447.52).
TABLE-US-00096 Retention Scale Yield Yield Purity time Compound
(mmol)* (mg) (%)* (%) [M + H] (min)** 105-1 0.38 21.7 10 99.0 447.3
6.49 *Based on the amount of carboxylic acid used in the coupling
reaction **HPLC-MS Method B
Synthesis of
(S)-3-(2-bromo-acetylamino)-2-[4-((E)-4-phenyl-but-3-en-1-ynyl)-benzoylam-
ino]-propionic acid methyl ester (7)
TABLE-US-00097 [1521] Reagent MW Eq. mg/mL mmol Compound 3 .times.
HCl 384.9 1.0 146 mg 0.38 Bromoacetyl bromide 201.86 1.08 36 .mu.l
0.41 DIEA 129.24 2.6 174 .mu.l 1.0 CH.sub.2Cl.sub.2 3 mL
[1522] The target product 7 (150 mg, 85%), as yellow solid, was
prepared using the method described in compound 4 of Example 19.
LC-MS [M+H] 470.7 (C23H21BrN2O4+H, requires 470.34).
Synthesis of
(S)-2-[4-((E)-4-phenyl-but-3-en-1-ynyl)-benzoylamino]-3-[2-((S)-1-phenyl--
ethylamino)-acetylamino]-propionic acid methyl ester (8)
TABLE-US-00098 [1523] Reagent MW Eq. mg/mL mmol Compound 7 469.3
1.0 150 mg 0.32 (S)-(-)-alpha-Methylbenzylamine 121.18 3.0 124
.mu.l 0.96 CH.sub.2Cl.sub.2 3 mL
[1524] The target compound 8 (155 mg, 95%) as a solid, was prepared
using the method described in compound 5 of Example 19. LC-MS [M+H]
510.3 (C31H31N3O4+H, requires 510.61).
N--{(S)-1-Hydroxycarbamoyl-2-[2-((S)-1-phenyl-ethylamino)-acetylamino]-eth-
yl}-4-((E)-4-phenyl-but-3-en-1-ynyl)-benzamide (105-2)
TABLE-US-00099 [1525] Reagent MW Eq. mg/mL mmol Compound 8 509.61
1.0 155 mg 0.30 NH.sub.2OH .times. HCl 69.49 8.0 167 mg 2.4 25%
NaOMe/MeOH 10.0 685 .mu.l 3.0 MeOH 3 mL THF 1.2 mL
[1526] The product 105-2 (41.7 mg) as white solid was made using
the General Method for hydroxamate formation. LC-MS [M+H] 511.8
(C30H30N4O4+H, requires 511.61).
TABLE-US-00100 Com- Scale Yield Yield Purity Retention pound
(mmol)* (mg) (%)* (%) [M + H] time (min)** 105-2 0.38 41.7 17.5
97.3 511.8 7.38 *Based on the amount of carboxylic acid used in the
coupling reaction **HPLC-MS Method B
Each of the following compounds was synthesized as described
above.
TABLE-US-00101 Ret. Compound MH.sup.+ Time HPLC-MS # Structure
(m/z) (min) Method 105-3 ##STR00353## 460.4 7.79 B 105-4
##STR00354## 511.8 7.37 B 105-5 ##STR00355## 525.2 7.56 B
Example 106
Methyl 4-[(3E)-4-chlorobut-3-en-1-yn-1-yl]benzoate
##STR00356##
[1527] Methyl 4-[(3E)-4-chlorobut-3-en-1-yn-1-yl]benzoate
[1528] Methyl 4-ethynylbenzoate (2.0 g, 12.5 mmol, 1 eq) was
dissolved in 200 mL anhydrous THF under nitrogen. n-Butylamine (2.5
mL, 25.3 mmol, 2 eq) was added followed by
trans-1,2-dichloroethylene (1.95 mL, 25.3 mmol, 2 eq).
Bis(triphenylphosphine)palladium(II) dichloride (0.44 g, 0.63 mmol,
0.05 eq) was added as a solid, and the reaction mixture was stirred
for 20-30 minutes under nitrogen. Copper iodide (0.26 g, 1.4 mmol,
0.11 eq) was added as a solid to the clear amber solution, which
became very dark within ten minutes. Stirring under nitrogen at
room temperature was continued overnight. The reaction mixture was
filtered through Celite and THF passed through the filtercake until
the filtrate was colorless. The volatiles were removed via rotary
and the dark red-brown residue partitioned between ethyl acetate
and water. The layers were separated and the organic layer washed
with brine, dried over Na.sub.2SO.sub.4, and stripped to give the
product as a dark brown solid. The crude material was purified by
chromatography on silica gel using 2.5% ethyl acetate in hexanes as
eluent. Yield: 1.55 g, 56%. TLC R.sub.f=0.46 (1:9 ethyl
acetate:hexanes). APCI(-) m/z=219 amu as a minor signal. .sup.1H
NMR (CDCl.sub.3, 300 MHz) .delta. ppm: 7.99 (d, J=8.5 Hz, 2H), 7.48
(d, J=8.5 Hz, 2H), 6.67 (d, J=13.8 Hz, 2H), 6.16 (d, J=13.5 Hz,
2H), 3.92 (s, 3H).
Methyl 4-[(3E)-4-pyridin-4-ylbut-3-en-1-yn-1-yl]benzoate
##STR00357##
[1529] Methyl 4-[(3E)-4-pyridin-4-ylbut-3-en-1-yn-1-yl]benzoate
[1530] Methyl 4- [(3E)-4-chlorobut-3-en-1-yn-1-yl]benzoate (47 mg,
0.21 mmol, 1 eq), 4-pyridylboronic acid (28 mg, 0.23 mmol, 1.1 eq)
and tetra-n-butylammonium bromide (58 mg, 0.21 mmol, 1 eq) were
placed in a flask and dissolved in 5 mL toluene. Aqueous
K.sub.3PO.sub.4 (3 M, 0.20 mL, 0.60 mmol, 2.8 eq) was added,
followed by tetrakis(triphenylphosphine)palladium(0) (18 mg, 0.016
mmol, 0.08 eq). The reaction mixture was heated at reflux for three
hours, then stirred at room temperature overnight. TLC in 1:9 ethyl
acetate:hexanes confirmed the absence of starting material. The
reaction mixture was diluted with ethyl acetate and washed
sequentially with water and brine, then the volatiles were removed
via rotary. The residue was plated onto silica and eluted with 33%
ethyl acetate/hexanes to give the product as a yellow solid. Yield:
26 mg (46%). TLC R.sub.f=0.20 (40% ethyl acetate/hexanes). APCI(+)
m/z=246 amu. .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta. ppm: 8.60
(d, J=6.1 Hz, 2H), 8.02 (d, J=8.3 Hz, 2H), 7.54 (d, J=8.5 Hz, 2H),
7.28 (d, J=6.3 Hz, 2H), 6.99 (d, J=16.2 Hz, 2H), 6.59 (d, J=16.2
Hz, 2H), 3.93 (s, 3H).
N-((1S,2R)-2-Hydroxy-1-hydroxycarbamoyl-propyl)-4-((E)-4-pyridin-4-yl-but--
3-en-1-ynyl)-benzamide (106-1)
##STR00358##
[1531] Synthesis of
(2S,3R)-3-hydroxy-2-[4-((E)-4-pyridin-4-yl-but-3-en-1-ynyl)-benzoylamino]-
-butyric acid methyl ester (2)
TABLE-US-00102 [1532] Reagent MW Eq. mg/mL mmol Compound 1 .times.
sodium salt 271.25 1.0 109 mg 0.4 H--(S)-Thr-OMe .times. HCl 169.6
1.2 82 mg 0.48 HATU 380.2 1.2 183 mg 0.48 DIEA 129.24 3.0 209 .mu.l
1.2 DMF 2.5 mL
[1533] The compound 2 (146 mg, 100%) as light yellow solid was
prepared using the General Method for HATU coupling. LC-MS [M+H]
365.7 (C21H20N2O4+H, requires 365.4). Compound was used in next
synthetic step without additional purification.
Synthesis of
N-((1S,2R)-2-hydroxy-1-hydroxycarbamoyl-propyl)-4-((E)-4-pyridin-4-yl-but-
-3-en-1-ynyl)-benzamide (106-1)
TABLE-US-00103 [1534] Reagent MW Eq. mg/mL mmol Compound 2 364.4
1.0 146 mg 0.4 NH.sub.2OH .times. HCl 69.49 8.0 222 mg 3.2 25%
NaOMe/MeOH 10.0 914 .mu.l 4.0 MeOH 5 mL THF 2 mL
[1535] The product 106-1 (52 mg) as off-white solid was made using
the General Method for hydroxamate formation. LC-MS [M+H] 366.8
(C20H19N3O4+H, requires 366.4).
TABLE-US-00104 Retention Com- Scale Yield Yield Purity time pound
(mmol)* (mg) (%)* (%) [M + H] (min)** 106-1 0.4 52 mg 27.2% 99.2
366.8 2.30 *Based on the amount of carboxylic acid used in the
coupling reaction **HPLC-MS Method A
Each of the following compounds was synthesized as described
above.
TABLE-US-00105 Ret. Compound MH.sup.+ Time HPLC-MS # Structure
(m/z) (min) Method 106-2* ##STR00359## 380.6 3.22 B 106-3**
##STR00360## 365.8 1.97 B 106-4 ##STR00361## 365.9 1.98 A 106-5
##STR00362## 380.8 3.22 B 106-6 ##STR00363## 382.8 4.46 A 106-7
##STR00364## 397.7 5.14 A *Methyl ester of di-Me-Ser was prepared
according to general procedure. **Fmoc-protecting group before
hydroxamate formation was removed by 20% piperidine/EtOAc.
Example 107
4-((E)-4-Cyclopropyl-but-3-en-1-ynyl)-N--((S)-2-hydroxy-1-hydroxycarbamoyl-
-2-methyl-propyl)-benzamide (107-1)
##STR00365##
[1536] Synthesis of ((E)-2-Iodo-vinyl)-cyclopropane (2)
[1537] The chromium (II) chloride (15.0 g, 122.1 mmol) was placed
in a flask in the glove box with a stir bar and capped with a
septum. With good stirring, the THF (anh., 120 mL) was added
quickly at ambient temperature. After stirring for 15-30 min under
nitrogen, the flask was immersed in an ice bath for 30 min. To the
cold suspension was added dropwise a solution of iodoform (11.42 g,
29.0 mmol) in THF (anh., 75 mL). After 5 min, the solution of
cyclopropylaldehyde 1 (2.43 mL, 30.5 mmol) in THF (anh., 60 mL) was
added neat dropwise to the vigorously stirred suspension. After
stirring at 0.degree. C. for 2 h, the reaction was allowed to warm
to room temperature overnight. The reaction mixture was poured into
and ice water and extracted with pentane (300 mL.times.2). The
organic phase was washed with 20% aq. Na.sub.2S.sub.2O.sub.3 (150
mL), water (300 mL), brine (300 mL), then dried over MgSO4 (anh.),
filtered and pentane was concentrated in vacuo at 220 mbar to
minimum volume (20 mL). The residue was used in the next synthetic
step without additional purification (caution: cyclopropyl vinyl
iodide is volatile material).
Synthesis of 4-((E)-4-cyclopropyl-but-3-en-1-ynyl)-benzoic acid
methyl ester (3)
[1538] A solution of 4-ethynyl-benzoic acid methyl ester (1.76 g,
11.0 mmol), diisopropylamine (4.7 mL, 33 mmol), the catalysts
PdCl.sub.2(dppf).sub.2 (302 mg, 0.37 mmol) and the copper (I)
iodide (46 mg, 0.24 mmol) in THF (anh., 30 mL) was purged for 10
min with dry nitrogen. Then, this mixture was added to a pentane
solution of compound 1 (13.5 mL, C=.about.200 mg/mL, .about.2.7 g,
14 mmol). Reaction mixture was heated at 80.degree. C. for 20 min
and cooled to ambient temperature. The reaction mixture was then
dissolved in EtOAc (200 mL), washed with water (150 mL), 0.5 N HCl
(150 mL) and brine (150 mL.times.2). Organic phase was dried over
anh. Na2SO4, evaporated in vacuo. Residue was subjected to flash
chromatography on CombiFlash.RTM. Companion unit equipped with
RediSep.RTM. flash column (normal phase, 35-60 micron average
particle size silica gel, 40 g, Teledyne Isco); flow rate=40
mL/min; mobile phase A: hexane; mobile phase B: EtOAc; gradient
0-30% B in 60 min. Fractions containing the desired material were
combined and concentrated in vacuo to provide target material 3 (1
g, 40%) as yellow oil. LC-MS [M+H] 227.7 (C15H14O2+H, requires
227.29).
Synthesis of 4-((E)-4-cyclopropyl-but-3-en-1-ynyl)-benzoic acid
(4)
TABLE-US-00106 [1539] Reagent MW Eq. g/mL mmol Compound 3 226.28
1.0 1.0 g 4.41 1N NaOH 4.0 18 mL 18.0 THF/MeOH (1:1) 18 mL
[1540] The compound 4 (800 mg, 85%) as a white solid was made and
separated using the General Method for basic hydrolysis. LC-MS
[M+H] 213.5 (C14H12O2+H, requires 213.3). Compound was used in next
synthetic step without additional purification. Check of a sample
by LC-MS showed a major product peak (Rt=5.10 min, E-isomer) with
.about.12% of the cis-isomer (Rt=4.96 min) (HPLC-MS Method A).
Synthesis of
(S)-2-[4-((E)-4-cyclopropyl-but-3-en-1-ynyl)-benzoylamino]-3-hydroxy-3-me-
thyl-butyric acid methyl ester (5)
TABLE-US-00107 [1541] Reagent MW Eq. mg/mL mmol Compound 4 212.25
1.0 85 mg 0.4 H--(S)-diMe-Ser-OMe .times. HCl* 169.6 1.13 76 mg
0.45 HATU 380.2 1.2 183 mg 0.48 DIEA 129.24 3.0 209 .mu.l 1.2 DMF 2
mL *Methyl ester of di-Me-Ser was prepared according to general
procedure.
[1542] The compound 5 (130 mg, 96%) as white solid was prepared
using the General Method for HATU coupling. LC-MS [M+H] 342.8
(C20H23N04+H, requires 342.4).
Synthesis of
4-((E)-4-cyclopropyl-but-3-en-1-ynyl)-N--((S)-2-hydroxy-1-hydroxycarbamoy-
l-2-methyl-propyl)-benzamide (107-1)
[1543] Isopropyl alcohol (2 mL) was added to triple-double ester 5
(130 mg, 0.38 mmol) and the mixture was cooled in an ice bath for 5
min. NH.sub.2OH (50% aq, 2 mL, 32.8 mmol) was added to the mixture.
After 5 min, the ice bath was removed and the reaction mixture was
stirred until reaction was complete (.about.16 h, as determined by
LC-MS analysis). Solvent volume was reduced by half using a
nitrogen stream and water (8 mL) was added. The suspension was
thoroughly agitated (vibro mixer and sonication), centrifuged and
the supernatant was discarded. Water (8 mL) was added to the solid
and the suspension was thoroughly agitated, centrifuged and the
supernatant was discarded. Solid was dissolved in DMSO (600 .mu.l)
and subjected to HPLC purification. [Phenomenex Gemini C-18 column,
110 .ANG. (30.times.100 mm); flow rate=20 mL/min; mobile phase A:
100% water, 0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient
elution from 8% B to 28% B in 60 min., detection 254 nm]. Fractions
containing the desired product were combined and lyophilized to
provide the target product (66.3 mg) as white solid. LC-MS [M+H]
343.7 (C19H22N2O4+H, requires 343.4).
TABLE-US-00108 Com- Scale Yield Yield Purity [M + Retention pound
(mmol)* (mg) (%)* (%) H] time (min)** 107-1 0.4 66.3 mg 48.4% 97.5
343.7 6.41 *Based on the amount of carboxylic acid used in the
coupling reaction **HPLC-MS Method B
Each of the following compounds was synthesized as described
above.
TABLE-US-00109 Ret. Compound MH.sup.+ Time HPLC-MS # Structure
(m/z) (min) Method 107-2 ##STR00366## 328.7 3.86 A 107-3
##STR00367## 329.8 4.32 B 107-4* ##STR00368## 342.7 5.59 B 107-5*
##STR00369## 330.7 6.01 A 107-6* ##STR00370## 344.8 6.14 B
*Boc-protecting group before hydroxamate formation was removed by
2N HCl/dioxane **Desired scaffold for this product was prepared
starting from isobutyraldehyde
Example 108
Synthesis of (E)-4-(hex-3-en-1-ynyl) benzoic acid (IC-10)
##STR00371##
[1544] (E)-1-iodobut-1-ene (2)
[1545] To but-1-yne (1.5 g, 27.78 mmol) in a sealable tube at
0.degree. C. was added DIBAL-H in hexane (1M; 28 mL, 28 mmol). The
tube was sealed and allowed to stand for 30 min at R.T. before
being heated to 55-60.degree. C. for 4 h. After cooling down, the
reaction mixture was evaporated in vacuo (using a vacuum manifold)
and the residue was dissolved in THF (15 mL) at 0.degree. C. The
resultant solution was cooled to -78.degree. C. and I.sub.2 (8.47
g, 33.3 mmol) in THF (30 mL) was added dropwise. The mixture was
allowed to warm to 0.degree. C. And transferred via cannula to a
stirred mixture of 1 M HCl (70 mL) and Et.sub.2O (40 mL). the
layers were separated and the aqueous layer was extracted with
saturated aqueous sodium thioslufate (40 mL), 1M NaOH (40 mL),
distilled water (40 mL) and brine (40 ml), dried over
Na.sub.2SO.sub.4, filtered, and rotary evaporated at 0.degree. C.
to give compound 2 as a brown liquid and to next step without
purification.
(E)-Methyl 4-(hex-3-en-1-ynyl) benzoate (4)
TABLE-US-00110 [1546] Reagent MW Eq. mmol g, mL Compound 2 182.00
1.0 16.2 2.94 g Methyl 4-ethynylbenzoate 160.17 1.0 16.2 2.58 g
PdCl.sub.2(PPh.sub.3).sub.2 701.90 0.1 1.62 1.13 g CuI 190.45 0.1
1.62 0.216 g TEA 101.19 13.0 220 30 mL THF 150 mL
[1547] The compound 4 (1.8 g, 52%) as a light yellow liquid was
prepared by using the method described in compound 5 of Example 96.
.sup.1H NMR (500 MHz, CDCl.sub.3): .delta. ppm, 1.06 (t, J=15 Hz,
3H), 2.2 (m, 2H), 3.91 (s, 3H), 5.70 (d, J=15.5 Hz, 1H), 6.35 (m,
1H), 7.46 (d, J=8 Hz, 2H), 7.97 (d, J=8.5 Hz, 2H).
(E)-4-(hex-3-en-1-ynyl) benzoic acid (IC-10)
TABLE-US-00111 [1548] Reagent MW Eq. mmol g, mL Compound 4 214.26
1.0 8.41 1.8 g NaOH(2N solution) 9 mL THF 9 mL Methanol 9 mL
[1549] The compound IC-10 (1.5 g, 89%) as a white solid was made
and separated using the General Method for basic hydrolysis.
.sup.1H NMR (500 MHz, DMSO-d.sub.6): .delta. ppm, 1.0 (t, J=15 Hz,
3H), 2.18 (m, 2H), 5.83 (d, J=16 Hz, 1H), 6.37 (m, 1H), 7.53 (d,
J=8.5 Hz, 2H), 7.92 (d, J=8.5 Hz, 2H), 13.12 (s, 1H)
Synthesis of (E)-4-(4-(1-methyl-1H-pyrazol-4-yl)but-3-en-1-ynyl)
benzoic acid (IC-11)
##STR00372##
[1550] (E)-4-(2-iodovinyl)-1-methyl-1H-pyrazole (2)
TABLE-US-00112 [1551] Reagent MW Eq. mmol g, mL Compound 1 110.11
1.0 8.2 900 mg Chromium chloride 122.90 6.0 49.2 5.555 g
triiodomethane 393.73 4.0 32.8 12.914 g THF 185 mL
[1552] The target compound 2 (635 mg, 33%) was prepared by using
the method described in compound 5 of Example 96. [M+1]: 234.9.
.sup.1H-NMR: (400 MHz, DMSO-d.sub.6): .delta. 3.87 (s, 3H), 6.43
(d, J=14.8 Hz, 1H), 7.21 (s, J=14.8 Hz, 1H), 7.34 (s, 1H), 7.49 (s,
1H).
(E)-methyl 4-(4-(1-methyl-1H-pyrazol-4-yl)but-3-en-1-ynyl)benzoate
(4)
[1553] To a mixture of compound
(E)-4-(2-iodovinyl)-1-methyl-1H-pyrazole (635 mg, 2.7 mmol, 1.0
equiv), methyl 4-ethynylbenzoate (434 g, 2.7 mmol, 1.0 equiv),
PdCl.sub.2(PPh.sub.3).sub.2 (190 mg, 0.3 mmol, 0.1 equiv) and
(i-Pr).sub.2NH (546 mg, 5.4 mmol, 2 equiv) in THF (100 mL) was
added CuI (51 mg, 0.3 mmol, 0.1 equiv) under nitrogen at room
temperature. The mixture was stirred at room temperature for 12
hours. The reaction mixture was diluted with EtOAc (50 mL),
filtered and concentrated. The residue was dissolved into EtOAc
(100 mL) and washed with water (100 mL) and brine (50 mL) and dried
(MgSO.sub.4). After filtration and concentration, the residue was
purified by chromatography on silica gel (0 to 5% EtOAc/Hexanes) to
give the title compound 4 (532 mg, 74%). [M+H].sup.+: 267.0
(E)-4-(4-(1-methyl-1H-pyrazol-4-yl)but-3-en-1-ynyl)benzoic acid
(IC-11)
TABLE-US-00113 [1554] Reagent MW Eq. g/ml mmol ACHL059-4 266.29 1.0
1.00 g 3.74 2M NaOH aq. 40.00 2.0 2.4 mL 4.8 THF 25 mL MeOH 25
mL
[1555] The product (650 mg, 71%) was made and separated using the
General Method for basic hydrolysis. [M+1].sup.+: 369.0.
.sup.1H-NMR: (400 MHz, DMSO-d.sub.6): .delta. 3.83 (s, 3H), 6.29
(d, J=16.0 Hz, 1H), 7.00 (s, J=16.0 Hz, 1H), 7.55 (d, J=8.4 Hz,
2H), 7.75 (s, 1H), 7.92-7.96 (m, 3H).
Synthesis of 4-(4-methylpent-3-en-1-ynyl)benzoic acid (IC-12)
##STR00373##
[1556] Methyl 4-(4-methylpent-3-en-1-ynyl)benzoate (2)
[1557] To a solution of methyl 4-ethynylbenzoate (3.84 g, 24 mmol),
Pd(PPh.sub.3).sub.4 (2.22 g, 1.92 mmol), CuI (0.32 g, 1.68 mmol)
and PPh.sub.3 (1.13 g, 4.32 mmol) in degassed piperidine (160 mL)
was added 1-bromo-2-methylprop-1-ene (6.38 g, 47.26 mmol) at room
temperature. After the mixture was heated at 60.degree. C. for 3 h,
the reaction was quenched by sat. NH.sub.4Cl solution and then was
extracted with ethyl acetate twice. The combined organic layer was
washed with brine and dried over anhydrous sodium sulfate. After
filtration of the drying agent, the filtrate was evaporated, and
the residue was purified by silica-gel column (1% ethyl acetate in
petroleum) to give compound 2 (1.9 g, the yield was 37%) as a light
yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. ppm, 1.88
(s, 3H), 1.99 (s, 3H), 3.91 (s, 3H), 5.49 (s, 1H), 7.46 (d, J=8.4
Hz, 2H), 7.96 (d, J=8.4 Hz, 2H).
4-(4-methylpent-3-en-1-ynyl)benzoic acid (IC-12)
[1558] The compound (IC-12)(1.45 g, 82%) as a white solid was made
and separated using the General Method for basic hydrolysis.
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. ppm, 1.87 (s, 3H),
1.96 (s, 3H), 5.59 (s, 1H), 7.52 (d, J=8.8 Hz, 2H), 7.91 (d, J=8
Hz, 2H), 13.01 (s, 1H)
The following compounds were prepared by using the corresponding
intermediate acids synthesized as described above.
TABLE-US-00114 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 108-1 ##STR00374## 329 108-2 ##STR00375## 343
108-3 ##STR00376## 383 108-4 ##STR00377## 381 108-5 ##STR00378##
327 108-6 ##STR00379## 329
Example 109
Synthesis of
4-(2-fluoro-4-(4-(morpholinomethyl)phenyl)but-1-en-3-ynyl)-N-((2S,3R)-3-h-
ydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide (109-1)
##STR00380##
[1559] Synthesis of 4-(2-bromo-2-fluorovinyl)benzonitrile (1)
[1560] The THF solution (10 ml) of p-cyanobenzaldehyde (1.31 g,
10.0 mmol), triphenylphosphine (3.14 g, 12 mmol) and
Tribromofluromethane (3.25 g, 12 mmol) was cooled to 0.degree. C.
The THF solution (1 ml) of Diethyl zinc (1.47 g, 12 mmol) was added
drop wise over 20 min. The reaction was warmed to r.t and stirred
overnight. The reaction mixture was cooled to 0.degree. C. and
aqueous NH.sub.4Cl (Sta'd, 20 ml) was added to quench the reaction.
The mixture was extracted with Ethyl Acetate (100 ml.times.3). The
combined organic layers was washed with HCl (1N, 100 ml), H.sub.2O
(100 ml.times.2) and brine (100 ml). The crude product was purified
with ISCO normal phase silica gel column (0-10% EtOAc/Hex) to give
desired 1.33 g product 1 as a trans/cis mixture (1:1) in the yield
of 58.8%.
Synthesis of 4-(2-fluoro-4-(4
(morpholinomethyl)phenyl)-but-1-en-3-ynyl)benzonitrile
[1561] The THF solution (5 ml) of compound 1 (226 mg, 1.0 mmol) and
2 (201 mg, 1.0 mmol) was charged N.sub.2 gas for 15 min. PdCl.sub.2
(PPh.sub.3).sub.2 (21 mg, 0.03 mmol), CuI (19.0 mg, 0.1 mmol) and
TEA (0.5 mml) were added to reaction sequentially at r.t. The
reaction was stirred at r.t. overnight. Diluted with EtOAc, the
reaction mixture was filtered through celite. The filtrate was
washed with brine (50 ml) and concentrated. The crude product was
purified with ISCO normal phase silica gel column (0-50% EtOAc/Hex)
to give 300 mg compound 3 in the yield of 86.7% as a 1:1 mixture of
trans and cis against F-double bond.
Synthesis of 4-(2-fluoro-4-(4
(morpholinomethyl)phenyl)-but-1-en-3-ynyl)benzoic acid (4)
[1562] Compound 3 (300 mg, 0.87 mmol) was dissolved in 10 ml Dioxin
and 5 ml H.sub.2O. LiOH (104 mg, 4.3 mmol) was added to the
solution. The reaction was heated to 120.degree. C. under microwave
for 2 hr. after cooling to r.t, the reaction mixture was acidified
with 1N HCl to pH=3.about.4. Diluted with H.sub.2O, the mixture was
extracted with EtOAc to give 240 mg compound 4 as crude product in
the yield of 75.5%.
Synthesis of 4-
2-fluoro-4-(4-(morpholinomethyl)phenyl)but-1-en-3-ynyl)-N-((2S,3R)-3-hydr-
oxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide (6)
[1563] DIPEA (0.67 ml, 3.85 mmol) was added to the DMF solution (5
ml) of compound 4 (240 mg, 0.77 mmol) and 5 (211 mg, 1.15 mmol) and
HATU (380 mg, 1.0 mmol) at r.t. the reaction was stirred at r.t
overnight. H.sub.2O was added to quench the reaction. The reaction
mixture was extracted with EtOAc (50 ml.times.3). The combined
organic layers was washed with H.sub.2O (50 ml.times.2) and brine
(50 ml) then dried with Na.sub.2SO.sub.4. The crude product was
purified with ISCO normal phase silica gel column (0-10% MeOH/DCM)
to give compound 6 (140 mg, 37.8%) as a 1:1 mixture of trans and
cis against F-double bond
Synthesis of
4-(2-fluoro-4-(4-(morpholinomethyl)phenyl)but-1-en-3-ynyl)-N-((2S,3R)-3-h-
ydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide (109-1)
[1564] Aqueous NH2OH (50% in H.sub.2O, 0.5 ml) was added to the IPA
solution (4 ml) of compound 6 (140 mg, 0.29 mmol) at r.t. The
reaction was stirred overnight at r.t. After removing the reaction
solvent, the crude product was purified by prep. HPLC to give
compound (109-1), a mixture of trans and cis against double bond,
(13 mg, 7.4%, m+z=482.2) as TFA salt.
TABLE-US-00115 Com- Scale Yield Yield Purity Retention pound
(mmol)* (mg) (%)* (%) [M + H] time (min)** 109-1 0.29 13 mg 7.4%
94.4 492.2 1.508/1.634
Synthesis of (2S,3R)-methyl
2-(4-((Z)-3-fluoro-4-(4-(morpholinomethyl)phenyl)but-3-en-1-ynyl)benzamid-
o)-3-hydroxybutanoate 109-2
##STR00381##
[1565] Synthesis of 4-(2-bromo-2-fluorovinyl)benzaldehyde (2)
[1566] Compound 1 (417 mg, 1.85 mmol) was dissolved in DCM/Tol
mixed solvent (6 ml, 1:1). The solution was cooled to -78 C. DIBAL
(2.2 ml, 2.21 mmol, 1.0M in DCM) was added dropwise. The reaction
was stirred at -78 C for 2 hrs. NH4Cl (50 ml, aq. sta'd) was added
to quench the reaction and the mixture was stirred at r.t. for 2
hrs. The reaction mixture was extracted with EtOAc (50 ml.times.3).
The combined organic layers was washed with H.sub.2O (50
ml.times.2) and brine (50 ml). The crude product was purified with
ISCO normal phase silica gel column (0-20% EtOAc/Hex) to give 250
mg compound 2 (250 mg, 59%) as 1:1trans/cis mixture against double
bond.
Synthesis of (E)-4-(4-(2-bromo-2-fluorovinyl)benzyl)morpholine
(3)
[1567] NaBH(OAc).sub.3 (693 mg, 3.27 mmol) was added to the THF
solution (5 ml) of compound 2 (250 mg, 1.09 mmol) and morphline
(190 mg, 2.18 mmol). The reaction was stirred at r.t. overnight.
THF was removed and the residue was dissolved in 50 ml EtOAc and 50
ml H.sub.2O. After separation, the water layer was extracted with
EtOAc (50 ml.times.2). The combined organic layers was washed with
H.sub.2O (50 ml.times.2) and brine (50 ml) and dried with
Na.sub.2SO4. the crude the product was purified with ISCO normal
phase silica gel column (0-50% EtOAc/DCM) to give compound 3 (209
mg, 63.9%) as a mixture of trans/cis in the ration of 7:1 based on
NMR.
Synthesis of methyl
4-(3-fluoro-4-(4-(morpholinomethyl)phenyl)but-3-en-1-ynyl)benzoate
(4 & 5)
[1568] Compound 3 (210 mg, 0.67 mmol) and methyl 4-ethynylbenzoate
(119 mg, 0.75 mmol) were dissolved in 5 ml degassed THF. PdCl.sub.2
(PPh.sub.3).sub.2 (14 mg, 0.02 mmol), CuI (13 mg, 0.07 mmol) and
TEA (0.3 ml, 2.0 mmol) were added sequentially to the reaction at
r.t. The reaction was stirred at R.T. for 4 hrs. The reaction
mixture was filtered. The filtered solid was washed with EtOAc (100
ml). The organic solution was washed with H.sub.2O (50 ml.times.2)
and brine (50 ml) and dried with Na.sub.2SO.sub.4. The crude
product was purified with ISCO normal phase silica gel column
(0-50% EtOAc/DCM) to give compound 4 (197 mg) and 5 (33 mg) in
81.4% total yield.
Synthesis of
(Z)-4-(3-fluoro-4-(4-(morpholinomethyl)phenyl)but-3-en-1-ynyl)benzoic
acid (6)
[1569] Compound 4 (197 mg, 0.52 mmol) was dissolved in THF/MEOH (4
ml, 1:1). The aq. solution (2 ml) of LiOH (25 mg, 1.04 mmol) was
added to the reaction. Reaction was stirred at r.t overnight.
Diluted with H.sub.2O (10 ml), the reaction mixture was neutralized
with HOAc to pH=7 and extracted with EtOAc (20 ml.times.5) to give
180 mg crude product 6 in the yield of 94.8%.
Synthesis of (2S,3R)-methyl
2-(4-((Z)-3-fluoro-4-(4-(morpholinomethyl)phenyl)but-3-en-1-ynyl)benzamid-
o)-3-hydroxybutanoate 7
TABLE-US-00116 [1570] Reagent MW Eq. g/ml mmol Compound 6 365.4 1
180 mg 0.493 Threonine 169.61 1.1 99.3 mg 0.54 HATU 380 1.2 225 mg
0.59 DIPEA 129 4.5 0.38 ml 2.2 DMF 5 ml
[1571] The compound 7 in the yield of 86.6% was prepared using the
General Method for HATU coupling.
Synthesis of (2S,3R)-methyl
2-(4-((Z)-3-fluoro-4-(4-(morpholinomethyl)phenyl)but-3-en-1-ynyl)benzamid-
o)-3-hydroxybutanoate 109-2
TABLE-US-00117 [1572] Reagent MW Eq. g/ml Mmol Compound 7 480.53 1
221 mg 0.44 NH.sub.2OH (50% in H.sub.2O) 1.1 ml IPA 2 ml
[1573] The compound 109-2 (70 mg, 30.7%, m+z=482.2) as HCl salt was
made using the General Method for hydroxamate formation.
The following compound was synthesized as described above.
TABLE-US-00118 Compound Amount # Structure obtained Yield M + Z
109-3 ##STR00382## 0.7 mg TFA salt 0.1% 482.2
Example 110
Synthesis of
(E)-4-(4-(4-(morpholinomethyl)phenyl)but-1-en-3-ynyl)benzoic acid
(1)
##STR00383##
[1574] The detail procedure refers to Example 30 for synthesis of
alternative intermediate 009 Each of the following compounds were
prepared by the same synthetic route as described in Example 96 and
as for compound 110-12 as described in Example 97
TABLE-US-00119 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 110-1 (same as 30-12a) ##STR00384## 464.5 3.62 A
110-2 ##STR00385## 462.4 5.19 B 110-3 ##STR00386## 463.4 6.11 B
110-4 ##STR00387## 504.4 4.67 B 110-5 ##STR00388## 464.4 3.61 A
110-6 ##STR00389## 478.5 4.79 B 110-7 ##STR00390## 478.5 4.79 B
110-8 ##STR00391## 552.5 4.50 B 110-9 ##STR00392## 460.3 4.84 B
110-10 ##STR00393## 501.1 4.23 B 110-11 ##STR00394## 496.4 5.57 B
110-12 ##STR00395## 488.4 5.41 B
Example 111
N-[2-Amino-1-((S)-hydroxycarbamoyl)-ethyl]-4-[(E)-4-(4-morpholin-4-ylmethy-
l-phenyl)-but-1-en-3-ynyl]-benzamide (111-1)
N-[2-(2-dimethylamino-acetylamino)-1-((S)-hydroxycarbamoyl)-ethyl]-4-[(E)--
4-(4-morpholin-4-ylmethyl-phenyl)-but-1-en-3-ynyl]-benzamide
(111-2)
N-[2-acetylamino-1-((S)-hydroxycarbamoyl)-ethyl]-4-[(E)-4-(4-morpholin-4-y-
lmethyl-phenyl)-but-1-en-3-ynyl]- (111-3)
N-[1-((S)-Hydroxycarbamoyl)-2-methylamino-ethyl]-4-[(E)-4-(4-morpholin-4-y-
lmethyl-phenyl)-but-1-en-3-ynyl]-benzamide (111-4)
[1575] The following compounds were prepared by the same synthetic
route as described in Examples 98 and 99.
TABLE-US-00120 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 111-1 ##STR00396## 449.4 3.46 B 111-2
##STR00397## 534.3 3.64 B 111-3 ##STR00398## 491.4 4.17 B 111-4
##STR00399## 463.5 3.59 B
Example 112
Synthesis of (E)-methyl
4-(4-(4-(hydroxymethyl)phenyl)but-1-en-3-ynyl)benzoate (1)
##STR00400##
[1576] The detail procedure refers to Example 30 for synthesis of
alternative intermediate 011 Each of the following compounds was
synthesized using the synthetic route as described in Example
101.
TABLE-US-00121 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 112-1 ##STR00401## 394.5 4.59 B 112-2
##STR00402## 380.0 4.53 B 112-3 ##STR00403## 395.2 5.29 B 112-4
##STR00404## 409.4 5.99 B 112-5 ##STR00405## 409.4 5.57 B
Example 113
[1577] Each of the following compounds was synthesized using the
synthetic route as described in Example 102 and for compound 113-11
as described in Example 103
TABLE-US-00122 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 113-1 ##STR00406## 419.4 3.86 B 113-2
##STR00407## 433.4 3.79 B 113-3 ##STR00408## 434.5 4.49 B 113-4
##STR00409## 434.4 4.56 B 113-5 ##STR00410## 449.0 4.98 A 113-6
##STR00411## 447.1 3.95 B 113-7 ##STR00412## 448.3 5.01 B 113-8
##STR00413## 511.3 3.88 B 113-9 ##STR00414## 408.3 6.22 B 113-10
##STR00415## 422.4 6.65 B 113-11 ##STR00416## 477.5 4.74 B
Example 114
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-((E)-4-phenyl-but-1-en-3--
ynyl)-benzamide
##STR00417## ##STR00418##
[1578] Synthesis of 4-((E)-2-Iodo-vinyl)-benzoic acid methyl ester
(2)
[1579] The title compound 2 (3.8 g) as a slightly yellow solid was
prepared by using the procedure of compound 4 of Example 96. Check
of a sample by HPLC-MS showed the product peak (Ret. time (Method
C) 3.10 min, MH.sup.+=289.2). This material could be further
purified by silica gel chromatography using hexanes or pentane with
0-30% EtOAc as eluant.
Synthesis of 4-((E)-4-Phenyl-but-1-en-3-ynyl)-benzoic acid methyl
ester (4)
[1580] The 4-((E)-2-iodo-vinyl)-benzoic acid methyl ester (403 mg,
1.40 mmol, 1.0 eq), phenylacetylene* (157 mg, 1.54 mmol, 1.1 eq),
copper(I) iodide (10.7 mg, 0.056 mmol, 0.04 eq) and
PdCl.sub.2(dppf) (22.9 mg, 0.028 mmol, 0.02 eq) were dissolved with
THF (4.5 mL) and diisopropylamine (396 uL, 2.8 mmol, 2.0 eq) and
sealed under nitrogen. The reaction mixture was then stirred
rapidly for 1 min and placed in the microwave reactor at
80-120.degree. C. for 6-18 min until the vinyl iodide was consumed
(HPLC-MS). The reaction mixture was then stirred and evaporated
under a nitrogen stream to a slurry, and diluted with EtOAc (25 mL)
and water (10 mL). After mixing and adjusting to pH.about.5 with 3
M HCl, the aqueous phase was removed. The organic phase was washed
with 0.3 M HCl (15 mL, 2.times.), and satd aq NaCl (10 mL).
Filtration of the brown solution through Na.sub.2SO.sub.4 and
evaporation of the solvents yielded the title compound as a crude
product (.about.450 mg). This material could be further purified by
silica gel chromatography using hexanes or pentane with 0-100%
EtOAc as eluant, and evaporation of the title compound as a yellow
glass. Check of a sample by HPLC-MS showed a major product peak
(Ret. time (Method C) 3.53 min, MH.sup.+=263.3). *--For aliphatic
alkynes, using 3 eq of alkyne is required to obtain similar
yields.
Synthesis of 4-((E)-4-Phenyl-but-1-en-3-ynyl)-benzoic acid (5)
TABLE-US-00123 [1581] Reagent MW Eq. mmol mg, ml
4-((E)-4-Phenyl-but-1-en-3-ynyl)- 262.31 1.0 ~1.4 ~367 mg benzoic
acid methyl ester (4) THF 3.6 mL MeOH 1.2 mL 1M aq NaOH 2.0 2.8 2.8
mL
[1582] The 4-((E)-4-phenyl-but-1-en-3-ynyl)-benzoic acid methyl
ester was hydrolyzed and the acid precipitated using the "General
Method for basic hydrolysis". Check of a sample by HPLC-MS showed a
major product peak (Ret. time (Method A) 5.79 min,
[MH+DMSO].sup.+=327.1).
Synthesis of
(2S,3R)-3-(9H-Fluoren-9-ylmethoxycarbonylamino)-2-[4-((E)-4-phenyl-but-1--
en-3-ynyl)-benzoylamino]-butyric acid methyl ester (6)
TABLE-US-00124 [1583] Reagent MW, d Eq. mmol mg, ml
4-((E)-4-Phenyl-but-1-en-3- 248.28 1.0 0.30 74.5 mg ynyl)-benzoic
acid (5) DIEA 129.24, 0.742 3.0 0.90 157 ul HATU 380.23 1.25 0.375
157 mg DMF 1.2 ml N-Fmoc-(S)-MeDAP-OMe .times. 390.87 1.12 0.336
131 mg HCl
[1584] The 4-((E)-4-phenyl-but-1-en-3-ynyl)-benzoic acid was
coupled to Fmoc-Me-DAP using the "General Method for HATU
coupling". Check of a sample by HPLC-MS showed a major product peak
(Ret. time (Method C) 3.57 min, MH.sup.+=585.4).
Synthesis of (2S,3R)-3-Amino-2-
[4-((E)-4-phenyl-but-1-en-3--benzoylamino]-butyric acid methyl
ester (7)
[1585] The FMOC group of (2S,3R)-3-(9H-fluoren-9-ylmethoxycarbonyl
amino)-2-[4-((E)-4-phenyl-but-1-en-3-ynyl)-benzoylamino]-butyric
acid methyl ester was deprotected by dissolving in 50% piperidine
in THF (6 mL), stirring for 1-8 h, and evaporating the volatiles
under vacuum or a nitrogen stream to yield the desired product
residue which may be optionally purified by silica gel
chromatography using hexanes with 0-100% EtOAc as eluant. Check of
a sample by HPLC-MS showed a major product peak (Ret. time (Method
C) 2.51 min, MH.sup.+=363.2).
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-((E)-4-phenyl-but-1-en-3--
ynyl)-benzamide (114-1)
[1586] The (2S,3R)-3-amino-2-
[4-((E)-4-phenyl-but-1-en-3-ynyl)-benzoyl amino] butyric acid
methyl ester was dissolved in dioxane (0.6 mL), isopropanol (2.4
mL) and 50% aq hydroxylamine (3 mL), and optionally a catalytic
amount of potassium cyanide (2 mg) was added at room temperature
and stirred for 8-24 h until disappearance of the methyl ester
(HPLC-MS). The reaction mixture was diluted in dichloromethane (8
mL), and the organic layer separated, dried (Na.sub.2SO.sub.4), and
evaporated on the rotovap to yield a slurry that was dissolved in
DMSO. After subjecting the sample to preparative HPLC, a major peak
was collected which showed an HPLC-MS of the desired product (Ret.
time (Method A) 4.10 min, MH.sup.+=364.2). A second minor peak from
preparative HPLC could also be collected as an isomer of the
hydroxamic acid.
Each of the following compounds was synthesized as described above
using the appropriate alkyne.
TABLE-US-00125 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 114-1 ##STR00419## 363.4 6.2 B 114-2
##STR00420## 382.3 6.59 B 114-3 ##STR00421## 382.3 6.23 B 114-4
##STR00422## 397.9 7.13 B 114-5 ##STR00423## 397.9 6.73 B 114-6
##STR00424## 432.3 7.54 B 114-7 ##STR00425## 447.9 7.71 B 114-8
##STR00426## 365.1 2.38 B 114-9 ##STR00427## 365.1 2.67 B 114-10
##STR00428## 398.4 4.56 A
Each of the following compounds of was synthesized as described
above using the appropriate alkyne, threonine methyl ester
hydrochloride or (S)-Me.sub.2-BOC-DAP-OMe and BOC deprotection.
TABLE-US-00126 Ret. HPLC- Compound MH.sup.+ Time MS # Structure
(m/z) (min) Method 114-11 ##STR00429## 383.1 7.21 B 114-12
##STR00430## 383.1 7.01 B 114-13 ##STR00431## 366.3 3.30 B 114-14
##STR00432## 365.3 7.01 B 114-15 ##STR00433## 328.7 3.27 A 114-16
##STR00434## 378.8 6.48 B 114-17 ##STR00435## 370.3 6.99 B 114-18
##STR00436## 342.3 5.54 B 114-19 ##STR00437## 344.3 6.09 B 114-20
##STR00438## 370.3 6.88 B
General Procedure for Following Examples
Method 6 (Sonogashira Coupling)
[1587] A microwave tube was charged with bromo- or iodo-phenyl
derivative (1.9 mmol), 4-ethynyl-benzoic acid methyl ester or acid
(2.0 mmol), PdCl.sub.2(dppf).CH.sub.2Cl.sub.2 (0.038 mmol, 2 mol
%), CuI (0.076 mmol, 4 mol %), DIPA (4 mL), and THF (12 mL). The
tube was backfilled with nitrogen, sealed, and irradiated in a
microwave reactor (max. power 250 W) at 100-125.degree. C. for
10-20 min. THF was removed in vacuo and the residue was taken up in
EtOAc (100 mL). The organic layer was washed with water (2.times.50
mL) and brine (50 mL), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo. Crude product was purified by normal phase
flash chromatography on a CombiFlash.RTM. Companion.TM. unit using
hexanes-EtOAc gradient elution. Fractions containing the desired
product were combined and concentrated to give the target compound
(Fmoc protecting groups are cleaved during the reaction).
Example 115
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-((4-fluoropiper-
idin-1-yl)methyl)phenyl)ethynyl)benzamide (115-1)
##STR00439##
[1588] Synthesis of 4-ethynyl-benzoic acid (1)
[1589] A mixture of 4-ethynylbenzonitrile (1.27 g, 10 mmol) and 2M
aq. LiOH (25 ml, 50 mmol) in dioxane (20 ml) was irradiated in
microwave oven (max. power 250 W, 120.degree. C.) for 30 min and
cooled to ambient temperature. Reaction mixture was diluted with
water (300 ml) and acidified with 1 M aq. HCl to pH.about.3. Formed
precipitate was filtrated and washed with water and ether and dried
in vacuum overnight to produce hydrochloric salt of target material
(2.30 g, 63%) as yellow solid.
Synthesis of 4-(4-formyl-phenylethynyl)-benzoic acid (2)
[1590] A solution of compound 1 (1.46 g, 10 mmol),
4-iodobenzaldehyde (2.32 g, 10 mmol) and diisopropylamine (3 ml) in
THF (6 ml) was purged for 10 min with dry nitrogen. A mixture of
PdCl.sub.2(PPh.sub.3).sub.2 (210 mg, 0.03 mmol), and CuI (114 mg,
0.06 mmol) was added and reaction mixture was stirred at ambient
temperature overnight. Formed precipitate was filtrated. Filtrate
was evaporated in vacuum. Residue was dissolved in EtOAc (100 ml)
and stirred with 5% aq. NaHCO.sub.3 (30 ml). Formed precipitate was
filtrated, washed with water, EtOAc, ether and dried in vacuum to
provide target product (2.4 g, 96%) as off-white solid.
Synthesis of
4-[4-(4-fluoro-piperidin-1-ylmethyl)-phenylethynyl]-benzoic acid
(3)
[1591] A mixture of compound 2 (150 mg, 0.6 mmol),
4-fluoropiperidine hydrochloride (84 mg, 0.6 mmol), AcOH (30 .mu.l)
and silica-supported NaCNBH.sub.3 (120 mg, 0.12 mmol) in EtOH (1
ml) was irradiated in microwave oven (max. power 250 W, 120.degree.
C.) for 25 min and cooled to ambient temperature. Solids were
filtrated. Filtrate was evaporated. Residue was dissolved in EtOAc
(100 ml), washed with 5% aq. NaHCO.sub.3 (30 ml) and brine (30 ml),
dried over anh. Na.sub.2SO.sub.4 and evaporated in vacuum. Residue
was dried in vacuum overnight to provide target material (68 mg,
34%) as white solid. LC-MS [M+H] 338.4.
Synthesis of (2S,3R)-3-azido-2-tert-butoxycarbonylamino-butyric
acid methyl ester (4)
[1592] A solution of di-tert-butyl dicarbonate (810 mg, 3.7 mmol),
(2S,3R)-2-amino-3-azido-butyric acid methyl ester hydrochloride
(660 mg, 3.38 mmol) and DIEA (645 .mu.l, 3.7 mmol) in i-PrOH (10
ml) was maintained at ambient temperature for 10 h. Reaction
mixture was evaporated in vacuum. Residue was dissolved in water
and extracted with hexane/ether (1:1). Combined organics were dried
over anhydrous MgSO.sub.4 and concentrated in vacuum. Residue was
subjected to flash chromatography on CombiFlash.RTM. Companion unit
equipped with RediSep.RTM. flash column (normal phase, 35-60 micron
average particle size silicagel, 40 g, Teledyne Isco); flow rate=35
ml/min; injection volume 2 ml; mobile phase A: hexane; mobile phase
B: EtOAc; gradient 0-50% B in 1 h. Fractions containing the desired
product were combined and concentrated in vacuum to provide target
compound (564 mg, 65%) as colorless oil. LC-MS [M+H] 259.0.
Synthesis of (2S,3R)-3-amino-2-tert-butoxycarbonylamino-butyric
acid methyl ester (5)
[1593] Compound 4 (786 mg, 3.05 mmol) was dissolved in methanol (20
ml) followed by the addition of Pd/C (5% wt, 200 mg). Reaction
mixture was subjected to hydrogenation (Parr apparatus, 80 psi) at
ambient temperature for 40 min. Catalyst was filtered and washed
with methanol. Filtrate was evaporated in vacuum to provide 3 (682
mg, 96%) as colorless oil. LC-MS [M+H] 233.0.
Synthesis of
(2S,3R)-2-tert-butoxycarbonylamino-3-(9H-Fluoren-9-ylmethoxycarbonyl-amin-
o)-butyric acid methyl ester (6)
[1594] A mixture of 5 (682 mg, 2.94 mmol) and Fmoc-OSu (1.04 g,
3.08 mmol) in acetone (5 ml) was stirred at ambient temperature for
2 h. Solvent was evaporated in vacuum. Residue was dissolved in
EtOAc (50 ml) and washed with 5% NaHCO.sub.3, and brine. Organic
layer was dried over Na.sub.2SO.sub.4 and evaporated in vacuum.
Residue was subjected to flash chromatography on CombiFlash.RTM.
Companion unit equipped with RediSep.RTM. flash column (normal
phase, 35-60 micron average particle size silicagel, 40 g, Teledyne
Isco); flow rate=35 ml/min; injection volume 2 ml; mobile phase A:
hexane; mobile phase B: EtOAc; gradient 0-45% B in 1 h. Fractions
containing the desired product were combined and concentrated in
vacuum to provide 6 (1.10 g, 82%) as colorless oil that was
solidified during vacuum drying. LC-MS [M+H] 455.3.
Synthesis of
(2S,3R)-2-amino-3-(9H-fluoren-9-ylmethoxycarbonylamino)-butyric
acid methyl ester hydrochloride (7)
[1595] Compound 6 (1.10 g, 2.42 mmol) was dissolved in 4 N
HCl/dioxane (8 ml) and solution was maintained at ambient
temperature for 20 min. The resulting suspension was diluted with
ether and the precipitate was filtered and washed with ether.
Compound was dried in vacuum to provide the hydrochloride of 7 (840
mg, 89%) as white solid. LC-MS [M+H] 355.2.
Synthesis of
(2S,3R)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-2-{4-[4-(4-fluoro-piperid-
in-1-ylmethyl)-phenylethynyl]-benzoylamino}-butyric acid methyl
ester (8)
[1596] A solution of 3 (31 mg, 0.09 mmol), HATU (34 g, 0.09 mmol)
and DIEA (50 .mu.l, 0.27 mmol) in DMF (1 ml) was maintained at
ambient temperature for 10 min followed by the addition of compound
7 hydrochloride (35 mg, 0.09 mmol). Reaction mixture was stirred at
ambient temperature overnight followed by the dilution with EtOAc
(100 ml). Solution was extracted with water (20 ml.times.2) and
brine (20 ml). Organic layer was dried over MgSO.sub.4 and
evaporated. Residue was dried in vacuum to provide target compound
(41 mg, 67%) as brown solid. LC-MS [M+H] 674.6.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(4-fluoro-piperidin-1--
ylmethyl)-phenylethynyl]-benzamide (115-1)
[1597] A solution of hydroxylamine hydrochloride (26 mg, 0.36 mmol)
in MeOH (2 ml) was cooled to -5.degree. C. followed by the addition
of 25% NaOMe/MeOH (125 .mu.l, 0.55 mmol) under nitrogen. Reaction
mixture was stirred at -5.degree. C. for additional 5 min, cooled
to -20.degree. C., and solution of 8 (41 mg, 0.061 mmol) in
THF/MeOH (1:1, 2 ml) was added dropwise over the period of 5 min.
Temperature of reaction mixture was raised to ambient. Completion
of the reaction was monitored by LC-MS. Reaction mixture was
acidified with 1 N aq. HCl to pH-'7 and evaporated in vacuum.
Residue was dissolved in DMSO (500 .mu.l) and subjected to HPLC
purification. [Phenomenex Gemini C-18 column, 110 .ANG.
(30.times.100 mm); flow rate=20 ml/min; mobile phase A: 100% water,
0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient elution from
8% B to 28% B in 60 min., detection 254 nm]. Fractions containing
the desired product were combined and lyophylised to provide the
trifluoracetate salt of 115-1 as white solid. LC-MS [M+H]
452.9.
TABLE-US-00127 Retention Scale Yield Yield Purity time Compound
(mmol) (mg) (%) (%) [M + H] (min)* 115-1 0.061 15.6 37 99.1 452.9
2.58 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.6 min,
detection 254 nm]
The following compounds were made as described for 115-1 above.
TABLE-US-00128 Compound # Structure RT (min) [M + H] 115-2
##STR00440## 5.11.sup.1 407.1 115-3 ##STR00441## 5.61.sup.1 471.5
115-4 ##STR00442## 2.59.sup.2 450.3 115-5 ##STR00443## 2.67.sup.2
472.3 115-6 ##STR00444## 3.01.sup.2 437.1 115-7 ##STR00445##
3.31.sup.2 514.3 115-8 ##STR00446## 3.54.sup.2 465.1 .sup.1Using
LC-MS Analytical Method D. .sup.2Using LC-MS Analytical Method
B.
Example 116
(S)--N-(3-amino-1-(hydroxyamino)-1-oxopropan-2-yl)-4-((4-((2-aminoacetamid-
o)methyl)phenyl)ethynyl)benzamide (116-1)
##STR00447##
[1598] Synthesis of
(S)-2-[4-(4-Aminomethyl-phenylethynyl)-benzoylamino]-3-(9H-fluoren-9-ylme-
thoxycarbonylamino)-propionic acid methyl ester hydrochloride
(2)
[1599] Compound 1 (500 mg, 1.42 mmol), DAP (Fmoc, OMe).HCl (589 mg,
1.56 mmol), HATU (597 mg, 1.57 mmol), DIEA (0.791 mL, 4.54 mmol)
and DMF (2 mL) were combined and the mixture was stirred at ambient
temperature for 30 min. Reaction mixture was diluted with EtOAc
(100 mL), washed with water (2.times.50 mL) and brine (50 mL),
dried over anhydrous MgSO.sub.4, and concentrated in vacuo. LC-MS:
RT (Method A) 7.37 min; [M+H] 674.4. The residue was dissolved in
dioxane (10 mL) and 4 M HCl/dioxane (25 mL, 100 mmol) was added.
Reaction mixture was stirred at ambient temperature for 1 h, and
volatiles were removed in vacuo to give target compound 2 (1.134 g,
131%). LC-MS: RT (Method A) 5.07 min; [M+H] 574.5.
Synthesis of
(S)-2-(4-{4-[(2-tert-Butoxycarbonylamino-acetylamino)-methyl]-phenylethyn-
yl}-benzoylamino)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-propionic
acid methyl ester hydrochloride (3)
[1600] Compound 2 (365 mg, 0.598 mmol), Boc-Gly-OH (126 mg, 0.719
mmol), HATU (274 mg, 0.721 mmol), DIEA (0.365 mL, 2.09 mmol) and
DMF (1 mL) were combined and the mixture was stirred at ambient
temperature for 1 h. Reaction mixture was diluted with EtOAc (100
mL), washed with water (2.times.50 mL) and brine (50 mL), dried
over anhydrous MgSO.sub.4, and concentrated in vacuo. LC-MS: RT
(Method A) 6.36 min; [M+H] 731.5 (C.sub.42H.sub.42N.sub.4O.sub.8+H,
requires 731.84). The residue was dissolved in dioxane (5 mL) and 4
M HCl/dioxane (15 mL, 60 mmol) was added. Reaction mixture was
stirred at ambient temperature for 1 h, and volatiles were removed
in vacuo to give target compound 3 (489 mg, 122%). LC-MS: RT
(Method A) 5.23 min; [M+H] 631.5.
(S)--N-(3-amino-1-(hydroxyamino)-1-oxopropan-2-yl)-4-((4-((2-aminoacetamid-
o methyl)phenyl)ethynyl)benzamide (116-1)
TABLE-US-00129 [1601] Reagent MW Eq. mg/mL mmol Compound 3 667.17
1.0 147 mg 0.220 Hydroxylamine hydrochloride 69.49 6 92 mg 1.32 25%
NaOMe/MeOH 54.02 12 0.607 mL 2.66 THF 2 mL MeOH 2 mL
[1602] The target compound 116-1 (3.1 mg, 2.2% yield) as a white
solid was prepared by following General Method for hydroxamate.
LC-MS: RT (Method A) 2.39 min; [M+H] 410.5.
TABLE-US-00130 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
116-1 0.220 3.1 2.2 99.1 410.4 2.39 .sup.1Based on the amount of
compound used in the last step of the reaction. .sup.2Using LC-MS
Analytical Method A.
Example 117
N-((1S,2R)-2-Amino-1-methylcarbamoyl-propyl)-4-(4-morpholin-4-ylmethyl-phe-
nylethynyl)-benzamide (117-1) and
(2S,3R)-3-Amino-2-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoylamino]-
-butyric acid (117-2)
##STR00448##
[1603] Synthesis of
(2S,3R)-3-(9H-Fluoren-9-ylmethoxycarbonylamino)-2-[4-(4-morpholin-4-ylmet-
hyl-phenylethynyl)-benzoylamino]-butyric acid methyl ester (2)
[1604] Compound 1 (137 mg, 0.383 mmol), MeDAP (Fmoc, OMe).HCl (150
mg, 0.384 mmol), HATU (173 mg, 0.455 mmol), DIEA (0.298 mL, 1.71
mmol) and DMF (1 mL) were combined and the mixture was stirred at
ambient temperature for 1 h. Reaction mixture was diluted with
EtOAc (50 mL), washed with water (2.times.30 mL) and brine (30 mL),
dried over anhydrous MgSO.sub.4, and concentrated in vacuo to give
target compound 2 (314 mg, 125%). LC-MS: RT (Method A) 5.35 min;
[M+H] 658.4.
Synthesis of
N-((1S,2R)-2-Amino-1-methylcarbamoyl-propyl)-4-(4-morpholin-4-ylmethyl-ph-
enylethynyl)-benzamide (117-1)
[1605] A solution of compound 2 (.about.0.19 mmol) in 2 M
NH.sub.2Me/THF (2 mL) was stirred at 80.degree. C. in a sealed
reaction vessel for 16 h. Reaction mixture was concentrated in
vacuo and the residue was purified by preparative scale
reverse-phase HPLC (Phenomenex Gemini C-18 column, 110 .ANG.,
30.times.100 mm, flow rate: 20 mL/min, mobile phase A: 0.1%
TFA/water, mobile phase B: 0.1% TFA/ACN, gradient elution from 5% B
to 40% B over 90 min, MS detection). Fractions containing the
desired product were combined and lyophilized to provide the
trifluoroacetate salt of target compound 117-1 (10.8 mg, 8.58%
yield) as a white solid. LC-MS: RT (Method A) 2.80 min; [M+H]
435.4.
TABLE-US-00131 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
117-1 0.19 10.8 8.58 98.5 435.4 2.80 .sup.1Based on the amount of
compound used in the last step. .sup.2Using LC-MS Analytical Method
A.
Synthesis of
(2S,3R)-3-Amino-2-[4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzoylamino]-
-butyric acid (117-2)
[1606] To a solution of compound 2 (.about.0.19 mmol) in THF (1
mL), was added 2 M NaOH (aq) (0.475 mL, 0.950 mmol), and the
mixture was stirred at ambient temperature for 1 h. Reaction
mixture was neutralized with 1 M HCl (aq) and concentrated in
vacuo. The residue was purified by preparative scale reverse-phase
HPLC (Phenomenex Gemini C-18 column, 110 .ANG., 30.times.100 mm,
flow rate: 20 mL/min, mobile phase A: 0.1% TFA/water, mobile phase
B: 0.1% TFA/ACN, gradient elution from 5% B to 40% B over 60 min,
MS detection). Fractions containing the desired product were
combined and lyophilized to provide the trifluoroacetate salt of
target compound 117-2 (26.7 mg, 21.6% yield) as a white solid.
LC-MS: RT (Method A) 2.42 min; [M+H] 422.1.
TABLE-US-00132 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
117-2 0.19 26.7 21.6 98.9 422.1 2.42 .sup.1Based on the amount of
compound used in the last step. .sup.2Using LC-MS Analytical Method
A.
Example 118
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-azetidin-1-ylmethyl-phe-
nylethynyl)-benzamide (118-1)
##STR00449##
[1607] Synthesis of
(2S,3R)-3-(9H-Fluoren-9-ylmethoxycarbonylamino)-2-[4-(4-hydroxymethyl-phe-
nylethynyl)-benzoylamino]-butyric acid methyl ester (2)
[1608] Compound 1 (615 mg, 2.44 mmol), MeDAP (Fmoc, OMe).HCl (954
mg, 2.44 mmol), HATU (928 mg, 2.93 mmol), DIEA (1.4 mL, 8.04 mmol)
and DMF (5 mL) were combined and the mixture was stirred at ambient
temperature for 1 h. Reaction mixture was diluted with EtOAc (100
mL), washed with water (2.times.50 mL) and brine (50 mL), dried
over anhydrous Na.sub.2SO.sub.4, and concentrated in vacuo to give
target compound 2 (1.429 g, 99.6%). LC-MS: RT (Method A) 6.19 min;
[M+H] 589.3.
Synthesis of
(2S,3R)-2-[4-(4-Azetidin-1-ylmethyl-phenylethynyl)-benzoylamino]-3-(9H-fl-
uoren-9-ylmethoxycarbonylamino)-butyric acid methyl ester (3)
[1609] To a stirred solution of compound 2 (1.429 g, 2.43 mmol) and
DIEA (1.27 mL, 7.29 mmol) in DCM (10 mL), cooled in ice/salt bath,
was added dropwise methanesulfonyl chloride (0.571 mL, 7.38 mmol).
Reaction mixture was allowed to attain ambient temperature and stir
for 30 min. One sixth of the reaction mixture (.about.1.8 mL,
.about.0.41 mmol) was added dropwise to a solution of azetidine
(0.111 mL, 1.64 mmol) and DIEA (0.286 mL, 1.64 mmol) in DCM (1 mL).
Reaction mixture was stirred at ambient temperature for 16 h, then
diluted with EtOAc (100 mL), washed with water (2.times.50 mL) and
brine (50 mL), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo to give target compound 3 (247 mg, 96%).
LC-MS: RT (Method A) 2.90 min; [M+H] 628.4.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-azetidin-1-ylmethyl-ph-
enylethynyl)-benzamide (118-1)
TABLE-US-00133 [1610] Reagent MW Eq. mg/mL mmol Compound 3 627.75
1.0 247 mg 0.393 Hydroxylamine hydrochloride 69.49 6 164 mg 2.36
25% NaOMe/MeOH 54.02 12 1.08 mL 4.72 THF 2 mL MeOH 2 mL
[1611] The target compound 118-1 (3.0 mg, 1.2% yield) as a white
solid was prepared by following General Method for hydroxamate.
LC-MS: RT (Method A) 2.54 min; [M+H] 407.3.
TABLE-US-00134 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
118-1 0.393 3.0 1.2 97.1 407.3 2.54 .sup.1Based on the amount of
compound used in the last step of the reaction. .sup.2Using LC-MS
Analytical Method A.
Each of the following compounds was synthesized as described
above.
TABLE-US-00135 Compound # Structure RT.sup.1 (min) [M + H] 118-2
##STR00450## 2.56 473.2 118-3 ##STR00451## 2.76 457.1 118-4
##STR00452## 2.90 437.4 118-5 ##STR00453## 2.61 451.5 118-6
##STR00454## 2.82 435.3 118-7 ##STR00455## 2.38 451.3 118-8
##STR00456## 2.25 420.3 118-9 ##STR00457## 2.27 412.9 118-10
##STR00458## 5.18 490.3 .sup.1Using LC-MS Analytical Method A.
Example 119
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-{4-[(2,2-difluoro-ethylami-
no)-methyl]-phenylethynyl}-benzamide (119-1)
##STR00459##
[1612] Synthesis of
(3S,4R)-3-(9H-Fluoren-9-ylmethoxycarbonylamino)-2-[4-(4-formyl-phenylethy-
nyl)-benzoylamino]-butyric acid methyl ester (2)
[1613] Compound 1 (448 mg, 1.79 mmol; see Example A), MeDAP (Fmoc,
OMe).HCl (700 mg, 1.79 mmol), HATU (816 mg, 2.15 mmol), DIEA (1.09
mL, 6.26 mmol) and DMF (3 mL) were combined and the mixture was
stirred at ambient temperature for 1 h. Reaction mixture was
diluted with EtOAc (50 mL), washed with water (2.times.30 mL) and
brine (30 mL), dried over anhydrous MgSO.sub.4, and concentrated in
vacuo to give target compound 2 (1.533 g, 146%). LC-MS: RT (Method
A) 7.06 min; [M+H] 587.2.
Synthesis of
(2S,3R)-2-(4-{4-[(2,2-Difluoro-ethylamino)-methyl]-phenylethynyl}-benzoyl-
amino)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-butyric acid methyl
ester (3)
[1614] To a stirred solution of compound 2 (147 mg, 0.251 mmol) and
2,2-difluoroethylamine (27 mg, 0.337 mmol) in THF (2 mL), was added
NaBH(OAc).sub.3 (74 mg, 0.349 mmol), and the mixture was stirred at
ambient temperature for 72 h. LC-MS analysis of the reaction
mixture showed only 10% conversion to desired product.
2,2-Difluoroethylamine (20 mg, 0.251 mmol), acetic acid (0.1 mL,
1.75 mmol) and NaBH(OAc).sub.3 (100 mg, 0.472 mmol) were added, and
the reaction mixture was stirred at ambient temperature for 2 h.
LC-MS analysis of the reaction mixture showed complete conversion
to desired product. Reaction mixture was quenched with 5%
NaHCO.sub.3 (aq) (50 mL) and extracted with EtOAc (3.times.20 mL)
Combined organic layers were washed with water (30 mL) and brine
(30 mL), dried over anhydrous MgSO.sub.4, and concentrated in vacuo
to give target compound 3 (178 mg, 109%). LC-MS: RT (Method A) 5.60
min; [M+H] 652.3.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-{4-[(2,2-difluoro-ethylam-
ino)-methyl]-phenylethynyl}-benzamide (119-1)
TABLE-US-00136 [1615] Reagent MW Eq. mg/mL mmol Compound 3 627.75
1.0 -- ~0.251 Hydroxylamine hydrochloride 69.49 6 105 mg 1.51 25%
NaOMe/MeOH 54.02 12 0.685 mL 3.00 THF 2 mL MeOH 2 mL
[1616] The target compound 119-1 (20.1 mg, 12.2% yield) as a white
solid was prepared by following General Method for hydroxamate.
LC-MS: RT (Method A) 2.38 min; [M+H] 431.1
(C.sub.22H.sub.24F.sub.2N.sub.4O.sub.3+H, requires 431.47).
TABLE-US-00137 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
119-1 0.251 20.1 12.2 99.2 431.1 2.38 .sup.1Based on the amount of
compound used in the reductive amination. .sup.2Using LC-MS
Analytical Method A.
The following compounds were made as described above.
TABLE-US-00138 Compound # Structure RT (min) [M + H] 119-2
##STR00460## 2.81.sup.1 421.2 119-3 ##STR00461## 2.35.sup.1 461.2
119-4 ##STR00462## 3.51.sup.2 432.3 119-5 ##STR00463## 3.78.sup.2
446.3 119-6 ##STR00464## 2.91.sup.2 395.1 .sup.1Using LC-MS
Analytical Method A. .sup.2Using LC-MS Analytical Method B.
Example 120
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-ethoxymethyl-phenylethy-
nyl)-benzamide (120-1)
##STR00465##
[1617] Synthesis of 1-Ethoxymethyl-4-ethynyl-benzene (2)
[1618] To a solution of 4-ethynylbenzyl alcohol (436 mg, 3.30 mmol)
in THF (2 mL) was added NaH (101 mg, 4.21 mmol) and iodoethane
(0.486 mL, 6.08 mmol). Reaction mixture was stirred at ambient
temperature for 16 h. Reaction mixture was diluted with brine (50
mL) and extracted with EtOAc (2.times.50 mL). Combined organic
layers were washed with brine (50 mL), dried over anhydrous
MgSO.sub.4, and concentrated in vacuo. Residue was purified by
normal phase flash chromatography on a CombiFlash.RTM.
Companion.TM. unit equipped with Luknova flash column (80 g silica
gel, 40-60 .mu.M average particle size, 60 .ANG. pore size); flow
rate: 60 mL/min; mobile phase A: hexane; mobile phase B: EtOAc;
gradient elution from 0% B to 30% B over 60 min. Fractions
containing the desired product were combined and concentrated in
vacuo to give target compound 2 (290 mg, 55%). LC-MS: RT (Method A)
5.16 min; compound not significantly ionizable.
Synthesis of 4-(4-Ethoxymethyl-phenylethynyl)-benzoic acid (3)
[1619] Compound 2 (271 mg, 1.69 mmol), 4-iodobenzoic acid (419 mg,
1.69 mmol), PdCl.sub.2(PPh.sub.3).sub.2 (36 mg, 0.051 mmol), CuI
(19 mg, 0.100 mmol), DIPA (4 mL, 28.3 mmol), and THF (12 mL) were
combined in a microwave tube. The tube was backfilled with
nitrogen, sealed, and irradiated in a microwave reactor (max. power
250 W) at 120.degree. C. for 10 min. Reaction mixture was diluted
with EtOAc (200 mL), washed with 2% H.sub.2SO.sub.4 (75 mL) and
water (75 mL), dried over MgSO.sub.4 and concentrated in vacuo to
give target compound 3 (470 mg, 99%). LC-MS: RT (Method A) 5.79
min; compound not significantly ionizable.
Synthesis of (2S,3R)-2-[4-(4-Ethoxymethyl-phenyleth
1)-benzoylamino]-3-(9H-fluoren-9-ylmethoxycarbonylamino)-butyric
acid methyl ester (4)
[1620] Compound 3 (115 mg, 0.410 mmol), MeDAP (Fmoc, OMe).HCl (161
mg, 0.412 mmol), HATU (187 mg, 0.492 mmol), DIEA (0.235 mL, 1.34
mmol) and DMF (0.8 mL) were combined and the mixture was stirred at
ambient temperature for 1 h. Reaction mixture was diluted with
EtOAc (50 mL), washed with water (2.times.30 mL) and brine (30 mL),
dried over anhydrous MgSO.sub.4, and concentrated in vacuo to give
target compound 4 (230 mg, 91%). LC-MS: RT (Method A) 7.45 min;
[M+H] 617.2.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-ethoxymethyl-phenyleth-
ynyl)-benzamide (120-1)
TABLE-US-00139 [1621] Reagent MW Eq. mg/mL mmol Compound 4 616.72
1.0 230 mg 0.372 Hydroxylamine hydrochloride 69.49 6 157 mg 2.26
25% NaOMe/MeOH 54.02 12 1.023 mL 4.48 THF 2 mL MeOH 2 mL
[1622] The target compound 120-1 (28.7 mg, 15.1% yield) as a white
solid was prepared by following General Method for hydroxamate.
LC-MS: RT (Method A) 4.06 min; [M+H] 396.2
(C.sub.22H.sub.25N.sub.3O.sub.4+H, requires 396.47).
TABLE-US-00140 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
120-1 0.372 28.7 15.1 99.7 396.2 4.06 .sup.1Based on the amount of
compound used in the last step. .sup.2Using LC-MS Analytical Method
A.
The following compounds were synthesized according to procedures
for compound 5.
TABLE-US-00141 Compound # Structure RT (min) [M + H] 120-2
##STR00466## 2.95.sup.1 430.1 120-3 ##STR00467## 4.22.sup.2 382.3
.sup.1Using LC-MS Analytical Method A. .sup.2Using LC-MS Analytical
Method B.
Example 121
N--((S)-2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-(4-cyclopropylaminom-
ethyl-phenylethynyl)-benzamide (121-1)
##STR00468##
##STR00469##
[1623] Synthesis of
2-Benzyloxycarbonylamino-3-tert-butoxycarbonylamino-3-methyl-butyric
acid (2)
[1624] Compound 1 (1.467, 3.86 mmol) was dissolved in EtOH (10 mL),
3 M NaOH (aq) (10 mL, 30 mmol) was added, and the mixture was
heated at 70.degree. C. for 1 h. Reaction mixture was concentrated
in vacuo and residue was dissolved in water (50 mL), cooled in
ice/water bath, and acidified to pH 2 with 10% H.sub.3PO.sub.4
(aq). Mixture was extracted with EtOAc (30 mL, 2.times.20 mL).
Combined organic layers were washed with water (30 mL) and brine
(30 mL), dried over anhydrous Na.sub.2SO.sub.4, and concentrated in
vacuo to give target compound 2 (0.977 g, 69.1%) as a viscous clear
oil. LC-MS: RT (Method A) 4.96 min; [M+H] 367.3
(C.sub.18H.sub.26N.sub.2O.sub.6+H, requires 367.43). Crude product
was used in next synthetic step without additional
purification.
Synthesis of
2-Benzyloxycarbonylamino-3-tert-butoxycarbonylamino-3-methyl-butyri
c acid pentafluorophenyl ester (3)
[1625] To a solution of compound 2 (967 mg, 2.64 mmol) and PFP (680
mg, 3.69 mmol) in DCM (15 mL) was added DCC (653 mg, 3.16 mmol).
Reaction mixture was allowed to stir at ambient temperature for 3
h. Reaction mixture was filtered, and solids (DCU) were washed with
DCM (3.times.5 mL). Combined filtrate and washes were concentrated
in vacuo, and the residue was purified by normal phase flash
chromatography on a CombiFlash.RTM. Companion.TM. unit equipped
with Luknova flash column (40 g silica gel, 40-60 .mu.m average
particle size, 60 .ANG. pore size); flow rate: 40 mL/min; mobile
phase A: hexane; mobile phase B: EtOAc; gradient elution from 0% B
to 40% B over 60 min. Fractions containing the desired product were
combined and concentrated in vacuo to give target compound 3 (1.025
g, 72.9%) as a viscous clear oil. LC-MS: RT (Method A) 7.25 min;
[M+H] 533.2.
Synthesis of
[3-((R)-4-Benzyl-2-oxo-oxazolidin-3-yl)-2-benzyloxycarbonylamino-1,1-dime-
thyl-3-oxo-propyl]-carbamic acid tert-butyl ester (4)
[1626] Compound 3 (1.025 g, 1.92 mmol),
(R)-(+)-4-benzyl-2-oxazolidinone (0.5117 g, 2.89 mmol), LiBr
(0.3344 g, 3.85 mmol), TEA (0.5366 mL, 3.85 mmol), and THF (10 mL)
were combined and allowed to stir at ambient temperature for 14 h.
Reaction mixture was concentrated in vacuo, and residue was
partitioned between water (50 mL) and EtOAc (30 mL). Aqueous layer
was extracted with EtOAc (2.times.20 mL). Combined organic layers
were washed with water (30 mL) and brine (30 mL), dried over
anhydrous Na.sub.2SO.sub.4, and concentrated in vacuo to give
target compound 4 (1.153 g, 115%) as an off-white solid foam. LC-MS
analysis (Method A) showed diastereomers, compounds 5 and 6, with
retention times RT.sub.5=6.60 min, RT.sub.6=6.78 min. Both with
[M+H] 526.3 (C.sub.28H.sub.35N.sub.3O.sub.7+H, requires
526.62).
Separation of diastereomers,
[(R)-1-((R)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-2-tert-butoxycarbonyla-
mino-2-methyl-propyl]-carbamic acid benzyl ester (5) and
[(S)-1-((R)-4-Benzyl-2-oxo-oxazolidine-3-carbonyl)-2-tert-butoxycarbonyla-
mino-2-methyl-propyl]carbamic acid benzyl ester (6)
[1627] Method 1:
[1628] Crude compound 4 (1.153 g) was purified and its component
diastereomers were separated by normal phase flash column
chromatography on a CombiFlash.RTM. Companion.TM. unit equipped
with Luknova flash column (80 g silica gel, 40-60 .mu.m average
particle size, 60 .ANG. pore size); flow rate: 50 mL/min; mobile
phase A: hexane; mobile phase B: EtOAc; gradient elution from 0% B
to 10% B over 5 min, then 10% B to 25% B over 90 min. 25 mL
fractions. Fractions containing target compound with diastereomeric
excess (d.e.) greater than 95% were combined and concentrated in
vacuo to give products as white solid foams (789.9 mg total yield,
78.1% from 3). F104-110: compound 6, 106.3 mg, 96% d.e. F111-127:
overlap, mixture of 5 and 6, 580.9 mg. F128-140: compound 5, 102.7
mg, -96% d.e.
[1629] Method 2:
[1630] The residue from combined fractions 111-127 (580.9 mg),
overlap from purification by Method A, was subjected to preparative
scale reverse-phase HPLC
[1631] (Varian Microsorb 100-10 C-18 column (50.times.300 mm), flow
rate: 50 mL/min, mobile phase A: 0.1% TFA/water, mobile phase B:
0.1% TFA/ACN, gradient elution from 20% B to 95% B over 90 min, UV
254 nm monitor, 50 mL fractions). Fractions containing target
compound with d.e. greater than 95% were combined, neutralized with
NaHCO.sub.3 (aq), concentrated in vacuo to approximately one half
of original volume, and extracted with EtOAc (3.times.1:2 vol.
EtOAc:vol. aq). The combined organic layers were washed with water
(1:2 vol. H.sub.2O:vol. organics) and brine (1:2 vol. brine:vol.
organics), dried over anhydrous Na.sub.2SO.sub.4, and concentrated
in vacuo to give products as white solid foams (441 mg total yield,
75.9% recovery). F56-58: compound 5, 153 mg, 99.7% d.e. F59+60:
overlap, mixture of 5 and 6, 181 mg. F61-63: compound 6, 107 mg,
97.7% d.e.
Synthesis of
[(S)-2-Amino-3-((R)-4-benzyl-2-oxo-oxazolidin-3-yl)-1,1-dimethyl-3-oxo-pr-
opyl]-carbamic acid tert-butyl ester hydrochloride (7)
[1632] To a solution of compound 6 (207 mg, 0.394 mmol) (combined
portions from separation methods 1 and 2, 96.7% d.e.) in MeOH (2.5
mL), were added 1 N HCl (0.394 mL) and 10% Pd/C (22.3 mg). Reaction
vessel was evacuated and backfilled with H.sub.2 three times, and
reaction mixture was allowed to stir under an atmosphere of H.sub.2
at ambient temperature for 1 h. Reaction mixture was filtered and
concentrated in vacuo to give target compound 7 (174.6 mg, 103%) as
a viscous clear oil which crystallized upon standing. LC-MS: RT
(Method A) 4.11 min; [M+H] 392.4.
Synthesis of [(S)-3-((R)-4-Benzyl-2-oxo-oxazolidin-3-yl)-2-(4-
{4-[(tert-butoxycarbonyl-cyclopropyl-amino)-methyl]-phenylethynyl}-benzoy-
lamino)-1,1-dimethyl-3-oxo-propyl]-carbamic acid tert-butyl ester
(9)
[1633] To a solution of compound 8 (167.7 mg, 0.428 mmol) and DIEA
(0.355 mL, 2.04 mmol) in DMF (5 mL) was added HATU (162.9 mg, 0.428
mmol), and the mixture was stirred at ambient temperature for 5
min. Compound 7 (174.6 mg, 0.408 mmol) was added, and the mixture
was stirred at ambient temperature for 20 min. Reaction mixture was
added to 0.1 M HCl (aq) (80 mL), and extracted with EtOAc
(3.times.25 mL). Combined organic layers were washed with water (40
mL) and brine (40 mL), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo to give target compound 9 (351 mg, 112%) as a
sticky amber solid foam. LC-MS: RT (Method A) 8.60 min; [M+H]
765.7.
Synthesis of [(S)-2-(4-
{4-[(tert-Butoxycarbonyl-cyclopropyl-amino)-methyl]-phenylethynyl}-benzoy-
lamino)-2-hydroxycarbamoyl-1,1-dimethyl-ethyl]-carbamic acid
tert-butyl ester (10)
[1634] Compound 9 (0.408 mmol) was dissolved in dioxane (8 mL) with
sonication, and 50% NH.sub.2OH (aq) (2 mL) was added. Reaction
mixture was allowed to stir at ambient temperature for 64 h.
Reaction mixture was reduced to approximately 1/3 of original
volume by concentration in vacuo, diluted with water (50 mL),
neutralized with 1 M HCl (aq), and extracted with EtOAc (3.times.30
mL). Combined organic layers were washed with water (40 mL) and
brine (40 mL), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo to give target compound 10 as an amber solid
foam. LC-MS: RT (Method A) 6.72 min; [M+H] 621.6.
Synthesis of
N--((S)-2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-(4-cyclopropylamino-
methyl-phenylethynyl)-benzamide (121-1)
[1635] To compound 10 was added 4 M HCl/dioxane (5 mL), and the
mixture was stirred at ambient temperature for 1 h. Volatiles were
removed in vacuo to give a sticky amber solid residue. Crude
product was purified by preparative scale reverse-phase HPLC
(Phenomenex Gemini C-18 column, 110 .ANG., 30.times.100 mm, flow
rate: 20 mL/min, mobile phase A: 0.1% TFA/water, mobile phase B:
0.1% TFA/ACN, gradient elution from 5% B to 20% B over 90 min, MS
detection). Fractions containing the desired product were combined
and lyophilized to provide the trifluoroacetate salt of target
compound 121-1 (44.6 mg, 20.1% yield from 7) as a white solid.
LC-MS: RT (Method A) 2.61 min; [M+H] 421.3.
TABLE-US-00142 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
121-1 0.408 44.6 20.1 99.7 421.3 2.61 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
The following compound was synthesized as described above for
121-1.
TABLE-US-00143 Compound Structure RT (min).sup.1 [M + H] 121-2
##STR00470## 2.61 421.2 .sup.1Using LC-MS Analytical Method A.
Example 122
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-
{4-[(2-methoxy-ethylamino)-methyl]-phenylethynyl}-benzamide
(122-1)
##STR00471##
[1636] Synthesis of
4-{4-[(2-Methoxy-ethylamino)-methyl]-phenylethynyl}-benzoic acid
methyl ester (2)
[1637] To a stirred suspension of compound 1 (200 mg, 0.751 mmol)
and DIEA (0.654 mL, 3.76 mmol) in DCM (3 mL), cooled in ice/water
bath, was added dropwise methanesulfonyl chloride (0.070 mL, 0.901
mmol). After 5 min the ice/water bath was removed and reaction
mixture was stirred at ambient temperature for 5 min. LC-MS: RT
(Method A) 6.03 min; compound not significantly ionizable. Reaction
mixture was added dropwise to a solution of 2-methoxyethylamine
(0.5 mL, 5.83 mmol) in DMF (5 mL), and the mixture was stirred at
ambient temperature for 15 min. Reaction mixture was concentrated
in vacuo, and residue was partitioned between water (100 mL) and
EtOAc (50 mL). Layers were separated and aqueous layer was
extracted with EtOAc (2.times.30 mL). Combined organic layers were
washed with water (50 mL) and brine (50 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give target compound
2 (257 mg, 106%) as a viscous amber oil. LC-MS: RT (Method A) 4.19
min; [M+H] 324.3. Crude product was used in next synthetic step
without additional purification.
Synthesis of 4-(4-
{[tert-Butoxycarbonyl-(2-methoxy-ethyl)-amino]-methyl}-phenylethynyl)-ben-
zoic acid (3)
[1638] To compound 2 (0.751 mmol) dissolved in CHCl.sub.3 (15 mL)
were added DIEA (0.262 mL, 1.50 mmol) and Boc.sub.2O (197 mg, 0.903
mmol), and the mixture was stirred at ambient temperature for 20
min.* LC-MS analysis of the reaction mixture showed complete
reaction. LC-MS: RT (Method A) 7.48 min; [M+H] 424.4. Reaction
mixture was concentrated in vacuo, and residue was dissolved in
EtOH (5 mL). NaOH (3M, aq) (2 mL, 6 mmol) was added, and the
mixture was stirred at ambient temperature for 30 min. Reaction
mixture was diluted with water (75 mL), cooled in ice/water bath,
acidified to pH 2 with 10% H.sub.3PO.sub.4 (aq), and extracted with
EtOAc (40 mL, 2.times.20 mL). Combined organic layers were washed
with water (40 mL) and brine (40 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give target compound
3 (326 mg, 106% from 1) as an off-white solid. LC-MS: RT (Method A)
6.20 min; [M+H] 410.2. Crude product was used in next synthetic
step without additional purification. *Boc protection was omitted
for secondary amines.
Synthesis of
(2S,3R)-3-tert-Butoxycarbonylamino-2-[4-(4-{[tert-butoxycarbonyl-(2-metho-
xy-ethyl)-amino]-methyl}-phenylethynyl)-benzoylamino]-butyric acid
methyl ester (4)
[1639] To a solution of compound 3 (100 mg, 0.244 mmol) and DIEA
(0.128 mL, 0.735 mmol) in DMF (2 mL) was added HATU (111.4 mg,
0.293 mmol), and the mixture was stirred at ambient temperature for
5 min. Methyl DAP.HCl (72.2 mg, 0.269 mmol) was added, and the
mixture was stirred at ambient temperature for 20 min. Reaction
mixture was added to 0.1 M HCl (aq) (80 mL), and extracted with
EtOAc (3.times.25 mL). Combined organic layers were washed with
water (40 mL) and brine (40 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give target compound
4 (207.8 mg, 136%) as a sticky amber solid. LC-MS: RT (Method A)
7.00 min; [M+H] 624.4 (C.sub.34H.sub.45N.sub.3O.sub.8+H, requires
624.76). Crude product was used in next synthetic step without
additional purification.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-{4-[(2-methoxy-ethylamino-
)-methyl]-phenylethynyl}-benzamide (122-1)
TABLE-US-00144 [1640] Reagent MW Eq. mg/mL mmol Compound 4 623.75
1.0 -- 0.244 HCl, 4.0M solution in 1,4-dioxane 36.46 82 5 mL 20
Isopropyl alcohol (IPA) 2 mL Hydroxylamine, 50 wt. % solution in
33.03 133 2 mL 32.6 water
[1641] The target compound 122-1 (11.0 mg, 8.37% yield from 3) as a
white solid was prepared by following General Method for
hydroxamate. LC-MS: RT (Method A) 2.35 min; [M+H] 425.2.
TABLE-US-00145 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
122-1 0.244 11.0 8.37 96.7 425.2 2.35 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
The following compounds were synthesized as described for
122-1.
TABLE-US-00146 Compound Structure RT (min) [M + H] 122-2
##STR00472## 2.96.sup.1 451.5 122-3 ##STR00473## 2.41.sup.1 445.1
122-4 ##STR00474## 2.58.sup.1 499.2 122-5 ##STR00475## 3.21.sup.2
465.6 122-6 ##STR00476## 2.94.sup.2 427.6 122-7 (same as 121-1)
##STR00477## 3.20.sup.2 421.1 122-8 ##STR00478## 3.77.sup.2 466.3
.sup.1Using LC-MS Analytical Method A. .sup.2Using LC-MS Analytical
Method B.
Example 123
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-cyclopropoxymethyl-phen-
ylethynyl)-benzamide (123-1)
##STR00479##
[1642] Synthesis of 4-(4-Vinyloxymethyl-phenylethynyl)-benzoic acid
methyl ester (1)
[1643] Pd(TFA).sub.2 (3.1 mg, 0.5 mol %) and bathophenanthroline
(3.1 mg, 0.5 mol %) were dissolved in BVE (5 mL, 38.8 mmol) in a
vial, and the mixture was stirred at ambient temperature for 5 min.
Compound 1 (500 mg, 1.88 mmol) and DIEA (0.0164 mL, 0.094 mmol)
were added, vial was backfilled with nitrogen, capped, and heated
at 75.degree. C. for 20 h. Reaction mixture was concentrated in
vacuo, and the residue was purified by normal phase flash
chromatography on a CombiFlash.RTM. Companion.TM. unit equipped
with Luknova flash column (40 g silica gel, 40-60 .mu.m average
particle size, 60 .ANG. pore size); flow rate: 40 mL/min; mobile
phase A: hexane; mobile phase B: EtOAc; gradient elution from 0% B
to 40% B over 60 min. Fractions containing the desired product were
combined and concentrated in vacuo to give target compound 2 (0.394
g, 71.8%) as an off-white solid. LC-MS: RT (Method A) 7.28 min;
compound not significantly ionizable.
Synthesis of 4-(4-Cyclopropoxymethyl-phenylethynyl)-benzoic acid
methyl ester (3)
[1644] To a stirred solution of compound 2 (150 mg, 0.513 mmol) and
CH.sub.2I.sub.2 (0.100 mL, 1.24 mmol) in anhydrous DCE (3 mL),
under a nitrogen atmosphere, cooled in an ice/water bath, was
cautiously added diethylzinc (1.0 M in hexanes; 1.13 mL, 1.13
mmol). After 5 min the ice/water bath was removed and reaction
mixture was allowed to stir at ambient temperature for 20 h.
Reaction mixture was added cautiously to saturated NH.sub.4Cl (aq)
(50 mL) and extracted with DCM (3.times.20 mL). Combined organic
layers were washed with 1 N HCl (30 mL), water (30 mL), saturated
NaHCO.sub.3 (aq) (30 mL) and brine (20 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give target compound
3 (180 mg, 115%) as an off-white solid. LC-MS: RT (Method A) 7.30
min; compound not significantly ionizable. .sup.1H NMR (250 MHz,
CDCl.sub.3) .delta. 0.5-0.65 (4H, m), 3.3 (1H, m), 3.9 (3H, s),
4.55 (2H, s), 7.3 (2H, d), 7.5-7.6 (4H, m), 8.0 (2H, d).
Synthesis of 4-(4-Cyclopropoxymethyl-phenylethynyl)-benzoic acid
(4)
[1645] To compound 3 (.about.0.513 mmol) were added EtOH (5 mL),
DCM (2 mL), and 3 M NaOH (aq) (2 mL, 6 mmol), and the mixture was
stirred at ambient temperature for 30 min. Reaction mixture was
diluted with water (150 mL), cooled in ice/water bath, acidified to
pH 3 with 10% H.sub.3PO.sub.4 (aq), and extracted with EtOAc
(3.times.30 mL). Combined organic layers were washed with water (30
mL) and brine (30 mL), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo to give to give target compound 4 (113.9 mg,
76% from 2) as a slightly off-white solid. LC-MS: RT (Method A)
6.06 min; compound not significantly ionizable.
Synthesis of
(2S,3R)-3-tert-Butoxycarbonylamino-2-[4-(4-cyclopropoxymethyl-phenylethyn-
yl)-benzoylamino]-butyric acid methyl ester (5)
[1646] To a solution of compound 4 (111 mg, 0.382 mmol) and DIEA
(0.200 mL, 1.15 mmol) in DMF (5 mL) was added HATU (174 mg, 0.458
mmol), and the mixture was stirred at ambient temperature for 5
min. Methyl DAP.HCl (113 mg, 0.420 mmol) was added, and the mixture
was stirred at ambient temperature for 20 min. Reaction mixture was
added to water (100 mL), and extracted with EtOAc (3.times.30 mL).
Combined organic layers were washed with water (50 mL) and brine
(50 mL), dried over anhydrous Na.sub.2SO.sub.4, and concentrated in
vacuo to give target compound 5 (239.2 mg, 123%) as a sticky amber
solid foam. LC-MS: RT (Method A) 6.87 min; [M+H] 507.0
(C.sub.29H.sub.34N.sub.2O.sub.6+H, requires 507.61). Crude product
was used in next synthetic step without additional
purification.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-cyclopropoxymethyl-phe-
nylethynyl)-benzamide (123-1)
TABLE-US-00147 [1647] Reagent MW Eq. mg/mL mmol Compound 5 506.60
1.0 -- ~0.382 HCl, 4.0M solution in 1,4-dioxane 36.46 31.4 3 mL 12
Isopropyl alcohol (IPA) 4 mL Hydroxylamine, 50 wt. % solution in
33.03 171 4 mL 65.3 water
[1648] The target compound 123-1 (67.5 mg, 33.9% yield from 4) as a
white solid was prepared by following General Method for
hydroxamate. LC-MS: RT (Method A) 4.19 min; [M+H] 408.3.
TABLE-US-00148 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
123-1 0.382 67.5 33.9 97.7 408.3 4.19 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
Example 124
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(2,2,2-trifluoro-ethoxy-
methyl)-phenylethynyl]-benzamide (124-1)
##STR00480##
[1649] Synthesis of 4-(4-Methanesulfonyloxymethyl-phenyleth n
1)-benzoic acid methyl ester (2)
[1650] To a suspension of compound 1 (200 mg, 0.751 mmol) and DIEA
(0.262 mL, 1.5 mmol) in DCM (5 mL), cooled in ice/water bath, was
added dropwise methanesulfonyl chloride (0.070 mL, 0.901 mmol) and
the mixture was stirred in ice/water bath for 5 min. Reaction
mixture was allowed to attain ambient temperature and stir for 10
min. Reaction mixture was diluted with DCM (40 mL), and washed with
water (2.times.30 mL). Combined aqueous layers were back-extracted
with DCM (2.times.20 mL). Combined organic layers were dried over
anhydrous Na.sub.2SO.sub.4, and concentrated in vacuo to give
target compound 2 (254.5 mg, 98.4%) as an off-white solid. LC-MS:
RT (Method A) 6.05 min; compound not significantly ionizable.
Synthesis of
4-[4-(2,2,2-Trifluoro-ethoxymethyl)-phenylethynyl]-benzoic acid
(3)
[1651] Sodium (25 mg, 1.09 mmol) was dissolved completely in
2,2,2-trifluoroethanol (8 mL, 111 mmol). Compound 2 (254.5 mg,
0.739 mmol) was added, and the mixture was heated to reflux for 5
min. NaOH (3M, aq) (6 mL, 18 mmol) was added, and the mixture was
heated at 70.degree. C. for 1 h. Reaction mixture was diluted with
water (150 mL), cooled in ice/water bath, acidified to pH 3 with
10% H.sub.3PO.sub.4 (aq), and filtered. Solids were washed with
water (3.times.50 mL) and dried by lyophilization to give target
compound 3 (238.9 mg, 96.7%) as a slightly off-white solid. LC-MS:
RT (Method A) 6.01 min; compound not significantly ionizable.
Synthesis of
(2S,3R)-3-tert-Butoxycarbonylamino-2-{4-[4-(2,2,2-trifluoro-ethoxymethyl)-
-phenylethynyl]-benzoylamino}-butyric acid methyl ester (4)
[1652] To a solution of compound 3 (100 mg, 0.299 mmol) and DIEA
(0.156 mL, 0.897 mmol) in DMF (2 mL) was added HATU (136 mg, 0.359
mmol), and the mixture was stirred at ambient temperature for 5
min. Methyl DAP.HCl (88.4 mg, 0.329 mmol) was added, and the
mixture was stirred at ambient temperature for 20 min. Reaction
mixture was added to 0.1 M HCl (aq) (80 mL), and extracted with
EtOAc (3.times.25 mL). Combined organic layers were washed with
water (40 mL) and brine (40 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give target compound
4 (192 mg, 117%) as a sticky light amber solid. LC-MS: RT (Method
A) 6.81 min; [M+H] 549.5. Crude product was used in next synthetic
step without additional purification.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(2,2,2-trifluoro-ethox-
ymethyl)-phenylethynyl]-benzamide (124-1)
TABLE-US-00149 [1653] Reagent MW Eq. mg/mL mmol Compound 4 548.56
1.0 -- 0.299 HCl, 4.0M solution in 1,4-dioxane 36.46 53.5 4 mL 16
Isopropyl alcohol (IPA) 2 mL Hydroxylamine, 50 wt. % solution in
33.03 109 2 mL 32.6 water
[1654] The target compound 124-1 (38.1 mg, 22.6% yield from 3) as a
white solid was prepared by following General Method for
hydroxamate. LC-MS: RT (Method A) 4.35 min; [M+H] 449.9.
TABLE-US-00150 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
124-1 0.299 38.1 22.6 95.8 449.9 4.35 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
The following compounds were synthesized according to procedures
above for 124-1.
TABLE-US-00151 Compound Structure RT (min).sup.1 [M + H] 124-2
##STR00481## 4.25 410.1 124-3 ##STR00482## 3.98 432.3 .sup.1Using
LC-MS Analytical Method A.
Example 125
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-cyclopropoxy-phenylethy-
nyl)-benzamide (125-1)
##STR00483##
[1655] Synthesis of 1-Bromo-4-(2-chloro-ethoxy)-benzene (1)
[1656] To a mixture of 4-bromophenol (2.0 g, 11.6 mmol) and
K.sub.2CO.sub.3 (3.20 g, 23.2 mmol) in DMF (50 mL) was added
3-chloroethyl p-toluenesulfonate (2.52 mL, 13.9 mmol), and the
mixture was stirred at 60.degree. C. for 16 h. Reaction mixture was
concentrated in vacuo, and the residue was partitioned between
water (200 mL) and DCM (50 mL). Aqueous layer was further extracted
with DCM (3.times.20 mL). Combined organic layers were washed with
water (30 mL) and brine (30 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give target compound
1 (3.12 g, 115%) as a light amber oil. LC-MS: RT (Method A) 5.83
min; compound not significantly ionizable. .sup.1H NMR (250 MHz,
CDCl.sub.3) .delta. 3.8 (2H, t), 4.2 (2H, t), 6.8 (2H, d), 7.4 (2H,
d). Crude product was used in next synthetic step without
additional purification.
Synthesis of 1-Bromo-4-vinyloxy-benzene (2)
[1657] To a stirred solution of compound 1 (.about.11.6 mmol) in
THF (30 mL), cooled in an ice/water bath, was added potassium
tert-butoxide (1.95 g, 17.3 mmol) in three portions. After 10 min
the ice/water bath was removed and reaction mixture was stirred at
ambient temperature for 16 h. Reaction mixture was concentrated in
vacuo and partitioned between water (150 mL) and DCM (50 mL).
Aqueous layer was further extracted with DCM (3.times.30 mL).
Combined organic layers were washed with water (40 mL) and brine
(40 mL), dried over anhydrous Na.sub.2SO.sub.4, and concentrated in
vacuo. Residue was purified by normal phase flash chromatography on
a CombiFlash.RTM. Companion.TM. unit equipped with Luknova flash
column (40 g silica gel, 40-60 .mu.m average particle size, 60
.ANG. pore size); flow rate: 40 mL/min; mobile phase: hexane.
Fractions containing the desired product were combined and
concentrated in vacuo to give target compound 2 (1.702 g, 74% from
4-bromophenol) as a clear oil. LC-MS: RT (Method A) 5.95 min;
compound not significantly ionizable. .sup.1H NMR (250 MHz,
CDCl.sub.3) .delta. 4.45 (1H, dd), 4.75 (1H, dd), 6.6 (1H, dd),
6.85 (2H, d), 7.4 (2H, d).
Synthesis of 1-Bromo-4-cyclopropoxy-benzene (3)
[1658] To a stirred solution of compound 2 (1.702 g, 8.55 mmol) and
CH.sub.2I.sub.2 (5.52 mL, 68.4 mmol) in anhydrous DCE (75 mL),
under a nitrogen atmosphere, cooled in an ice/water bath, was
cautiously added diethylzinc (1.0 M in hexanes; 68.4 mL, 68.4
mmol). After 30 min the ice/water bath was removed and reaction
mixture was allowed to stir at ambient temperature for 64 h.
Reaction mixture was added cautiously to saturated NH.sub.4Cl (aq)
(200 mL), mixture was shaken and layers separated, and aqueous
layer was extracted with DCM (3.times.30 mL). Combined organic
layers were washed with 1 N HCl (100 mL), water (100 mL), saturated
NaHCO.sub.3 (aq) (100 mL) and brine (80 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give a light amber
oil. Crude product was purified by normal phase flash
chromatography on a CombiFlash.RTM. Companion.TM. unit equipped
with Luknova flash column (40 g silica gel, 40-60 .mu.m average
particle size, 60 .ANG. pore size); flow rate: 40 mL/min; mobile
phase: hexane. Fractions containing the desired product were
combined and concentrated in vacuo to give target compound 3 (1.310
mg, 71.9%) as a clear oil. LC-MS: RT (Method A) 5.87 min; compound
not significantly ionizable. .sup.1H NMR (250 MHz, CDCl.sub.3)
.delta. 0.75 (4H, m), 3.7 (1H, m), 6.9 (2H, d), 7.4 (2H, d).
Synthesis of 4-(4-Cyclopropoxy-phenylethynyl)-benzoic acid methyl
ester (4)
[1659] A microwave tube was charged with compound 3 (400 mg, 1.88
mmol), 4-ethynyl-benzoic acid methyl ester (330 mg, 2.06 mmol),
PdCl.sub.2(dppf).CH.sub.2Cl.sub.2 (30.7 mg, 2 mol %), CuI (14.3 mg,
4 mol %), DIPA (0.40 mL, 2.83 mmol), and DMF (6 mL). Tube was
backfilled with nitrogen, sealed, and irradiated in a microwave
reactor (max. power 250 W) at 160.degree. C. for 5 min. Reaction
mixture was diluted with water (100 mL) and extracted with EtOAc
(3.times.30 mL). Combined organic layers were washed with water (50
mL) and brine (50 mL), dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo to give a sticky brown solid. Crude product
was purified by normal phase flash chromatography on a
CombiFlash.RTM. Companion.TM. unit equipped with Luknova flash
column (40 g silica gel, 40-60 .mu.m average particle size, 60
.ANG. pore size); flow rate: 40 mL/min; mobile phase A: hexane;
mobile phase B: EtOAc; gradient elution from 0% B to 40% B over 60
min. Fractions containing the desired product were combined and
concentrated in vacuo to give target compound 4 (47.7 mg, 8.7%) as
a light brown solid. LC-MS: RT (Method A) 7.32 min; compound not
significantly ionizable. .sup.1H NMR (250 MHz, CDCl.sub.3) .delta.
0.75 (4H, m), 3.7 (1H, m), 3.85 (3H, s), 7.0 (2H, d), 7.5 (2H, d),
7.6 (2H, d), 8.0 (2H, d).
Synthesis of 4-(4-Cyclopropoxy-phenylethynyl)-benzoic acid (5)
[1660] To compound 4 (47.7 mg, 0.163 mmol) were added EtOH (5 mL)
and 3 M NaOH (aq) (2 mL, 6 mmol). Reaction mixture was heated at
70.degree. C. for 30 min. Reaction mixture was diluted with water
(150 mL), cooled in ice/water bath, acidified to pH 3 with 10%
H.sub.3PO.sub.4 (aq), and extracted with EtOAc (3.times.30 mL).
Combined organic layers were washed with water (30 mL) and brine
(30 mL), dried over anhydrous Na.sub.2SO.sub.4, and concentrated in
vacuo to give to give target compound 5 (44.7 mg, 98.8%) as a
slightly off-white solid. LC-MS: RT (Method A) 6.11 min; compound
not significantly ionizable.
Synthesis of
(2S,3R)-3-tert-Butoxycarbonylamino-2-[4-(4-cyclopropoxy-phenylethynyl)-be-
nzoylamino]-butyric acid methyl ester (6)
[1661] To a solution of compound 5 (44.7 mg, 0.161 mmol) and DIEA
(0.084 mL, 0.482 mmol) in DMF (2 mL) was added HATU (73.5 mg, 0.193
mmol), and the mixture was stirred at ambient temperature for 5
min. Methyl DAP.HCl (47.6 mg, 0.177 mmol) was added, and the
mixture was stirred at ambient temperature for 20 min. Reaction
mixture was added to water (100 mL), and extracted with DCM
(3.times.30 mL). Combined organic layers were washed with water (30
mL), dried over anhydrous Na.sub.2SO.sub.4, and concentrated in
vacuo to give target compound 6 (159.7 mg, 201%) as a viscous amber
oil. LC-MS: RT (Method A) 6.89 min; [M+H] 493.2. Crude product was
used in next synthetic step without additional purification.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-cyclopropoxy-phenyleth-
ynyl)-benzamide (125-1)
[1662] To compound 6 (.about.0.161 mmol) was added 4 M HCl/dioxane
(3 mL), and the mixture was stirred at ambient temperature for 1 h.
Volatiles were removed in vacuo, and the residue was washed with
diethyl ether (2.times.10 mL), centrifuging and removing
supernatant after each wash, to give a light amber powdery solid.
LC-MS: RT (Method A) 4.91 min; [M+H] 393.2
(C.sub.23H.sub.24N.sub.2O.sub.4+H, requires 393.47). Isopropyl
alcohol (4 mL) was added to the solid and the mixture was cooled in
an ice/water bath for 5 min. NH.sub.2OH (50%, aq) (4 mL) was added
to the mixture, dropwise for the first 2 mL. Reaction mixture was
allowed to stir in ice bath for 5 min, and then allowed to stir at
ambient temperature for 16 h. Solvent volume was reduced
approximately by half under a stream of nitrogen, and water (10 mL)
was added. The suspension was thoroughly agitated (vibro mixer and
sonication), centrifuged and the supernatant was discarded. Water
(10 mL) was added to the solid and the suspension was thoroughly
agitated, centrifuged and the supernatant was discarded. Wet solid
was dried by lyophilization to give crude product (41.7 mg, 69.3%
crude yield from 5) as an off-white solid. Crude product was
purified by preparative scale reverse-phase HPLC (Phenomenex Gemini
C-18 column, 110 .ANG., 30.times.100 mm, flow rate: 20 mL/min,
mobile phase A: 0.1% TFA/water, mobile phase B: 0.1% TFA/ACN,
gradient elution from 15% B to 40% B over 60 min, MS detection).
Fractions containing the desired product were combined and
lyophilized to provide the trifluoroacetate salt of target compound
125-1 (30.2 mg, 37.0% yield from 5, 56.1% recovery from crude
product) as a white solid. LC-MS: RT (Method A) 4.39 min; [M+H]
394.3.
TABLE-US-00152 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
125-1 0.161 30.2 37.0 100 394.3 4.39 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
Example 126
N--((S)-2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-(4-ethoxymethyl-phen-
ylethynyl)-benzamide (126-1)
##STR00484##
[1663] Synthesis of 4-(4-Ethoxymethyl-phenylethynyl)-benzoic acid
(2)
[1664] To a solution of compound 1 (1.5 g, 5.63 mmol) in dry DMSO
(30 mL) was added sodium hydride (2.25 g, 56.3 mmol), and the
mixture was stirred at ambient temperature for 10 min. Iodoethane
(0.591 mL, 7.32 mmol) was added, and the mixture was stirred at
ambient temperature for 1 h. Reaction mixture was diluted with
water (150 mL), cooled in ice/water bath, acidified to pH 3 with 1
M HCl (aq), and extracted with EtOAc (80 mL, 2.times.50 mL).
Combined organic layers were washed with water (80 mL) and brine
(80 mL), dried over anhydrous Na.sub.2SO.sub.4, and concentrated in
vacuo to give a yellow solid. Crude product was purified by normal
phase flash chromatography on CombiFlash.RTM. Companion.TM. unit
equipped with Luknova flash column (80 g silica gel, 40-60 .mu.m
average particle size, 60 .ANG. pore size); flow rate: 50 mL/min;
mobile phase A: CH.sub.2Cl.sub.2; mobile phase B: MeOH; gradient
elution from 0% B to 8% B over 60 min. Fractions containing the
desired product were combined and concentrated in vacuo to give
target compound 2 (995 mg, 63%) as an off-white solid. LC-MS: RT
(Method A) 5.89 min; compound not significantly ionizable. .sup.1H
NMR (250 MHz, DMSO-d6) .delta. 1.1 (3H, t), 3.6 (2H, q), 4.5 (2H,
s), 7.4-8.0 (8H, m).
Synthesis of (S)-3-tert-Butoxycarbonylamino-2-[4-(4-
ethoxymethyl-phenylethynyl)-benzoylamino]-3-methyl-butyric acid
methyl ester (3)
[1665] To a solution of compound 2 (150 mg, 0.535 mmol) and DIEA
(0.280 mL, 1.61 mmol) in DMF (5 mL) was added HATU (244 mg, 0.642
mmol), and the mixture was stirred at ambient temperature for 5
min. Chiral dimethyl DAP (145 mg, 0.589 mmol) was added, and the
mixture was stirred at ambient temperature for 20 min. Reaction
mixture was added to 0.1 M HCl (aq) (100 mL), and extracted with
EtOAc (3.times.30 mL). Combined organic layers were washed with
water (50 mL) and brine (50 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give target compound
3 (386 mg, 142%) as a viscous amber oil. LC-MS: RT (Method A) 7.20
min; [M+H] 509.3. Crude product was used in next synthetic step
without additional purification.
Synthesis of
N--((S)-2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-(4-ethoxymethyl-phe-
nylethynyl)-benzamide (126-1)
[1666] To compound 3 was added 4 B: 0.1% TFA/ACN, gradient elution
from 20% B to 55% B over 90 min, MS detection M HCl/dioxane (4 mL),
and the mixture was stirred at ambient temperature for 1 h.
Volatiles were removed in vacuo to give a sticky amber solid.
LC-MS: RT (Method A) 4.70 min; [M+H] 408.9
(C.sub.24H.sub.28N.sub.2O.sub.4+H, requires 409.51). Isopropyl
alcohol (4 mL) was added to the solid and the mixture was cooled in
an ice/water bath for 5 min. NH.sub.2OH (50%, aq) (4 mL) was added
to the mixture, dropwise for the first 2 mL. Reaction mixture was
allowed to stir in ice bath for 5 min, and then allowed to stir at
ambient temperature for 16 h. Solvent volume was reduced
approximately by half under a stream of nitrogen, and water (10 mL)
was added. The suspension was thoroughly agitated (vibro mixer and
sonication), centrifuged and the supernatant was discarded. Water
(10 mL) was added to the solid and the suspension was thoroughly
agitated, centrifuged and the supernatant was discarded. Wet solid
was dried by lyophilization to give crude product (160.7 mg, 73.3%
crude yield from 2) as an off-white solid. Crude product was
purified by preparative scale reverse-phase HPLC (Phenomenex Gemini
C-18 column, 110 .ANG., 30.times.100 mm, flow rate: 20 mL/min,
mobile phase A: 0.1% TFA/water, mobile phase). Fractions containing
the desired product were combined and lyophilized to provide the
trifluoroacetate salt of target compound 126-1 (44.7 mg, 16% yield
from 2, 22% recovery from crude product) as a white solid. LC-MS:
RT (Method A) 4.07 min; [M+H] 410.5
(C.sub.23H.sub.27N.sub.3O.sub.4+H, requires 410.50).
TABLE-US-00153 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
126-1 0.535 44.7 16 99.5 410.5 4.07 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
Each of the following compounds was synthesized as described above
for compound 4.
TABLE-US-00154 Compound # Structure RT (min).sup.1 [M + H] 126-2
##STR00485## 4.24 410.3 .sup.1Using LC-MS Analytical Method A.
Example 127
N-[2-(Formyl-hydroxyamino)-ethyl]-4-(4-morpholin-4-ylmethyl-phenylethynyl)-
-benzamide (127-1)
##STR00486##
[1667] Synthesis N-(2-N,O-Di-Boc-hydroxyaminoethyl)phthalimide
(1)
[1668] To the mixture of N-(2-bromoethyl)-phthalimide (473 mg, 1.86
mmol) and N,O-di-Boc-hydroxylamine (500 mg, 2.14 mmol) in DMF (5
ml) was added K.sub.2CO.sub.3 (483 mg, 3.49 mmol). Reaction mixture
was stirred at 65.degree. C. overnight followed by the dilution
with EtOAc (50 ml). Solution was extracted with water (15
ml.times.2) and brine (30 ml). Organic layer was dried over
Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was subjected to
flash chromatography on CombiFlash.RTM. Companion unit equipped
with RediSep.RTM. flash column (normal phase, 35-60 micron average
particle size silicagel, 12 g, Teledyne Isco); flow rate=30 ml/min;
injection volume 2 ml; mobile phase A: hexane; mobile phase B:
EtOAc; gradient 0-50% B in 25 min. Fractions containing the desired
product were combined and concentrated in vacuum to provide target
compound 450 mg (59.2%) as colorless oil. LC-MS [M+H] 407.0.
Synthesis of 2-N,O-DiBoc-Hydroxyaminoethylamine (2)
[1669] A solution of compound 2 (450 mg, 1.11 mmol) and
N.sub.2H.sub.4.times.H.sub.2O (250 mg, 5.00 mmol) in EtOH (5 ml)
was heated at 80.degree. C. for 1 h. The reaction mixture was
cooled to r.t., the formed white precipitant was filtrated and
washed with EtOH (5 ml). Filtrate was concentrated in vacuum and
dried in vacuum for 4 h. Compound 2 was used as is for the next
chemical transformation with no additional purification. LC-MS
[M+H] 277.4.
Synthesis of
N-(2-N,O-di-Boc-hydroxyamino-ethyl)-4-(4-morpholin-4-ylmethyl-phenylethyn-
yl)-benzamide (4)
[1670] A mixture of compound 2 (0.55 mmol), compound 3 (160 mg, 0.5
mmol), DIEA (330 .mu.l, 2.0 mmol) and HATU (230 mg, 0.6 mmol) was
stirred at ambient temperature overnight followed by the dilution
with EtOAc (50 ml) and extraction extracted with water (15
ml.times.2) and brine (30 ml). Organic layer was dried over
Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was subjected to
flash chromatography on CombiFlash.RTM. Companion unit equipped
with RediSep.RTM. flash column (normal phase, 35-60 micron average
particle size silicagel, 4 g, Teledyne Isco); flow rate=18 ml/min;
injection volume 2 ml; mobile phase A: hexane; mobile phase B:
EtOAc; gradient 0-30% B in 30 min. Fractions containing the desired
product were combined and concentrated in vacuum to provide target
compound 250 mg (86.2%) as white solid. LC-MS [M+H] 480.2
(-Boc).
Synthesis of
N-(2-hydroxyamino-ethyl)-4-(4-morpholin-4-ylmethyl-phenylethynyl)-benzami-
de (5)
[1671] A solution of compound 4 (250 mg, 0.43 mmol) in of 4 M
HCl/dioxane (5 ml) was stirred at RT for 1 h. Solvents were
evaporated in vacuum. Residue was dried in vacuum to provide
dihydrochloride of compound 5 (184 mg, 95%) as yellow solid. LC-MS
[M+H] 380.1.
N-[2-(Formyl-hydroxyamino)-ethyl]-4-(4-morpholin-4-ylmethyl-phenylethynyl)-
-benzamide (127-1)
[1672] A mixture of compound 5 (184 mg, 0.43 mmol),
2,2,2-triflouroethyl formate (74 mg, 0.58 mmol), DIEA (165 .mu.l,
1.0 mmol) in THF (5 ml) was stirred at 65.degree. C. for 2 h. The
reaction mixture was concentrated in vacuum, the residue was
dissolved in DMSO (600 .mu.l) and subjected to HPLC purification.
[Phenomenex Gemini C-18 column, 110 .ANG. (30.times.100 mm); flow
rate=20 ml/min; mobile phase A: 100% water, 0.1% TFA; mobile phase
B: 100% ACN, 0.1% TFA; gradient elution from 10% B to 40% B in 60
min., detection 254 nm]. Fractions containing the desired product
were combined and lyophilized to provide trifluoroacetic salt of
target compound (40.3 mg, 17.9%) as white solid. LC-MS [M+H]
408.4.
TABLE-US-00155 Scale Yield Yield Purity Retention time Compound
(mmol) (mg) (%) (%) [M + H] (min)* 127-1 0.43 40.3 17.9 95.7 408.4
3.15 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.5 min,
detection 254 nm]
Example 128
N-[2-(Formyl-hydroxy-amino)-1-hydroxymethyl-ethyl]-4-(4-morpholin-4-yl-met-
hyl-phenylethynyl)-benzamide (128-1)
##STR00487##
[1673] Synthesis of (2-tert-Butoxy-1-iodomethyl-ethyl)-carbamic
acid benzyl ester (1)
[1674] A mixture of N-Cbz-O-tert-Bu-serinol (420 mg, 1.5 mmol),
Ph.sub.3P (487 mg, 1.86 mmol) and imidazole (150 mg, 2.2 mmol) was
dissolved in THF (10 ml) followed by the addition of I.sub.2 (483
mg, 3.49 mmol) portion wise during 3 min. The reaction mixture was
stirred at ambient temperature overnight followed by the dilution
with EtOAc (100 ml), and extraction with water (50 ml.times.3) and
brine (30 ml). The organic layer was dried over Na.sub.2SO.sub.4
and evaporated in vacuum. The residue was used as is for the next
chemical transformation with no additional purification. LC-MS
[M+H.sup.+] 392.0.
Synthesis of
(2-tert-Butoxy-1-(N,O-di-Boc-hydroxyaminomethyl-ethyl)-carbamic
acid benzyl ester (2)
[1675] A mixture of compound 1 (1.5 mmol), N,O-di-Boc-hydroxylamine
(350 mg, 1.5 mmol) and K.sub.2CO.sub.3 (483 mg, 3.49 mmol) in DMF
(5 ml) was stirred at 65.degree. C. for 2 h. The reaction mixture
was diluted with EtOAc (50 ml), and extracted with water (15
ml.times.2) and brine (30 ml). The organic layer was dried over
Na.sub.2SO.sub.4 and solvent was removed in vacuum. Residue was
subjected to flash chromatography on CombiFlash.RTM. Companion unit
equipped with RediSep.RTM. flash column (normal phase, 35-60 micron
average particle size silicagel, 12 g, Teledyne Isco); flow rate=30
ml/min; injection volume 2 ml; mobile phase A: hexane; mobile phase
B: EtOAc; gradient 0-95% B in 60 min. Fractions containing the
desired product were combined and concentrated in vacuum to provide
target compound (518 mg, 73.3% overall for 2 steps) as colorless
oil. LC-MS [M+H.sup.+] 497.2.
Synthesis of
(2-tert-Butoxy-1-(N,O-di-Boc-hydroxyaminomethyl)-ethylamine (3)
[1676] A mixture of solution of compound 2 (518 mg, 1.04 mmol) in
15 ml of MeOH and 5% Pd/C (200 mg) was subjected to hydrogenation
in Parr shaker at 65 psi overnight. Pd/C was removed by filtration
and filtrate was concentrated in vacuum to yield colorless oil,
which was used on the next step with no additional purification.
LC-MS [M+H.sup.+] 363.4.
Synthesis of
N-(2-tert-Butoxy-1-(N,O-di-Boc-hydroxyaminomethyl)-ethyl)-4-(4-morpholin--
4-ylmethyl-phenylethynyl)-benzamide (5)
[1677] A mixture of compound 3 (1.04 mmol), compound 4 (250 mg,
0.71 mmol), DIEA (496 .mu.l, 3.0 mmol) and HATU (380 mg, 1.0 mmol)
was stirred at ambient temperature for 45 min followed by the
dilution with EtOAc (50 ml) and extraction with water (15
ml.times.2) and brine (30 ml). Organic layer was dried over
Na.sub.2SO.sub.4 and evaporated in vacuum. Residue was subjected to
flash chromatography on CombiFlash.RTM. Companion unit equipped
with RediSep.RTM. flash column (normal phase, 35-60 micron average
particle size silicagel, 4 g, Teledyne Isco); flow rate=18 ml/min;
injection volume 2 ml; mobile phase A: hexane; mobile phase B:
EtOAc; gradient 0-60% B in 60 min. Fractions containing the desired
product were combined and concentrated in vacuum to provide target
compound 5 250 mg (48.2%) as white solid. LC-MS [M+H] 666.1.
Synthesis of
N-(2-Hydroxyamino-1-hydroxymethyl-ethyl)-4-(4-morpholin-4-ylmethyl-phenyl-
ethynyl)-benzamide (6)
[1678] The mixture of compound 5 (0.37 mmol, 250 mg) and 4 N
HCl/dioxane (6 ml, 24 mmol) was stirred at r.t. for 1.5 h. Solvents
were removed in vacuum and HCl salt was dissolved in a THF/DIEA
mixture (10 ml/220 .mu.l). A half of resulting solution was used on
next step. LC-MS [M+H.sup.+] 410.0.
N-[2-(Formyl-hydroxyamino)-ethyl]-4-(4-morpholin-4-ylmethyl-phenylethynyl)-
-benzamide (128-1)
TABLE-US-00156 [1679] Reagent MW Eq. mg/ml mmol Compound 6 (as a
solution, see pr. 276.34 1.0 -- 0.18 step.) Trifluoroethyl formate
128.05 11.1 195 mg 2.00 DIEA (as a solution, see pr. step.) 129.24
3.6 110 .mu.l 0.65 THF (as a solution, see pr. step.) 5 ml
[1680] Trifluoroethyl formate (20 mg, 2 mmol) was added to the
solution (.about.5 ml) from previous step and the reaction mixture
was stirred at 55.degree. C. for 1 h. The reaction mixture was
concentrated in vacuum. Residue was dissolved in DMSO (600 .mu.l)
and subjected to HPLC purification. [Phenomenex Gemini C-18 column,
110 .ANG. (30.times.100 mm); flow rate=20 ml/min; mobile phase A:
100% water, 0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient
elution from 10% B to 40% B in 60 min., detection 254 nm].
Fractions containing the desired product were combined and
lyophilized to provide trifluoroacetic salt of target compound
(10.6 mg, 10.7%) as white solid.
TABLE-US-00157 Scale Yield Yield Purity Retention time Compound
(mmol) (mg) (%) (%) [M + H] (min)* 128-1 0.18 10.6 10.7 97.7 438.1
2.94 *[Chromolith SpeedRod RP-18e C18 column (4.6 .times. 50 mm);
flow rate 1.5 ml/min; mobile phase A: 0.1% TFA/water; mobile phase
B 0.1% TFA/ACN; gradient elution from 5% B to 100% B over 9.5 mm,
detection 254 nm]
Example 129
3-Amino-N-hydroxy-3-methyl-2-[3-(4-morpholin-4ylmethyl-phenyl)-propynoylam-
ino]-butyramide (129-1)
##STR00488##
[1681] Synthesis of 3-Amino-2-
[4-(4-hydroxymethyl-phenylethynyl)-benzoylamino]-3-methyl-butyric
acid methyl ester (2)
[1682] To a cold solution of compound 1 (700 mg, 1.7 mmol) in 6 mL
NMP and 10 mL AcOH of at 0.degree. C., Zn dust (1.2 g, 18 mmol.)
was added. The reaction mixture was vigorously stirred for 2 h at
25.degree. C., monitored by LC-MS until there was no start material
left. The reaction mixture was filtered though a celite pad, the
solid was washed with DCM (3.times.10 mL) and MeOH (2.times.10 mL),
combined the filtrate and washing liquid, and then concentrated to
give 420 mg (65%) pure compound 2 as colorless oil. LC-MS: RT
(Method A) 3.36 min; [M+H] 638.7.
Synthesis of
3-tert-Butoxycarbonylamino-2-[4-(4-hydroxymethyl-phenylethynyl)-benzoylam-
ino]-3-methyl-butyric acid methyl ester (3)
[1683] To a cold solution of compound 2 (320 mg, 0.84 mmol) in THF
(4 mL) at 0.degree. C., di-tert-butyl dicarbonate (200 mg, 0.92
mmol) was added. The reaction mixture was stirred at ambient
temperature for 2 h, until TLC (30% EtOAc in hexanes) indicated the
disappearance of starting material. The reaction mixture was
diluted with DCM (20 mL), washed with saturated NaHCO.sub.3, brine,
dried over Na.sub.2SO.sub.4, and then concentrated to give the
crude compound 3 370 mg (92%).
Synthesis of
3-tert-Butoxycarbonylamino-3-methyl-2-[4-(4-morpholin-4-ylmethyl-phenylet-
hynyl)-benzoylamino]-butyric acid methyl ester (5)
[1684] To a cold solution of compound 3 (370 mg, 0.77 mmol.) and
DIEA (0.30 mL, 1.6 mmol) was added MsCl (0.12 mL, 1.54 mmol.) at
0.degree. C. The reaction mixture was stirred at ambient
temperature for 30 min. until TLC (30% EtOAc in Hexanes) indicated
the disappearance of starting material. The reaction mixture was
diluted with DCM (20 mL), washed with brine (2.times.20 mL), dried
over Na.sub.2SO.sub.4, concentrated to give the crude product 4
(400 mg, 90%). The methanesulfonate 4 was re-dissolve in DCM (10
mL). To the solution at 0.degree. C., morpholine (0.35 mL, 4.0
mmol) was added dropwise. The mixture was stirred at ambient
temperature for 30 min. Reaction mixture was concentrated in vacuo,
and residue was partitioned between water (30 mL) and EtOAc (30
mL). Layers were separated and aqueous layer was extracted with
EtOAc (2.times.10 mL). Combined organic layers were washed with
water (10 mL) and brine (10 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give compound 5 (439
mg, 100%) as a off-white solid.
Synthesis of
N-(2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-(4-morpholin-4-ylmethyl--
phenylethynyl)-benzamide (6)
[1685] To a mixture of compound 5 (148 mg) in dioxane (4 mL), HCl
(4 M in dioxane, 4 mL) was added at 0.degree. C. The reaction
mixture was stirred at ambient temperature for 1 h, until LC-MS
indicated the disappearance of starting material. HCl and solvent
were removed by vacuum; the residue was dissolve in DCM, washed
with sat. NaHCO.sub.3, and brine, concentrated to give crude
compound 6.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(2-cyclopropylamino-ac-
etylamino)-phenylethynyl]-benzamide (129-1)
[1686] Compound 7 was made using the General Method for hydroxamate
formation. Crude product was purified by preparative scale
reverse-phase HPLC (Phenomenex Gemini C-18 column, 110 .ANG.,
30.times.100 mm, flow rate: 20 mL/min, mobile phase A: 0.1%
TFA/water, mobile phase B: 0.1% TFA/ACN, gradient elution from 15%
B to 40% B over 60 min, MS detection). Fractions containing the
desired product were combined and lyophilized to provide the
trifluoroacetate salt of target compound 129-1 (11.4 mg, 6.2%
yield) as a white solid. LC-MS: RT (Method A) 2.79 min; [M+H]
451.1.
TABLE-US-00158 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
129-1 1 11.4 6.2 99.5 451.1 2.79 .sup.1Based on compound 5.
.sup.2Using LC-MS Analytical Method A.
Example 130
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(2-cyclopropylamino-ace-
tylamino)-phenylethynyl]-benzamide (130-1)
##STR00489##
[1687] Synthesis of (4-Iodo-benzyl)-carbamic acid tert-butyl ester
(1)
[1688] To a solution of 4-iodoaniline (1.95 g, 5.0 mmol) in iPrOH
(10 mL) was added Boc.sub.2O (1.199 g, 5.5 mmol), and the mixture
was stirred at ambient temperature for 16 h. iPrOH was removed in
vacuo and the residue was crystallized from Et.sub.2O/hexanes
mixture to give target compound 1 (1.219 g, 76%) as a off-white
solid. LC-MS: RT (Method A) 6.14 min; [2M+H] 638.7.
Synthesis of 4-(4-tert-Butoxycarbonylamino-phenylethynyl)-benzoic
acid (2)
TABLE-US-00159 [1689] Reagent MW Eq. mg, ml mmol 4-Ethynyl benzoic
acid 146.15 1.0 146 mg 1.0 Compound 1 319.14 1.0 319 mg 1.0
PdCl.sub.2(PPh.sub.3).sub.2 703.91 0.03 21 mg 0.03 CuI 190.45 0.06
12 mg 0.06 (iPr).sub.2NH 101.19 0.6 mL 0.3 THF 1.2 mL
[1690] The compound 2 was made using the General Method for
Sonogashira coupling, but without PPh.sub.3. Yield: 355 mg. Crude
product was used in next synthetic step without additional
purification. LC-MS: RT (Method A) 6.05 min, [M+H] 338.6.
Synthesis of
(2S,3R)-2-[4-(4-tert-Butoxycarbonylamino-phenylethynyl)-benzoylamino]-3-(-
9H-fluoren-9-ylmethoxycarbonylamino)-butyric acid methyl ester
(3)
TABLE-US-00160 [1691] Reagent MW Eq. mg/mL mmol Compound 2 337.38
1.0 355 mg 1.0 Fmoc-Methyl DAP.cndot.HCl 390.87 1.0 390 mg 1.0 HATU
380.2 1.2 456 mg 1.2 DIEA 129.25 3.5 0.609 mL 3.5 DMF 1 mL
[1692] Compound 3 was made using the General Method for HATU
coupling. LC-MS: RT (Method A) 7.49 min, [M+H] 674.2. Crude product
was used in next synthetic step without additional
purification.
Synthesis of
(2S,3R)-2-[4-(4-Amino-phenylethynyl)-benzoylamino]-3-(9H-fluoren-9-ylmeth-
oxycarbonylamino)-butyric acid methyl ester (4)
TABLE-US-00161 [1693] Reagent MW Eq. mg/mL mmol Compound 3 673.77
1.0 -- 1.0 HCl, 4.0M solution in 1,4-dioxane 4 mL Dioxane 2 mL
[1694] Compound 4 was made using the General Method for Boc
deprotection. Crude product was used in next synthetic step without
additional purification.
Synthesis of
(2S,3R)-2-{4-[4-(2-Bromo-acetylamino)-phenylethynyl]-benzoylamino}-3-(9H--
fluoren-9-ylmethoxycarbonylamino)-butyric acid methyl ester (5)
[1695] To a suspension of compound 5 (137 mg, 0.22 mmol) and DIEA
(96 uL, 0.55 mmol) in CHCl.sub.3 (1 mL), cooled in ice/water bath,
was added dropwise bromoacetyl chloride (24 .mu.L, 0.29 mmol) and
the mixture was stirred in ice/water bath for 5 min. Reaction
mixture was allowed to attain ambient temperature and stirred for
1.5 h. The reaction mixture was used on next step. LC-MS: RT
(Method A) 6.91 min, MH.sup.+=695.5.
Synthesis of (2S,3R)-2-
{4-[4-(2-Cyclopropylamino-acetylamino)-phenylethynyl]-benzoylamino}-3-(9H-
-fluoren-9-ylmethoxycarbonylamino)-butyric acid methyl ester
(6)
[1696] Cyclopropyl amine (24 .mu.L, 0.35 mmol) was added to the
reaction mixture of compound 6 and resulting mixture was stirred
for 1 h at ambient temperature. The reaction mixture was diluted
with EtOAc (80 mL) and organic layer was washed with water
(2.times.40 mL) and brine (40 mL), dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give target compound
6 (133 mg, 90%) as a brown solid. LC-MS: RT (Method A) 6.82 min,
MH.sup.+=671.3.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-(2-cyclopropylamino-ac-
etylamino)-phenylethynyl]-benzamide (130-1)
TABLE-US-00162 [1697] Reagent MW, d Eq. mg, ml mmol Compound 6
670.77 1.0 133 mg 0.2 NH.sub.2OH .times. HCl 69.49 6.0 92 mg 0.78
25% MeONa in MeOH 12 0.6 mL 1.56 THF 2 mL MeOH 2 mL
[1698] Compound 130-1 was made using the General Method for
hydroxamate formation. LC-MS: RT (Method A) 2.48 min,
MH.sup.+=450.2. Crude product was purified by preparative scale
reverse-phase HPLC (Phenomenex Gemini C-18 column, 110 .ANG.,
30.times.100 mm, flow rate: 20 mL/min, mobile phase A: 0.1%
TFA/water, mobile phase B: 0.1% TFA/ACN, gradient elution from 15%
B to 40% B over 60 min, MS detection). Fractions containing the
desired product were combined and lyophilized to provide the
trifluoroacetate salt of target compound 130-1 (3.7 mg, 0.54%
yield) as a white solid. LC-MS: RT (Method A) 3.08 min; [M+H]
449.9.
TABLE-US-00163 Scale Yield Yield Purity Retention Compound
(mmol).sup.1 (mg) (%).sup.1 (%).sup.2 [M + H] time (min).sup.2
130-1 1 3.7 0.54 95.0 449.9 3.08 .sup.1Based on the amount of
carboxylic acid used in the coupling reaction. .sup.2Using LC-MS
Analytical Method A.
Example 131
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-aminomethyl-phenylethyn-
yl)-benzamide (131-1),
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-methanesulfonylamino-m-
ethyl)-phenylethynyl]-benzamide (131-2) and
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-guanidinomethyl-phenyl-
ethynyl)-benzamide (131-3)
##STR00490##
[1699] Synthesis of (4-Iodo-benzyl)-carbamic acid tert-butyl ester
(1)
[1700] To a solution of 4-iodobenzylamine (1.35 g, 5.0 mmol) and
DIEA (0.96 mL, 5.5 mmol) in DMF (5 mL) was added Boc.sub.2O (1.09
g, 5.0 mmol), and the mixture was stirred at ambient temperature
for 1 h. The reaction mixture was diluted with EtOAc (125 mL) and
organic layer was washed with water (2.times.40 mL) and brine (40
mL), dried over anhydrous Na.sub.2SO.sub.4, and concentrated in
vacuo to give target compound 1 (1.635 g, 98%) as a off-white
solid. LC-MS: RT (Method A) 6.02 min; [2M+H] 667.0. Crude product
was used in next synthetic step without additional
purification.
Synthesis of
4-[4-(tert-Butoxycarbonylamino-methyl)-phenylethynyl]-benzoic acid
methyl ester (2)
TABLE-US-00164 [1701] Reagent MW Eq. mg, ml mmol Methyl 4-Ethynyl
benzoate 160.17 1.0 1635 mg 4.9 Compound 1 333.17 1.1 864 mg 5.4
PdCl.sub.2(PPh.sub.3).sub.2 703.91 0.03 104 mg 0.15 PPh.sub.3
262.29 0.1 129 mg 0.49 CuI 190.45 0.06 56 mg 0.3 (iPr).sub.2NH
101.19 3 mL THF 6 mL
[1702] The compound 2 was made using the General Method for
Sonogashira coupling. Crude product was used in next synthetic step
without additional purification. LC-MS: RT (Method A) 5.92 min,
[M+H] 366.2).
Synthesis of
4-[4-(tert-Butoxycarbonylamino-methyl)-phenylethynyl]-benzoic acid
(3)
TABLE-US-00165 [1703] Reagent MW Eq. mg, ml mmol Compound 2 365.43
1.0 1.79 g 4.91 2N NaOH aq. 160.17 6.0 15 mL 30 MeOH 100 mL THF 50
mL
[1704] All components were stirred for 16 h at room temperature.
Most of solvent was removed in vacuo. Water (100 mL) was added to
residue. The aqueous solution was acidified with 2% H.sub.2SO.sub.4
aq. to pH=2-3 and extracted with EtOAc (2.times.50 mL) The combined
organic layer was washed with water (2.times.40 mL), brine (50 mL)
and dried over Na.sub.2SO.sub.4. EtOAc was removed in vacuo to give
desired compound 3 (1.650 g, 96% based on compound 1) as an
off-white solid. LC-MS: RT (Method A) 5.76 min; low ionization.
Synthesis of (2S,3R)-2-
{4-[4-(tert-Butoxycarbonylamino-methyl)-phenylethynyl]-benzoylamino}-3(9H-
-fluoren-9-ylmethoxycarbonylamino)-butyric acid methyl ester
(4)
TABLE-US-00166 [1705] Reagent MW Eq. mg/mL mmol Compound 3 351.41
1.0 235 mg 0.67 Fmoc-Methyl 390.87 1.0 200 mg 0.67 DAP.cndot.HCl
HATU 380.2 1.2 306 mg 0.8 DIEA 129.25 3.5 0.408 mL 2.35 DMF 1
mL
[1706] Compound 4 was made using the General Method for HATU
coupling. LC-MS: RT (Method A) 7.54 min, [M+H] 688.2). Crude
product was used in next synthetic step without additional
purification.
Synthesis of
(2S,3R)-2-[4-(4-Aminomethyl-phenylethynyl)-benzoylamino]-3-(9H-fluoren-9--
ylmethoxycarbonylamino)-butyric acid methyl ester (5)
TABLE-US-00167 [1707] Reagent MW Eq. mg/mL mmol Compound 4 687.8
1.0 -- 0.67 HCl, 4.0M solution in 1,4-dioxane 15 mL Dioxane 5
mL
[1708] Compound 5 was made using the General Method for Boc
deprotection. LC-MS: RT (Method A) 5.47 min, [M+H] 588.3. Crude
product was used in next synthetic step without additional
purification.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-aminomethyl-phenylethy-
nyl)-benzamide (131-1)
TABLE-US-00168 [1709] Reagent MW, d Eq. mg, ml mmol Compound 5 HCl
624.14 1.0 137 mg 0.22 NH.sub.2OH .times. HCl 69.49 6.0 92 mg 1.32
25% MeONa in MeOH 12 0.63 mL 2.64 THF 2 mL MeOH 2 mL
[1710] Compound 131-1 was made using the General Method for
hydroxamate formation. LC-MS: RT (Method A) 2.17 min,
MH.sup.+=367.0.
Synthesis of
(2S,3R)-3-(9H-Fluoren-9-ylmethoxycarbonylamino)-2-{4-[4-(methanesulfonyla-
mino-methyl)-phenylethynyl]-benzoylamino}-butyric acid methyl ester
(7)
[1711] To a suspension of compound 5 (137 mg, 0.22 mmol) and DIEA
(77 .mu.L, 0.44 mmol) in CHCl.sub.3 (0.5 mL), cooled in ice/water
bath, was added dropwise methanesulfonyl chloride (22 .mu.L, 0.29
mmol) and the mixture was stirred in ice/water bath for 5 min.
Reaction mixture was allowed to attain ambient temperature and stir
for 30 min. Reaction mixture was diluted with EtOAc (100 mL),
washed with water (2.times.30 mL) and brine (25 mL). Combined
organic layers were dried over anhydrous Na.sub.2SO.sub.4, and
concentrated in vacuo to give target compound 7 (141 mg, 97%) as an
off-white solid. LC-MS: RT (Method A) 6.37 min,
M+H.sup.+=666.4.
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-[4-methanesulfonyl-amino-m-
ethyl)-phenylethynyl]-benzamide (131-2)
TABLE-US-00169 [1712] Reagent MW, d Eq. mg, ml mmol Compound 7
665.77 1.0 141 mg 0.21 NH.sub.2OH .times. HCl 69.49 6.0 92 mg 1.32
25% MeONa in MeOH 12 0.63 mL 2.64 THF 2 mL MeOH 2 mL
[1713] Compound 131-2 was made using the General Method for
hydroxamate formation. LC-MS: RT (Method A) 3.13 min,
MH.sup.+=445.3.
Synthesis of
(2S,3R)-3-(9H-Fluoren-9-ylmethoxycarbonylamino)-2-[4-(4-guanidino-methyl--
phenylethynyl)-benzoylamino]-butyric acid methyl ester (9)
[1714] To a suspension of compound 5 (137 mg, 0.22 mmol) and DIEA
(191 .mu.L, 1.1 mmol) in DMF (0.5 mL), was added
1H-pyrazole-1-carboxamidine HCl (71 mg, 0.48 mmol) and the mixture
was stirred at 60.degree. C. for 1 h. The reaction mixture was
diluted with EtOAc (80 mL), washed with water (2.times.30 mL) and
brine (25 mL). Combined organic layers were dried over anhydrous
Na.sub.2SO.sub.4, and concentrated in vacuo to give target compound
9 (82 mg, 65%) as an off-white solid. LC-MS: RT (Method A) 5.48
min, MH.sup.+=630.3.
Synthesis of
N-((1S,2R)-2-Amino-1-hydroxycarbamoyl-propyl)-4-(4-guanidinomethyl-phenyl-
ethynyl)-benzamide (131-3)
TABLE-US-00170 [1715] Reagent MW, d Eq. mg, ml mmol Compound 9
629.72 1.0 82 mg 0.13 NH.sub.2OH .times. HCl 69.49 6.0 55 mg 0.78
25% MeONa in MeOH 12 0.35 mL 1.56 THF 2 mL MeOH 2 mL
[1716] Compound 131-3 was made using the General Method for
hydroxamate formation. LC-MS: RT (Method A) 2.72 min,
MH.sup.+=409.2.
The following compounds were made as described above.
TABLE-US-00171 Ret. HPLC- Compound Time MH.sup.+ MS # Structure
(min) (m/z) Method 131-1 ##STR00491## 2.58 367.1 A 131-2
##STR00492## 4.23 445.5 A 131-3 ##STR00493## 2.99 409.1 A
Example 132
N--[(S)-2-(2-Cyclopropylamino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-phe-
nylethynyl-benzamide (132-1)
##STR00494##
[1717] Synthesis of
(S)-3-tert-butoxycarbonylamino-2-(4-phenylethynyl-benzoylamino)-propionic
acid methyl ester (2)
[1718] To the mixture of compound 1 (210 mg, 0.94 mmol) and
H--(S)-DAP(N'-Boc)-OMe hydrochloride (275 mg, 1.08 mmol) in DMF (5
mL) was added HATU (429 mg, 1.13 mmol) followed by DIEA (491 .mu.l,
2.82 mmol). Reaction mixture was stirred at ambient temperature for
20 min, diluted with 0.1 M HCl.sub.aq (50 mL) and extracted with
EtOAc (60 mL.times.2). Combined organic layers were washed with
water (60 mL) and brine (60 mL), dried over anh. Na.sub.2SO.sub.4
and evaporated in vacuo to give target compound 2 (397 mg, 100%) as
an yellow oil. LC-MS [M+H] 424.0. Compound was used in next
synthetic step without additional purification.
Synthesis of (S)-3-amino-2-(4-phenylethynyl-benzoylamino)-propionic
acid methyl ester (3)
[1719] To the solution of compound 2 (397 mg, 0.94 mmol) in dioxane
(2 mL) and MeOH (2 mL) was added solution of 4 N HCl in dioxane (4
mL, 16 mmol). Reaction mixture was stirred at ambient temperature.
Completion of the reaction was monitored by LC-MS. After completion
(in 2 h) solvent was evaporated in vacuo. Residue was dissolved in
i-PrOH (10 mL) and evaporated in vacuo. The aforementioned
procedure was repeated twice to provide hydrochloride salt of
target product 3 (337 mg, 100%) as a light yellow solid. LC-MS
[M+H] 323.7.
Synthesis of
(S)-3-(2-bromo-acetylamino)-2-(4-phenylethynyl-benzoylamino)-propionic
acid methyl ester (4)
[1720] To the mixture of compound 3 hydrochloride (337 mg, 0.94
mmol) and DIEA (410 .mu.l, 2.35 mmol) in CH.sub.2Cl.sub.2 (8 mL)
was added bromoacetyl bromide (82 .mu.l, 0.94 mmol) at 0.degree. C.
Reaction mixture was allowed to warm to ambient temperature and
stirred for 30 min. CH.sub.2Cl.sub.2 was evaporated in vacuo. The
residue was dissolved in EtOAc (100 mL), washed with water (50 mL)
and brine (50 mL.times.2). Organic phase was dried over anh.
Na.sub.2SO.sub.4 and evaporated in vacuo. The crude product was
purified by flash column chromatography on silica gel utilizing a
5% MeOH/CH.sub.2Cl.sub.2 as an gradient to give the target product
4 (270 mg, 65%) as a white solid. LC-MS [M+H] 445.9.
Synthesis of
(S)-3-(2-cyclopropylamino-acetylamino)-2-(4-phenylethynyl-benzoylamino)-p-
ropionic acid methyl ester (5)
[1721] To a solution of compound 4 (67 mg, 0.15 mmol) in
CH.sub.2Cl.sub.2 (2 mL) was added cyclopropylamine (36 .mu.l, 0.53
mmol) at 0.degree. C. Reaction mixture was maintained at 0.degree.
C. for 10 min, mixture was then allowed to warm to ambient
temperature and stirred overnight. After completion the solvent was
removed in vacuo. The residue was diluted with water (40 mL),
acidified with 1 N HCl to pH 4 and extracted with EtOAc (40
mL.times.2). Combined organic layers were washed with water (50 mL)
and brine (50 mL), dried over anh. Na.sub.2SO.sub.4 and evaporated
in vacuo to provide the target product 5 (63 mg, 100%) as a light
yellow oil. LC-MS [M+H] 420.9.
Synthesis of N-- [(S)-2-(2-cyclopropyl
amino-acetylamino)-1-hydroxycarbamoyl-ethyl]-4-phenylethynyl-benzamide
(132-1)
[1722] To a stirred suspension of compound 5 (63 mg, 0.15 mmol) and
hydroxylamine hydrochloride (83 mg, 1.2 mmol) in MeOH (anh, 2 mL)
and THF (anh, 0.8 mL) was added dropwise 25% NaOMe/MeOH (343 .mu.l,
1.5 mmol) at -5.degree. C. under nitrogen. Reaction mixture was
stirred at -5.degree. C. for additional 5 min. Temperature of
reaction mixture was raised to ambient. Completion of the reaction
was monitored by LC-MS. After completion (in 20 min) reaction
mixture was acidified with 1 N HCl in MeOH to pH.about.5 at low
temperature and evaporated in vacuo. Residue was dissolved in DMSO
(400 .mu.l) and subjected to HPLC purification. [Phenomenex Gemini
C-18 column, 110 .ANG. (30.times.100 mm); flow rate=20 mL/min;
mobile phase A: 100% water, 0.1% TFA; mobile phase B: 100% ACN,
0.1% TFA; gradient elution from 8% B to 60% B in 60 min., detection
254 nm]. Fractions containing the desired product were combined and
lyophilized to provide trifluoroacetate salt of target product
132-1 (32.4 mg) as a white solid. LC-MS [M+H] 421.1.
TABLE-US-00172 Scale Yield Yield Purity Retention time Compound
(mmol)* (mg) (%)* (%) [M + H] (min)** 132-1 0.15 32.4 40.5 97.9
421.1 5.63 *Based on the amount of compound 4 **HPLC-MS Method
B
Each of the following compounds was synthesized as described above
using (S)-DAP(N'-Boc)-OMe.times.HCl or
(S)-Me-DAP(N'-Boc)-OMe.times.HCl and the appropriate amine.
TABLE-US-00173 Ret. MH.sup.+ Time HPLC-MS Compound # Structure
(m/z) (min) Method 132-2 ##STR00495## 435.1 4.04 A 132-3
##STR00496## 485.1 6.55 B 132-4 ##STR00497## 485.1 4.49 A 132-5
##STR00498## 499.1 4.60 A 132-6 ##STR00499## 499.1 4.61 A
Example 133
N-((1S,2S)-2-Amino-1-hydroxycarbamoyl-propyl)-4-phenylethynyl-benzamide
(133-1)
##STR00500##
[1723] Synthesis of 4-phenylethynyl-benzoic acid (1)
[1724] The 4-ethynyl-benzoic acid (146 mg, 1.0 mmol), bromobenzene
(116 .mu.l, 1.1 mmol), PdCl.sub.2(dppf).sub.2 (24.5 mg, 0.03 mmol)
and copper(I) iodide (11 mg, 0.06 mmol), and diisopropylamine (7.0
mL, 2.3 mmol) were dissolved in THF (2 mL) and sealed under
nitrogen. The reaction mixture was then stirred rapidly for 1 min
and placed in the microwave reactor at 130.degree. C. for 15 min.
Then, mixture was diluted with EtOAc (50 mL) and water (40 mL).
After mixing and adjusting to pH.about.5 with 3 M HCl, the aqueous
phase was removed. The organic phase was washed with 0.3 M HCl (20
mL.times.2), and brine (30 mL). Filtration of the brown solution
through anh Na.sub.2SO.sub.4 and evaporation of the solvents
yielded the target crude product, which was purified by HPLC
purification. [Phenomenex Gemini C-18 column, 110 .ANG.
(30.times.100 mm); flow rate=20 mL/min; mobile phase A: 100% water,
0.1% TFA; mobile phase B: 100% ACN, 0.1% TFA; gradient elution from
30% B to 70% B in 60 min., detection 254 nm]. Fractions containing
the desired product were combined and ACN was concentrated in
vacuo. Product was extracted with EtOAc (50 mL), washed with brine
(50 mL.times.2), dried over anh. Na.sub.2SO.sub.4 and solvent was
evaporated in vacuo. Residue was dried in vacuo overnight to
provide target compound 2 (160 mg, 72%) as white solid. LC-MS [M+H]
223.3.
Synthesis of
(2S,3S)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-2-(4-phenylethynyl-benzoy-
lamino)-butyric acid methyl ester (2)
TABLE-US-00174 [1725] Reagent MW Eq. g/mL mmol Compound 1 222.25
1.0 53 mg 0.24 H-(Allo)-Me-DAP-(N'-Fmoc)-OMe .times. 390.86 1.2 113
mg 0.29 HCl* HATU 380.23 1.2 110 mg 0.29 DIEA 129.24 3 125 .mu.l
0.72 DMF 1.5 mL *amino acid was synthesized according to Scheme
2
[1726] Compound 2 was prepared by reaction with
H-(Allo)-Me-DAP-(N'-Fmoc)-OMe.times.HCl according to General Method
for HATU coupling in quantitative yield. LC-MS [M+H] 559.5
(C.sub.35H.sub.30N.sub.2O.sub.5+H, requires 559.64). Compound was
used in next synthetic step without additional purification.
Synthesis of
N-((1S,2S)-2-amino-1-hydroxycarbamoyl-propyl)-4-phenylethynyl-benzamide
(133-1)
TABLE-US-00175 [1727] Reagent MW Eq. mg/mL mmol Compound 2 558.64
1.0 134 mg 0.24 NH.sub.2OH .times. HCl 69.49 10 167 mg 2.40 25%
NaOMe/MeOH 12 658 .mu.l 2.88 MeOH 3 mL THF 1.2 mL
[1728] Compound 133-1 was prepared by following General Method for
hydroxamate formation, anhydrous. Crude compound was purified by
HPLC. [Phenomenex Gemini C-18 column, 110 .ANG. (30.times.100 mm);
flow rate=20 mL/min; mobile phase A: 100% water, 0.1% TFA; mobile
phase B: 100% ACN, 0.1% TFA; gradient elution from 15% B to 40% B
over 60 min., detection 254 nm]. Fractions containing the desired
product were combined and lyophilized to provide the
trifluoroacetate salt of target compound 133-1 (21.1 mg) as a white
solid. LC-MS: [M+H] 338.3.
TABLE-US-00176 Scale Yield Yield Purity Retention time Compound
(mmol)* (mg) (%)* (%) [M + H] (min)* 133-1 0.24 21.1 mg 23.4 98.6
338.3 5.62 *Based on the amount of carboxylic acid used in the
coupling reaction **HPLC-MS Method B
Each of the following compounds was synthesized as described above
starting from appropriate carboxylic acid.
TABLE-US-00177 Ret. HPLC- MH.sup.+ Time MS Compound # Structure
(m/z) (min) Method 133-2 ##STR00501## 437.1 2.88 B 133-3
##STR00502## 407.1 3.24 B 133-4 ##STR00503## 368.3 3.41 B
The following compound was synthesized as described for synthesis
of compound 132-1 in Example 132 using
H-(Allo)-Me-DAP-(N'-Fmoc)-OMe.times.HCl and Fmoc deprotection (20%
piperidine in EtOAc).
TABLE-US-00178 Ret. HPLC- MH.sup.+ Time MS Compound # Structure
(m/z) (min) Method 133-5 ##STR00504## 453.1 5.89 B
Each of the following compounds was synthesized as described above
starting from appropriate carboxylic acid.
TABLE-US-00179 Ret. MH.sup.+ Time HPLC-MS Compound # Structure
(m/z) (min) Method 133-6 ##STR00505## 352.3 5.68 B 133-7
##STR00506## 339 133-8 ##STR00507## 338 133-9 ##STR00508## 338
133-10 ##STR00509## 408.1 133-11 ##STR00510## 423.1 133-12
##STR00511## 355.1 133-13 ##STR00512## 340.1 131-14 ##STR00513##
353.1 131-15 ##STR00514## 354.1
Example 134
N--((S)-2-Amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-(2-phenyl-cyclopropy-
lethynyl)-benzamide (134-1)
##STR00515##
[1729] (2-phenylcyclopropyl)methanol (S2)
[1730] 3.5 g Me.sub.3SiCl (32 mmol) was added dropwise to the
mixture of 53 g Zn/Cu powder and 50 ml Et.sub.2O at stirring under
N.sub.2. The mixture was stirred for 10 min and the solution of 1.6
ml CH.sub.2I.sub.2 and 10 ml Et.sub.2O was added. The mixture was
warmed to reflux and the solution of 26.7 ml CH.sub.2I.sub.2 (320
mmol), 21.5 g ACHL025-1 (160 mmol) and 160 ml Et.sub.2O was added
dropwise at refluxing. After the addition, the solution of 13.6 ml
CH.sub.2I.sub.2 (160 mmol) and 30 ml Et.sub.2O was added. The
reaction mixture was stirred for 15 h. After the reaction, 300 ml
Sat. NH.sub.4Cl was added and the mixture was filtered. The organic
layer was washed with Sat. NH.sub.4Cl, brine, dried by MgSO.sub.4,
concentrated. The residue was purified by column chromatography to
give 9.7 g ACHL025-2 (41% yield). 1H-NMR (400 MHz, CDCl.sub.3):
ppm: 0.91-0.99 (m, 2H), 1.43 (m, 1H), 1.81 (m, 1H), 3.52-3.62 (m,
2H), 4.78 (s, 1H), 7.07-7.28 (m, 5H).
2-phenylcyclopropanecarbaldehyde (S3)
[1731] 18.7 g IBX (66.9 mmol, 3.0 eq.) was added to the solution of
3.3 g ACHL025-2 (22.3 mmol) in 60 ml EA. The mixture was warmed to
80.degree. C. overnight. TLC showed the material was consumed
completely. The reaction mixture was filtered, and the filtrate was
concentrated to give 3.5 g crude ACHL025-3. .sup.1H-NMR (400 MHz,
DMSO): ppm, 1.53-1.56 (m, 1H), 1.66-1.71 (m, 1H), 2.08-2.10 (m,
1H), 2.63-2.68 (m, 1H), 7.16-7.29 (m, 5H), 9.07 (s, 1H).
(2-ethynylcyclopropyl)benzene (S4)
[1732] To a solution of diazophoaphonate (9.56 g, 50 mmol) and
ACHL015-3 (8 g, 54.8 mmol, 1.1 eq) in MeOH (200 ml) was added
K.sub.2CO.sub.3 (13.8 g, 100 mmol). The mixture was stirred
overnight at rt. The mixture was filtered and the filtrate was
concentrated to give crude. The crude was purified by column
chromatography on silica gel (PE/EA=50/0-50/1) to give 4.1 g
ACHL025-4 (57% yield). 1H-NMR (400 MHz, DMSO): ppm, 1.23 (m, 2H),
1.59 (m, 1H), 2.21 (m, 1H), 2.79 (s, 1H), 7.10-7.26 (m, 5H)
Methyl 4-((2-phenylcyclopropyl)ethynyl)benzoate (S5)
[1733] To a solution of 4.1 g ACHL025-4 (28.9 mmol) and 6.2 g
methyl 4-bromobenzoate (28.9 mmol) in 100 ml TEA was added 2 g
PdC.sub.2I (PPh.sub.3) (2.89 mmol) and 0.55 g CuI (2.89 mmol) under
N.sub.2. The mixture was warmed to 90.degree. C. and stirred
overnighte. The reaction mixture was filtered and concentrated to
crude product. The crude product was purified by column
chromatography (PE/EA=100/0-100-1) to give 3.4 g (S5) (42% yield).
.sup.1H-NMR (400 MHz, CDCl.sub.3): ppm, 1.40-1.47 (m, 2H),
1.72-1.74 (m, 1H), 2.39-2.42 (m, 1H), 3.92 (s, 3H), 7.13-7.32 (m,
5H), 7.45-7.47 (d, J=8 Hz, 2H), 0.7.96-7.98 (d, J=8 Hz, 2H).
Methyl 4-((2-phenylcyclopropyl)ethynyl)benzoate (1)
[1734] To a solution of 4.1 g ACHL025-5 (14.8 mmol) in 30 ml MeOH
and 20 ml water was added 6 g NaOH. The mixture was stirred at rt
for 4 h. 200 ml water was added and the mixture was adjusted to
PH=4 with 1N HCl. The mixture was extracted with EA and the organic
layer was washed by brine, dried by MgSO.sub.4, concentrated to
give 3.3 g ACHL025 (85% yield). .sup.1H-NMR (400 MHz, DMSO): ppm,
1.43 (m, 2H), 1.89 (m, 1H), 2.43 (m, 1H), 7.17-7.31 (m, 5H),
7.50-7.52 (d, J=8 Hz, 2H), 7.90-7.92 (d, J=8 Hz, 2H), 13.10 (s,
1H)
Synthesis of
(S)-3-tert-butoxycarbonylamino-3-methyl-2-[4-(2-phenyl-cyclopropylethynyl-
)-benzoylamino]-butyric acid methyl ester (2)
TABLE-US-00180 [1735] Reagent MW Eq. mg/mL mmol Compound 1 262.3
1.0 150 mg 0.57 H--(S)-diMe-DAP-(N'-Boc)-OMe 246.3 1.15 162 mg 0.66
HATU 380.23 1.2 259 mg 0.68 DIEA 129.24 3 298 .mu.l 1.71 DMF 3
mL
[1736] Compound 2 was prepared by coupling with
H--(S)-diMe-DAP-(N'-Boc)-OMe according to General Method for HATU
coupling in quantitative yield. LC-MS [M+H] 492.0
(C.sub.29H.sub.34N.sub.2O.sub.5+H, requires 491.60). Compound was
used in next synthetic step without additional purification.
Synthesis of
(S)-3-amino-3-methyl-2-[4-(2-phenyl-cyclopropylethynyl)-benzoylamino]-but-
yric acid methyl ester (3)
TABLE-US-00181 [1737] Reagent MW Eq. mg/mL mmol Compound 2 490.6
1.0 280 mg 0.57 4N HCl/dioxane 14.0 2 mL 8.0 dioxane 2 mL
[1738] Compound 3 was prepared using the General Method for Boc
deprotection in quantitative yield. LC-MS [M+H] 392.0
(C.sub.24H.sub.26N.sub.2O.sub.3+H, requires 391.49). Compound was
used in next synthetic step without additional purification.
Synthesis of
N--((S)-2-amino-1-hydroxycarbamoyl-2-methyl-propyl)-4-(2-phenyl-cycloprop-
ylethynyl)-benzamide (134-1)
TABLE-US-00182 [1739] Reagent MW Eq. mg/mL mmol Compound 3 .times.
HCl 426.94 1.0 243 mg 0.57 50% aq NH.sub.2OH 33 57.5 2 mL 32.8
i-PrOH 2 mL
[1740] Compound 134-1 was prepared by following General Method for
hydroxamate formation, aqueous. Crude compound was purified by
HPLC. [Phenomenex Gemini C-18 column, 110 .ANG. (30.times.100 mm);
flow rate=20 mL/min; mobile phase A: 100% water, 0.1% TFA; mobile
phase B: 100% ACN, 0.1% TFA; gradient elution from 15% B to 60% B
over 60 min., detection 254 nm]. Fractions containing the desired
product were combined and lyophilized to provide the
trifluoroacetate salt of target compound 134-1 (63.2 mg) as a white
solid. LC-MS: [M+H] 392.3.
TABLE-US-00183 Scale Yield Yield Purity Retention Compound (mmol)*
(mg) (%)* (%) [M + H] time (min)* 134-1 0.57 63.2 22.0 98.8 392.3
6.45 *Based on the amount of carboxylic acid used in the coupling
reaction **HPLC-MS Method B
The following compound was synthesized as described above using
H--(S)-Me-DAP-(N'-Boc)-OMe.
TABLE-US-00184 Ret. HPLC- MH.sup.+ Time MS Compound # Structure
(m/z) (min) Method 134-2 ##STR00516## 378.3 6.24 B
Example 135
Synthesis of
N-(1-(1-aminocyclopropyl)-2-(hydroxyamino)-2-oxoethyl)-4-((4-(morpholinom-
ethyl)phenyl)ethynyl)benzamide (135-1)
##STR00517## ##STR00518##
[1741] Synthesis of 1-(2,2-dimethoxyethyl)cyclopropanol (2)
[1742] A solution of methyl 3,3-dimethoxypropanoate (28.2 g, 190
mmol) in a three-neck flask equipped with a overhead stirrer was
cooled to 0.degree. C. under N.sub.2. The Ti(OiPr).sub.4 (11.3 mL,
38.1 mmol) was then slowly added and the solution was allowed to
stir for 10 min at 0.degree. C. To this cooled solution with
vigorous stirring was then added the EtMgBr solution (158 mL, 475
mmol) via syringe pump at .about.3 mL/min. After the addition was
complete, the solution was allowed to slowly warm to ambient
temperature and stirred for an additional 18 h. The solution was
then cooled to 0.degree. C. and deionized water (45 mL) was slowly
added with vigorous stirring. After stirring for 20 min at
0.degree. C. the mixture vacuum filtered through a pad of anhydrous
MgSO.sub.4. The clear, colorless solution was the concentrated in
vacuo and purified by flash chromatography (0-50% EtOAc/Hex) to
provide the desired product (2) as a clear, colorless oil (8.60 g,
31%). .sup.1H NMR (DMSO) .delta. 5.04 (s, 1H), 4.62 (t, J=5.3, 1H),
3.22 (s, 6H), 1.69 (d, J=5.3, 2H) 0.50 (dd, J=4.9, 6.9, 2H), 0.37
(dd, J=4.2, 6.2, 2H).
Synthesis of 1-(2,2-dimethoxyethyl)cyclopropyl mesylate (3)
[1743] To a solution of compound 2 (8.60 g, 58.9 mmol) in
CH.sub.2Cl.sub.2 was added TEA (12.6 mL, 124 mmol) sequentially.
The solution was then cooled to 0.degree. C. and methane sulfonyl
chloride (8.09 g, 70.65 mmol) was added drop wise. After the
addition was complete, the solution was stirred at 0.degree. C. for
10 min then allowed to warm to ambient temperature and stirred for
4 h. The solution was then washed with aqueous NaHSO.sub.4 (1.0 N,
2.times.100 mL), aqueous NaHCO.sub.3 (sat., 2.times.100 mL), dried
(MgSO.sub.4), filtered and concentrated in vacuo. Isolated the
desired product, (3) as a clear, colorless oil (13.62 g).
Synthesis of 2-(1-(methylsulfonyloxy)cyclopropyl)acetic acid
(4)
[1744] Compound 3 (13.62 g, 60.8 mmol) was dissolved in THF (150
mL) and water (50 mL) and cooled to 0.degree. C. To this cooled
solution was added Oxone.RTM. (54.07 g, 88 mmol) in portions. After
complete addition the slurry was allowed to stir at 0.degree. C.
for 10 min the warmed to ambient temperature. After 8 h at ambient
temperature the slurry was diluted with deionized H.sub.2O (100 mL)
and extracted with EtOAc (3.times.150 mL). The combined organics
were dried (MgSO.sub.4), filtered and concentrated in vacuo. The
product (4) was isolated as a thick, colorless oil (8.4 g).
Synthesis of methyl 2-chloro-2-cyclopropylideneacetate (5)
[1745] Compound 4 (4 g, 20.6 mmol) was dissolved in anhydrous DCE
(100 ml) under N.sub.2 and cooled to 0.degree. C. Thionyl chloride
(1.8 ml, 30 mmol) was then added slowly and the solution was
refluxed for 30 min. At ambient temperature, were added NCS (3.32
g, 25 mmol) and 4 drops of concentrated HCl and the solution was
heated under reflux for 8 h. MeOH (50 ml) was added at room
temperature and the solution was stirred at rt for 3 h, Followed by
TEA (10 ml. 100 mmol) and stirring was continued for additional 1 h
The solvent were removed under reduced pressure, water (100 ml) was
added and product was extracted with ethyl acetate, dried (Na2SO4),
and and purified by flash chromatography (0-15% EA in Hex) to give
1.2 g of methyl 2-chloro-2-cyclopropylideneacetate 5. H1 NMR
(DMSOd6) 1.5 (t, 2H), 1.73 (t, 2H) 3.73 (s, 3H)
Synthesis of methyl
2-chloro-2-(1-(diphenylmethyleneamino)cyclopropyl)acetate (6)
[1746] To diphenyl imine (2.05 g, 11.37 mmol) in methanol (35 ml),
the chloride product 5 (1.39 g, 9.48 mmol) was added in dry
methanol (14 ml) and stirred at room temp for 24 h. The reaction
mixture was concentrated to give 3.39 g of 6:1H NMR (CDCl3)
0.70-0.9 (m, 3H), 1.20-1.24 (m, 1H) 3.62 (s, 3H), 4.29, (s, 1H),
7.23-7.58 (m, 10H).
Synthesis of methyl
2-azido-2-(1-(diphenylmethyleneamino)cyclopropyl)acetate (7)
[1747] The chloride product 6 (3.24 g, 99 mmol) was redessolved in
dry DMF (25 ml), NaN3 (1.3 g, 200 mmol) was added and heated at
85.degree. C. for 18 h. The reaction mixture was diluted with ethyl
acetate (100 ml) and water 5 ml was added. The organic layer was
separated, dried and concentrated to give 2.8 g of 7. LCMS (M+1)
335, Chemical Formula: C19H18N4O2 MW: 334.37.
Synthesis of methyl
2-amino-2-(1-(diphenylmethyleneamino)cyclopropyl)acetate (8)
[1748] The compound 7 (480 mg, 1.43 mmol), PPh3 (278 mg, 1.06 mmol)
in THF (5 ml) and water (1 ml) stirred for 18 h. The reaction
mixture was diluted with ethyl acetate (100 ml) and water 5 ml was
added. The organic layer was separated, dried and concentrated to
give crude 8 which were used for the next step without any further
purification.
Synthesis of methyl
2-(4-(cyclopropylbuta-1,3-diynyl)benzamido)-2-(1-hydroxycyclopropyl)aceta-
te (9)
[1749] A solution of compound 4-((4-(morpholinomethyl)phenyl)
ethynyl)benzoic acid (100 mg, 0.31 mmol), HATU (120 mg, 0.31 mmol)
and DIEA (0.5 ml, excess) in CH3CN (15 mL) was maintained at
ambient temperature for 10 min followed by the addition of compound
8 (408 mg, 1.31 mmol). Reaction mixture was stirred at ambient
temperature 20 min and concentrated followed by the dilution with
water (10 ml). Solution was extracted with ethyl acetate (20
ml.times.2) and brine (20 ml). Organic layer was dried over
MgSO.sub.4 and evaporated to give crude product 9, 160 mgs of
methyl
2-(1-aminocyclopropyl)-2-(4-((4-(morpholinomethyl)phenyl)ethynyl)
benzamido)acetate. LC-Ms (M+1) 448; Chemical Formula: C26H29N3O4;
MW: 447.53.
Synthesis of
N-(1-(1-aminocyclopropyl)-2-(hydroxyamino)-2-oxoethyl)-4-((4-(morpholinom-
ethyl)phenyl)ethynyl)benzamide (135-1)
[1750] Aq. Hydroxylamine (2 ml, 50% aq.) was added to a stirred
solution of ester 9, (0.16 g, 0.35 mmol) in isopropanol (15 ml),
stirred for 18 h. Excess solvent was removed and the product was
purified on a reverse phase HPLC to give compound (135-1) (6 mg).
LC-MS (M+1) 449: Chemical Formula: C25H28N4O4; MW: 448.51.
Example 136
N-((2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(4-(morpholinomethy-
l)phenethyl)benzamide (137-1)
##STR00519##
[1752] Compound 1 (200 mg, 0.45 mmol) was dissolved in methanol (20
ml) followed by the addition of Pd/C (10% wt, 46 mg). Reaction
mixture was subjected to hydrogenation (Parr apparatus, 46 psi) at
room temperature for 15 min. Catalyst was filtered and washed with
methanol. Filtrate was evaporated in vacuum to provide target
compound 136 (184 mg) as colorless oil. LC-MS [M+H] 441.0
(C10H20N2O4+H, requires 440.24).
Example 137
[1753] The following compounds were made according to the above
synthetic procedures.
TABLE-US-00185 Compound MH.sup.+ # Structure (m/z) 137-1
##STR00520## 383.4 137-2 ##STR00521## 534.6 137-3 ##STR00522##
465.5 137-4 ##STR00523## 381.4 137-5 ##STR00524## 382.4 137-6
##STR00525## 421.5 137-7 ##STR00526## 445.5 137-8 ##STR00527##
442.5 137-9 ##STR00528## 358.4 137-10 ##STR00529## 370.4 137-11
##STR00530## 452.4 137-12 ##STR00531## 365.4 137-13 ##STR00532##
441.5 137-14 ##STR00533## 383.4 137-15 ##STR00534## 341.4 137-16
##STR00535## 449.4 137-17 ##STR00536## 467.5 137-18 ##STR00537##
398.4 137-19 ##STR00538## 364.4 137-20 ##STR00539## 368.4 137-21
##STR00540## 302.3 137-22 ##STR00541## 369.4 137-23 ##STR00542##
383.5 137-24 ##STR00543## 450.5 137-25 ##STR00544## 344.4 137-26
##STR00545## 364.4 137-27 ##STR00546## 364.4
Example 138
[1754] The following compounds may be made according to the above
synthetic procedures.
TABLE-US-00186 Compound MH.sup.+ # Structure (m/z) 138-1
##STR00547## 460.5 138-2 ##STR00548## 461.6 138-3 ##STR00549##
363.4 138-4 ##STR00550## 300.3 138-5 ##STR00551## 324.3 138-6
##STR00552## 473.6 138-7 ##STR00553## 329.4 138-8 ##STR00554##
343.3 138-9 ##STR00555## 338.4 138-10 ##STR00556## 344.4 138-11
##STR00557## 437.5 138-12 ##STR00558## 437.5
LC-MS Analytical Methods
[1755] All LC-MS spectra were acquired using HPLC (Column:
Phenomenex, Onyx Monolithic C18, 4.6.times.50 mm. Flow rate: 1.5
mL/min. Mobile phase A: 0.1% trifluoroacetic acid in water. Mobile
phase B: 0.1% trifluoroacetic acid in acetonitrile.) with an ion
spray MS detector (PE SCIEX API 365 LC/MS/MS), and UV/VIS (254 nm)
detection (Shimadzu SPD-10A) under the following gradients:
[1756] Method A (12 minute method): 5% B to 100% B over 9.6
min.
[1757] Method B (Analytical 5-60): 5% B to 60% B over 9.1 min.
[1758] Method C (6 minute method): 5% B to 100% B over 4.6 min.
[1759] Method D (Analytical 5-35): 5% B to 35% B over 9.1 min.
NMR Data
[1760] All NMR spectra were taken on a Bruker 250 NMR (250 MHz) or
Varian 400 (400 MHz), using DMSO-d.sub.6 or CDCl.sub.3
Biological Protocols and Data
Bacterial Screens and Cultures
[1761] Bacterial isolates were cultivated from -70.degree. C.
frozen stocks by overnight passages at 35.degree. C. in ambient air
on Mueller-Hinton agar (Beckton Dickinson, Franklin Lakes, N.J.).
Clinical isolates tested were obtained from various geographically
diverse hospitals in the US and abroad (Focus Diagnostics, Herndon,
Va. and JMI, North Liberty, Iowa). Quality control strains were
from the American Type Culture Collection (ATCC; Rockville, Md.).
Additional primary panel strains were generated using standard
molecular biology techniques. Strain AECO063 does not express the
principal multidrug efflux pump for E. coli and is hypersusceptible
to many antibacterials. Target enzyme replacement strains (AECO061
--E. coli, AECO062 --P. aeruginosa and AECO065 --A. baumannii)
possess a non-functional genomic copy of the E. coli lpxC gene
complemented by a plasmid-borne sequence from the species indicated
under the control of the native E. coli lpxC promoter (E. coli
strain background MG1655).
Susceptibility Testing
[1762] Minimum Inhibitory Concentrations (MICs) were determined by
the broth microdilution method in accordance with the Clinical and
Laboratory Standards Institute (CLSI) guidelines. In brief,
organism suspensions were adjusted to a 0.5 McFarland standard to
yield a final inoculum between 3.times.10.sup.5 and
7.times.10.sup.5 colony-forming units (CFU)/mL. Drug dilutions and
inocula were made in sterile, cation adjusted Mueller-Hinton Broth
(Beckton Dickinson). An inoculum volume of 100 .mu.L was added to
wells containing 100 .mu.L of broth with 2-fold serial dilutions of
drug. All inoculated microdilution trays were incubated in ambient
air at 35.degree. C. for 18-24 hours. Following incubation, the
lowest concentration of the drug that prevented visible growth
(OD600 nm<0.05) was recorded as the MIC. Performance of the
assay was monitored by the use of laboratory quality-control
strains and levofloxacin, a compound with a defined MIC spectrum,
in accordance with CLSI guidelines. Typically, compounds of the
present invention have MIC values of 0.03-64 mic/mL. To this end,
data for certain representative compounds is shown in Table 1
below.
Efficacy in Mouse Model of Systemic Pseudomonas aeruginosa and
Escherichia coli Infection
[1763] Male CD-1 mice weighing 22-26 g were infected
intraperitoneally with 0.5 mL of a bacterial suspension of P.
aeruginosa strain ATCC27853 or E. coli ATCC25922 in blood heart
infusion broth (BHI, DIFCO, USA) plus 5% Mucin (Sigma, USA). The
number of bacterial cells used was approximately 2 times the dose
that would kill 90% of animals (LD.sub.90, 6.5.times.10.sup.4 CFU
for P. aeruginosa, 4.5.times.10.sup.5 CFU for E. coli). At one hour
(1 hr) post infection, the test compound was injected intravenously
in doses ranging from 0.3 mg/kg to 50 mg/kg, ten mice per dosing
group. Survival of the mice was observed daily for 7 days, and the
dose of compound resulting in survival of 50% of mice (ED.sub.50)
was calculated. Example 3/12a demonstrated an ED50<20 mg/kg in
the E. coli septicemia model.
Efficacy in Neutropenic Thigh Model
[1764] Mice were rendered neutropenic prior to infection with 2
doses of cyclophosphamide, and then infected intramuscularly in the
thigh with 10.sup.5-10.sup.6 CFU of bacteria. See Gudmundsson S.,
Erlensdottir H., "Murine Thigh Infection Model" Handbook of Animal
Models of Infection, M. A. Sande and O. Zak, Eds.; London: Academic
Press, 1999, pp 137-144. Antibiotics or vehicle alone as a negative
control were administered twice at 2 hrs and 14 hrs post-infection.
At 24 hrs post-infection, thighs were harvested, homogenized, and
plated to measure the number of CFUs surviving per thigh. Thighs
from a subset of animals were also harvested 2 hrs post-infection
to record the CFUs present just prior to the first antibiotic
treatment (pre-treatment). The static dose, defined as the dose
required to result in a CFU load at 24 hours that is identical to
that measured at 0 hours post infection, was calculated by standard
methods in Prizm from a dose response curve.
TABLE-US-00187 TABLE 1 AECO 001 APAE Compound AECO HSA AECO APAE
APAE 006 + # 001 AGP 063 001 006 PMBN AABA1060 ASAU001 62-6 C D B D
62-7 C C B D B C D 62-10 B D A D 62-8 C D C D 62-11 B D A D 62-9 C
D B D 62-4 B D B D 62-5 B D C D 48-5 D D D D D D D 47-5 D D D D C D
D 46-4 C C B C A D D 41-5 D D C C A A D D 43-7 D D C C A A D D 42-7
C C C C A A C D 60-5 C D C D C B D D 115-2 A B A A A A B D 115-3 A
A A B A A B D 66-5 A B A B A A B D 67-9 B C A C A A D D 67-7 A B A
B A A B D 67-8 A B A B A A B D 65-6 C D B C B A C D 64-7 B C A B A
A C D 59-8 C D C D C C D D 67-5 A B A B A A C D 68-6 A B A B A A C
D 66-6 A B A C A A C D 30-12a A A A A A A B D 30-12b B C A B A A C
D 30-11a B C B C B A C D 115-4 B C A A A A C D 115-5 A B A B A A B
D 115-6 B B A A A A C D 115-7 A B A B A A B D 115-8 A B A A A A B D
96-1 A A A B A A B D 110-3 A B A A A A B D 110-6 A B A B A A B D
111-3 A B A B A A B D 110-7 A B A B A A A D 111-2 B B A B A A B C
111-4 A C A B A A C D 110-4 A B A B A A C C 110-2 A B A B A A B D
118-10 A B A C B A B D 96-4 A B A B A A B D 132-4 A B A B A A B C
113-2 A B A A A A B D 113-1 A B A B A A C D 113-3 A B A B A A B D
113-4 A B A B A A B D 110-5 A B A B A A B D 112-1 A C A A A A B D
112-2 B C A B A A D D 112-3 A C A B A A C C 110-8 A C A B A A C D
110-9 A B A B A A B D 110-10 A B A B A A C C 110-11 A B A C A A C C
110-12 A A A B A A A C 112-4 A B A A A A A C 112-5 A B A A A A A C
127-1 C C B D C C D D 97-1 A A A B A A B C 97-2 A A A A A A A C
98-1 A A A A A A C C 116-1 C C C B A A C C 117-1 D D D D D D D D
117-2 D D D D D C D D 118-1 C C B B A A C C 118-2 A C A A A A B C
118-3 A B A B A A B C 128-1 C C C C C C C C 113-11 A C A B A A C D
96-2 A B A B A A B C 96-3 A B A B A A B C 98-3 A A A B A A C D 98-2
A B A B A A C C 99-1 A B A B A A C C 100-1 A B A B A A C C 119-1 A
B A A A A B C 119-2 B C B A A A D D 119-3 B B A B A A C D 131-1 C D
C B A A D D 131-2 B C A A A A C D 131-3 C C C B A A C C 82-2 A C A
A A A C C 82-3 A C A A A A B C 86-2 A A A B A A B C 82-4 A B A B A
A B B 101-2 A C A B A A C C 102-3 A B A A A A C C 101-3 A B A A A A
B C 101-1 A B A B A A C C 101-4 A B A B A A C C 102-2 A B A B A A B
C 102-1 A B A B A A C C 102-4 A B A B A A C D 133-7 A B A A A A A B
133-8 C C B B A A C D 133-9 C C B B A A C D 86-3 A A A A A A B C
82-5 A B A A A A B B 82-6 A B A B B A C C 113-9 A B A A A A A C
113-10 A B A B A A B C 103-1 A B A B A A D D 137-1 A B A B A A D D
137-2 A B A B A A C D 137-3 A B A B A A C C 120-3 A B A A A A B D
113-8 A B A B A A A C 104-2 A B A B A A C C 104-1 A B A B A A B C
104-3 A B A A A A A C 104-4 A B A A A A B C 113-7 A B A B A A B D
113-5 A A A A A A A C 101-5 A B A A A A A C 137-4 D D C D C C D D
82-7 A B A A A A A B 82-8 A B A C A A D D 82-9 A B A B A A B B
82-10 A B A B A A B B 82-11 B B A C B A C C 88-3 A B A A A A B D
88-4 B C A A A A C D 91-2 A B A A A A A B 82-12 A B A B A A B C
102-5 A A A A A A B D 88-2 A B A A A A B B 133-2 A C A A A A C D
109-1 A B A B A A B D 137-5 A B A A A A B C 129-1 A B A A A A B D
137-6 A B A A A A B C 137-7 A B A A A A B C 120-1 A B A A A A B C
82-13 A A A A A A A C 133-4 B C A A A A D D 136-1 B C A B A A C C
137-8 B C A B A A C C 137-9 A B A B A A B C 118-4 A B A A A A C D
118-5 B B A A A A C D 118-6 B B A A A A C C 118-7 A B A A A A B C
85-2 A B A B A A C C 85-1 A B A B A A C C 87-2 A A A A A A C C 87-3
A A A A A A A C 133-3 A B A A A A C D 133-1 A B A A A A A C 133-10
B B A C A A C C 133-11 A C A C B A C C 118-8 A B A A A A B C 88-1 A
B A B A A C C 133-5 A B A C A A A C 114-2 A B A B A A B C 105-1 A B
A B A A C C 105-3 C C B C B A C C 109-2 A B A B A A B C 133-12 A B
A A A A C C 118-9 A B A A A A B C 119-6 B B A A A A C C 114-3 A B A
A A A A C 114-4 A B A B A A B B 114-5 A B A B A A A B 114-6 A B A B
B A B B 114-7 B B A B B A B B 114-8 A B A A A A B C 114-9 B B A A A
A B C 114-1 A B A A A A A B 88-9 A B A B A A C C 88-10 A B A B A A
B C 114-10 A B A B A A B C 137-26 C C B C B A C C 137-27 C C B C A
A C C 82-14 A C A A A A A C 82-15 A C A A A A A C 88-5 A A A B A
N/A A C 137-12 B C B B A A C C 91-3 A B A A A A B B 91-4 A B A B A
A B B 120-2 B C A B A A C C 82-16 A B A A A A A C 105-2 A A A B A A
C C 105-4 A B A C B A C C 105-5 B B A C B A C C 91-5 A A A A A A B
C 82-17 A A A A A A A B 119-4 A A A A A A B C 119-5 A A A A A A A C
133-13 C C B C A A C C 133-15 B B A B A A B C 133-14 A A A B A A A
C 137-13 C C B C A A C C 91-30 C C B A A A C C 130-1 B C A A A A B
C 82-18 A B A B A A C C 82-19 A B A B A A A C 91-6 A A A A A A A C
114-11 A C A C A A B C 137-14 A C A B A A B C 114-12 A B A B A A A
C 114-13 A B A B A A B C 114-14 A B A B A A A C 82-20 A B A B A A B
C 82-21 A B A B A A A C 132-1 A B A B A A B C 132-3 A B A C A A B C
88-12 A B A A A A A B 92-2 C C B C B B C C 91-17 A B A A A A B C
82-22 A C A C C A C C 91-10 A A A A A A A C 87-1 A B A A A A A C
88-6 A B A B A A B C 104-5 A A A B A A A B 126-2 A A A B A A A C
121-1 A A A A A A B C 121-2 B C B C A A C C 101-6 A C A A A A B C
92-1 B C B B A A C C 122-1 B B A B A A C C 123-1 A B A B A A B C
137-16 A B A B A A B C 106-6 A C A B A A B C 106-7 A B A B A A B C
137-17 C C C C B A C C 137-18 C C C C B B C C 137-19 A B A B A A C
C 124-1 A B A B A A C C 91-11 A C A B A A C C 88-7 A B A B A A B C
91-12 A A A A A A A B 124-2 A B A B A A B C 124-3 A B A B A A B C
132-5 C C N/A C A N/A C C 132-2 A B A B A A C C 132-6 B C A C A A C
C 106-4 B C A B A A C C 91-13 A B A A A A B B
82-23 A C A C A A C C 114-15 B C A A A A B C 86-4 A B A B A A B C
82-24 A B A B A A A B 107-2 A B A A A A A B 106-1 A B A C A A C C
107-3 A B A A A A B C 106-5 A B A B A A B C 107-1 A B A A A A B C
106-3 A C A A A A C C 137-20 C C C C B A B C 133-6 A A A A A A A B
91-14 A B A A A A A B 82-25 A A A A A A A C 82-26 A C A B B A B B
91-1 A A A A A A A B 106-2 A B A B A A B C 91-7 A B A A A A B B
91-8 A B A A A A B B 89-1 A B A A A A B C 93-1 A C A A A A A C
137-21 C C C B A A B C 114-16 A A A B A A A C 107-4 A A A A A A A B
122-5 A A A A A A A C 88-8 A A A A A A B C 122-6 A A A A A A B C
91-15 A B A A A A A B 125-1 A B A B A A A C 86-1 A B A A A A B C
137-22 C C C B B B C C 137-23 C C C B A B C C 137-24 A B A B A A B
C 94-1 A B A A A A B C 82-1 A B A B A A B C 84-1 A B A C B A C C
86-5 A C A A A A B C 114-17 A B A B A A B B 91-9 A A A A A A A B
137-25 C C B C A A C C 107-5 A B A B A A A B 88-13 A A A A A A A B
88-15 A A A A A A A B 83-2 A C A A A A B C 91-16 A A A A A A A B
83-1 A B A A A A A C 88-11 A A A A A N/A A C 88-14 A B A A A A A C
107-6 A B A B A A A C 134-1 B B A B A A A C 134-2 B C B B A A B C
122-8 A A A A A A B C 126-1 A A A A A A A C 82-27 A B A B A A B C
89-2 A B A A A A A C 114-18 A B A A A A A C 122-2 A B A A A A B C
122-3 A A A A A A A C 122-4 A B A A A A A C 102-6 A B A A A A B C
89-3 A A A A A A B C 91-21 A B A B A A B B 91-22 A B A B A A B B
91-23 A B A B A A B B 138-10 A B A B A A B B 87-4 A B A A A A A C
88-16 A B A A A A A C 89-4 C C B B A A C C 89-5 B B A A A A B C
82-28 A B A B A A A B 113-6 A A A A A A A C 91-18 A A A B B A B C
91-19 A A A B A A B C 91-20 A B A B B A B C 89-6 B B A A A A B C
89-7 B B A B A A C C 114-19 A B A A A A A B 114-20 A B A B A A A B
82-29 A A N/A A A N/A A B 86-6 A B A B A A B C 86-7 A B A B A A A C
91-24 A B A A A N/A B B 91-25 C C C C B B C C 91-26 A A A A A N/A A
C 91-27 A B A A A N/A B C 91-28 A B A B A A B B 88-17 A C A A A A B
C 115-1 A B A B A A B D 137-11 D D C C B B D D 137-10 D D D D C C D
D MIC Key MIC's of 2.0 .mu.g/mL or less = A MIC's of greater than
2.0 .mu.g/mL to 16.0 .mu.g/mL = B MIC's of greater than 16.0
.mu.g/mL to 64.0 .mu.g/mL = C MIC's of greater than 64.0 .mu.g/mL =
D *AEC001 is ATCC25922, AECO063 is ATCC25922 bearing an acrAB
mutation, APAE001 is ATCC27853, APAE006 is a strain of P.
aeruginosa in which all efflux pumps are inactivated, APAE006 +
PMBN indicates MICs with the indicated strain in the presence of 8
micrograms per milliliter of polymyxin B nonapeptide, AABA1060 is a
clinical isolate of Acinetobacter baumannii, ASAU001 is a
laboratory strain of S. aureus (ATCC29213).
[1765] As shown in the following Table 2, the MICs on AECO001 for
fourteen pairs of compounds were compared (n=2 data). For each pair
of compounds, the compounds were identical in structure except for
the A moiety. More specifically, A is --C(CH.sub.3).sub.2NH.sub.2
in one compound and A is --CHCH.sub.3NH.sub.2 in the other
compound. As shown, for each pair of compounds, the compound
wherein A is --C(CH.sub.3).sub.2NH.sub.2 was more potent.
TABLE-US-00188 TABLE 2 Compound # Ratio of MICs on AECO001 (A =
Compound # [Cpd (A = --CHCH.sub.3NH.sub.2)/ --CHCH.sub.3NH.sub.2)
(A = --C(CH.sub.3).sub.2NH.sub.2) Cpd (A =
--C(CH.sub.3).sub.2NH.sub.2)] 91-2 91-12 5.6 91-3 91-14 3.3 82-16
82-25 1.6 91-7 91-1 7.2 88-3 88-8 5.1 91-13 91-15 6.5 91-8 91-9 5.2
88-12 88-13 4.1 91-17 91-16 2.6 89-1 89-2 1.6 115-2 121-1 4.0 133-7
133-6 20.8 118-7 122-5 2.4 118-9 122-6 2.1
[1766] As shown in the following Table 3, three pairs of compounds
were tested in the neutropenic thigh efficacy model. For each pair
of compounds, the compounds were identical in structure except for
the A moiety. More specifically, A is --C(CH.sub.3).sub.2NH.sub.2
in one compound and A is --C(CH.sub.3).sub.2OH in the other
compound. A ratio of >1 indicates that the compound wherein A is
--C(CH.sub.3).sub.2NH.sub.2 had a lower static dose and is
therefore a more potent compound in vivo. For all three pairs of
compounds, the compound wherein A is --C(CH.sub.3).sub.2NH.sub.2
had superior in vivo efficacy to that of the compound wherein A is
--C(CH.sub.3).sub.2OH. In addition, the ratios of the MICs of each
pair of compounds on the infecting strain (ATCC43816) was
calculated. A ratio of >1 indicates that the compound wherein A
is --C(CH.sub.3).sub.2NH.sub.2 had a lower MIC and was therefore
more potent on this strain. When the ratio of neutropenic thigh
potencies was normalized to reflect the differences in MICs, it was
found that the compounds wherein A is --C(CH.sub.3).sub.2NH.sub.2
still have superior activity relative to the compounds wherein A is
--C(CH.sub.3).sub.2OH, demonstrating that the functional group
--C(CH.sub.3).sub.2NH.sub.2 confers advantageous properties for in
vivo antibacterial activity that is not readily predictable from
the MICs.
TABLE-US-00189 TABLE 3 Ratio of Ratio of MICs on thigh static Ratio
of ATCC43816 dose Compound # Compound # thigh static [Cpd (A =
--CH(CH.sub.3).sub.2OH/Cpd normalized (A =
--C(CH.sub.3).sub.2NH.sub.2) (A = --C(CH.sub.3).sub.2OH) doses (A =
--C(CH.sub.3).sub.2NH.sub.2)] to MICs 88-13 88-11 >7x 1.6
>4.4x 91-12 91-6 >3x 1.0 >3x 122-5 122-8 >2x 0.5
>4x
[1767] It should be understood that the organic compounds according
to the invention may exhibit the phenomenon of tautomerism. As the
chemical structures within this specification can only represent
one of the possible tautomeric forms, it should be understood that
the invention encompasses any tautomeric form of the drawn
structure.
[1768] Furthermore, while particular embodiments of the present
invention have been shown and described herein for purposes of
illustration, it will be understood, of course, that the invention
is not limited thereto since modifications may be made by persons
skilled in the art, particularly in light of the foregoing
teachings, without deviating from the spirit and scope of the
invention. Accordingly, the invention is not limited except as by
the appended claims.
[1769] All of the U.S. patents, U.S. patent application
publications, U.S. patent applications, foreign patents, foreign
patent applications and non-patent publications referred to in this
specification are incorporated herein by reference, in their
entirety to the extent not inconsistent with the present
description.
* * * * *